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ABSTRACT 
 
PROTEOMIC TECHNIQUES FOR THE DISCOVERY OF BIOMARKERS 
ASSOCIATED WITH UVEAL MELANOMA AND CUTANEOUS MELANOMA 
DISEASE PROGRESSION 
Deirdre O’Flynn 
 
Uveal melanoma is the most common primary intraocular cancer. Cutaneous 
melanoma accounts for the highest number of deaths of any skin cancer. This 
research outlines the discovery of proteins potentially associated with disease 
progression in uveal and cutaneous melanomas. 
 
It was hypothesised that patterns of differential protein expression would be 
observed between primary uveal melanoma tumour tissues of patients who 
subsequently developed metastasis versus those who did not and that such proteins 
could be used as potential biomarkers of disease progression. Using 2-D DIGE and 
quantitative LC-MS/MS, and functional validation by siRNA knockdown, five 
proteins were identified; EEF1G, SELENBP1, KPNB1, TPI1, and FABP3, which 
were found to play a role in invasion and migration in uveal melanoma cell lines.  
 
Vitreous fluid from patients with uveal melanoma was subjected to various sample 
pre-treatments and analyses in order to determine an optimal method for studying 
this biofluid. Fractionation by copper-activated IMAC resin and subsequent LC-MS 
analysis was carried out which resulted in the identification of 62 differentially 
expressed proteins between patients with monosomy 3 tumours (associated with 
poor prognosis) and patients with disomy 3 tumours (good prognosis).  
 
It was hypothesised that protein expression differences would be present throughout 
the process of cutaneous melanoma disease progression. Using quantitative label-
free LC-MS/MS, 57 proteins differentially expressed between the control and 
disease groups were identified. Four of these proteins, and three targets from a 
previous transcriptomic microarray analysis, were analysed across a panel of control, 
cutaneous melanoma (benign, early stage, advanced), and uveal melanoma sera 
using ELISA. This identified two potential markers of melanoma progression; 
lactotransferrin and BACE-2. 
 
Cutaneous melanoma serum and healthy, control serum were profiled and compared 
by SELDI TOF MS. This analysis revealed an 8.9 kDa candidate which was 
overexpressed in the disease samples in comparison to the control samples. In an 
attempt to identify the potential marker, IMAC purification with 1-D gel 
electrophoresis and quantitative LC-MS was used. 34 proteins were found to be 
differentially expressed between control and advanced cutaneous melanoma sera.  
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1.1 General Introduction 
Cancer is defined as the unregulated growth of cells. Cells which grow 
uncontrollably can eventually form a large cell mass; a neoplasm, more commonly 
known as a tumour. These tumours grow exponentially as each cell divides to 
produce two daughter cells, with cells in rapidly-growing tumours replicating every 
one to four weeks, while the cells of a slow-growing tumour may double every six 
months. Benign tumours are those which remain in one location and are often 
removed from the area to which they are confined through the use of surgery; 
however metastatic tumours are those which contain more aggressive cells. The cells 
of malignant tumours have a higher invasive potential than those of benign tumours 
and so, are capable of spreading from the primary location to distant organs.  
Although there are more than 100 cancer types, it has been suggested that virtually 
all show the same hallmarks which are required to breach any physiological barriers 
and to thus achieve a state of malignancy (Figure 1.1). For example, neoplastic cells 
must increase and sustain a level of angiogenesis which is conducive to providing 
the tumour with the oxygen and nutrients it needs for growth, while growth signals 
must successfully be produced or mimicked, and anti-growth signals supressed, in 
order to promote proliferation. If a neoplasm achieves such hallmarks, it can 
eventually reach a point where it will spread and form secondary neoplasms in 
regions of the body where space and nutrients are more plentiful (Hanahan and 
Weinberg 2011). 
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Figure 1.1 The hallmarks of cancer which ultimately contribute to the development 
of metastases. As adapted from (Hanahan and Weinberg 2011). 
Melanomas are malignancies which derive from dendritic melanocytes, i.e. pigment-
producing cells, found in the skin, eye, mucosal epithelia, and leptomeniges. 
However, the skin is the most common site of melanoma development; this type of 
neoplasm is referred to as a cutaneous melanoma (Hurst, Harbour et al. 2003). 
Cutaneous melanoma is currently regarded as being a life-threatening malignancy, 
and a steady increase in incidence has been observed over the past few decades (van 
den Bosch, Kilic et al. 2010). Cutaneous melanoma accounts for more than 90% of 
all melanomas. However, melanoma is recognised as being difficult to treat, mainly 
due to the large number of patients who are resistant to immune therapy as well as 
chemotherapy (Mehnert and Kluger 2012). Moreover, malignant melanoma often 
exhibits unpredictable behaviour. For example, many patients with significant 
vertical growth remain metastasis-free while some with thin lesions subsequently 
perish as a result of their disease (Torabian and Kashani-Sabet 2005). A better 
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understanding of the mechanisms of disease initiation and progression involved in 
cutaneous melanoma is critical for the development of predictive biomarkers which, 
to-date, have been elusive.  
Uveal melanoma only accounts for 5% of all melanomas, albeit, it is the most 
common intraocular malignancy, accounting for 85% of all cases in the western 
world. The incidence of uveal melanoma remains reasonably steady at 
approximately 7 people per million per year, a figure which increases with age (van 
den Bosch, Kilic et al. 2010). The disease is rarely caused by inherited mutations 
and develops from melanocytoma (tumour of melanocytes of the ophthalmic disc) 
(Damato 2004). The uvea consists of the iris, the choroid and the ciliary body, with 
the disease arising in the choroid of 90% of cases, the ciliary body in 5-10% of 
patients, and in the iris of 3% of patients, which is associated with the best outcome  
(Damato 2004, Pardo, Dwek et al. 2007). The 5-year survival rate of uveal 
melanoma is 72%, however, the median survival rate following metastasis is 
approximately six months (Triozzi, Eng et al. 2008). This is due to the highly 
aggressive nature of the metastatic disease which spreads to vital organs such as the 
kidneys, bone, lungs, and in 95% of metastatic cases, the liver (Damato 2004). As 
there are no current protein biomarkers available for the detection of uveal 
melanoma, a prognostic marker would greatly help in the detection and possible 
treatment of the metastatic disease. 
Although uveal and cutaneous melanomas both derive from melanocytes, they are 
distinct in their mechanisms of tumorigenesis and metastasis, as well as in their 
therapeutic response and genetic aberrations (van den Bosch, Kilic et al. 2010). The 
differences between both melanomas are poorly understood, but it is hoped that 
genetic and proteomic analyses of the nature of melanoma as a disease will aid us in 
understanding variations between both melanomas. 
Proteomic analysis is used for the characterisation of the proteins, and associated 
protein and peptide modifications which compose signalling networks. Hence, it can 
be useful, particularly when used in conjunction with genomic markers, in 
determining deregulated pathways in cancer, thus furthering our understanding of 
the disease and potentially identifying new drug targets. In addition to this, 
proteomic analysis can be used for the detection of biomarkers, i.e. features which 
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are measured and evaluated as indicators of normal or disease state, disease 
progression or response to therapy. Biomarkers can often be used in the clinic for 
diagnostic or prognostic tests. Ideally, if a biomarker is intended for use in the clinic, 
it should illustrate an unbiased diagnosis result, whether or not the patient is 
symptomatic. The marker should also demonstrate high specificity, high sensitivity, 
ease of use, regularity, and clarity in results. Proteomic studies for the identification 
of biomarkers are typically carried out in clinical specimens such as blood (which 
may be separated into serum and plasma), urine, cerebrospinal fluid (CBS), saliva, 
and sputum. Techniques such as mass spectrometry (MS), and matrix-assisted laser 
desorption and ionisation with time-of-flight (MALDI-TOF) have been key methods 
in the search for differential protein expression patterns in both clinical and cell 
culture specimens (Lee and Kohn 2010, Boja, Hiltke et al. 2011). 
 
1.2 Uveal Melanoma 
Uveal melanoma is the most common primary intraocular malignancy affecting 
approximately 5 people per million in the Western world each year, however this 
incidence increases with age (Pardo, Dwek et al. 2007). Uveal melanoma is rarely 
caused by inherited mutations but can develop from melanocytoma (Damato 2004).  
The uvea consists of the iris, the choroid and the ciliary body (Pardo, Dwek et al. 
2007). The malignancy arises in the iris of 3% of patients and has the best prognosis 
in comparison to uveal melanoma of the choroid (90% of patients) or of the ciliary 
body (5-10% of cases) (Damato 2004). It is unclear why this is but may be due to the 
fact that iris melanoma is generally smaller than either of the posterior ciliary or 
choroid tumours at the time of diagnosis. Most iris melanomas consist of spindle 
cells, according to the Callender classification (Henderson and Margo 2008). 
Choroidal melanoma tumours have been classified by spindle, epithelioid and mixed 
cell populations. Spindle cell tumours are associated with a much more promising 
prognosis than epithelioid cell tumours (Albert 1998).  
The 5-year survival rate of uveal melanoma is 72%, however in a 15-year follow up, 
53% have been shown to die of metastatic disease. The median survival rate 
following metastasis is approximately six months (Triozzi, Eng et al. 2008). In 95% 
of metastatic cases, uveal melanoma spreads to the liver, but it can also spread to 
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regions such as the kidneys, the bone and the lungs (Damato 2004). Clinical features 
which are associated with metastatic death include large tumour size, ciliary body 
involvement and higher patient age. Epithelioid cytology, tumour infiltration by 
macrophages and/or lymphocytes, and nucleolar size are all histopathologic features 
which can indicate poor prognosis (Landreville, Agapova et al. 2008).  
 
1.2.1 Pathogenesis of Uveal Melanoma 
Uveal melanoma is characterised by a number of disrupted molecular signalling 
pathways including the retinoblastoma pathway, p53 signalling, Phosphoinositide 3-
kinase/Protein Kinase B (P13K/AKT) and mitogen-activated protein 
kinase/extracellular signal-related kinase pathways (MAPK/ERK) (Coupland, Lake 
et al. 2013).  
The retinoblastoma pathway is mediated by the interaction between the anti-growth 
protein retinoblastoma tumour suppressor (Rb) and the E2F transcription factor. Rb 
function is regulated through phosphorylation by the D-type cyclin-dependent 
kinases. Growth stimulation is induced by D-cyclin/cyclin-dependent kinase 4 
(cdk4) activity which induces a cascade of events leading to E2F accumulation and 
the transition from G1 to S-phase. Overexpression of cyclin D1 causes a disruption 
of the Rb pathway in uveal melanoma through the hyperphosphorylation and 
inactivation of Rb, hence disrupting signalling and causing uncontrolled cell 
proliferation (Nevins 2001, Onken, Worley et al. 2008). Previous research has 
shown that overexpression of cyclin D1 may be driven by the BRAF
V599E
/MEK/ERK 
pathway, as one group illustrated when MEK/ERK inhibition significantly decreased 
the proliferation rate of uveal melanoma cells in culture (Calipel, Lefevre et al. 
2003). Significant cyclin D1 over-expression has been associated in the literature 
with unfavourable outcome when tumour tissue was examined using 
immunohistochemistry and has been associated with the presence of extraocular 
extension of the tumour (Coupland, Anastassiou et al. 2000).  High levels of cyclin 
D1 are found in choroidal melanomas which are the more aggressive tumours and 
have poorer prognosis in comparison to their iris and ciliary body counterparts 
(Calipel, Lefevre et al. 2003). 
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Mutations of the p53 tumour suppressor gene, TP53, are present in over half of 
human neoplasia, making it one of the most frequent molecular events in human 
cancer (Davies, Spiller et al. 2011). p53 initiates growth arrest, thus antagonising 
cyclin D1, or apoptosis due to stressful conditions. Murine double minute 2 
(MDM2) is necessary for the regulation of p53, however it is a proto-oncogene, 
independent of p53, which is often overexpressed in human cancers. Previous 
research has illustrated a potential link between MDM2 over-expression and the 
development of metastases (Coupland, Anastassiou et al. 2000). In uveal melanoma, 
high expression of the MDM2 gene, located on chromosome 12q15, occurs in 97% 
of cases, resulting in the inhibition of p53 (van den Bosch, Kilic et al. 2010). 
PI3K signalling is activated by receptor tyrosine kinases and G-coupled receptors. 
Once activated, PI3K triggers a series of events which allows for the activation of 
AKT (essential for several proliferation and survival pathways). This process is 
regulated by phosphatase and tensin homolog (PTEN), a protein which antagonises 
PI3K signalling through the conversion of Phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) to Phosphatidylinositol 4,5-bisphosphate (PIP2). A total loss of PTEN is 
associated with a more aggressive uveal melanoma; patients have a median survival 
of 60 months in comparison to those with normal or close to normal expression. A 
decrease in PTEN relative to another primary uveal melanoma is correlated with a 
more aggressive tumour (Patel, Smyth et al. 2011). 
During the screening of potential oncogenes which could potentially activate the 
Mitogen-activated protein kinase (MAPK) pathways, mutations were discovered in 
Guanine nucleotide-binding protein G(q) subunit alpha (GNAQ), a stimulatory 
heterotrimeric G protein α-subunit, and Guanine nucleotide-binding protein G(q) 
subunit alpha-11 (GNA11), its paralogue (Gaudi and Messina 2011). GNAQ 
mediates signalling between G protein-coupled receptors (GPCRs) and catalyses the 
hydrolysis of PIP2 through the stimulation of all isoforms of β phospholipase C 
(PLCβ). Mutations of GNAQ and GNA11 have been detected in 83% of uveal 
melanomas, both primary and metastatic, and exclusively affect exon 5 (Q209) and 
exon 4 (R183). This causes constitutive activation of the MAPK pathway in the 
absence of Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and BRAF 
mutations, thus GNAQ acts as a dominant oncogene (Lamba, Felicioni et al. 2009, 
Van Raamsdonk, Griewank et al. 2010, Metz, Scheulen et al. 2013). It is possible 
9 
 
that GNAQ and GNA11 mutations represent an early stage in tumour development 
and that these mutations may contribute directly to the risk of hereditary melanoma 
in families with an increased incidence of uveal melanoma. However, previous 
research has suggested an absence of germ-line mutations in exon 5 of GNAQ and 
GNA11 in familial melanoma patients (Hawkes, Campbell et al. 2013). 
The Insulin-like growth factor (IGF) signalling pathway plays a role in both cell-cell 
adhesion and tumour invasiveness through the binding of Insulin-like growth factor 
1 (IGF-1) to Insulin-like growth factor 1 receptor (IGF-1R) for the activation of the 
intrinsic receptor tyrosine kinase activity and phosphorylation of insulin receptor 
substrate. IGF-1R is expressed on primary uveal melanoma tumours; however, IGF-
1 is neither secreted nor expressed by melanoma cells. Despite this, it is produced by 
the liver which is the main site of metastasis for uveal melanoma. A decrease in 
IGF-1R has been shown to affect uveal melanoma cell line proliferation as well as 
metastatic potential (All-Ericsson, Girnita et al. 2002). Recent research has 
illustrated that a decrease in IGF-1 levels in serum can be directly correlated to 
prognosis. In one such study, IGF-1 serum levels of 10-years disease-free patients 
were lower than those of their healthy counterparts, and lower again were those of 
metastatic patients (Frenkel, Zloto et al. 2013). Indications which illustrate the 
potential role of IGF-1 in follow-up care have been noted, such as an increased IGF-
1 6-month post-operative serum level in relation to pre-operative specimens (Topcu-
Yilmaz, Kiratli et al. 2010). 
BRCA1-associated protein-1 (BAP1) is a tumour suppressor which can mediate its 
effects through transcriptional regulation and chromatin modulation. It is also 
possible that it acts through the ubiquitin-proteasome system and the DNA damage 
response pathway. BAP1 mutations can occur in the germline, thus leading to a 
familial cancer syndrome in malignancies such as mesothelioma, renal cell 
carcinoma, and cutaneous melanoma (Murali, Wiesner et al. 2013). An increased 
susceptibility is associated with a number of cancers such as cutaneous melanoma, 
epithelioid atypical Spitz tumours and uveal melanoma. Mutations of BAP1 appear 
to occur later in tumour progression in comparison to other uveal melanoma-
associated molecular defects and are associated with metastasis (Harbour 2013, 
Murali, Wiesner et al. 2013). Somatic mutations of BAP1 are found to occur in 84% 
of metastatic uveal melanoma cases but also in 3-4% of sporadic uveal melanoma 
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cases where there is a BAP1 germline mutation (Njauw, Kim et al. 2012, Aoude, 
Vajdic et al. 2013).  
Perhaps the most recently identified recurrent mutation, associated with 18.6% of 
uveal melanoma cases, is in splicing factor 3B subunit 1 (SF3B1), which affects 
codon 625. SF3B1 is a splice factor; hence, mutations in this gene result in altered 
pre-mRNA splicing. However, the target of the altered splicing is unknown and 
might be cell dependent. In terms of melanoma, SF3B1 mutations are uveal 
melanoma-specific as they do not appear to occur in cutaneous melanoma (Schilling, 
Bielefeld et al. 2013). Mutations in SF3B1 have previously been identified in 
myeloid malignancies as well as in breast cancer (Papaemmanuil, Cazzola et al. 
2011, Ellis, Ding et al. 2012). Such mutations have been associated with good 
prognostic features in uveal melanoma, such as a younger patient age, and fewer 
undifferentiated epithelioid cells. In addition to this, they were found to be inversely 
linked with features of poor prognosis such as monosomy three and BAP1 mutations 
(Harbour, Roberson et al. 2013). 
c-KIT, a receptor protein tyrosine kinase involved in numerous processes including 
the development of uveal melanocytes, has been shown to be expressed  in 63-78% 
of primary uveal melanoma cases as well as being expressed in the majority of 
metastatic cases (Daniels and Abramson 2009, Mahipal, Tijani et al. 2012).  
 
1.2.2 Chromosomal Status and Classification of Uveal Melanoma 
Cytogenetic aberrations occur as part of uveal melanoma disease progression. 
Typically, regions of chromosome gain are thought to harbour oncogenes while 
regions of chromosome loss may contain tumour suppressors. Along with features 
such as tumour size and histology, chromosome status, particularly that of 
chromosomes 1, 3, 6, and 8, is now recognised in contributing to the risk of 
metastasis in uveal melanoma.  
Loss of chromosome 1p occurs frequently in many other cancers, such as 
neuroblastoma where it is an indicator of poor prognosis. In uveal melanoma, it has 
been found to be indicative of metastasising tumours and its loss has also been 
identified as concurrent with monosomy three; an indicator of poor prognosis (Kilic, 
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Naus et al. 2005). Loss of 1p has been associated with large ciliary body tumours 
and also with secondary tumours, i.e. those which have metastasised (Sisley, Parsons 
et al. 2000, Aalto, Eriksson et al. 2001).  
An imbalance of chromosome six has been described as a recurrent aberration 
associated with uveal melanoma. Typically, a gain of 6p and/or a loss of 6q are 
observed, albeit not as frequently as other abnormalities. Gain of 6p has been 
reported in 18% of cases while loss of 6q has been shown to occur in 28% (Kilic, 
van Gils et al. 2006). Gain of 6p has been associated with a good prognosis, while 
the loss of 6q implies the presence of tumour suppressors in this region (Damato and 
Coupland 2009). However, the deletion and amplification of these regions has been 
shown to occur independently of other abnormalities on chromosomes 1p, 3, and 8 
(van Gils, Kilic et al. 2008). 
Abnormalities of chromosome eight, namely trisomy eight and isochromosome 8q, 
have been reported in uveal melanoma  (Damato and Coupland 2009). Trisomy eight 
is often associated with monosomy three, for an overall risk of metastasis. However, 
when trisomy eight occurs in conjunction with disomy three, it is not linked with the 
spread of disease (Thomas, Putter et al. 2012). In addition to this, monosomy three 
and aneusomy eight have been shown to be present in liver metastases (Singh, Tubbs 
et al. 2009). 
In 1996, Prescher et al. unearthed a link between monosomy of chromosome three 
and metastasis-associated death in uveal melanoma (Prescher, Bornfeld et al. 1996). 
Through the years, this finding has been proven by multiple studies (Sisley, Rennie 
et al. 1997, White, Chambers et al. 1998, Scholes, Damato et al. 2003). Monosomy 
three is thought to occur as an early event, with the loss of 1p, 8p, and gain of 8q 
occurring later on in disease progression as secondary events (Kilic, van Gils et al. 
2006). As mentioned above, the combination of chromosome 8q gain and 
chromosome three loss further modulates the metastatic progression of monosomy 
three tumours and has been associated with hepatic metastases (Singh, Tubbs et al. 
2009). It is clear that chromosome three loss provides valuable prognostic 
information, however, not all tumours can be classified as high or low risk based on 
chromosome three status alone as some tumours have been shown to undergo a 
partial loss of chromosome three. This has been illustrated to provide inconsistent 
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prognostic information, although Thomas et al. recently found that patients with 
“equivocal abnormality” of chromosome three are more likely to develop and die 
from metastases (Thomas, Putter et al. 2012).  
  Harbour et al., using cytogenetic analysis and genome-wide profiling, have 
developed a gene expression profile which distinguishes uveal melanoma tumours 
into two genomic groups; class 1 and class 2, based on the expression of 15 genes 
(Harbour 2014). Each class is used as a determinant of outcome due to the 
correlation between gene expression and prognosis. Class 1 tumours are deemed to 
have a low risk of metastasis, typically associated with gain of chromosome 6p or 
disomy three. In contrast, class 2 tumours carry a high risk of metastasis, often 
characterised by loss of chromosome three or gain of 8q (Onken, Worley et al. 2004, 
Couturier and Saule 2012).This method has been shown to superior in its prognostic 
accuracy in comparison to other prognostic biomarkers available, including 
monosomy three status alone (Onken, Worley et al. 2010, Harbour 2014). The gene 
expression profile is available as a quantitative polymerase chain reaction (qPCR)-
based assay, known commercially as DecisionDX-UM, which is used on a routine 
basis on very small samples acquired through fine needle aspiration and on archival 
formalin-fixed samples, as well as on samples acquired in a multi-centre study 
(Harbour and Chen 2013, Harbour 2014). For the prognostic characterisation of 
uveal melanomas, DecisionDX-UM illustrated sensitivity and specificity values of 
84.6% and 92.9% respectively. Monosomy three detected by array comparative 
genomic hybridisation illustrated sensitivity and specificity values of only 58.3% 
and 85.7%, respectively. Monosomy three detected by FISH illustrated even lower 
sensitivity and specificity values of 50% and 72.7%, respectively (Worley, Onken et 
al. 2007). 
Class 1 tumours can be divided into two groups; 1A and 1B. Class 1A shows a 2% 
5-year tumour-survival rate while 1B has a rate of 21%. In contrast to class 2 
lesions, class 1 cells are well-differentiated and typically maintain disomy three, 
generally a more promising indication in terms of prognosis. The metastatic rate is 
low as is the rate of chromosomal aneuploidy, despite chromosome 6p gain (Gill and 
Char 2012).  
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Typically, class 2 uveal melanoma lesions demonstrate high levels of aneuploidy, 
particularly monosomy three, i.e. loss of heterozygosity (LOH) for chromosome 
three (Ehlers, Worley et al. 2008, Gill and Char 2012). Approximately 25% of class 
2 tumours, class 2B, have a deletion mutation of the chromosome fragment 8p which 
increases the aggressiveness of the malignancy. Class 2 tumours often exhibit stem-
cell like ectodermal differentiation, a high rate of metastasis and a tumour-related 
mortality rate of 40-60% (Gill and Char 2012).  Clinical and histological features 
such as a large basal tumour diameter, high mitotic rate, epithelioid morphology and 
ciliary body involvement are also associated with such tumours (Scholes, Damato et 
al. 2003, Kilic, van Gils et al. 2006, Damato, Duke et al. 2007).  
Among the deregulated pathways in uveal melanoma, exome sequencing has 
identified mutations associated with class 2 tumours; overexpression of PTP4A3, 
which maps to chromosome 8q and a high rate of inactivating mutations in BAP1, 
which maps to chromosome 3p (Couturier and Saule 2012). Harbour et al. 
implicated loss of BAP1 in the onset of uveal melanoma metastasis. They also noted 
that this occurred independently of the presence or absence of GNAQ activating 
mutations at codon 209. It is important to note that mutations in GNAQ occur early 
in uveal melanoma and are not sufficient for malignant transformation however they 
may create a reliance of the tumour cells on GNAQ activity. Mutations of BAP1 
occur at a later stage of disease progression and, as illustrated above, coincide with 
the development of metastatic disease. The dual targeting of both BAP1 and GNAQ 
mutations could therefore act as a synergistic therapy for uveal melanoma (Onken, 
Worley et al. 2008, Harbour, Onken et al. 2010). Somatic mutations in exon five at 
position 209 in GNA11 were found to be present in 57% of uveal melanoma 
metastases, in contrast to GNAQ, where the Q209 mutation was identified in 22% of 
metastases. This mutation affects the production of glutamine, thus blocking 
intrinsic GTPase activity. Overall, 83% of uveal melanomas have been shown to 
have a constitutive mutation in either GNAQ or GNA11 (Van Raamsdonk, Griewank 
et al. 2010). However, it has recently been reported that mutations in either GNAQ 
or GNA11 are not associated with patient outcome (Koopmans, Vaarwater et al. 
2013). A mutation at Arg625 in SF3B1 in disomy three uveal melanomas has been 
shown to correlate with a good prognosis. An absence of the mutation appears to be 
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associated with metastasis, regardless of the chromosome status of the tumour 
(Martin, Masshofer et al. 2013). 
It is unclear if class 1 tumours can evolve into class 2 tumours or if they simply 
develop along different pathways. Harbour et al. suggested that the presence of a 
class 1 tumour with a BAP1 mutation may represent a transition state which suggests 
that BAP1 mutations develop prior to the emergence of the class 2 signature. Fully 
understanding this would impact on primary tumour therapy; if the tumour can 
change from class 1 to 2 then the treatment of the primary tumour could potentially 
be entirely curative and early treatment would be critical, if it cannot evolve between 
stages then it is possible that primary tumour treatment would have no impact on 
survival (Harbour 2006, Harbour, Onken et al. 2010). 
 
1.2.3 Clinical Treatment Options for Uveal Melanoma  
Enucleation, or removal of the eye, has traditionally been the method of choice for 
uveal melanoma treatment. Nowadays, primary ocular tumours can be treated by a 
variety of methods tailored to factors such as size, extent and location (Damato 
2012).  
Unfortunately, there are very few systemic treatments available for metastatic uveal 
melanoma, all with doubtful efficacy. However, as our molecular knowledge 
improves, so does the potential for the development of better treatment options 
(Velho, Kapiteijn et al. 2012). 
 
1.2.3.1 Enucleation 
Historically, enucleation has been the definitive treatment for uveal melanoma. 
Today more than a third of patients still require enucleation; occasionally due to 
pain, such as in the case of intraocular pressure elevation; and due also to the 
excessive size of the tumour when there is no hope for useful vision (De Potter 2003, 
Damato 2012). However, the cosmetic trauma of losing an eye can often be difficult 
for the patient psychologically. The possibility of sparing vision is also destroyed by 
enucleation. Therefore a number of alternative treatments have been developed 
including; plaque or proton beam radiotherapy; stereotactic radiosurgery; trans-
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scleral or trans-retinal local resection; and transpupillary thermotherapy (Damato 
2012). 
 
1.2.3.2 Radiotherapy and Radiosurgery 
Plaque brachytherapy and proton beam radiotherapy are some of the more common 
forms of radiotherapy used in the treatment of uveal melanoma, particularly in the 
case of small and medium sized tumours. The possibility of either method 
preserving the eye and/or retaining vision is dependent on the tumour size and 
location. The type of radiotherapy used can depend on factors such as; tumour 
location, tumour size, and adjacent radiation-sensitive ocular structures (Finger 
1997, Munzenrider 2001, De Potter 2003).  
Ophthalmic plaque brachytherapy involves the use of a thin implant composing of a 
radioactive element such as iodine, ruthenium, or cobalt which can vary in its 
dimensions, depending on the tumour size and shape (Giblin, Shields et al. 1989). 
The purpose of the plaque is to deliver a highly concentrated dose of radiation 
therapy to a specific region of the eye where the tumour is located. Plaque 
brachytherapy has been shown to be effective in terms of local control with 
recurrence following treatment at only 15%, however this rate may be as high as 
37% at 15 years in the case of metastatic disease (Freire, De Potter et al. 1997, 
Munzenrider 2001).   
Proton beam radiotherapy is a much more effective method than conventional 
radiotherapy as it provides a superior distribution of the dose due to the physical 
nature of protons (Weber, Mirimanoff et al. 2007). If vision is reduced in the 
affected eye, tumours of all sizes, including some large tumours, can be treated with 
the proton beam, with a 75-80% probability of preservation of the eye and of some 
visual function (Munzenrider 2001).  
Gamma knife surgery is a form of stereotactic radiosurgery which has been used as 
an alternative to enucleation for the reduction of the tumour while maintaining the 
structure of the eyeball and its function. In one study, tumour regression was 
observed in 90.9% of the sample set (Kang, Lee et al. 2012). The growth control 
rates and long-term outcome of the method compare well with enucleation and 
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brachytherapy and so it has been suggested as an alternative treatment for uveal 
melanoma (Toktas, Bicer et al. 2010). However, retinal detachment, cataract and 
radiation-induced retinopathy are most commonly reported as side-effects of the 
procedure (Toktas, Bicer et al. 2010, Kang, Lee et al. 2012). 
 
1.2.3.3 Local Tumour Resection 
Trans-scleral resection is generally suitable for certain iris, ciliary body, or anterior 
choroidal melanoma, especially in those with smaller basal dimensions and greater 
thickness (De Potter 2003). 
 
1.2.3.4 Transpupillary Thermotherapy 
Transpupillary thermotherapy with an infrared diode laser is used as a primary 
treatment or as a complement to radiotherapy or surgical resection in selected cases 
of choroidal melanoma. Using thermotherapy as part of a combined therapy appears 
to be more effective in reducing the intraocular tumour recurrence rate (De Potter 
2003). 
 
1.2.3.5 Systemic Treatment 
Although the above methods are successful in the eradication of the primary tumour, 
there is currently no standard systemic therapy available for metastatic uveal 
melanoma treatment, with typical options, such as immunotherapy, rarely 
prolonging life. Chemotherapeutic agents, used both in combination and alone, have 
also been tested, albeit showing poor anti-tumour activity with the response rate 
ranging from 0 to 15% and a median overall survival time of 6 to 12 months (Pons, 
Plana et al. 2011).  
Currently, the most promising therapies appear to be mitogen-activated protein 
kinase kinase (MEK) and Histone deacetylase (HDAC) inhibitors. HDAC inhibitors 
are capable of blocking the Bmi1/Ring1 complex which is responsible for the 
monoubiquitinylation of histone H2A. This in turn may be able to replace 
deubiquitinating activity to the cells which is absent following the loss of BAP1. 
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Hence, HDAC inhibitors such as valproic acid, LBH-589, and trichostatin A may be 
able to reverse the hyperubiquitinylation of histone H2A resulting from BAP1 loss 
(Harbour 2012). Cell culture and animal studies have illustrated the therapeutic 
potential of this approach in uveal melanoma metastasis treatment (Landreville, 
Agapova et al. 2012). GNAQ/11 mutations are also currently being investigated as 
potential therapeutic targets. As the direct inhibition of either gene would not be 
possible due to the role of the mutations in abrogating intrinsic GTPase activity, the 
goal of this approach would be to inhibit oncogenic signalling downstream as a 
result of the mutations. MEK would be a suitable target in this regard as it is a 
member of the MAPK pathway which is activated by GNAQ/11 mutations. 
Recently, selumetinib was shown to induce tumour shrinkage in 50% of metastatic 
uveal melanoma patients with 15.9 weeks progression-free survival, in comparison 
to seven weeks in those treated with temozolomide, a chemotherapy drug (AACR 
2013). The combined use of selumetinib with a target of rapamycin (mTOR) 
inhibitor, AZD8055, has also been described. mTOR inhibitors target the 
PI3K/AKT/mTOR pathway, which has been thought to cooperate with MAPK 
activation to generate and preserve the malignant phenotype in uveal melanoma. The 
results from this cell line-based study indicated that the dual-inhibition approach 
appeared to be effective in certain genotypes; the viability of BRAF and GNAQ 
mutant cells was suppressed with the treatment but apoptosis was only induced in 
BRAF mutant cells. In addition to this, tumour regression was only observed in the 
BRAF mutant xenograft model (Ho, Musi et al. 2012). Temozolomide and the MEK 
inhibitor AZD6244 are currently being tested in a randomized phase II trial; clinical 
trial identifier NCT01143402. This two-pronged approach uses a chemotherapeutic 
agent, temozolomide, to kill tumour cells and targeted therapy, AZD6244, to prevent 
tumour cell growth (Lima, Schoenfield et al. 2011, www.clinicaltrials.gov 2013).  
There are some ongoing phase II clinical trials which are testing the use of targeted 
therapies for the treatment of metastatic uveal melanoma. The anti-angiogenic 
monoclonal antibody, Bevacizumab, which targets vascular endothelial growth 
factor (VEGF), has been tested as a treatment for choroidal melanoma as VEGF 
levels have been noted to be elevated in choroidal melanoma; however it was found 
that the drug did not halt tumour progression but in fact masked its presence thus 
delaying appropriate diagnosis (Lima, Schoenfield et al. 2011). Bevacizumab was 
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found to be useful in the management of complications due to current therapies, such 
as in the case of retinopathy following plaque brachytherapy treatment through the 
reduction of macular oedema. Bevacizumab is currently undergoing clinical trials 
for intravitreal use in the treatment of large uveal melanoma in the hope that it will 
significantly reduce tumour size in patients scheduled to undergo enucleation. It is 
also being used as a combination therapy with temozolomide in the treatment of 
metastatic ocular melanoma. Ranibizumab, another monoclonal antibody treatment 
derived from the same mouse monoclonal antibody fragment as bevacizumab, is also 
being tested in clinical trials in combination with proton beam radiotherapy for its 
safety and tolerability in the treatment of choroidal melanoma (Lima, Schoenfield et 
al. 2011).  
Various drugs known to be effective in the treatment of cutaneous melanoma have 
been tested on uveal melanoma with little or no success. Ipilimumab, the 
monoclonal antibody therapy which targets cytotoxic T-lymphocyte associated-
antigen 4 (CTLA-4) in order to block its downregulation of the pathways of T-cell 
activation and hence induce antitumour effects, has been approved for use in the 
treatment of advanced cutaneous melanoma as it shows a survival benefit in 
randomised trials.  A limited number of initial trials have been conducted in relation 
to its use as a therapy for uveal melanoma patients where it was reported to be a 
well-tolerated treatment with no objective responses (Danielli, Ridolfi et al. 2012). 
In one study, two out of five patients maintained stable disease following 
ipilimumab administration. One of these patients was found to have maintained 
disease control at 11 months following treatment and showed a 10% reduction in 
tumour mass. The other individual developed progressive disease after 15 months. 
The response patterns of the patients and tumour kinetics resembled those of 
cutaneous melanoma following ipilimumab therapy. The other three patients 
developed progressive disease despite treatment. This early clinical trial indicates 
that ipilimumab may be used in the future as a therapy for uveal melanoma, 
however, further tests are now required (Khattak, Fisher et al. 2013).  
As shown above, many of the therapies being developed target genetic anomalies as 
there are currently no protein biomarkers for uveal melanoma. The identification of 
such proteins could provide a therapeutic target for the treatment of the disease. 
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1.2.4 Proteomic Analysis of Uveal Melanoma  
A limited number of proteomic studies have been performed in relation to uveal 
melanoma to date. A summary of these studies is illustrated in Table 1.1. 
Many studies which have been carried out involve differential protein expression 
analysis of cell lysates using two-dimensional (2-D) based methods in combination 
with mass spectrometry (MS). Zuidervaart et al. isolated and compared cell lines 
derived from a primary tumour and from two liver metastases of a patient, 
identifying twenty-four differentially expressed proteins using two-dimensional 
differential gel electrophoresis (2-D DIGE) and MS, most of which were previously 
correlated with metastasis (Zuidervaart, Hensbergen et al. 2006). Using 2-D gel 
electrophoresis (2-DE) and MS, Pardo et al. identified MUC18 and HMG-1 in uveal 
melanoma cell lines and using functional assays, correlated their expression levels 
with invasion. They also found DJ-1 oncoprotein to be both expressed and secreted 
by uveal melanoma cell lines as well as being detected in uveal malignant melanoma 
patient serum and therefore could be used as a potential, non-invasive biomarker 
(Pardo, Garcia et al. 2006). Wang et al. recently used a combination of stable isotope 
labelling with amino acids in culture (SILAC) and two-dimensional liquid 
chromatography tandem mass spectrometry (2-D LC-MS/MS) to assess proteomic 
changes in 92.1 uveal melanoma cell lines following exposure to radiation. The 
study illustrated a number of proteins which were associated with cell suspension 
induced by irradiation, such as those associated with cell cycle regulation, DNA 
replication, cell growth and senescence. From this they identified the 
downregulation of S100A11, PHB1, PHB2, and TPI1, and upregulation of HSP-27. 
However the combination of SILAC and 2-D LC-MS/MS was not conducive to 
smaller, lower abundant proteins as they were often masked by more numerous, high 
abundant proteins (Wang, Bing et al. 2013). Yan et al. also combined SILAC and 
MS/MS for the analysis of irradiated uveal melanoma cell lines and identified 29 
proteins which correlated with cell survival, cell cycle arrest and growth inhibition 
(Yan, Shi et al. 2013).  
Although cell culture-based studies are a useful method for initial proteomic analysis 
and may identify markers of disease, these markers may not always occur in the 
same pattern as they would in their natural biological setting. Therefore, pure cell 
culture-based studies do not consistently bear an accurate representation of the 
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disease. Using uveal melanoma cell lines; UM-A, SP6.5, UW-1, 92.1, OCM-1, and 
one-dimensional (1-D) electrophoresis combined with MS, Pardo et al. identified a 
number of secreted proteins. From this, they used autoantibodies to verify 15 
secreted proteins which induced a humoral response in the serum of cancer patients. 
Using 2-D DIGE, 61 differentially-expressed proteins were found between control 
and uveal melanoma sample sets, with 38 of these being identified. However, none 
of the secreted proteins were found in this analysis (Pardo, Garcia et al. 2006). It 
may be useful to follow-up clinical specimen research, such as in serum, tissue or 
vitreous fluid, with cell culture studies, thereby identifying a potential target by one 
method and validating it by the other.  
Therefore, a number of studies have used clinical specimens for the discovery of 
biomarker in uveal melanoma. Coupland et al. examined primary uveal melanoma 
tumour tissue from monosomy three and disomy three specimens using 2-D gel 
electrophoresis and western blot validation for the identification of heat shock 
protein 27 (HSP-27), vimentin, and pyruvate dehydrogenase beta (PDHB) as being 
differentially expressed between the sample sets. They correlated the 
downregulation of HSP-27 expression with monosomy three status and hence, 
metastatic mortality (Coupland, Vorum et al. 2010). Our group also conducted a 
proteomic analysis of primary tumour tissue looking at the differential expression of 
proteins between primary tumours which subsequently metastasised and those which 
did not. From this study, we identified triosephosphate isomerase (TPI1) and fatty 
acid binding protein 3 (FABP3) to be upregulated in those which metastasised, and 
showed that they played a vital role in the invasion and migration of uveal 
melanoma cells (Linge, Kennedy et al. 2012). The results of this work are outlined 
in chapter three. 
A small number of proteins have been suggested as potential biomarkers for uveal 
melanoma but to-date none have been followed-up in a clinical setting or as a 
potential target VEGF has been identified as a potential marker of disease 
progression and metastasis in uveal melanoma as it was found to be significantly 
overexpressed in primary tumour tissue, and in serum following the development of 
secondary neoplasms, in both murine models and patient samples (Notting, 
Missotten et al. 2006, Barak, Pe'er et al. 2011, Crosby, Yang et al. 2011). 
Correlations between VEGF, C-X-C motif chemokine receptor 4 (CXCR4) and its 
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ligand, C-X-C chemokine ligand 12 (CXCL12) have also been noted. The cross-talk 
between these three proteins insinuates a role in uveal melanoma metastasis (Franco, 
Botti et al. 2010). As malignant cells are CXCR4-positive and solely bind to 
CXCL12, this mono-axis has been implicated in guiding cells to specific CXCL12-
producing organs, such as the liver. In addition to this, inhibition of the axis has been 
shown to repress the metastatic process (Bakalian, Marshall et al. 2008). Coupland 
et al. illustrated that cyclin D1, as determined by immunohistochemical analysis of 
95 enucleated eyes, is a marker for aggressive uveal melanoma (Coupland, 
Anastassiou et al. 2000). Lack of IGF-1 expression has been associated with uveal 
melanoma metastasis and was examined by Frenkel et al. when serum from healthy, 
disease-free subjects, and metastatic uveal melanoma patients serum was compared 
using enzyme-linked immunosorbent assays (ELISA). The study illustrated that 
IGF-1 levels decrease along the progression to metastasis with the highest 
expression of IGF-1 being associated with healthy serum and the lowest with 
metastatic melanoma (Frenkel, Zloto et al. 2013). They postulated that this may be 
due to the fact that IGF-1R has been reported to be highly overexpressed in liver 
metastases and as the secondary tumour grows, more IGF-1, which is produced in 
the liver, binds. Therefore, once IGF-1 binds to its receptor, less circulating ligand is 
available. It has also been suggested that IGF-1R may have a chemoattractant role in 
establishing liver metastases. This implies that IGF-1 could be used as a predictive 
biomarker for liver metastases in uveal melanoma, when continuously measured 
(Economou, Andersson et al. 2008, Frenkel, Zloto et al. 2013). Other protein 
expression patterns have been implicated with preferential spread of uveal 
melanoma to the liver such as the down-regulation of hepatocyte growth factor 
(HGF) and up-regulation of c-MET, its receptor. This may be a similar scenario to 
IGF-1/IGF-1R but research suggests that IGF-1R has a more significant prognostic 
value than that of c-MET (Mallikarjuna, Pushparaj et al. 2007, Bakalian, Marshall et 
al. 2008, Abdel-Rahman, Boru et al. 2010).  
The identification of proteins which indicate the prognosis of a tumour could 
improve our understanding of the biology of the metastatic disease, and could 
possibly lead to the discovery of a therapeutic target against which a rational therapy 
may be designed. Biomarkers, in conjunction with genetic information, may also 
help in a clinical setting when monitoring patients who are at risk of metastasis. 
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However, the search for potential targets is hindered by the relatively small sample 
numbers available for study, due to the rarity of the disease. Larger studies are 
needed to improve the statistical power of biomarker identification and validation in 
uveal melanoma. The uveal melanoma tumour tissue acquired is often a very small 
specimen, which also limits proteomic research. 
 
Table 1.1 Summary of all uveal melanoma proteomic studies carried out to-date.  
 
1.3 Vitreous Fluid 
Vitreous humour is a hydrogel-like substance which makes up approximately 80% 
of the eyeball volume (Grus, Joachim et al. 2007). The vitreous can be a useful tool 
for analysing pathophysiological events which take place within the orbit of the eye, 
such as in the case of diabetic retinopathy, and may contain valuable proteomic 
information (Simo-Servat, Hernandez et al. 2012). In recent years, ocular fluids have 
been more frequently examined on a proteomic-level. This is mainly due to 
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advances in protein analysis in areas such as MS, which measures the mass to charge 
ratio of a molecule, and multiplexing methods. Such advances allow us to better 
understand major ocular diseases, such as diabetic retinopathy, as they can be 
associated with pathological concentrations of many proteins within the aqueous and 
vitreous humour (Pollreisz, Funk et al. 2013).  
 
1.3.1 Vitreous Fluid  Sample Preparation 
There are many challenges in using vitreous fluid for proteomic analysis, such as 
contaminating the specimen by rupturing of the blood retina barrier (BRB) or 
varying protein concentration of samples. The BRB can easily be damaged during 
sample collection or rupture as a side-effect of the disease and would result in an 
influx of serum proteins such as serum albumin, therefore contaminating the 
specimen with other biological fluids (Simo-Servat, Hernandez et al. 2012). Vitreous 
humour can vary in its protein concentration between control and disease specimens, 
see Figure 1.2, but also within groups of samples from the same condition (Shitama, 
Hayashi et al. 2008).  In addition to the above, the volume of sample acquired can 
often also be low, which can hinder experiments requiring a significant protein 
concentration.  
 
 
Figure 1.2 Illustration of the variation in protein concentration between control 
(collected from patients with benign disease or from a healthy post-mortem donor) 
vitreous and vitreous samples taken from patients with various forms of retinopathy; 
Non-proliferative diabetic retinopathy (NPDR), Proliferative diabetic retinopathy 
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(PDR), Rhegmatogenous retinal detachment (RRD), Proliferative vitreoretinopathy 
(PVR) (Shitama, Hayashi et al. 2008). 
Typically, the proteomics workflow of vitreous humour analysis is a multi-step 
process. It begins with appropriate collection of approximately 1-3 mL of fluid, 
depending on the underlying condition. Any haemorrhaging must be taken into 
account during collection as this can affect later analysis. The preservation of the 
biological nature of the specimen is of paramount importance and hence it must be 
protected against proteolytic degradation, preferably by snap freezing and storage at 
-80°C. The high viscosity of vitreous samples can hinder sample manipulation, for 
example during pipetting, hence it is necessary to centrifuge the samples at high-
speed prior to experimental use (Angi, Kalirai et al. 2012).  
Vitreous from patients with macular hole or macular epiretinal membrane are often 
used as controls as vitreous fluid cannot be collected from healthy eyes. Ocular fluid 
can only be collected during surgery, such as vitrectomy, or enucleation (Grus, 
Joachim et al. 2007, Wang, Feng et al. 2012).  
The gel-like consistency of the fluid is mainly due to the hydrated network of fibular 
macro-molecules, such as proteoglycans and collagen fibrils, however the majority 
of vitreous fluid is composed of high abundance proteins such as albumin, 
immunoglobulin G (IgG) and apolipoproteins. Hence, it is similar to serum in 
composition (Feener 2012). Therefore, the viscosity and proteomic nature of 
vitreous make sample pre-treatment a necessary step (Thierauf, Musshoff et al. 
2009).  
Pre-treatment, such as immunoaffinity subtraction (Section 1.6.1) can be used in 
order to promote the detection of less abundant proteins in later experiments 
(Pollreisz, Funk et al. 2013). Immunodepletion may involve removing one or more 
prominent high molecular weight proteins and is compatible with all downstream 
applications, but it has been shown to produce the best spectrum of results when 
used with LC-MS/MS (Smith, Wood et al. 2011). However, it is also possible that 
by removing many of the high abundance proteins, the protein concentration will be 
severely decreased and thus inadequate for research. Kim et al. speculated that this 
could be due to the fact that the majority of the vitreous fluid proteome is composed 
of high abundance proteins, to which low abundance proteins may be bound. Hence, 
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some low abundance proteins can be removed along with the depleted proteins 
(Kim, Kim et al. 2007). ProteoMiner, a protein equalising technology, allows for the 
simultaneous depletion of high abundance proteins and concentration of low 
abundance proteins may be a better option (Section 1.6.1). 
 
1.3.2 Proteomic Fractionation and Analysis of Vitreous Fluid 
Despite pre-treating vitreous specimens, due to the complexity of the proteome, 
further fractionation is often required in order to gain a comprehensive view of all 
proteins in the specimen, particularly low abundant proteins. This may be done using 
protein fractionation methods which separate all proteins present and hence allow 
access to the entire proteome. Following this, the entire proteome would be digested 
into peptides, which are then fractionated and identified by MS. This is known as 
“shotgun proteomics” and is useful for gaining quantitative information (Angi, 
Kalirai et al. 2012).   
1-D electrophoresis can be used as a basic fractionation method whereby proteins 
are separated based on their size. 2-D electrophoresis is a useful gel-based method 
for separating proteins based on both their mass and charge through the combination 
of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
isoelectric focusing to generate a “spot map” of proteins of interest. This technique 
is described in more detail in section 1.6.3. Protein gels are visualised using staining 
methods such as fluorescent dyes which have high a dynamic range and sensitivity, 
e.g. SYPRO Ruby, or a global protein stain such as colloidal silver stain or 
Coomassie Brilliant Blue. Stained protein spots can then be excised from the gel and 
directly compared to those of another gel in the same region for their protein content 
following peptide fractionation and identification. Using vitreous fluid, Ouchi et al. 
identified 6 proteins as being differentially regulated between patients with and 
without diabetic macular oedema (DMO) using 2-D electrophoresis and optical 
density analysis of protein spots (Ouchi, West et al. 2005). 2-D DIGE (2-
Dimensional Difference Gel Electrophoresis), is one of the most sensitive staining 
methods available for 2-D electrophoresis, and continues to be the method of choice 
for differential protein expression analysis in vitreous fluid (Kim, Kim et al. 2007, 
Wang, Feng et al. 2012, Hernandez, Garcia-Ramirez et al. 2013). Using DIGE, 
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Hernandez et al. identified four proteins as being exclusively associated with DMO, 
when 8 control vitreous were compared to 8 DMO vitreous; four with proliferative 
diabetic retinopathy (PDR) and four without. All targets were subsequently validated 
using ELISA. They concluded that DIGE proved to be an accurate method for 
making quantitative comparisons and allowed for the identification of new 
candidates in DMO pathogenesis (Hernandez, Garcia-Ramirez et al. 2013). 
Proteins of interest are ultimately identified using MS. This process is described in 
more detail in section 1.6.4. In terms of vitreous fluid analysis, Kim et al. utilised 
both 2-D electrophoresis and LC-MS/MS for the analysis of the same vitreous fluid 
sample set and identified 49 and 531 proteins, respectively. This illustrates the 
power of new proteomics technologies and how the quality of results generated from 
a sample may be dependent in the technology used (Kim, Kim et al. 2007, Angi, 
Kalirai et al. 2012). Quantitative label-free proteomics is also being more commonly 
used for vitreous fluid analysis. Hauck et al. used quantitative LC-MS/MS in 
combination with pathway analysis for the identification of two proteins which led 
to the discovery of retinal Müeller glial cells involved in autoimmune triggers of 
uveitis (Hauck, Hofmaier et al. 2012). 1-D SDS-PAGE has also proved useful when 
utilised in conjunction with reverse-phase LC-MS/MS. Yu et al. used both 
techniques for the characterisation of the vitreous proteome in rhegmatogenous 
retinal detatchment (RRD) patients with Proliferative vitreoretinopathy (PVR) and 
identified 516 proteins. (Yu, Peng et al. 2012).  
 
1.3.3 Clinical Significance of Analysis of the Vitreous Fluid Proteome 
Variations in protein composition occur within the vitreous. For example, in the 
proximity of the cortex, collagen isoforms are significantly more concentrated than 
in the central vitreous. Such extracellular matrix proteins provide a framework for 
the binding of molecules and soluble proteins, hence influencing biochemical 
transport within the eye. This compartmentalisation of proteins also suggests that 
soluble proteins are heterogeneously distributed within the fluid. This extracellular 
network allows for the diffusion of proteins between the vitreous and its surrounding 
tissues, such as the retina and it is in this regard that the vitreous can be seen as a 
hub of biochemical indicators representative of the surrounding environment since it 
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is directly impacted by ongoing disease related events (Feener 2012). Therefore, the 
vitreous is most interesting to analyse when it is close to the site of damage or 
disease, for example in the case of uveal melanoma or DMO (Grus, Joachim et al. 
2007). 
Proteins relating to both proliferative and non-proliferative diabetic retinopathy have 
been studied in the vitreous. Diabetic retinopathy is a progressive disease caused by 
chronic exposure to hyperglycaemia and is the main cause of vision loss in adults in 
the developed world. Many proteomic studies have been carried out in the vitreous 
for the development of a therapeutic target. The disease can be divided into 
proliferative and non-proliferative retinopathy, depending on the stage of disease. In 
addition to this, DMO can occur which involves the breakdown of the BRB, hence 
leading to visual impairment (Ouchi, West et al. 2005, Wang, Feng et al. 2013). 
Wang et al. used reverse-phase HPLC coupled to ESI-MS/MS for the quantitative 
analysis of the vitreous proteome in PDR patients. They identified 96 proteins which 
were differentially expressed between PDR and control vitreous, with many of these 
proteins being correlated to pathways such as glycolysis/gluconeogenesis and 
complement and coagulation cascades. Using label-free quantification proteomics 
methods, they identified a total of 62 proteins which were not yet associated with 
PDR (Wang, Feng et al. 2013). Other studies attempting to understand the basis of 
PDR and DMO through the proteomic analysis of the vitreous have also recently 
been carried out; with MS-based methods being used more frequently (Gao, Chen et 
al. 2008, Hernandez, Garcia-Ramirez et al. 2010). In spite of this, 2-D 
electrophoresis methods are still relevant and are commonly used (Garcia-Ramirez, 
Canals et al. 2007, Wang, Feng et al. 2012).  
Uveitis is an inflammatory disease of the uveal tract which is poorly understood and, 
as there is no therapy available, can lead to loss of vision (Turgut, Gul et al. 2013). 
Proteomic analysis of the vitreous fluid has been carried out in equine models in 
order to better understand the disease in both horses and humans. Using label-free 
LC-MS/MS quantification followed by pathway analysis, they identified a number 
of human and equine shared auto-antigens, including cellular retinaldehyde-binding 
protein (CRALBP), involved in autoimmune uveitis and found that the Wnt signal 
transduction pathway was highly involved in pathogenesis of uveitis (Hauck, 
Hofmaier et al. 2012). Turgut et al. used ELISA for the analysis of potential uveitis 
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treatments using vitreous fluid, identifying IL-1, IL-6 and TNF-α as all being 
upregulated in murine uveitis models despite treatment with gherlin (Turgut, Gul et 
al. 2013). 
 
1.4 Cutaneous Melanoma 
Cutaneous melanoma is a cancer which affects skin melanocytes. Despite 
accounting for only 4% of all skin cancer cases, it is the form of skin cancer which 
has the highest death toll in the USA and Europe (Ugurel, Utikal et al. 2009). The 
rate of incidence of melanoma is rising; in stark contrast to many other cancers. In 
the USA in 1935, the lifetime risk of developing the cancer was 1 in 1,500. It has 
now risen to 1 in 68, despite improved patient awareness and better surveillance 
(Balch, Buzaid et al. 2001, Siegel, Naishadham et al. 2013). However,  melanoma 
has been traditionally known as being difficult to treat, mainly due to the large 
number of patients who are resistant to immune therapy as well as chemotherapy 
(Mehnert and Kluger 2012). In addition to this, malignant melanoma often exhibits 
unpredictable behaviour. For example, many patients with significant vertical 
growth remain metastasis-free while some patients with thin die as a result of their 
disease (Torabian and Kashani-Sabet 2005). Therefore, a more thorough 
understanding of the pathways of cutaneous melanoma is critical for the 
development of predictive biomarkers.  
 
1.4.1 Cutaneous Melanoma Staging 
Primary cutaneous melanomas are characterised by horizontal growth within the 
epidermis only. However, the malignancies can become more aggressive which 
leads to rapid growth and invasion of the dermis. Later stages of the disease are 
associated with rapid invasion and metastasis of tissues other than the dermis. When 
melanoma is detected and treated prior to the development of lymph node 
metastasis, the five-year survival rate is 99%, however, the five-year survival rate 
for distant stage melanoma patients is approximately 15% (Al-Ghoul, Bruck et al. 
2008).  
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Cutaneous melanoma is staged by the TNM system devised by the American Joint 
Committee on Cancer (AJCC). This determines how widespread the cancer is by 
taking into account the status of three main criteria; tumour, lymph nodes, and 
metastasis (TNM) using both clinical staging and pathologic staining.  
The tumour category (T) is defined by thickness, ulceration and mitotic rate. Using 
Breslow measurement, the thickness of a melanoma is determined. The 
extensiveness of tumour infiltration is defined by a number ranging from 0 to 4 and 
ulceration and mitotic rate, i.e. the rate of cell proliferation, defined by a letter; a or 
b. Melanomas which have a higher mitotic rate and are ulcerated tend to have a 
poorer prognosis. (Balch, Gershenwald et al. 2009, http://www.cancer.org/ 2013).  
Lymph node (N) involvement is decided by spread of the malignancy to nearby 
nodes or lymphatic channels attached and is designated a number from 0 to 3, 
depending on the degree of melanoma spread in the lymphatic system. As sentinal 
lymph node biopsies are now considered to be necessary for the staging of 
microscopic nodal metastases, a letter, a, b, or c, which is based on pathological 
staining of lymph node tissue can also be assigned. This spread may also be 
macroscopic or simply composed of satellite tumours which are close to but have 
not yet reached the lymph nodes (Balch, Gershenwald et al. 2009).  
Finally, the M category is defined by spread, or metastasis, of the cancer to distant 
organs and blood levels of lactate dehydrogenase (LDH) found in such organs. 
Levels of LDH are now taken into account as a prognostic value for stage IV 
patients. Indeed, LDH measurements now appear to act as an independent and 
significant indicator of survival outcome in advanced stage patients. This is further 
discussed in section 1.4.3. Unfortunately, melanoma can spread to virtually any site 
in the body which can make detection and diagnosis of metastases both time-
consuming and challenging. It most commonly spreads to regions such as the lungs, 
abdomen, pelvis and the brain (Davies, Liu et al. 2011, Kedinger, Meulle et al. 2013, 
Trout, Rabinowitz et al. 2013). The spread of melanoma to the brain is often most 
indicative of poor outcome as 54% of all melanoma deaths are due to the presence of 
brain metastases (Davies, Liu et al. 2011).  
The result from each category is then combined to give an overall TNM stage (Table 
1.2). 
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Table 1. Anatomic Stage Groupings for Cutaneous Melanoma 
 Clinical Staging  Pathological Staging 
 T N M  T N M 
0 Tis N0 M0 0 Tis N0 M0 
IA T1a N0 M0 IA T1a N0 M0 
IB T1b N0 M0 IB T1b N0 M0 
 T2a N0 M0  T2a N0 M0 
IIA T2b N0 M0 IIA T2b N0 M0 
 T3a N0 M0  T3a N0 M0 
IIB T3b N0 M0 IIB T3b N0 M0 
 T4a N0 M0  T4a N0 M0 
IIC T4b N0 M0 IIC T4b N0 M0 
III Any T N > N0 M0 IIIA T1-4a N1a M0 
     T1-4a N2a M0 
    IIIB T1-4b N1a M0 
     T1-4b N2a M0 
     T1-4a N1b M0 
     T1-4a N2b M0 
     T1-4a N2c M0 
    IIIC T1-4b N1b M0 
     T1-4b N2b M0 
     T1-4b N2c M0 
     Any T N3 M0 
IV Any T Any N M1 IV Any T Any N M1 
 
 
 
1.4.2 Pathogenesis of Cutaneous Melanoma 
Many genetic studies have been carried out on malignant melanoma. Some of the 
best characterised mutations and epigenetic changes have involved the receptor 
tyrosine kinase (RTK) pathway.   
V-raf murine sarcoma viral oncogene homolog B1 (BRAF) was the first commonly 
occurring somatic mutation identified in cutaneous melanoma (Davies, Bignell et al. 
2002). BRAF is a cytoplasmic serine/threonine kinase of the RAS-RAF-MEK-ERK-
Table 1.2 Anatomic Stage Groupings for Cutaneous Melanoma. As adapted 
from Balch, Gershenwald et al. 2009. 
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MAP kinase pathway, a cascade which is responsible for cellular responses to 
growth signalling. RAS is responsible for the regulation of BRAF however, in 
approximately 15% of cancers RAS is mutated into an oncogenic form. 66% of 
melanomas contain a single mutation, valine is substituted for glutamic acid at 
position 600, associated with BRAF. When BRAF
V600E
 is expressed in melanoma cell 
lines, the MAPK pathway is hyperstimulated which leads to malignant cellular 
transformation (Davies, Bignell et al. 2002, Jakob, Bassett et al. 2012, Mehnert and 
Kluger 2012). It has been illustrated that BRAF mutations more commonly develop 
in skin which is intermittently exposed to sun exposure than in unexposed regions 
such as palms, soles and mucosal membranes. It has also been found that such 
mutations do not occur in melanomas on chronically sun-damaged skin (Maldonado, 
Fridlyand et al. 2003). BRAF mutations appear to occur early on in the development 
of melanoma as benign nevi contain a high number of such mutations. Both early 
stage melanocytic lesions and metastatic lesions also seem to harbour a similar 
number of BRAF mutations (Mehnert and Kluger 2012). It is also notable that 
patients treated with BRAF inhibitors had a better prognosis than those who were 
not, indicating the significance of BRAF activation throughout the disease, despite 
its mutation being an early event (Davies, Liu et al. 2011).  
Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) is a member of the 
RAS family which includes HRAS and KRAS, and is central to the development of 
the malignant phenotype. NRAS codes for a guanine triphosphate (GTP)-binding 
protein and once mutated can constitutively activate the downstream RAS-RAF-
MEK-MAPK pathway via exclusive point mutations found primarily on codon 61, 
but also on codon 12 and 13. NRAS is mutated in 15-20% of melanomas, making it 
the second most commonly mutated gene in cutaneous melanoma (Aguissa-Toure 
and Li 2012, Jakob, Bassett et al. 2012, Posch and Ortiz-Urda 2013). Interestingly, 
most melanomas have either a BRAF
V600E
 or an NRAS mutation but not both 
(Banerji, Affolter et al. 2008, Jakob, Bassett et al. 2012). It has been found that the 
incidence of either BRAF or NRAS may be due to differences in histological type and 
tumour site, based on the extent of sun exposure. BRAF mutations typically occur in 
patients with superficial spreading melanoma, in skin which has not been chronically 
sun damaged. In contrast, NRAS mutations are found in patients with nodular 
melanoma and have been correlated to continuous ultraviolet (UV) light exposure as 
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it is suggested that sunlight acts as a mutagenic agent in the development of NRAS 
anomalies (van 't Veer, Burgering et al. 1989, Lee, Choi et al. 2011). NRAS 
mutations are associated with a higher rate of metastasis to the central nervous 
system (CNS) in comparison to the wild type counterpart and have been identified as 
a potential, independent indicator of poor prognosis following diagnosis of advanced 
melanoma (Jakob, Bassett et al. 2012). 
PTEN is one of the most commonly inactivated tumour suppressor genes in sporadic 
cancers and has been detected in a wide spectrum of cancers including, breast, 
thyroid and prostate. It occurs at a frequency of 30-40% in melanoma cell lines and 
at 10% in primary melanomas. PTEN protein has both lipid and protein phosphatase 
activity and is necessary for cell-cycle regulation (Aguissa-Toure and Li 2012). It 
has also been suggested that it may inhibit tumorgenicity and metastasis through the 
regulation of matrix metalloproteases (MMP), insulin-like growth factor (IGF) and 
VEGF expression (Hwang, Yi et al. 2001). Loss of PTEN function results in 
aberrant cell growth, uncontrolled migration and lack of apoptosis. It appears to 
explain many phenotypic hallmarks of melanoma, although, PTEN mutation is also 
associated with other genetic changes which clouds our understanding of its role. 
Loss of function of PTEN occurs later on in melanoma progression but may be 
implicated in early-stage tumorigenesis (Palmieri, Capone et al. 2009, Aguissa-
Toure and Li 2012). In addition to this, mutations of PTEN are often linked with 
other melanoma-associated mutated genes, such as Cyclin-Dependent Kinase 
Inhibitor 2A (CDKN2A) and BRAF; loss of CDKN2A may work in cooperation with 
PTEN in relation to tumorigenesis, and PTEN is involved in the inhibition of 
growth-factor stimulated MAPK signalling which can cause a knock-on effect on the 
BRAF-MAPK pathway (Palmieri, Capone et al. 2009). 
CDKN2A has been found to be mutated in a variety of cancers, including familial 
melanoma where germline mutations occur. The gene, which is located on 
chromosome 9p21, encodes for p14 and p16. p14 has an anti-proliferative function 
through the regulation of the cell cycle at G1/G2 transition stage. p16 is a cyclin-
dependent kinase inhibitor necessary in the regulation of G1/S phase through the 
inhibition of cyclin-dependent kinase D (CDK). Mutated p16 is unable to interact 
with CDK4, thus preventing the regulation of cell cycle arrest, allowing for the 
uncontrolled progression through the cell cycle and aiding in the development of 
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neoplastic transformation. CDKN2A is frequently mutated or deleted in tumour cells, 
which suggests the role of p16 as a tumour suppressor (Mehnert and Kluger 2012, 
Szponar-Bojda, Pietrzak et al. 2012). Familial melanoma as a result of CDK4 
germline mutations has been observed, which is associated with the subsequent 
development of additional malignancies such as pancreatic cancer (Goldstein, 
Struewing et al. 2000). Sporadic melanoma has also occurred as a result of somatic 
mutations in p16 and CDK4 (Gast, Scherer et al. 2010). 
Chromosomal aberrations are found throughout melanoma, each of which are often 
correlated with a particular outcome due to the associated genes present on each 
chromosome. LOH has been reported at frequency of 47% in chromosome arm 9p 
and is known to occur prior to the loss of other chromosome arms. LOH of 
chromosome regions 3p, 6q, 10q, 11q, and 17p have also been described as regularly 
occurring. Of these LOH of 6q, 11q and 17 p are associated with invasiveness 
(Healy, Rehman et al. 1995). 
Fountain et al. were the first to convincingly associate aberrations of chromosome 
10 with melanoma (Fountain, Bale et al. 1990). Both chromosomes 9 and 10 have 
been found to be most interesting, despite other chromosomes being more regularly 
altered, due to their singularity in early irregularities and dysplastic lesions. LOH of 
chromosome 10q in particular has been commonly identified as a feature of 
melanoma as it is found to occur at a frequency of 30-50%. Due to the presence of a 
number of tumour suppressor genes on chromosome 10q, such as PTEN, its loss is 
associated with tumour progression (Herbst, Weiss et al. 1994, Aguissa-Toure and 
Li 2012). 
 
1.4.3 Current Protein Biomarkers for Cutaneous Melanoma 
To date, few protein biomarkers have been identified as prognostic indicators of 
cutaneous melanoma and even less are used in the clinic as tools for diagnosis or 
prognosis.  
LDH has been extensively studied in melanoma patient serum for nearly 60 years. It 
has been identified as an initial marker of disease recurrence in 12.5% of stage II 
patients, and has shown sensitivity and specificity values of 72% and 97%. In 
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relation to liver metastases, it was found to have sensitivity and specificity of 95% 
and 82% in the stage II group and 86% and 57% in the stage III group (Finck, 
Giuliano et al. 1983). Serum LDH has also been associated with the presence of 
extra- and intracranial metastases and the overall survival as a result of such (Partl, 
Richtig et al. 2013). In addition to this, elevated LDH has been reported to be 
associated with decreased survival, regardless of the presence or absence of liver 
metastases (Finck, Giuliano et al. 1983). Due to the strong correlation between 
increased serum LDH concentration and diminished survival following multivariate 
analysis, the AJCC has decided to include LDH in its cutaneous melanoma staging 
system as a factor used to delineate the M categories into three groups (Balch, 
Buzaid et al. 2001). 
S100 calcium binding protein B (S100B) is a calcium-binding protein, which was 
first described in melanoma cell cultures and is now a well-used marker for 
pigmented lesions of the skin (Gogas, Eggermont et al. 2009). Despite extensive 
research, the function of S100B is not yet fully understood. As it is known to interact 
with the p53 tumour suppressor gene, it is thought that it may have a prominent role 
in cutaneous melanoma pathogenesis (Vereecken, Cornelis et al. 2012). It is highly 
abundant in neuronal tissue and can be measured in the cerebrospinal fluid (CSF) or 
the blood; for example, it is found to be elevated in the blood following brain trauma 
(Astrand, Unden et al. 2013). S100B is also significantly overexpressed in malignant 
melanoma serum (Astrand, Unden et al. 2013). The clinical significance of S100B in 
monitoring and staging was first identified when its levels in serum were directly 
proportional to disease progression. As well as this, a decline in S100B expression 
correlated with response to treatment (Guo, Stoffel-Wagner et al. 1995). Other such 
studies have reaffirmed this observation, describing S100B as an indicator of poor 
prognosis and in some cases, as an indicator of metastasis (Zissimopoulos, 
Karpouzis et al. 2006, Mocellin, Zavagno et al. 2008). Serum S100B protein has 
been shown to be more effective than LDH in predicting prognosis and response to 
treatment for patients with advanced melanoma and it has been suggested that it 
should be used as part of the AJCC staging system (Torabian and Kashani-Sabet 
2005, Egberts, Pollex et al. 2008). In fact, Switzerland and Germany both 
recommend measuring serum S100B every 3-6 months in patients with a tumour 
thickness of less than 1 mm (Gogas, Eggermont et al. 2009). Despite its 
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effectiveness as an advanced stage marker of prognosis, S100B has been found to be 
limited in its determination of prognosis in early stages, i.e. stages I and II. Also, 
S100B is not melanoma specific and can be over-expressed in other disorders such 
as AIDS, non-melanoma skin cancer, liver and renal injury, central nervous system 
cancers and various inflammatory conditions (Peric, Zagar et al. 2011, Vereecken, 
Cornelis et al. 2012). 
Melanoma inhibitory activity (MIA) is a low-molecular weight autocrine growth 
inhibitor which has multiple roles including regulation of cell growth and cell 
adhesion (Vereecken, Cornelis et al. 2012). It was initially found to be over-
expressed in malignant melanoma cells in vitro but not in benign skin melanocytes 
or benign melanocytic nevi. In malignant tumour tissue, MIA messenger RNA 
(mRNA) was detected at elevated levels in 100% of malignant melanoma samples, 
and when compared to normal skin, benign human skin melanocytes, benign 
melanocytic nevi, and malignant melanomas, MIA mRNA levels mirrored the 
progressive malignancy of the lesions (Bosserhoff, Kaufmann et al. 1997). The 
comparison of early stage patient sera to advanced stage sera, illustrated that MIA 
was up-regulated in 13% and 23% of stage I and II patients, respectively, in 
comparison to 100% of those with stage III and IV disease. Any patients who 
expressed MIA at a normal level did not develop metastases in the follow-up period 
of 6-12 months (Bosserhoff, Kaufmann et al. 1997). Other studies have correlated 
MIA with the development of metastases and suggest that it could be useful as a 
serum marker for the detection of secondary malignancies (Stahlecker, Gauger et al. 
2000). Despite this, MIA has been described as a less reliable tumour marker in 
comparison to S100B or S100B in combination with LDH (Krahn, Kaskel et al. 
2001). It has also been suggested that MIA, when added to combinations of other 
markers, does not improve the overall efficacy of stage III – IV detection (Garnier, 
Letellier et al. 2007).  
Better prognostic and predictive markers in cutaneous melanoma are sorely needed, 
but to date have been elusive. The experimental work detailed here was intended to 
further understand the cutaneous melanoma serum proteome over the course of 
disease progression. Therefore, this work could lead to the development of a 
prognostic test which could easily be used in a clinical setting and could also 
potentially lead to the discovery of a therapeutic target in cutaneous melanoma.  
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1.4.4 Clinical Treatment Options for Cutaneous Melanoma 
Prior to 2011, the treatment options for metastatic melanoma were limited; 
chemotherapy and high-dose interleukin-2 (HDIL-2) were the only approved options 
(Burgeiro, Mollinedo et al. 2013). Due to the high rate of resistance to such 
treatment, the efficacy of chemotherapy was poor. HDIL-2 was also a limited 
therapy as most patients were ineligible for treatment due to a high, associated 
toxicity. As well as this, patient response rates are low. Treatment using other 
conventional methods, such as radiotherapy and immunotherapy, failed due to 
significant resistance (Burgeiro, Mollinedo et al. 2013, Salama 2013). In recent 
years, a number of advances have been made in better understanding immune 
regulation and driver mutations in melanoma which have driven the development of 
new therapies which, according to stage III clinical trials, demonstrate an overall 
survival benefit in metastatic melanoma patients (Salama 2013). 
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a modulator of the 
immune system whose protein expression is induced through the interaction between 
a T-cell receptor (TCR) and an antigen. CTLA-4 suppresses T-cell activation by 
recruiting tyrosine and serine or threonine phosphatases and outcompeting CD28; a 
co-stimulatory receptor which binds the same ligands in order to induce signalling 
cascades related to proliferation, cytokine secretion, metabolism and apoptosis 
(Melero, Hervas-Stubbs et al. 2007). Ipilimumab is a humanised, IgG1 monoclonal 
antibody which blocks CTLA-4 in order to induce an anti-tumour immune response 
and reduce tolerance to tumour-associated antigens (Burgeiro, Mollinedo et al. 
2013). It has successfully been used in the treatment of other cancers such as ovarian 
carcinoma and metastatic renal cell cancer (Hodi, Mihm et al. 2003, Yang, Hughes 
et al. 2007). Ipilimumab was the first therapy to improve overall survival in phase III 
randomised controlled trials in previously treated metastatic melanoma patients both 
in combination with experimental vaccine glycoprotein 100 (gp100) and without. It 
was found that ipilimumab decreased the risk of death by 32-34%, leading to FDA 
approval in 2011 for unresectable or metastatic melanoma (Hodi, O'Day et al. 2010, 
Salama 2013). These findings have also been confirmed in untreated patients, 
regardless of the presence of other prognostic factors such as serum LDH level. In 
addition to this, the inclusion of dacarbazine in ipilimumab treatment decreased the 
chance of death by 28% in comparison to chemotherapy alone and improved the 
37 
 
median overall survival by 2.1 months (Robert, Thomas et al. 2011). Recently, 
chemotherapy in combination with ipilimumab has been tested illustrating that no 
pharmacokinetic or pharmacodynamic interactions occur between the monoclonal 
antibody and paclitaxel, dacarbazine, or its metabolite, 5-aminoimidazole-4-
carboxamide (Weber, Hamid et al. 2013). As ipilimumab is an antibody, it is unable 
to cross the blood-brain barrier; however this may not be essential for it to exert anti-
tumour effects as it activates T-cells which can migrate into the CNS. A phase II 
trial has shown that 16.67% and 25% of patients with stable brain metastases who 
were treated with the agent showed a partial response or stable disease, respectively. 
The median overall survival of all ipilimumab-treated patients in the study was 14 
months. Further to this, a separate trial has taken place which illustrated the efficacy 
of combining ipilimumab and foretmustine, a chemotherapeutic drug which can 
penetrate the blood-brain barrier (Murrell and Board 2013). 
Programmed death-1 (PD-1), a member of the CD28 family, is an inhibitory co-
receptor expressed on antigen-activated T-lymphocytes, on antigen-specific T-
lymphocytes chronically exposed to antigen, and on B-lymphocytes. One of its 
ligands is B7-H1/PD-L1, the predominant mediator of PD-1 immunosuppression. 
Hence, tumours express PD-L1 as part of a mechanism to evade the immune system 
(Simeone and Ascierto 2012). The suppression of effector T-cell function through 
PD-1 interaction has been shown to prevent deletion/apoptosis, inhibition of 
proliferation, and production of cytokines. In conjunction with chronic antigen 
exposure, this results in T-cell exhaustion, hence, deeming PD-1 to be a potential 
target for the augmentation of the immune response (Fong and Small 2008). The 
anti-PD1 monoclonal antibody, nivolumab, is actively being examined for use as an 
immune activator; both on its own and in combination with Ipilimumab for 
enhancing its effectiveness (Gogas, Polyzos et al. 2013). 
Vemurafenib is an orally-administered, small molecule inhibitor of the BRAF
V600E 
mutation which has been shown to be highly effective in the treatment of cutaneous 
melanoma through the inhibition of unregulated cell growth. A phase III randomised 
clinical trial comparing vemurafenib to dacarbazine illustrated that metastatic 
melanoma patients treated with vemurafenib alone showed a reduction in the risk of 
death by 63% and a 74% reduction in the risk of disease progression. Response rates 
were 48% and 5% for vemurafenib and dacarbazine, respectively (Chapman, 
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Hauschild et al. 2011).  A study is currently ongoing to determine the efficacy of 
vemurafenib in treating melanoma patients who developed brain metastases 
(NCT01378975), however preliminary studies suggest that a synergistic 
combination of vemurafenib with radiation therapy appears to be a favourable 
method of treatment for  brain metastases with a median survival time of 13.7 
months observed (Narayana, Mathew et al. 2013, www.clinicaltrials.gov 2013). Up 
to 50% of patients respond to vemurafenib; however this response generally lasts 
only 6 months due to the emergence of resistance mechanisms (Coit and Olszanski 
2013). Despite the significant success of BRAF inhibitor treatment, a subset of 
patients has been found to develop resistance to the therapy following chronic 
treatment, despite an initial response. This is likely due to BRAF reactivation or 
number of mutations along the MAPK pathway, which is essential for tumour 
survival, thus inducing a bypass to BRAF inhibition. Villanueva et al. illustrated that 
upon chronic BRAF inhibition, melanoma cells can overcome the therapy by flexibly 
altering their signalling in order to exploit another RAF isoform, such as CRAF or 
ARAF, by an unknown mechanism. It has also been found that persistent BRAF 
inhibition in resistant cells is associated with enhanced IGF-1R and PI3K/AKT 
activity. Therefore, the targeting of both MEK and IGF-1R/PI3K using drug 
combinations may be a solution to overcome BRAF inhibitor resistance (Villanueva, 
Vultur et al. 2010).  
Dabrafenib is a small molecule inhibitor which also targets the V600E mutation of 
melanoma, although it works on a more general scale to vemurafenib, targeting both 
wild-type and mutant CRAF and BRAF. Data has also suggested that it is effective 
against the non-V600E BRAF mutation; V600 (Denton, Minthorn et al. 2013, 
Medina, Amaria et al. 2013).  In a recent stage III clinical trial, dabrafenib-treated 
patients reached a median progression-free survival of 5.1 months with an overall 
response rate of 50%, in comparison to dacarbazine-treated patients who reached 2.7 
months with an overall response rate of 6% (Huang, Karsy et al. 2013). However, 
the therapeutic use of dabrafenib has been associated with the development of 
squamous cell carcinoma (SCC) due to an upregulation of the MAPK pathway as a 
consequence of increased phosphorylated ERK in wild-type BRAF cells. Therefore, 
the use of dabrafenib in combination with a MEK inhibitor, such as trametinib, has 
been tested by King at al. They found that the two-pronged approach reduced the 
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occurrence of skin lesions in rats and enhanced the inhibition of tumour growth in 
human melanoma xenograft studies in mice. Clinical trials to test the combination 
therapy in melanoma patients are currently ongoing, however, data from a phase 1/2 
trial have illustrated an improvement in progression-free survival and a non-
significant reduction in the occurrence of skin lesions (King, Arnone et al. 2013). 
A summary of the targeted therapies for cutaneous melanoma mentioned above are 
shown in Table 1.3. 
 
Table 1.3 Summary of the most promising targeted therapies used in the systemic 
treatment of cutaneous melanoma.  
 
1.5 Comparing the Molecular Basis of Uveal and Cutaneous Melanomas 
Although cutaneous and uveal melanomas are of a similar embryonic origin, they 
notably differ in behaviour such as tumorigenesis, metastatic spread and therapeutic 
response. The differences between both melanomas are poorly understood, albeit, it 
is hoped that genetic and proteomic analyses of the nature of melanoma as a disease 
will aid us in understanding variations between both melanomas. 
Chromosomal aberrations transpire differently in both melanomas. Most frequently 
in uveal melanoma, loss of one or two copies of chromosome three occurs or the 
gain of chromosome 8q, however both anomalies can arise together. Monosomy 
three also occurs at a rate of 50% in uveal melanoma, but is rarely found in 
cutaneous melanoma (Hoglund, Gisselsson et al. 2004). Other modifications have 
been reported in uveal melanoma in relation to chromosome 1p36 where loss can 
occur in combination with monosomy three. This appears to indicate a poorer 
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prognosis than either factor occurring alone (Kilic, Naus et al. 2005). Loss of 
chromosome 1p is reported in 28% of uveal melanoma cases; however gain occurs 
more frequently at a rate of 33%. Gain of chromosome 6p occurs in both uveal and 
cutaneous melanoma. It is an indicator of low risk of metastasis in uveal melanoma 
and rarely occurs with monosomy three (van den Bosch, Kilic et al. 2010). 
Monosomy ten is the most frequent chromosomal aberration seen in cutaneous 
melanoma, at a rate of 60% of all cases. It also occurs in uveal melanoma, however 
at a less significant rate of 27% (van den Bosch, Kilic et al. 2010). 
There are a number of genetic mutations which mutually occur in both melanomas. 
Genetic mutations associated with either cutaneous or uveal melanoma and their 
relative frequencies are outlined in Table 1.4.  
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Proteomic similarities have been identified between the melanomas, such as CXCR4 
and its ligand, CXCL12. CXCR4 is known to activate processes such as chemotaxis, 
angiogenesis, and proliferation. In addition to this, its inhibition has been shown to 
inhibit metastasis. 41.4% and 43.4% of uveal melanoma cases illustrate an 
overexpression of CXCR4 and CXCL12, respectively, which are shown to correlate 
with disease progression (Franco, Botti et al. 2010). Similarly, an over-expression of 
CXCR4 and CXCL12 has been associated with high clinical risk in cutaneous 
melanoma, while their under-expression is associated with a better prognosis. 
However, both proteins have been found to be overexpressed in a number of 
neoplasms which suggests that they may be considered to be general biomarkers for 
Table 1.4 Frequency of Genetic Changes in uveal and cutaneous melanoma. 
Table 1.4 Frequency of Genetic Changes in uveal and cutaneous melanoma. 
*Rarely observed or sporadic reports in literature. *
1
 Observed in 83% of blue 
naevi. *
2
 Observed in 48% of iris melanomas. *
3
 Only melanomas arising in 
chronically sun-damaged skin, or acral and mucosal melanomas 
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cancer (Toyozawa, Kaminaka et al. 2012). Melanoma cell adhesion molecule 
(MCAM) has been correlated with poor outcome in uveal melanoma according to 
immunohistochemical analysis of primary uveal melanoma paraffin sections (Beutel, 
Wegner et al. 2009). In addition to this it has been identified as a significant 
independent variable within advanced stage cutaneous melanoma patients and as a 
marker of negative treatment outcome in 43% of non-surgically treated individuals 
with stage IV melanoma (Rapanotti, Ricozzi et al. 2013, Reid, Millward et al. 2013). 
IGF-1R is closely associated with cutaneous melanoma as an increase in its 
expression is related to the transition from benign to malignant nevi (Ucar, 
Kurenova et al. 2012). Topu-Yilmaz et al. found that IGF-1R expression was found 
to be directly proportional to the degree of pigmentation, necrosis and lymphocyte 
infiltration in uveal melanoma tissue studies. Vitreal and serum specimens studied 
using ELISA confirmed that IGF-1 was increased in patients with scleral invasion. 
This suggests that IGF-1R is related to clincopathological features of uveal 
melanoma while IGF-1 has a role in disease progression and development (Topcu-
Yilmaz, Kiratli et al. 2010). Arrays of mutual proteins which exhibit similar 
expression patterns have been identified in both cutaneous and uveal melanoma. 
These include induced nitric oxide synthases (iNOS) which are necessary for tumour 
growth, and Hepatocyte growth factor (HGF), a protein known to be involved in 
processes such as angiogenesis and epithelial morphogenesis (Massi, Franchi et al. 
2001, Johansson, Mougiakakos et al. 2010, Topcu-Yilmaz, Kiratli et al. 2010, Lee, 
Kim et al. 2011). This illustrates that both uveal and cutaneous melanoma are linked 
through common paths of protein expression for establishing tumorigenesis, disease 
progression, and melanoma development. 
It has been reported that patients with uveal melanoma are approximately 4.6 times 
more likely to develop cutaneous melanoma than “healthy” individuals; however the 
same cannot be said for cutaneous melanoma patients developing uveal melanoma. 
This may be due to the fact that those who have developed uveal melanoma have 
been sufficiently exposed to enough UV radiation to develop cutaneous melanoma 
also (Shors and Weiss 2004). Of course, this may also be related to genetic factors 
but there is currently no evidence to support this. 
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1.6 Clinical Proteomics Methods 
The search for biomarkers is currently carried out, for the most part, using MS-based 
methods in combination with chromatography or gel electrophoresis techniques. 
Biomarker validation methods include immunohistochemistry (IHC), multiple 
reaction monitoring (MRM) and ELISA.  
Commonly analysed clinical specimens include serum and plasma, which are blood 
extracts. Serum is prepared when the blood sample is allowed to clot, centrifuged, 
and the blood clot is removed. Plasma on the other hand is prepared through the 
centrifugation of blood in order to remove red and white blood cells. Anti-
coagulants, such as ethylenediaminetetraacetic acid (EDTA) and heparin, are used 
during this procedure in order to prevent blood clots from forming (Lam, Rainer et 
al. 2004).  
However, prior to proteomic investigation, many samples, particularly serum and 
plasma, require a pre-treatment step. This is due to the fact that complex protein 
mixtures, such as blood, contain an abundance of 20 of the most common proteins 
which can interfere with the detection of potentially more interesting and less 
abundant proteins (Fernandez-Costa, Calamia et al. 2012). 
 
1.6.1 Sample Pre-Fractionation 
Clinical specimens are clearly a valid source of potential biomarkers, however, as 
explained, many can contain a large proportion of high abundant proteins, hence 
fractionation is required to remove these proteins (Kim and Kim 2007).  
Using biological fluids such as serum and plasma can be very useful in the 
biomarker discovery process as they most likely contain proteins and peptides from 
the site of disease and are minimally invasive during collection. Despite this, 99% of 
the total protein mass of plasma or serum is composed of 22 proteins; see Figure 1.3, 
which is the primary disadvantage of using such specimens. Immunodepletion 
involves the removal of any number of the most abundant proteins through an 
immunocapture-based technique. An example of an immunodepletion method 
includes the range of Multiple Affinity Removal System (MARS) columns (Agilent, 
CA, USA), which can variably remove 6, 7 or 14 abundant proteins, or the 
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ProteoPrep20 (Sigma-Aldrich, UK), which removes 20 proteins (Smith, Wood et al. 
2011). There have been questions over the benefit of depleting increased numbers of 
proteins in comparison to fewer proteins. Roche et al. immunodepleted one, six, 12 
or 20 high abundance proteins and subsequently analysed the treated sera using 
proteomic approaches such as SELDI-TOF and 2-D electrophoresis. An overall 
evaluation of results clearly demonstrated the benefit of immunodepletion in the 
detection of lower abundant and potentially more interesting proteins. However, they 
noticed that there was a limited advantage in increasing the number of depleted 
proteins from 12 to 20. By removing 20 proteins, this may also allow for the 
depletion of associated peptides and proteins, which could negatively impact on the 
discovery of biomarkers (Roche, Tiers et al. 2009). Other studies have shown that 
the “depletome” can often contain associated potential disease markers of interest 
and that more attention should be paid to such proteins and peptides (Koutroukides, 
Guest et al. 2011). 
 
 
Figure 1.3 The majority of the serum proteome is composed of highly abundant 
proteins, thus masking lower abundant proteins which may indicate the disease state 
of a patient (Tirumalai, Chan et al. 2003). 
 
Newer technologies, such as ProteoMiner, can also be employed for sample pre-
treatment in order to analyse the “hidden proteome” (Boschetti and Righetti 2008). 
This involves using a vastly heterogeneous library of hexapeptides bound to 
poly(hydromethacrylate) beads which allows for the compression of the dynamic 
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range of protein concentrations. Each hexapeptide binds to an exclusive protein 
sequence and as there are a finite number of ligands available for each molecule to 
bind, highly abundant proteins will quickly saturate theirs, with any excess being 
washed away. Simultaneously, any low abundance proteins are concentrated on their 
ligands (Figure 1.4). When bound proteins are eluted from the column, the dynamic 
range of proteins available is decreased, allowing for a greater range of proteins to 
be analysed in downstream analysis. It is therefore a useful method for quantitative 
analysis of low abundance proteins in complex clinical samples (Sennels, Salek et al. 
2007, Hartwig, Czibere et al. 2009). ProteoMiner equalises the protein in a sample 
without immunodepletion, which as mentioned above can lead to the loss of small 
proteins bound to highly abundant ones. ProteoMiner can also be used on many 
biological samples or a cell or tissue lysate and is compatible with many 
downstream protein analysis techniques. Sennels et al. used the protein equalising 
technology for the enrichment of human blood serum proteins, identifying 1559 
proteins in the resulting elution, of which 58% had not previously been reported in 
the literature (Sennels, Salek et al. 2007).  ProteoMiner has also been used on a 
variety of other biological samples including urine, saliva, and colostrum (Castagna, 
Cecconi et al. 2005, Coscia, Orru et al. 2012, Jagtap, Bandhakavi et al. 2012).  
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Figure 1.4 ProteoMiner allows for the simultaneous enrichment of low abundance 
proteins and depletion of high abundance proteins (http://www.genengnews.com/ 
2010) 
 
Hydrogel nanoparticles are another method used in the separation of highly 
abundant and low abundant proteins. These “smart” nanoparticles allow the 
enrichment and encapsulation of selected classes of proteins from complex mixtures, 
such as a clinical specimen, while protecting the analytes from degradation 
following separation (Figure 1.5). The captured proteins can then be extracted from 
the particles by electrophoresis and quantified (Luchini, Geho et al. 2008). As the 
fractionation method combines size exclusion, affinity separation, concentration, and 
stabilisation of proteins from a complex mix, it provides an ideal environment for 
biomarker discovery in complex biological specimens. 
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Figure 1.5 Animated representation of the molecular sieving property of hydrogel 
nanoparticles. Using an affinity bait and defined porosity, low molecular weight 
proteins (pink) are harvested while high molecular weight proteins are excluded 
(grey) (Luchini, Geho et al. 2008). 
 
1.6.2 Protein Fractionation  
The aim of proteomics is to have a global view of all of the proteins produced in a 
biological system, usually in order to understand a differential protein expression 
pattern (Berth, Moser et al. 2007). It is essentially used for the analysis of the final 
level of gene expression, and is widely utilised in the search for biomarkers of 
disease. In order to do this, it is first necessary to separate all of the proteins in the 
sample for analysis, such as by electrophoresis, as there are approximately 100,000 
proteins produced in humans and 2-D gels may separate up to 10,000 protein spots 
on one gel (Wang, Li et al. 2006, Berth, Moser et al. 2007). The subsequent 
identification of proteins is carried out using MS methods, such as MALDI-TOF and 
LC-MS/MS.  
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1.6.3 Two-Dimensional Polyacrylamide Gel Electrophoresis (2-D                                  
PAGE) 
One of the oldest and most useful methods for protein separation is two-dimensional 
polyacrylamide gel electrophoresis (2-D PAGE). This initially involves separating a 
fixed quantity of protein, as determined by protein assay, based on the isoelectric 
point (pI) of the proteins using immobilised pH gradient (IPG) strips, in the first 
dimension. The pI of a protein is described as the pH at which its net charge is zero, 
hence the protein cannot move freely in an electrical field. The strips are attached to 
the top of a polyacrylamide gel slab and once charge is applied, proteins migrate 
from the strip into the gel and are separated based on their size, using sodium 
dodecyl sulphate electrophoresis, in the second dimension. The result of this process 
is a 2-D gel which, when stained produces a series of spots, with each spot 
corresponding to a protein. Commonly used protein stains include Coomassie 
Brilliant Blue and silver nitrate colloidal stain, both of which are global protein 
stains.  
Although 2-D PAGE has been useful for the separation of complex protein mixtures, 
it was a very limited technique until the advent of micro-analytical techniques, such 
as quantitative LC-MS (O'Farrell 1975, Rabilloud 2002).  
 
1.6.3.1 Two-Dimensional Differential Gel Electrophoresis (2-D DIGE) 
2-D DIGE (Two-Dimensional Differential Gel Electrophoresis) is a highly sensitive 
method of minimal protein labelling of up to three different conditions using 
separate fluorescent dyes and their subsequent co-electrophoresis in order to 
examine the quantitative differential expression of proteins between the conditions 
(Alban, David et al. 2003).  
This technique uses three covalently-bound dyes: Cy2, Cy3 and Cy5, of which the 
NHS-ester reactive group of one molecule of each binds to the epsilon amino group 
of lysines in one protein through an amide linkage. The Cy3 dye is used to stain one 
sample group and Cy5 to stain the other. A pool of all samples can then be created 
and labelled with Cy2 which acts as an internal standard and is used on all gels. All 
gels can be normalised against the Cy2 standard which results in accurate 
reproducibility and protein abundance comparisons between gels. All three of the 
49 
 
dyes are size and charge matched, pH insensitive, photostable, sensitive, and 
spectrally resolvable (https://www.gelifesciences.com/ , Alban, David et al. 2003) .  
The gels are scanned at the appropriate excitation and emission wavelengths and the 
acquired images are imported onto a computer for analysis by software such as 
Progenesis SameSpots (Non-Linear Dynamics) or DeCyder (GE Life Sciences). 
These programmes accurately detect statistically significant protein abundance 
changes between the gels and effectively minimise gel-to-gel variation 
(https://www.gelifesciences.com/). The analysis of spot maps is divided into two 
categories, depending on the work flow; spot detection first, including aligning spots 
between gels, calculating spot volumes and subsequent expression profile 
generation, or image modification first, with a separate spot detection step, for 
removing running differences between gels using whole image information and 
generating expression profiles based on differences between spot maps. Newer 
programmes such as Z3, Decyder, Delta2D and Progenesis SameSpots all depend on 
the latter method (Berth, Moser et al. 2007). An overview of the process is shown in 
Figure 1.6. 
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Figure 1.6 A 2-D DIGE workflow from protein labelling with Cy3, Cy5 and Cy2 
(internal standard) to image acquisition using a fluorescent imager 
(https://www.gelifesciences.com/). 
 
As described above, 2D-DIGE has been used for many clinical studies in the past in 
the hunt for biomarkers and it is still relevant today, primarily due to its high 
sensitivity. However, there are a number of problems with gel-based methods; single 
protein spots can often contain more than one protein as molecules of similar charge 
and size would migrate together, and also, resolution can vary depending on the 
properties of the protein such as very high molecular weight and hydrophobicity.  
 
1.6.4 Mass Spectrometry 
MS is a method of protein fragmentation and identification. Traditionally, this 
involves digesting the protein at specific sites and fragmenting the peptides in the 
gas phase.  
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1.6.4.1 Ionisation 
In order to separate neutral molecules through an electromagnetic field, they must 
first be converted to ions and may be changed to a gas, i.e. desorption. Both 
processes are carried out using an ionisation source. A number of methods are 
available for the procedure although, ESI and MALDI are the most efficient ways in 
which to ionise peptides (Canas, Lopez-Ferrer et al. 2006). 
MALDI relies on the saturation and co-crystallisation of matrix with analyte in a low 
vacuum. When the sample combined with the matrix is bombarded with UV light, 
the matrix absorbs the energy which causes it to become vaporised along with the 
sample peptides. This produces a “plume” within which a transfer of protons occurs 
between the analyte and the matrix, thus producing analyte ions (Canas, Lopez-
Ferrer et al. 2006).  
The principle of ESI is based on the fact that if a high voltage is applied to a stream 
of liquid flowing through a narrow capillary, an electrical spray is created. ESI 
allows for ions to gain multiple charges, such as in the case of peptide ions which 
are often doubly or triply charged, thereby requiring less activation energy for 
fragmentation and giving information-rich results for database searches (Canas, 
Lopez-Ferrer et al. 2006). 
 
1.6.4.2 Mass Analysis 
A mass analysis step is used in order to examine ions based on their mass. ESI and 
MALDI mass spectrometers are combined with various mass analysers, depending 
on the sample and the research question. Mass analysers can be based on electric 
and/or magnetic fields for the separation of ions in the gaseous phase and can be 
used alone or in tandem (Aebersold and Mann 2003).  
TOF, the most basic mass analyser, accelerates ions with equal energies in a strong 
electric field through a high vacuum flight tube. Peptides are measured based on 
their velocity, as the velocity of each particle is inversely proportional to its mass, 
i.e. the heavier the peptides, the slower are in reaching the detector. (Canas, Lopez-
Ferrer et al. 2006). 
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In ion trap MS, ions are stored until the trap is full. Using radio frequency voltage, 
ions are ejected out and are detected by the electron multiplier. The orbitrap is a 
highly sensitive form of ion trap (Fitzgerald, O'Neal et al. 1997). 
 
1.6.4.3 Protein Identification 
The acquired data is then searched against a database in order to generate a set of 
identifications. For determining the mass of a peptide, peptide mass fingerprinting, 
which compares mass spectra to a protein database for matching molecular weights, 
or tandem mass spectrometry (MS/MS), which determines the mass and generates a 
partial amino acid sequence for further fragmentation, can be used. Software 
packages which can interpret proteomic data are available, such as MASCOT and 
Phenyx (Wright, Noirel et al. 2012). 
 
1.6.5 Surface enhanced laser desorption/ionisation (SELDI) 
Surface enhanced laser desorption/ionisation (SELDI) is an ionization method in MS 
that is used for the analysis of protein mixtures. It is a variation of MALDI that uses 
a target modified to achieve biochemical affinity with the analyte and is useful for 
the comparison of protein levels between patients and so, can be used for biomarker 
discovery.  
Initially, a chip-based target is charged and activated to bind a specific subset of 
proteins. The surface may consist of various materials of different affinity 
characteristics such as hydrophobic or hydrophilic properties, containing metal ions 
(such as immobilised metal affinity capture: IMAC) or anion and cation exchangers 
(Kiehntopf, Siegmund et al. 2007), or it can be pre-activated for the coupling of 
capture molecules such as protein, DNA, or RNA prior to sample loading. Any 
unbound proteins can be washed away, thus acting as a separation step. The sample 
is mixed with a matrix, such as sinapinic acid, which is allowed to dry and co-
crystallise with the analyte on a chip surface. A laser then strikes the mixture, 
causing ionisation of any bound proteins present. TOF is used to measure the m/z of 
each molecule which generates a spectrum where each peak corresponds to a 
protein.  
53 
 
A wide variety of biofluids can be used on a SELDI chip such as, serum, plasma, 
vitreous fluid and saliva. Although SELDI-TOF is a rapid method of protein 
profiling which requires little sample, it does not produce protein identifications; 
only the m/z ratio and the intensity of the peak (Peng, Stanley et al. 2009, De Bock, 
de Seny et al. 2010).   
 
1.6.6 Quantitative Label-Free LC-MS/MS 
LC-MS/MS is quickly becoming the method of choice for the analysis of complex 
samples due to its high sensitivity and exceptional dynamic range. This involves the 
use of nano-high performance liquid chromatography (HPLC) with reverse phase 
chromatography prior to MS/MS.  
Label-free proteomics identifies proteins through both bioinformatics and MS. The 
label-free approach is based on the separate LC-MS/MS analysis of all samples, 
followed by retention time control and normalisation between generated MS/MS 
spectra using a programme such as Progenesis LC-MS (Non-Linear Dynamics). 
Quantitative LC-MS/MS can be broken into two groups; area under the curve (AUC) 
or signal intensity measurement based on precursor ion spectra, and spectral 
counting, which is based on counting the number of peptides assigned to a protein in 
an MS/MS experiment. (Figure 1.7) (Neilson, Ali et al. , Zhu, Smith et al.).  
Measurement by ion intensity infers quantification through precursor ion signals at 
specific retention times without the use of a stable isotope standard. As ionised 
peptides elute from a reverse-phase column into the mass spectrometer, their ion 
intensities can be measured within the chosen detection limits, and differentially 
expressed peptides can be subsequently compared with those from other samples 
(Neilson, Ali et al.). This method requires that all data is collected in data-dependent 
„Triple Play‟ mode (allowing MS scan, Zoom scan, and MS/MS scan) and these 
together with chromatographic retention time determine the analytical accuracy of 
protein identification and quantification by ion intensity (Higgs, Knierman et al. 
2005).  
Spectral counting relies on the principal that the more of a specific protein present in 
a sample, the more MS/MS spectra collected for peptides of that protein. Hence, the 
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relative abundance of that protein can be obtained by comparing the number of 
MS/MS spectra between sample sets. Although this method has the advantage of 
simultaneous quantification and identification, it depends on the quality of MS/MS 
generated (Bantscheff, Schirle et al. 2007, Wang, You et al. 2008). 
As the quantitative label-free LC-MS/MS method does not require sample labelling, 
bias is limited while throughput is significantly increased; a highly reproducible LC 
profile must be generated to maximise mass resolution, accuracy, and proteome 
coverage.  
 
 
Figure 1.7 Label-free quantitative proteomics. Control and sample are subjected to 
individual LC-MS/MS analysis. Quantification is based on the comparison of peak 
intensity of the same peptide or the spectral count of the same protein (Zhu, Smith et 
al. 2010). 
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AIMS OF THESIS 
 
The goal of this thesis was to identify differential protein expression patterns 
between metastatic uveal melanoma in comparison to the non-metastatic disease and 
also, to determine potential biomarkers in the progression of cutaneous melanoma. It 
was intended that the analysis of both melanoma types would allow for a better 
understanding of the molecular mechanisms of the metastatic phenotype. It was also 
a possibility that this research could the lead to the discovery of biomarkers for the 
development of targeted therapies for disease treatment and the early detection of 
disease using proteomics tests. Specifically, the aims of this thesis were the 
following: 
 
 To identify protein expression differences in primary tumour tissue between 
two sets of uveal melanoma sample groups; those who subsequently developed 
metastasis in comparison to those who did not, using 2D-DIGE and quantitative 
label-free LC-MS, and to elucidate the role of such proteins in metastasis using 
functional analysis which may improve our understanding of the metastatic 
phenotype of the disease. 
 
 To compare control serum from disease-free patients to that of late stage 
cutaneous melanoma patients using fractionation methods in order to identify highly 
significant protein expression differences and to subsequently examine such 
differences across an array of control, benign, early stage melanoma, and advanced 
melanoma sera using ELISA in order to further understand the progression of the 
disease. 
 
 To optimise a protocol for the use of vitreous fluid from uveal melanoma 
patients in proteomic experiments by minimising the quantity of highly abundant 
proteins, while enhancing the presence of low abundance proteins. 
 
 To determine potential, differentially expressed biomarkers for uveal 
melanoma in the vitreous fluid between patients with monosomy of chromosome 
three status and those with disomy of chromosome three. It also intended to identify 
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proteins which were differentially expressed between control vitreous, which was 
collected from macular degeneration patients, and that of uveal melanoma patients. 
 
 To use surface-enhanced laser desorption-ionisation time-of-flight (SELDI-
TOF MS) for the proteomic profiling of advanced cutaneous melanoma serum, the 
vitreous fluid of uveal melanoma patients and the conditioned media of cutaneous 
melanoma cultured cells, in comparison to relevant controls for the direct analysis of 
potential biomarker expression between the sample sets.  
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CHAPTER TWO 
Materials and Methods 
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2.1 Cell Culture 
2.1.1 Preparation of Cell Culture Media 
Ultrapure water (UHP) was purified to a standard of 12-18 M/cm resistance by a 
reverse osmosis system (Millipore MillI-RO 10 Plus, Elgastat UHP). Glassware 
required for cell culture related applications were soaked in a 2% RBS-25 (Chemical 
Products R. Borghgraef S.A.) for 1 hour, washed in an industrial dishwasher, using 
Neodisher detergent and rinsed twice with UHP. All thermostable solutions, water 
and glassware were sterilised by autoclaving at 121C for 20 minutes at 15 bar 
(Thermolabile solutions were filtered through 0.22 m sterile filters (Millipore, 
Millex-GV SLGV025BS)). Complete media was prepared by adding serum as 
required (Table 2.1). An aliquot of complete medium was kept in a T-25cm
2
 flask in 
an incubator over 5-7 days to ensure that the complete medium is free of 
contamination at the time of use. Complete media was also stored at 4C for a 
maximum of one month in the dark. 
 
Table 2.1 Details of cell lines and complete growth media components 
 
2.1.2 Cell Lines and Cell Culture 
All cell culture work was carried out in a class II laminar air-flow cabinet (Nuaire). 
Before and after use the laminar air-flow cabinet was cleaned with 70% industrial 
methylated spirits (IMS). Any items brought into the cabinet were also swabbed 
down with IMS. At any time only one cell line was used in the laminar air-flow 
cabinet and upon completion of work with any given cell line, 15 minutes clearance 
was given to eliminate any possibilities of cross-contamination between the various 
cell lines. The cabinet was cleaned weekly with Virkon (Antech International, 
P0550) and IMS. Details pertaining to the cell lines used for the experiments are 
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provided in Table 2.2. All cells were incubated at 37°C and where required, in an 
atmosphere of 5% CO2. Cells were fed with fresh media or subcultured (see section 
2.1.1) every 2-3 days or as required in order to maintain active cell growth. 
 
2.1.3 Subculturing of Adherent Cell Lines 
The cell lines used during the course of this study, their sources, and detailed 
information are listed in Table 2.2. Exhausted cell culture medium was removed 
from the tissue culture flask and discarded into a sterile bottle. The flask was then 
rinsed out with 2 mL of PBS solution to ensure the removal of any residual media. 
Depending on the size of the flask, 2-5 mL of trypsin solution (0.25% (v/v) of trypsin 
(Gibco, 043-05090) and 0.01% (v/v) of EDTA (Sigma, E9884) solution in PBS 
(Oxoid, BRI4a)) was then added. Cells were incubated at 37C for approximately 2-5 
minutes until all of the cells detached from the inside surface of the flask. This was 
monitored by microscopic observation. An equal volume of complete media was 
added to the flask to deactivate the trypsin. The cell suspension was removed from 
the flask and placed in a sterile universal container (Sterilin, 128a) and centrifuged at 
1000 rpm for 5 minutes. The supernatant was then discarded from the universal and 
the pellet was suspended gently in fresh complete medium. A cell count was 
performed as described in section 2.1.4 and an aliquot of cells was used to seed a 
flask at the required density. All cell waste or media exposed to cells was autoclaved 
before disposal.  
Cell Lines 
Established 
by 
Source Cell Line Code 
Detailed 
Information 
SK-MEL 5 
Old, Lloyd J. 
Takahashi, T. 
ATCC HTB-70 
Malignant 
Melanoma 
MEL202 
(Ksander, 
Rubsamen et 
al. 1991) 
ESTDAB, University of Tubingen, 
Center for Medical Research, 
Germany 
ESTDAB-128 
Primary Uveal 
Melanoma 
Tumour 
92.1 
(De Waard-
Siebinga, 
Blom et al. 
1995) 
ESTDAB, University of Tubingen, 
Center for Medical Research, 
Germany 
ESTDAB-127 
Primary Uveal 
Melanoma 
Tumour 
 
Table 2.2 Details of cell lines used in this investigation. 
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2.1.4 Assessment of Cell Number and Viability 
Prior to cell counts, cells were prepared by subculturing as detailed in section 2.1.3 
An aliquot of the cell suspension was then added to trypan blue (Gibco, 525) at a 
ratio of 1:1 (v/v). The mixture was incubated for 2-3 minutes at room temperature. 
An aliquot (10 L) was then applied to the chamber of a glass coverslip-enclosed 
haemocytometer. For each of the four grids, cells in the 16 squares were counted. 
Non-viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained. The average number of viable 
and dead cells per 16 squares was multiplied by a factor of 5X10
3
 (volume of the 
grid) and the relevant dilution factor to determine the average cell number per mL in 
the original cell suspension. Using the data for viable and non-viable cells, 
percentage viability was calculated.  
The Cedex Automated Cell Counter (Roche), an automated cell counting system 
based on the Trypan Blue exclusion method, was also used for accurate 
determination of cell number. Cells were trypsinised and incubated with trypan blue 
in the same manner as above, prior to assessment of cell number through Cedex 
analysis. This involved pipetting 10 μL of Trypan Blue/cell suspension mix onto a 
Cedex Smart Slide (05650801001, Roche) and measuring the cell number using the 
automated system. 
 
2.1.5 Cryopreservation of Cells 
Cells for cryopreservation were harvested in the mid-log phase of growth and 
counted as described in section 2.1.4. Cell pellets were resuspended in a suitable 
volume of serum. An equal volume of filter sterilized solution of 10% (v/v) DMSO 
in serum was added dropwise with mixing into the cell suspension. 1 mL of cell 
suspension was then aliqoted into the cryovials (Greiner, 122278) and immediately 
placed in the -20 C freezer for 1 hour and then placed in a -80 C freezer for four 
hours or overnight. The cryovials were then transferred to liquid nitrogen tank for 
long term storage (-196 C). 
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2.1.6 Thawing of Cryopreserved Cells  
A volume of 5 mL of fresh complete culture medium was added to a sterile universal 
and into a T-25 cm
2
 flask and incubated at 37 °C for ~1 hour. The cryopreserved 
cells were removed from the liquid nitrogen and thawed at 37 C as quickly as 
possible. The cells were removed from the vials and transferred into the pre-warmed 
aliquoted media in the universal. The resulting cell suspension was centrifuged at 
250 g for 5 minutes. The supernatant was removed and the pellet was resuspended in 
the pre-warmed culture medium from T-25 cm
2
 flask. This cell suspension was then 
transferred to T-25 cm
2
 flask and allowed to attach and grow overnight in incubator. 
The following day, the culture media was replaced with fresh complete culture 
medium to remove any non-viable cells and floating cells. 
 
2.1.7 Mycoplasma Analysis of Cell Lines 
Mycoplasma testing was carried out for all cell lines for possible Mycoplasma 
contamination in house by Mr. Michael Henry at the NICB. All cell lines are found 
to be Mycoplasma free. 
 
2.1.7.1 Indirect Staining Procedure for Mycoplasma Analysis 
Normal rat kidney fibroblast (NRK) cells were seeded onto sterile coverslips in 
sterile Petri dishes (Greiner, 633 185) at a cell density of 2x10
3
 cells/ml and were 
allowed to attach overnight at 37°C in a 5% CO2 humidified incubator. 1 mL of cell-
free supernatant from each test cell line was inoculated onto an NRK petri dish and 
incubated as before until the cells reached 20-50% confluency. After this time, the 
waste medium was removed from the dishes, the coverslips (Chance Propper, 22 x 
22 mm) washed twice with sterile PBS, once with a cold PBS/Carnoys (50/50) 
solution and fixed with 2ml of Carnoys solution (acetic acid:methanol, 1:3) for 10 
minutes. The fixative was removed and dried coverslips were washed twice in 
deionised water and stained with 2ml of Hoechst stain (BDH) (50ng/ml) for 10 
minutes. From this point on, work proceeded without direct light to limit quenching 
of the fluorescent stain. The coverslips were rinsed three times in PBS. They were 
then mounted in 50% (v/v) glycerol in 0.05 M citric acid and 0.1 M disodium 
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phosphate and examined using a fluorescent microscope with a UV filter. A  
Mycoplasma infection would be seen as small fluorescent bodies in and sometimes 
outside the cells.  
 
2.2 Tumour Tissue Sample Preparation for 2-D DIGE Analysis 
Uveal melanoma tissue specimens were homogenised using a sample grinding kit 
(GE Healthcare, 80-6483-37) by placing the tissue specimen in a 1.5 mL eppindorf 
tube containing grinding resin. 2-D lysis buffer containing 7 M urea (Sigma Aldrich, 
208884), 2 M thiourea, 4% (w/v) (Sigma Aldrich, T8656), CHAPS (Sigma Aldrich, 
C3023), 40 mM DTT (Sigma Aldrich, D9163) and 0.5% IPG buffer pH 3-11 (GE, 
17-6000-86) was added to the tube and the tissue was degraded using a pestle. 
Insoluble material was removed by centrifugation at 14,000 rpm for 5 min at room 
temperature and supernatants were stored at -80 °C until required.  
 
2.3 Protein Quantification  
Protein concentration was determined using the thiourea-compatible Quick Start 
Bradford Protein Assay Kit (Bio-Rad, 500-0201), containing 2 mg/mL of bovine 
serum albumin (BSA) solution as a known standard. Dilutions of BSA stock for 
0.125, 0.25, 0.5 and 1.0 mg/mL was prepared and used for generating a protein 
standard curve. 5L of protein standard dilution or sample (diluted 1:10) was added 
to a 96-well plate. 245 L/well of thiourea-compatible Bradford protein assay 
reagent (Bio-Rad, 500-0205) was then added to the plate. All samples were assayed 
in triplicate. After 5 minutes incubation, the absorbance was assessed at 595nm. The 
concentration of the protein samples was determined from the plot of the absorbance 
at 595nm versus the concentration of the protein standard.  
 
2.4 2D-DIGE Sample Preparation 
2.4.1 Preparation of CyDye DIGE Fluor Minimal Dye Stock Solution 
The three CyDye DIGE Fluor Minimal dyes (Cy3, Cy5 and Cy2) (GE Life Sciences, 
25-8010-65) were thawed from –20 oC to room temperature for 5 minutes. To each 
microfuge tube dimethylformamide (DMF) (Sigma Aldrich, 22,705-6) was added to 
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a concentration of 1 nmol/μL. Each microfuge tube was vortexed vigorously for 30 
seconds to dissolve the dye. The tubes were then centrifuged for 30 seconds at 
14,000 rpm in a microcentrifuge. The reconstituted dyes can be stored at –20 oC for 
up to two months. 
 
2.4.2 Preparation of 10 μl working dye solution (200 pmol/μL) 
On thawing, the dye stock solutions were centrifuged in a microcentrifuge for 30 
seconds. To make 10 μL of the three working dye solutions, 8 μL of DMF was added 
to three fresh eppendorfs labelled Cy2, Cy3 and Cy5. A 0.2 nmol/μL volume of each 
of the reconstituted dye stock solutions was added to their respective tubes. The dyes 
can be stored at -20 
o
C in tinfoil in the dark for 3 months. 
 
2.4.3 Protein sample labelling  
A volume of the protein samples equivalent to 50 μg was placed into eppendorf 
tubes. An eppendorf tube for the Cy2 pool made up from aliquots from all the protein 
samples contained enough protein for 50ug for each gel. Each tube was mixed by 
vortexing, centrifuged and then left on ice for 30 minutes in the dark. To stop the 
reaction, 1 μL of 10 mM lysine (Sigma Aldrich, L5501) was added, the tubes were 
vortexed, centrifuged briefly, and left on ice for 10 minutes in the dark. The labelled 
samples were stored at –80 oC. To this tube 1 μl of working dye solution was added. 
 
2.4.4 Preparing the labelled samples for the first dimension 
The protein samples labelled with Cy2 (pooled internal standard), Cy3 and Cy5 were 
thawed on ice (in the dark), combined by placing into a single eppendorf tube and 
mixed. An equal volume of 2X sample buffer (2.5 mL rehydration buffer stock 
solution (8M urea, 4% CHAPS), pharmalyte broad range pH 4-7 (2%) (GE Life 
Sciences, 17-6000-86), DTT (2%) (Sigma, D9163)) was added to the labelled protein 
samples. The mixture was left on ice for at least 10 minutes then applied to 
Immobiline DryStrips for isoelectric focussing. 
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2.4.5 First dimension separation - isoelectric focussing methodologies 
Isoelectric focussing of all samples was carried out using pH 3-11, 24 cm immobiline 
pH gradient (IPG) strips (GE Life Sciences, 17-6003-77).  
 
2.4.5.1 Strip rehydration using Immobiline DryStrip reswelling tray  
A Immobiline Dry Strip Reswelling tray (GE Life Sciences, 17-1233-01) was 
levelled using the spirit level. A 350μl volume of rehydration buffer solution 
containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer pH 3-11, 50 mM 
DTT was slowly pipetted into the centre of each slot, all air bubbles generated were 
removed. The cover film from the IPG strip was removed and positioned with the gel 
side down and lowered, ensuring that the entire strip was evenly coated buffer and 
that no air bubbles were present. 
Each strip was overlaid with about 3 mL IPG Cover Fluid (GE Life Sciences, 17-
1335-01) starting on both ends of the strip, moving to the centre. The protective lid 
was then replaced and the strips were left at room temperature to rehydrate overnight 
(or at least 12 hours). 
 
2.4.5.2 Isoelectric focussing using the IPGphor manifold 
Following the rehydration procedure, the Manifold (GE Life Sciences) was placed 
onto the IPGphor unit by inserting the “T” shape into the hollow provided. A 9 mL 
volume of Cover Fluid was placed into each of the twelve lanes in the tray in order to 
cover the surface. Two wicks (GE Life Sciences, 80-6499-14) per strip were 
rehydrated with 150 μl of UHP water. The rehydrated strips were placed in the 
correct orientation (+ to anode) and aligned just below the indented mark, to allow 
for the wicks to overlap the strip. The rehydrated wicks were then placed over both 
ends of all the strips, ensuring that they were positioned over the gel portion of the 
strip and avoiding the indent in the lane so as to guarantee a good contact with the 
electrodes. The sample cups (GE Life Sciences, 80-6498-95) were then positioned 
approximately 1 cm from the cathodic end of the strip and an insertion tool was used 
to securely “click” the cups into place. The electrodes were then fitted, in direct 
contact with the wicks. 
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The amount of protein loaded per strip was 150 μg for DIGE or 400 μg for spot 
picking and identification. The protein samples were prepared by centrifuging to 
remove any insoluble material and the appropriate volume was loaded with a pipette 
tip placed just beneath the surface of the cover fluid. The cover of the IPGphor unit 
was closed and the desired programme selected. The temperature was set for 20
o
C 
with 50A/strip. The IEF parameters are as follows: step 1: 300 volts for 3 hours 
(step-and-hold), step 2: 600 volts for 3 hours (gradient), step 3 1000 volts for 3 hours 
(gradient), step 4: 8000 volts for 3 hours (gradient). The IEF was left at 8000 volts 
(step-and –hold) until ready for SDS-PAGE step. On completion of the IEF run, the 
strips were drained of the cover fluid and stored in glass tubes at –80 oC or used 
directly in the second dimension.  
 
2.4.6 Second Dimension – SDS polyacrylamide gel electrophoresis 
2.4.6.1 Casting gels in the ETTAN Dalt-12 gel caster 
For all 2-D gels, a 12.5% acrylamide gel solution was prepared in a glass beaker 
(acrylamide/bis 40%, 1.5 M Tris pH 8.8, 10% SDS). Prior to pouring, 10% 
ammonium persulfate (Sigma Aldrich, A3678) and neat TEMED (Sigma Aldrich, T-
9281) were added.  
Gels for use in DIGE experiments were poured into a sandwich of low fluorescent 
plates while those used for preparative gels were poured into hinged plates. 
Following pouring the acrylamide solution into the appropriate glass plate mould, a 
displacement solution (0.375M Tris-Cl 1.5M pH 8.8, 30% glycerol, UHP and 
bromophenol blue) was added to the reservoir, forcing the remaining gel solution 
into the gel caster. The gels were then overlaid with 1 mL of saturated butanol or 
sprayed with 0.1 % SDS solution and left to set for at least three hours at room 
temperature. The set gels were rinsed with distilled water and stored for up to four 
days in 1X running buffer at 4 
o
C, if they were not for immediate use. 
If gels were to be used for “spot picking” the plates were silanised to stick the 
acrylamide mixture to the plates. 2 mL of the following solution; 8 mL ethanol, 200 
L glacial acetic acid, 10 L bind-silane (GE Life Sciences, 17-1330-01) and 1.8 mL 
UHP was pipetted over the glass plate and wiped over with a lint free cloth. This was 
left to air dry for 15 minutes, after which 2 mL ethanol and 2 mL UHP were each 
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pipetted over the plate and wiped off respectively. The plate was left to air dry for 
approximately 1 hour 30 minutes.  
 
2.4.6.2 Preparing the ETTAN DALT 12 electrophoresis unit 
The electrophoresis chamber was prepared by adding 6.48 litres of UHP and 720 mL 
of 10X SDS running buffer. The pump was then turned on to cool the system to 10 
o
C.  
 
2.4.6.3 Equilibration and loading of focussed Immobiline DryStrips 
SDS equilibration buffer (30% glycerol, 6 M urea, 50 nM 1.5M Tris-Cl pH 8.8, 2% 
SDS, bromophenol blue and UHP) with either dithiothreitol (DTT) (65 mM) (Sigma 
Aldrich, D9163) or iodoacetamide (240 mM) (Sigma Aldrich, I1149) were prepared. 
Using a forceps, the rehydrated strips were removed from the IPGphor unit, and the 
cover fluid was drained off. Equilibration buffer (10 mL containing DTT) was added 
to each tube and incubated for 15 minutes with gentle agitation using an orbital 
shaker. The DTT containing equilibration solution was the removed and 5 mL of 
iodoacetamide containing equilibration buffer added. The strips were incubated for 
10 minutes with gentle agitation.  
The IPG strips were rinsed in 1X SDS electrophoresis running buffer and placed 
between the two glass plates of the gel. The strip was pushed down gently using a 
thin plastic spacer until it came in contact with the surface of the gel, gently 
removing any air bubbles trapped between the gel surface and the strip. 
Approximately 1 mL of the 0.5% agarose overlay solution was applied over the IPG 
strip to seal it in place. 
 
2.4.6.4 Inserting the gels into the Ettan DALT 12 electrophoresis buffer 
tank 
When the running buffer reached the desired temperature (10 
o
C) the loaded gel 
cassettes were inserted into the tank, filling any empty spaces with dummy plates if 
required. The upper chamber was filled with 2X running buffer. The cover of the unit 
was replaced and the required running conditions selected. The unit was run for 18–
24 hours at 1.5 Watts per gel at 10 °C or until the bromophenol blue dye front 
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reached the bottom of the gel. When the run was completed, the gel cassettes were 
removed from the tank one at a time using the DALT cassette removal tool and 
rinsed with UHP to remove the running buffer.  
 
2.4.6.5 Method for scanning DIGE labelled samples 
The Typhoon Variable Mode Imager (GE Healthcare) was turned on and left to 
warm up for 30 minutes prior to scanning. The scanning control software was opened 
and the fluorescence mode was selected. The appropriate emission filters and lasers 
were then selected for the separate dyes (Cy2 520 BP40 Blue (488), Cy3 580 BP30 
Green (532) and Cy5 670 BP 30 Red (633)). The first gel was placed in the scanner 
and pre-scanned at a 1000 pixel resolution in order to obtain the correct photo 
multiplier tube (PMT) value (to prevent saturation of the signal from high abundant 
spots). Once the correct PMT value was identified (a value ranging between 40,000 
and 60,000) the gel was scanned at 100 pixel resolution, resulting in the generation 
of three images, one each for Cy2, Cy3 and Cy5. Once the scanning was completed, 
the gel images were imported into the Progenesis SameSpots version 4.0 (NonLinear 
Dynamics) software. 
 
2.4.7 Differential Analysis of Gel Images 
Scanned fluorescent gel images were analysed using Progenesis SameSpots 
software. Images were loaded into the software and went through a process of 
quality assessment to optimise image capture. This highlights any positional errors 
which were introduced during scanning and allows for their correction using image 
cropping, flipping, or rotating. This also illustrates any gels or regions of the gel 
which may have been scanned at the incorrect wavelength and resulted in 
overexposed areas. Protein spots were detected and normalisation between gels was 
carried out. The spots on the gels were aligned against all gels in the experiment 
which allows for 100% matching.  
The software calculates the degree of difference in the standardized protein 
abundance between two spots from different groups and expressed these differences 
as average ratio. The values by the software are displayed in the range of -∞ to -1 for 
a decrease in expression and +1 to +∞ for an increase in expression. For example, a 
two-fold increase and decrease is represented by +2 and -2, respectively. The 
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„average ratio‟ has also been termed as „fold change‟ in this thesis. The software also 
calculates the consistency of the differences between samples across all the gels and 
applies statistics to associate a level of confidence (p-value) for each of the 
differences. Progenesis SameSpots also details t-test scores between sample sets to 
determine the expected proportion of false positives if the features p-value is chosen 
as the significant threshold.  
The spots with statistically significant changes in protein expression (±1.2 fold with 
p-value <0.05) were considered as differentially expressed proteins. These 
differentially expressed proteins observed using Progenesis SameSpots were 
designated “proteins of interest” and placed in a pick-list to pick from a preparative 
gel with the ETTAN Spot Picker (GE Healthcare) for identification using LC-
MS/MS.  
Preparative gels for spot picking with 300 μg of protein/gel were focussed and run 
out on SDS-PAGE gels. The gels were then stained with colloidal Coomassie 
(section 2.4.8). Spots that showed differential protein expression were picked with 
the ETTAN Spot Picker (section 2.4.10). 
 
2.4.8 Brilliant Blue G Colloidal Coomassie Staining 
After electrophoresis, plates attached to the preparative gels were placed in boxes 
containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol) for at least 
one hour. During this step, a 1X working solution of Brilliant Blue G colloidal 
coomassie (Sigma, B2025) was prepared by adding 800 mL UHP to the stock bottle. 
Following the fixing step, a solution containing 4 parts of 1X working colloidal 
coomassie solution and 1 part methanol was made, mixed by vortexing for 30 
seconds and then placed on top of the gels. The gels were left to stain for 2 hours. To 
destain, a solution containing 10% acetic acid in 25% methanol was poured over the 
shaking gels for 60 seconds. The gels were then rinsed with 25% methanol for 30 
seconds and then destained with 25% methanol for 24 hours.  
 
2.4.9 Other Staining Methods 
2.4.9.1 Silver staining  
After 2-DE, plates attached to the preparative gels were placed into a box containing 
fixing solution (50 mL ethanol, 12.5 mL acetic acid (Lennox) and 62.5 mL UHP). 
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The gel boxes were placed on an orbital shaker and fixed for at least 1 hour (usually 
overnight). After fixing, the solution was drained from the gels. The gels were then 
washed three times with 150 mL of UHP for 5 minutes each time and drained. The 
gels were next sensitised (60 mL ethanol, 13.6 g sodium acetate, 0.4 g sodium 
thiosulfate and UHP in 200 mL) for 30 minutes on the orbital shaker. 
Following this, the gels were washed three times, for 10 minutes each. Following the 
washes, 200 mL of silver staining solution (0.5 g silver nitrate, 80 µL formaldehyde 
and 200 mL UHP) was added and the boxes returned to the orbital shaker. After 20 
minutes the silver solution was drained and the gels were washed twice for 5 
minutes each with UHP water. After the last wash, 200 mL of developer (5 g sodium 
carbonate, 40 µL formaldehyde and 200 mL UHP) was added to each of the boxes. 
The gels were placed on the orbital shaker and allowed to develop. When the desired 
amount of spots appeared, the developer was drained into the silver-containing 5 L 
drum (this precipitated out the silver) and 200 mL of stopping solution (2.92 g 
EDTA and 200 mL UHP) was added. The gels were left on the orbital shaker for at 
least 10 minutes. The gels could then be stored in UHP water. 
 
2.4.10 Spot picking 
The glass surface of the gel plate was dried and two reference markers (GE 
Healthcare, 18-1143-34) were attached to the underside of the glass plate before 
scanning at 300 dpi resolution using a flatbed image scanner (GE Life Sciences). The 
resulting image was imported into the ImageMaster software (GE Healthcare) and 
the spots were detected, normalised and the reference markers selected. While 
keeping the shift key depressed, all spots of interest were manually selected. The 
resulting image was saved and exported into the Ettan Spot Picker software (GE 
Healthcare). The stained gel was placed in the tray of the Ettan Spot Picker (GE Life 
Sciences, 18-1145-28) with reference markers aligned appropriately and covered 
with UHP. The imported pick list was opened, the syringe primed and the system 
was set up for picking the spots from the pick list. The spots were robotically picked 
and placed in 50 μL of LC-MS grade water (Fluka, 14263) in polypropylene 96-well 
plates (Greiner Bio One, 651201) and covered in parafilm, and stored at 4 °C until 
gel destaining which is outlined in section 2.6.1. 
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2.5 Excision of Protein Bands from 1-D Gels  
The gel was placed on a piece of parafilm which had been swabbed with 70% 
methanol. The work surface had also been cleaned with 70% methanol. Each lane of 
the gel was sliced into thin sections, across the width of the lane, using a scalpel and 
cut into six smaller pieces. The pieces from each band were placed into individual 
wells of a polypropylene 96-well plate (Greiner Bio One, 651201) with 50 μL of LC-
MS grade water in each. The plate can then be stored at 4 °C, covered in parafilm, or 
the proteins can be destained as described in section 2.6.1.  
 
2.6 Identification of proteins with LC–MS/MS 
2.6.1 Destaining Gel Plugs 
2.6.1.1 Coomassie-Stained Gel Pieces 
Gel pieces were washed three times in a 96-well polypropylene plate using 100mM 
ammonium bicarbonate/acetonitrile (1:1, vol/vol) for 10 minutes each until the 
pieces were fully destained.  
 
2.6.1.2 Silver-Stained Gel Pieces 
Gel pieces were destained in a 96-well polypropylene plate using 100 mM sodium 
thiosulfate/30 mM potassium ferricyanide (1:1, vol/vol) and incubated for 30 
minutes until the pieces are fully destained. 
 
2.6.2 In-Gel Digestion of Proteins 
50 µL of neat acetonitrile was then added to each well at room temperature until the 
plug becomes dehydrated, i.e. white and shrunken. The acetonitrile was removed and 
the gel pieces were dried. 50 µl of 10 mM DTT in 100 mM ammonium bicarbonate 
was added to cover the gel piece and incubated for 30 minutes at 56 °C. The DTT 
solution was removed and the gel pieces were cooled to room temperature. Once 
cooled, 50 µL of neat acetonitrile was added to each gel piece until they became 
dehydrated again. The acetonitrile was removed and 50 µL of 55 mM iodoacetamide 
in 100 mM ammonium bicarbonate was added.  The gel pieces were then incubated 
for 20 minutes in the dark at room temperature. 50 µL of neat acetonitrile was added 
to each gel piece at room temperature to dehydrate them. After drying, the individual 
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gel pieces were rehydrated in 10 µL digestion buffer. The digestion buffer was made 
fresh and consisted of 12.5 ng sequence-grade trypsin (Promega, V5111) (a 100 µg 
vial of trypsin was dissolved in 100 μL of 50 mM acetic acid and stored in 10 µl 
aliquots at -20 °C)  per µL of 10% acetonitrile, 40 mM ammonium bicarbonate. 
Sufficient buffer was added to cover the dried gel pieces and the plate was stored at 
37 °C for 30 minutes. After this time, the pieces were checked to ensure that the 
buffer was absorbed and if more needed to be added. The gel pieces were left for 
another 90 minutes to saturate them with trypsin and then an additional 10-20 µL of 
ammonium bicarbonate buffer was added to cover the gel pieces and maintain 
moisture for the digestion.  
Exhaustive digestion was carried out overnight at 37 °C. Peptides were extracted 
from the gel pieces twice using 50 µL of 1:2 (vol/vol) 5% TFA in acetonitrile (made 
fresh daily) for 15 minutes each time at 37 °C with gentle agitation. The extracted 
peptides were transferred to a new 96 well plate and lyophilised using a Maxi Dry 
Plus vacuum (MSC). The plate were then stored at -20 °C, wrapped in parafilm, or 
the proteins were resuspended in 20 µL of 0.1% TFA containing 0.1% acetonitrile 
and analysed using mass spectrometry. 
 
2.6.3 Digestion of Proteins for Quantitative Label-Free LC-MS/MS Analysis 
100 μg of protein from the sample of interest (determined by Quick Start Bradford 
assay) was placed into an eppendorf and the protein was precipitated using a 2-D-
clean-up kit (Bio-Rad, 163-2130), overnight in acetone. The protein pellet was 
resuspended in 6M Urea, 2M Thiourea, 10mM Tris, pH 8. 0.4% ProteaseMAX 
(Promega, V2071), a surfactant and trypsin enhancer added to improve protein 
solubility. The sample was sonicated and vortexed to ensure complete suspension.  
A Quick Start Bradford assay was performed and 5 μg of protein was transferred into 
a new eppendorf. 1 μL of reduction buffer was added to the sample (100 mM DTT in 
50mM ammonium bicarbonate), vortexed and incubated at 56 ºC for 30 minutes. 1 
μL of alkylation buffer was added to the sample (300 mM iodoacetamide in 50 mM 
ammonium bicarbonate), vortexed and incubated for 20 minutes at room temperature 
in the dark. 0.5 μL of 1% ProteaseMAX and Lys-C (Promega, V1071), added at a 
ratio of 1:50 (enzyme:protein), were added and the mixture was incubated for 1 hour 
at 37 ºC. Samples were diluted with four volumes of 50 mM ammonium bicarbonate 
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to dilute the urea concentration to below 1 M and sequence grade trypsin (Promega, 
V5111) was added at a ratio of 1:25 (enzyme:protein) and incubated overnight at 37 
ºC, after which the reaction was stopped by adding 50% TFA in LC-MS grade water  
at a ratio of 1:25. 
Samples were then cleaned up using PepClean C18 spin columns (Thermo, 89870), 
dried under a vacuum and stored at −20 °C until use.  
The resulting lyophilised peptides were re-suspended in 0.1% TFA in 2% acetonitrile 
with agitation and sonication. 1 µg of sample was then analysed by LC-MS/MS.  
 
2.6.4 Mass Spectrometry using LC/MS Analysis 
Nano LC–MS/MS analysis was carried out using either an Ultimate 3000 nanoLC 
system (Dionex) coupled to either a hybrid linear ion trap/Orbitrap mass 
spectrometer (LTQ Orbitrap XL; Thermo Fisher Scientific) for quantitative analyses 
or Hybrid linear ion trap mass spectrometer (LTQ XL; Thermo Fisher Scientific) for 
qualitative analyses.  
A 5 μL injection of digested sample were picked up using an Ultimate 3000 nanoLC 
system (Dionex) autosampler using direct injection pickup onto a 20 μL injection 
loop.  The sample was loaded onto a C18 trap column (C18 PepMap, 300 μm 
ID × 5 mm, 5 μm particle size, 100 Å pore size; Dionex) and desalted for 10 min 
using a flow rate of 25 μL/min in loading buffer (0.1% TFA, 2% acetonitrile). The 
trap column was then switched online with the analytical column (PepMap C18, 
75 μm ID × 250 mm, 3 μm particle and 100 Å pore size; (Dionex)) using a column 
oven at 35 °C and peptides were eluted with the following binary gradients of: 
 
30 minute reverse phase gradient 
Mobile phase buffer A (0.1% formic acid in 2% acetonitrile) and Mobile phase 
buffer B (0.08% formic acid in 80% acetonitrile): 0–100% solvent B in 30 minutes 
where solvent A consisted of 2% acetonitrile (ACN) and 0.1% formic acid in water 
and solvent B consisted of 80% ACN and 0.08% formic acid in water. Column flow 
rate was set to 350 nL/min. This method was used for all qualitative analysis of 
proteins extracted from gel pieces. 
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60 minute reverse phase gradient 
Mobile phase buffer A (0.1% formic acid in 2% acetonitrile) and Mobile phase 
buffer B (0.08% formic acid in 80% acetonitrile): 0–50% solvent B in 50 min and 
50–100% solvent B in a further 10 min, where solvent A consisted of 2% acetonitrile 
(ACN) and 0.1% formic acid in water and solvent B consisted of 80% ACN and 
0.08% formic acid in water. Column flow rate was set to 350 nL/min. This method 
was used for the quantitative label-free LC-MS analysis of proteins differentially 
expressed between monosomy three and disomy three fractionated vitreous fluid, 
section 4.9. 
 
180 minute reverse phase gradient 
Mobile phase buffer A (0.1% formic acid in 2% acetonitrile) and Mobile phase 
buffer B (0.08% formic acid in 80% acetonitrile): 0–25% solvent B in 120 min and 
25–50% solvent B in a further 60 min, where solvent A consisted of 2% acetonitrile 
(ACN) and 0.1% formic acid in water and solvent B consisted of 80% ACN and 
0.08% formic acid in water. Column flow rate was set to 350 nL/min. This method 
was used for the quantitative label-free LC-MS analysis of proteins differentially 
expressed between healthy and advanced melanoma fractionated sera, section 5.4. 
 
Data were acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific).  
The Hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; Thermo 
Fisher Scientific) was operated in data-dependent mode and externally calibrated.  
 
Survey MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the 
resolution set to a value of 30,000 at m/z 400. Up to three of the most intense ions 
(1+, 2+ and 3+) per scan were CID fragmented in the linear ion trap. A dynamic 
exclusion was enabled with a repeat count of 1, repeat duration of 30 seconds, 
exclusion list size of 500 and exclusion duration of 40 seconds. The minimum signal 
was set to 500.  All tandem mass spectra were collected using a normalised collision 
energy of 35%, an isolation window of 2 m/z, activation Q was set to 0.250 with an 
activation time of 30. 
 
The Hybrid linear ion trap mass spectrometer (LTQ XL; Thermo Fisher Scientific) 
was operated in data-dependent mode. Survey MS scans were acquired in profile 
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mode at 400–1800 m/z range. Up to sixteen of the most intense ions (1+, 2+ and 3+) 
per scan were CID fragmented in the linear ion trap. A dynamic exclusion was 
enabled with a repeat count of 2, repeat duration of 30 seconds, exclusion list size of 
500 and exclusion duration of 40 seconds. The minimum signal was set to 500.  All 
tandem mass spectra were collected using a normalised collision energy of 30%, an 
isolation window of 2 m/z, activation Q was set to 0.250 with an activation time of 
30. 
 
2.6.5 Identification of Proteins from Mass Spectrometry Data 
Mass spectrometry data, generated as *.RAW files from LTQ XL and Orbitrap 
instruments, was analysed using the search algorithm TurboSequest (Thermo Fisher 
Scientific) through Bioworks Browser version 3.3.1 (Thermo Fisher Scientific) for 
qualitative analyses and the MASCOT (v2.3.01, Matrix Science, London, UK) 
search algorithm for quantitative analyses. In both cases, the human fasta database 
was downloaded from UniProKB/SwissProt (January 2013)  
ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete 
 
The MASCOT search parameters that were used allowed two missed cleavages, 
fixed modification of cysteine (carbamidomethyl-cysteine) and variable 
modification of methionine (oxidised). Peptide tolerance depended on the instrument 
used to acquire the mass spectrometry data, in this case the Hybrid linear ion 
trap/Orbitrap mass spectrometer used a peptide tolerance of 20 ppm. The MS/MS 
tolerance was set at 0.6 Da. On completion of the database search the peptide results 
were filtered using MASCOT criteria of 95% confidence interval (C.I.) threshold 
(p<0.05), with a minimum ion score of ≥40. Protein identifications were accepted if 
they had one matched peptide. 
 
The following TurboSequest filters were applied following database searches: for 
charge state 1, XCorr > 1.8; for charge state 2, XCorr > 2.0; for charge state 3, XCorr > 
2.5, a peptide probability of 0.05 and a delta CN of 0.1. Protein identifications were 
accepted if they had at least two matched identified peptides. 
 
 
75 
 
2.6.5.1 Bioworks Browser 
Bioworks Browser was used in the analysis of all qualitative identifications. Outputs 
from the analytical software illustrated the protein accession code, number of 
matched peptides, and per cent coverage. The protein accession number represents 
the UniProtKB/Swiss-Prot protein code. Number of peptides matched refers to the 
number of identified peptides which correspond to the protein. The per cent 
coverage represents the percentage of the protein‟s sequence represented by the 
peptides identified. The Xcorr score (XC) represents the cross correlation value from 
the search; that is the degree of how well theoretical spectra match to observed 
spectra. XC values are higher for well-matched, large peptides. 
 
2.6.5.2 Progenesis LCMS 
The resulting total ion chromatograms (TIC) of quantitative label-free LC-MS data 
were subjected to statistical analysis using Progenesis LC-MS software (NonLinear 
Dynamics). This programme imports all runs in an “ion intensity map” format which 
maps the ions discovered in the run, by plotting retention time against the 
mass/charge ratio. All ion maps may be aligned against one reference run which 
allows for any shift in retention time between runs. The intensity of each ion may 
then be compared against that of all other runs, thus generating quantitative data on 
patterns of differential expression between sample sets which may be analysed with 
statistical analysis tools such as ANOVA, and principal component analysis.  
For all experiments, unless stated otherwise, all peptides, and all proteins 
demonstrated ANOVA scores of ≤0.05 for differential analysis between sample sets.  
For all quantitative LC-MS/MS data, Progenesis provides the following information; 
protein accession number, peptide count, number of peptides matched, confidence 
score, an ANOVA value, the maximum fold change, and the average normalised 
abundance. The protein accession number represents the code corresponding to the 
protein in the UniProtKB/Swiss-Prot protein database. “Peptide count” refers to the 
number of peptides identified and “number of peptides matched” refers to the 
number of peptides which were matched to the protein. The MASCOT score (or ion 
score) is calculated from the combined scores of how well each peptide matches to 
the protein sequence. The significance of the differential expression between the two 
76 
 
groups is represented by an ANOVA score (p-value). The fold change, or average 
ratio, illustrates the greatest fold different in protein ion abundance between the two 
groups. The average normalised abundance is calculated from the sum of all peptide 
abundances from every run for each protein.  
 
2.7 Western blot Analysis 
2.7.1 1-D Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using 4-12% NuPAGE Bis-
Tris Gels (Life Technologies, NP0322PK2) in XCell SureLock™ Mini-Cell (Life 
technologies, EI0001) running instrument. Western blotting protein samples (2 
μg/μL) were prepared by diluting samples with PBS and then an equal volume of 2X 
loading buffer (Sigma, S3401). The samples were heated at 95 °C for 5 minutes and 
placed on ice prior to being centrifuged. 10-40 µg of protein and 5μL of molecular 
weight marker (Thermo, 26634) were loaded onto gels. The samples were 
electrophoretically separated at 200 V and 45 mA using a 1X MOPS/SDS running 
buffer (Life Technologies, NP001) until the bromophenol blue dye reached the 
bottom of the gel. 
 
2.7.2 Western blotting 
Once electrophoresis had been completed, the gel was equilibrated in a 1X tris-
glycine transfer buffer (Bio-Rad, 161-0734) containing 20% methanol for 
approximately 10 minutes. Five sheets of Whatman 3 mm filter paper (Whatman, 
1001824) were soaked in freshly prepared transfer buffer. These were then placed on 
the cathode plate of a semi-dry blotting apparatus (Bio-Rad). Air pockets were then 
removed from between the filter paper. PVDF membrane (GE Healthcare, 
10600021), which had been equilibrated in the same transfer buffer, was placed over 
the filter paper on the cathode plate. Air pockets were once again removed. The gels 
were then aligned onto the membrane. Five additional sheets of transfer buffer-
soaked filter paper were placed on top of the gel, all air pockets removed and excess 
transfer buffer removed from the cathode plate. All proteins were transferred from 
the gel to the membrane at a current of 340 mA at 15 V for 23 minutes (FABP3 was 
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transferred under the same conditions for 20 minutes), until all colour markers had 
transferred.  
Following protein transfer, membranes were stained using Ponceau (Sigma, P7170) 
to ensure efficient protein transfer. The membranes were then blocked for two hours 
using 5% Marvel (Cadburys; Marvel skimmed milk) in TBS-T (a mixture of 1X tris-
buffered saline (TBS) (Sigma, t5912) containing 0.05% Tween 20 (Sigma, P5927)).  
The membranes were washed with TBS-T prior to the addition of the primary 
antibody, prepared in 5% Marvel in TBS-T at recommended dilutions, and then 
incubated overnight at 4 °C. The membranes were then rinsed 3 times with TBS-T 
for a total of 30 minutes. Relevant secondary antibody (1/2000 dilution of anti-
mouse (Dako Cytomation, P0260) or anti-rabbit (Dako Cytomation, P0448) or anti-
goat (Santa Cruz Biotechnology, Sc2098) IgG peroxidase conjugate in 5% 
Marvel/TBS-T) was added for 2 hours at room temperature. The membranes were 
again washed three times thoroughly in TBS-T for 30 minutes.  
All primary and secondary antibodies used are shown in Tables 2.3 and 2.4. 
 
 
Table 2.3 Primary antibodies and dilutions 
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Table 2.4 Secondary antibodies and dilutions 
 
2.7.3 Enhanced chemiluminescence detection using autoradiographic films 
Immunoblots were developed using an enhanced chemiluminescence (ECL) kit (GE 
Life Sciences, RPN2106), which facilitated the detection of bound peroxidase-
conjugated secondary antibody. Following the final washing, membranes were 
subjected to ECL. The membrane was placed on a sheet of transparent plastic and 3 
mL of a freshly prepared 1:1 (v/v) mixture of ECL reagent A and B was used to 
cover the membrane. The ECL reagent mixture was completely removed after a 
period of five minutes and the membrane was covered in a layer of transparent 
plastic. All excess air bubbles were removed. The membrane was then exposed to 
autoradiographic film (GE Life Sciences, 95017-681) for various times (from 10 
seconds to 15 minutes depending on the intensity of the signal). The exposed 
autoradiographic film was developed for 3 minutes in developer solution (Kodak, 
LX24, diluted 1:5 in water). The film was then washed in water for 15 seconds and 
transferred to a fixative solution (Kodak, FX-40, diluted 1:5 in water) for 5 minutes. 
The film was washed with water for 5-10 minutes and left to dry at room 
temperature. 
 
2.8 RNA Interference 
RNAi using small interfering RNAs (siRNAs) was carried out to silence the FABP3, 
TPI1, EEF1G, SELENBP1, and KPNB1 genes. Two independent siRNA molecules 
were used for each protein (Applied Biosystems). These siRNAs were 21-23 bps in 
length and were introduced to the cells via reverse transfection with Lipofectamine 
RNAiMAX Transfection Reagent (Life Technologies, 13778150).  
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2.8.1 Transfection optimisation 
In order to determine the optimal conditions for siRNA transfection, optimisation 
with kinesin siRNA (Life Technologies, 16704) was carried out for the 92.1 and 
MEL202 cell lines. 
Cell suspensions were prepared at 5X10
4
, 7.5 X 10
4
, 1X 10
5
, 2.5 X 10
5
, and 5 X 10
5
 
cells per well. Solutions of negative control and kinesin siRNA at a final 
concentration of 50 nM were prepared in optiMEM (GibcoTM, 31985047). 
Lipofectamine RNAiMAX solutions at a range of concentrations were added the 
solutions and was mixed well and incubated for 12 minutes at room temperature. 100 
μL of the siRNA/lipofectamine solutions were added in a dropwise fashion to each 
well of a 6-well plate, of which each well contained 1 mL of a cell suspension. The 
plates were mixed gently and incubated at 37 °C for either 6 hours or overnight 
(depending on the cell line). After this time, the transfection mixture was removed 
from the cells and the plates were fed with fresh serum-containing medium. The 
plates were assayed for changes in proliferation at 72 hours using the acid 
phosphatase assay (Section 2.9). Optimal conditions for siRNA transfection were 
determined as the combination of conditions, which gave the greatest reduction in 
cell number after kinesin siRNA transfection and also the least cell kill in the 
presence of transfection reagent. Western blot analysis was used to establish the 
optimum conditions for a siRNA transfection. The optimised conditions for the cell 
lines are shown in Table 2.5.  
 
Table 2.5 Optimised conditions for the siRNA transfection of 92.1 and MEL202 cell 
lines. 
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2.8.2 siRNA Functional Analysis of Targets of Interest 
Two pre-designed siRNAs were chosen for the protein/gene targets and transfected 
into cells. In some cases two siRNAs were sufficient, however multiple siRNA were 
usually tested.  
For each set of siRNA transfections carried out, control, non-transfected cells and a 
scrambled siRNA transfected negative control were used. Scrambled siRNA are 
sequences that do not have homology to any genomic sequence. The scrambled non-
targeting siRNA used in this study is commercially produced, and guarantees siRNA 
with a sequence that does not target any gene product. It has also been functionally 
proven to have no significant effects on cell proliferation, morphology and viability.  
For each set of experiments investigating the effect of siRNA, the cells transfected 
with target-specific siRNAs were compared to cells transfected with scrambled 
siRNA. This took account of any effects due to the siRNA transfection procedure, 
reagents, and also any random effects of the scrambled siRNA. Western blots were 
used to determine if siRNA had an efficient knock-down effect at a protein-level.  
All siRNA used in these experiments are shown in Table 2.6. 
 
 
Table 2.6 siRNA used in uveal melanoma cell line transfections 
 
2.9 Acid Phosphatase Assay 
Following an incubation period of 96 hours, media was removed from the plates.  
Each well on the plate was washed twice with 2 mL PBS.  This was then removed 
and 2 mL of freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate 
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(Sigma 104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 (Sigma, 
X100), pH 5.5) was added to each well.  The plates were then incubated in the dark 
at 37 °C for 2 hours. Colour development was monitored during this time. The 
enzymatic reaction was stopped by the addition of 1 mL of 1 M NaOH.  The plate 
was read in a dual beam plate reader at 405 nm with a reference wavelength of 620 
nm. 
 
2.10 Proliferation assays on siRNA transfected cells 
As described, cells were seeded using 5.4 μL RNAiMAx Lipofectamine to transfect 
20 nM siRNA in a cell density of either 1X10
5
 or 7.5X10
4
 per well of a 6-well plate. 
After either 6 hours or overnight, the transfection medium was replaced with fresh 
media and cells were allowed to grow until they reached 80-90% confluency; a total 
of 96 hours. Cell viability was assessed using the acid phosphatase assay (section 
2.9). All experiments were carried out independently at least three times. 
 
2.11 Invasion assay 
2.11.1 Preparation of invasion chambers 
Invasion assays were carried out in Boyden chambers (8 μm pore size) (BD 
Biosciences, 35309) which were coated in 100 μL of matrigel (BD Biosciences, 734-
1100) diluted to 1 mg/mL in serum-free RPMI-1640 and incubated over-night at 4 
°C. Cell suspensions were prepared in serum-free basal media. 750 μL of complete 
media was added to the lower chamber of the insert in the 24-well plate. A volume of 
500 μL of the cell suspension was then added into the insert. The invasion assays 
were then incubated for 48 hours at 37 °C and 5% CO2. 
 
2.11.2 Staining of invasive cells 
After incubation, the non-invading cells were removed by wiping the inner side of 
the insert with a PBS-soaked cotton swab (Johnson and Johnson). The outer side of 
the insert was then stained with 0.25% crystal violet for 10 min. Excess stain was 
rinsed off the inserts with sterile water and allowed to dry. 
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2.11.3 Counting of invading cells 
To determine the total number of invading or migrating cells, the number of 
cells/field in 15 fields was counted at 200x magnification. The average number of 
cells per field was then multiplied by a conversion factor of 140 (growth area of 
membrane divided by field of viewed area at 200x magnification (calibrated using a 
microscope graticule)). All assays were subjected to statistical analysis using 
Student‟s t-tests (2-tailed, 2-sample unequal variance). 
 
2.12 Migration Assays 
Migration assays were carried out using an identical protocol to that of section 2.11 
except that uncoated 8 μm inserts were used. 
 
2.13 Apoptosis and FACS 
The effect of SELENBP1, EEF1G and KPNB1siRNA-mediated knockdown on 
apoptosis in the 92.1 uveal melanoma cell line was assessed by Annexin-V/7-AAD-
positive staining. Following detachment, cells were stained using PE Annexin V 
Apoptosis Detection Kit I (BD Pharmingen, 559763) according to manufacturer‟s 
instructions and analysed via flow cytometry (BD FACSAria, Ox, UK). 
Photomultiplier tube (PMT) voltages were set as described (Table 2.7) and a 
compensation matrix determined using single colour stained controls (Table 2.8). 
The percentage of early apoptotic (Annexin V positive only) and late apoptotic/dead 
(Annexin V and 7-AAD positive) cells were compared to those of the scramble 
control. 
 
 
Table 2.7 Flow cytometer settings for apoptosis Annexin-V/7AAD assay. Linear 
scales were used to collect forward and side scatter signals while logarithmetic 
scales were applied for detection of fluorescent PE and PerCP-Cy5.5 signals.  
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Table 2.8 Flow cytometer compensation matrix for apoptosis Annexin-V/7AAD 
assay. 
 
2.14 Analysis of Reactive Oxygen Species (ROS) 
92.1 cells were transfected with two independent SELENBP siRNA as described 
previously and set up at 1X10
5
 cells/well in a 24-well plate with at least two wells 
per condition.  After overnight incubation, the medium was removed and the cells 
were washed in PBS. Half of the wells were exposed to 5 μM DCFDA (Sigma, cat 
21884) in DMSO (Sigma, cat D2438) and diluted into HBSS (Invitrogen, cat 14025-
050), the remaining wells were exposed to HBSS (this allows for background 
fluorescence to be taken into account).  The cells were exposed to DCFDA for 15 
minutes and then washed twice with PBS to remove un-incorporated DCFDA.  The 
cells were fed with RPMI-1640 medium containing 1% FCS and incubated for 2 
hours at 37 ˚C after which time the cells were washed twice with PBS and read on a 
fluorescent plate reader with excitation of 485 nm and emission of 528 nm.  Sodium 
selenite was used as a pro-oxidant control and Trolox (Sigma, cat 238813) as an anti-
oxidant control. siRNA transfected cells and controls were exposed to 200 μM 
hydrogen peroxide (Sigma, cat H1009) during the 2 hour incubation in order to 
observe ROS.  The wells incubated with HBSS alone were used subtracted from the 
wells exposed to DCFDA for each condition.  
 
2.15 Zymography 
Serum-free conditioned media was collected from 1.5X10
5
 92.1 and 2X10
5 
MEL202 
cells which were transfected with siRNA against SELENBP, EEF1G, and KNPB1.  
Samples were mixed 1:1 with 2X Tris-Glycine SDS sample buffer (Serva, 42528.01) 
and were loaded onto the gel. A 5 μl aliquot of molecular weight marker (Thermo, 
26634) was also loaded onto the gel. The gelatin gels (Invitrogen, EC6175BOX) 
were run at 30 mA per gel in 1X Tris-Glycine SDS running buffer (Life 
Technologies, LC26755) until the dye front reached the bottom of the gel. After 
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electrophoresis, gels were soaked in renaturing buffer (Life Technologies, LC2670) 
at room temperature with gentle shaking for 30 min. The gels were then incubated in 
developing buffer (Life Technologies, LC2671) for 30 minutes after which time the 
buffer was decanted and fresh developing buffer was added. The gels were stored at 
37 °C overnight. The following day, the gels were stained with Coomassie as 
described in section 2.4.8. Gelatinase activity was illustrated as distinct, clear bands. 
 
2.16 Immunodepletion  
Immunodepletion of serum was performed using Multiple Affinity Removal Column 
Human-14 (Agilient, 5188-6560) according to the manufacturer‟s instructions. 
 
2.17 ProteoMiner 
2.17.1 Sequential Elution 
ProteoMiner sample enrichment was performed using a ProteoMiner sequential 
elution kit (Bio-Rad, 163-3010). The small capacity kit was used in which 200 µL of 
serum was added to the column. After following a standard protocol, four elution 
fractions were acquired per sample (each elution buffer is outlined in Table 2.9) and 
the protein from each was precipitated overnight using a 2-D clean-up kit (Bio-Rad, 
163-2130). The resulting protein pellets were resuspended in 6 M urea, 2 M thiourea, 
10 mM tris (pH 8) and stored at -80 °C until further analysis. 
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Table 2.9 ProteoMiner sequential elution buffers and their corresponding chemical 
properties. 
 
2.17.2 Modified ProteoMiner Protocol for Vitreous Fluid Treatment 
As the vitreous fluid specimens to be analysed were neither sufficiently concentrated 
nor plentiful, it was decided to modify the process of ProteoMiner treatment. This 
involved resuspending the resin in each column in 200 μL of wash buffer, and 
mixing each well by vortexing. 100 μL of resin was then immediately removed from 
each unit. This would reduce the volume of settled beads from 20 μL to 10 μL, This 
would also change the optimal sample volume to 100 μL, which provides the correct 
sample to beads ratio of 10:1. The adjusted protocol allowed for 300 μg of protein to 
be loaded onto the beads, which was present in the vitreous samples.  
Following this, the ProteoMiner protocol was adjusted to account for the lower bead 
volume although all of the reagents supplied with the kit (Bio-Rad, 163-3006) were 
utilised. Briefly, 100 μL of wash buffer was applied to the resin and incubated for 
five minutes while rotating. The buffer was then removed by centrifugation at 1000 g 
for 30 seconds following the removal of both caps. The bottom cap was reapplied 
and 100 μL of sample was added to the resin bed. The top cap was then replaced and 
the unit was allowed to rotate for a total of two hours incubation time at room 
temperature. Both caps were removed and unbound sample was discarded by 
centrifuging the tube at 1000 g for 30 seconds. 100 μL of wash buffer was applied to 
the resin and the tube caps were replaced prior to rotating the column for five 
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minutes. The buffer was then removed by centrifugation as before and the wash step 
was repeated. 100 μL of deionised water was added to the sealed tube and the 
column was rotated for one minute. The water was then removed by centrifugation as 
before and the column was resealed. 10 μL of rehydrated elution reagent was added 
to the column and the top cap was replaced prior to lightly vortexing the tube for five 
seconds. The elution buffer and resin were allowed to incubate for 15 minutes, 
during which time the tube was lightly vortexed several times. The elution fraction 
was collected into a clean eppindorf tube by centrifugation at 1000 g for 30 seconds. 
The elution step was repeated twice and all elutions were then pooled and stored at -
20 °C until use.  
 
2.18 Enzyme-Linked Immunosorbent Assay (ELISA) 
The majority of ELISAs performed for validation of cutaneous melanoma biomarker 
targets were sandwich ELISAs. These 96-well plates come with capture antibody 
precoated to the surface of the wells. Protein standards that come with the kit were 
prepared and along with serum samples at a kit specific dilution are added to the wells, 
with the standards in duplicate and a proportion of the serum samples in duplicate and 
triplicate. After incubation the plate was washed to remove any unbound antigen. An 
enzyme-linked detection antibody was added which binds specifically to the antigen. 
After another incubation period the plate was washed to remove any unbound detection 
antibody.  
A competitive ELISA involves the initial incubation of unlabelled primary antibody 
with serum. The samples, with the bound antibody/antigen complexes, were then added 
to an antigen coated well. The plate was washed so that unbound antibody is removed 
(the antibody/antigen complexes from initial incubation were removed). 
For both types of ELISA, a substrate was added that was converted by the enzyme into 
a colour or fluorescent signal. This colour or fluorescence was measured at a 
wavelength recommended in the ELISA manual to determine the presence and quantity 
of the antigen. From the standard curve produced from the standards of known 
concentrations, the concentration of antigen present in the serum sample was 
determined and comparisons were be made between the various types of samples. 
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Standard protocols were followed for each ELISA. An overview of all ELISA used is 
shown in Table 2.10. 
 
 
Table 2.10 Overview of conditions and details of ELISA used. 
 
2.19 Luminex Multiplex Bead-Based Assays 
A Luminex 12-plex cytokine/chemokine assay was performed according to Millipore 
Milliplex Map Kit protocol (Millipore). The assay quantified the levels of FGF2, 
IFNɣ, TNFα, TGFα, MIP1α, IL-10, IL-15, IL-1α, IL-2, IL-6, IL-8, and IP10. 
Initially, the 96-well filter bottom plate was pre-wet by adding 200 µL assay buffer. 
The microparticles of the panel were pooled together and 25 µL of the diluted 
microparticle solution and 25 µL of sample and standards and controls were also 
added to the necessary wells. 25 µL assay buffer was added to all wells. Next the 
plate was incubated overnight at 4 ºC and next day washed three times with wash 
buffer. Afterwards, 50 µL of diluted biotin antibody was added to each well and 
incubated for 1 hour. The plate was then washed as described above and 50 µL of 
diluted Streptavidin-PE was added to each well and incubated for 30 minutes. All 
incubations were performed at room temperature on an orbital shaker set at 15 g. 
Finally, the plate was washed again with 100 µL of Sheath Fluid. The median 
relative fluorescence units were measured using the Luminex 100 analyzer 
(Luminex, Austin, TX, USA).  
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2.20 SELDI-ToF MS 
2.20.1 Conditioned Media Preparation and Collection 
Cells (3X10
6
) were seeded in four biological replicates in T-175 cm
2
 flasks and 
allowed to grow until 50-60% confluent. The cell-containing flasks were then 
washed three times with 10 mL of serum-free (SF) basal media and incubated in 15 
mL of SF basal media for 60 minutes. After this time, cells were washed twice with 
SF basal media and 15 mL of fresh SF basal media was added to the cells and 
incubated for 72 hours. After such time, conditioned media was collected, 
centrifuged for 15 minutes at 250 g, and stored at –80 °C. At the time of analysis 
conditioned media was concentrated using 5,000 dalton (Da) molecular weight cut-
off concentrators (Millipore, UFC 900524). A volume of 15 mL was concentrated to 
500 µL by centrifuging at 1000 g at 4 °C. 
 
2.20.2 Preparation of IMAC30 Chip Surface 
IMAC30 array, 8-spot (Biorad, C730043) was activated by adding 5 μL of 100 mM 
CuSO4 (Sigma, 2091198) to each chip surface for a total of 30 minutes (2x15 minute 
applications), and then rinsed with high-performance liquid chromatography grade 
water (Sigma, 39295). The copper ions were charged by applying 50 μL of 100 mM 
sodium acetate (Sigma, S8625) for 5 minutes. The chip was placed in a bioprocessor 
(Biorad) and washed twice with 300 μL of 250 mM sodium chloride containing 0.1% 
Triton X-100 (Sigma Aldrich, T9284). The protein sample was diluted in 300 μL of 
250 mM sodium chloride containing 0.1% Triton X-100 and samples were applied to 
the spots of the array. The array was placed on a shaker and gently agitated for 90 
minutes to allow for interaction with the array surface. After removing the sample, 
the array was washed x2 with 300 μL of 250 mM sodium chloride for 5 minutes, 
followed by a brief high-performance liquid chromatography grade water wash. 5 mg 
of Sinapinic acid (Biorad, C730078) solution was prepared by dissolving in 200 μL 
of 50% LC-MS grade acetonitrile (Sigma, 34967) containing 0.5% LC-MS grade 
trifluoroacetic acid (Sigma, 302031). After removing the array from the 
bioprocessor, a 0.8 μL aliquot of saturated sinapinic acid was added to the spots, 
allowed to dry and repeated. 
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2.20.3 Analysis of Protein Chip Array in SELDI TOF Reader 
The IMAC-30 arrays were analyzed in a Ciphergen Series PBS-IIC ProteinChip® 
System, and time-of-flight (TOF) data was generated by averaging a total of 220 
laser shots collected at a laser intensity of 200, a detector sensitivity of 8 and 
molecular mass range from 5–20,000 Da for low molecular weight range and 20,000-
100,000 Da for high molecular weight range. 
 
2.20.4 Analysis of Differential Expression of Proteins/Peptides 
Molecular weights were calibrated externally using an all-in-1 protein standard 
(Biorad, N76006). All data was analyzed using Biomarker Wizards Software, version 
3.1 (Bio-Rad). After automatic baseline noise correction, all of the spectra were 
normalized together by the „„total ion content‟‟ method as described by the 
manufacturer, i.e. with an m/z between 5,000 and 100,000. The peaks with an m/z 
value <3000 were excluded, as these peaks were mainly ion noise from the matrix 
(sinapinic acid). Peak clusters were generated by automatically detecting qualified 
mass peaks with a signal to noise ratio (S/N) >5 in the first pass, completed with a 
second-pass peak selection of S/N >3, with a 0.3% mass error for 5000-20,000 Da, 
and the same for 20,000-100,000 Da. Statistically significant peaks were considered 
to be those with p <0.05.   
 
2.20.5 IMAC-Cu2+ Based Fractionation Using Imidazole 
The uncharged IMAC resin (Bio-Rad, 156-0123) was mixed in order to thoroughly 
resuspend the resin. 200 μL was then transferred into an eppindorf tube containing a 
spin column with a 0.22 μm filter (Sigma, CLS8161-100EA). The resin was 
centrifuged at 1000 g for 15 seconds in order to pack the resin and then washed with 
500 μL of distilled water. The centrifugation step was repeated. Following this, the 
resin was equilibrated with 500 μL of 50 mM sodium acetate, 0.3 M sodium 
chloride, pH4, and the column was centrifuged at 1000 g for 15 seconds. This step 
was repeated. 500 μL of a 0.2 M copper sulphate solution (of neutral to weakly 
acidic pH) was applied to the resin and removed by centrifugation. This step was 
repeated. The column was washed twice with 500 μL of 50 mM sodium acetate, 0.3 
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M sodium chloride, pH 4 prior to being washed twice with 500 μL of deionised 
water.  
To pre-equilibrate the resin before sample binding, 500 μL of binding buffer was 
applied (50 mM sodium phosphate, 300 mM sodium chloride, 5 mM imidazole 
(Sigma Aldrich I0125), pH 8) and removed by centrifugation. This step was 
repeated. 2 mg of protein in a volume of ≤500 μL was added to the resin and mixed 
by pipetting up and down five times. It was then incubated for up to 15 minutes and 
centrifuged at 1000 g for one minute. This step was repeated by reloading the flow-
through onto the resin bed. The unbound fraction was then collected. The spin 
column was placed into a new eppindorf and 500 μL of wash buffer (50 mM sodium 
phosphate, 300 mM sodium chloride, 20 mM imidazole, pH 8) was applied to the 
resin and mixed by pipetting up and down five times followed by centrifugation at 
1000 g for one minute. This wash step was then repeated after which the fraction was 
collected. The column was placed into a new collection vessel and an elution buffer 
(50 mM sodium phosphate, 300 mM sodium chloride, 50 mM imidazole, pH 8) was 
applied, the fraction was collected as before. Following this, any number of elutions 
can be collected by increasing the concentration of the imidazole in the elution buffer 
to a maximum of 500 mM.  
The protein present in the fractions was then precipitated by applying five volumes 
chilled acetone to each elution and storing at -20 °C overnight. The following day, 
the elution fractions were centrifuged at 14,000 rpm at 4 °C for 10 minutes and the 
acetone was removed from each sample. The resulting pellets were allowed to air dry 
for two minutes prior to being resuspended in 6 M Urea, 2 M Thiourea, 10 mM Tris, 
pH 8 and stored at -20 °C. 
 
2.20.6 On-Chip Elution of IMAC Cu2+ -Bound Proteins 
The SELDI chip surface was prepared and the appropriate specimen was allowed to 
bind, followed by a wash step as described in section 2.20.2. However, the matrix 
was not applied. Instead, an elution buffer (250 mM sodium chloride, 0.1% Triton X-
100, 10 mM imidazole) was applied to the chip, and gently agitated for ten minutes 
in order to remove bound proteins. The elution was removed and the process was 
repeated using elution buffers containing 50 mM and 100 mM imidazole. The three 
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fractions were then treated with PepClean C-18 Spin Columns (Thermo, 89870) 
according to the manufacturer‟s instructions, and further analysed. 
 
2.21 MALDI ToF Analysis 
All experiments were carried out on an AB Sciex 4800 Plus analyser equipped with 
TOF/TOF ion optics and a diode pumped Nd:YAG laser with 200 Hz repetition rate. 
The MS/MS capabilities of the instrument are facilitated through a timed ion 
selector, a deceleration lens, a collision cell, and a second ion source. All the MS/MS 
spectra resulted from accumulation of at least 1600 laser shots. Air was used as the 
collision gas such that nominally single collision conditions were achieved. A wide 
mass window was utilized so that all the precursor ions could pass the gate to enter 
the collision. Generally, the width of mass window is set to 100 Da for precursor 
masses between 5000 Da and 9000 Da. MS/MS data were acquired using the 
instrument default calibration, without applying internal or external calibration. The 
digitizer, voltage and calibration parameters used are shown in Table 2.11. 
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Table 2.11 Digitiser, laser intensity, and voltage settings for MALDI-TOF 
 
2.22 Statistical Analysis 
Patterns of differential protein abundance between disease and control groups were 
measured and, using statistical analysis, only the proteins which illustrated a 
significant difference between the groups were followed up. A two-tailed Student‟s t-
test was utilised to determine if the protein fold changes observed were statistically 
significant. Protein changes with a p-value of ≤0.05 were considered statistically 
significant. Any keratin identifications which were discovered in protein lists were 
considered to be of little interest as this may be indicative of contamination and may 
not accurately reflect the proteome in question. Any outliers present in ELISA 
readings were determined using Tukey‟s method which considers values at a distance 
of 1.5 times the interquartile range (IQR) below Q1 (quartile one) or at 1.5 times the 
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IQR above Q3 (quartile three) to be possible outliers (Tukey 1977). Identified 
outliers were subsequently removed from the analysis. 
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CHAPTER THREE 
Proteomic Analysis of Uveal Melanoma Tumour Tissue 
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3.1 Background 
To date, only a very limited number of proteomic studies have been carried out 
investigating the biology of the metastatic phenotype of uveal melanoma. In addition 
to this, the majority of these studies have used cell line models, as outlined in section 
1.2.4. It was hypothesised that patterns of differential protein expression would be 
observed between primary uveal melanoma tumour tissues of patients who 
subsequently developed metastasis versus those who did not. By examining 
differential protein expression patterns between these tumour tissue types, this may 
improve our understanding of the biology of uveal melanoma tumours. As few 
therapeutic targets currently exist for the treatment of metastatic disease, proteins 
which indicate prognosis may be developed as targeted therapies. In addition to this, 
protein biomarkers predicting metastatic uveal melanoma could (along with genetic 
analysis) improve interim monitoring of patients whose tumours are likely to 
metastasise.  
The purpose of this study was to identify differentially expressed proteins in uveal 
melanoma tissue specimens from patients with a minimum of seven years clinical 
follow-up comparing those who developed metastases to those who did not. Only 
primary tumours specimens were used in this analysis as secondary tumour tissue 
was not available. 
Nine subsequently metastasised and 16 non-metastasised primary tissue samples 
were compared using 2-D DIGE for the analysis of differential protein expression. 
This work was subsequently published with follow-up IHC analyses (Linge, 
Kennedy et al. 2012). In parallel, eight tumour tissue specimens from each group 
were compared using quantitative label-free LC-MS analysis. Identified proteins of 
interest from both studies were then followed up using functional analysis in cell 
line models.  
 
3.2 Clinical Specimens Included in the Analysis 
A total of 27 uveal melanoma primary tumour tissue specimens obtained by 
enucleation were included in a 2D-DIGE study carried out in collaboration with the 
Royal Victoria Eye and Ear Hospital, Dublin (RVEEH). These samples were 
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acquired from Prof. Susan Kennedy (RVEEH). The study was approved by the 
Research and Ethics Committee of the Royal Victoria Eye and Ear Hospital, Dublin 
and the research adhered to tenets of the Declaration of Helsinki. Ten of these 
specimens subsequently metastasised to regions such as the liver (six cases), lungs 
(two cases), kidney (one case) and both the liver and skin (one case). According to 
the Callender classification, of the tumours which metastasised, three were of the 
epithelioid cell type, four were of the spindle type and three were mixed.  
Chromosome three status was available for 14 of the non-metastatic patients which 
showed disomy in 12 and trisomy in two cases. In eight out of the ten patients who 
developed metastasis, loss of heterozygosity for chromosome three was observed 
which is in agreement with previous studies, detailed in section 1.2.2., which 
correlate loss of heterozygosity of chromosome 3 with poor outcome.  
25 of the samples were used in 2-D DIGE analysis while 16 were used in 
immunohistochemistry (IHC) analysis. This was due to the fact that this was 
intended to be a discovery-phase, pilot study and hence, eight samples from each 
group were chosen, see table 3.1 for details on the samples used.  
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3.3 Differential Protein Expression Analysis Between Non-Metastasised and 
Subsequently Metastasised Primary Tumour Tissue using 2-D DIGE 
In order to extract protein from the tumour specimens, a sample grinding kit with 
lysis buffer was used. Protein lysates of uveal melanoma primary tumour tissues 
were collected from both patient groups.  
A pool of two fluorescently labelled samples (from different groups) was mixed with 
the internal standard, which allows for normalisation between gels and for the 
comparison of protein abundances, and separated by isoelectric focusing (IEF). Each 
protein applied to the strip migrates toward its isoelectric point (pI); the point at 
which its net charge is zero. This represents the first dimension of two-dimensional 
(2-D) electrophoresis. The IPG strips were then overlaid onto a gel where the 
proteins were separated based on their size in the second dimension.  
Gels were scanned on a Typhoon 9400 Variable Mode Imager to generate images at 
the appropriate excitation and emission wavelengths. Progenesis Same Spots 
software statistically analysed these acquired images by comparing non-metastasised 
primary tumour tissue to that which metastasised in order to identify differentially 
regulated proteins. Proteins were defined as differentially expressed if the observed 
average ratio was ±1.2 with a t-test score <0.05 between sample groups.  
Fourteen protein spots were found to be differentially expressed between the two 
groups. These proteins were identified using MS. The list of identified differentially 
expressed proteins is outlined in Table 3.2. Their location on a representative 2D 
DIGE gel is shown in Figure 3.1. 
The following proteins were found to show increased expression in primary uveal 
melanomas that metastasised compared to non-metastasised uveal melanomas; 
protein disulphide-isomerase A3 precursor (PDIA3), selenium-binding protein 1 
(SELENBP1), alpha-enolase, F-actin capping protein subunit alpha-1 (CAPZA1), 
endoplasmic reticulum protein ERp29 precursor, triosephosphate isomerase (TPI1), 
protein DJ-1 (PARK7), and fatty acid-binding protein, heart-type (FABP3). Both 
CAPZA1 and FABP3 protein spots are shown in Figure 3.2. Protein identification of 
spot number 2 yielded two protein identifications, vimentin and beta-
hexosaminidase subunit alpha. Eukaryotic translation initiation factor 2 subunit 1, 
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proteasome subunit alpha type 3, 40S ribosomal protein SA, tubulin beta chain and 
tubulin alpha-1B chain were shown to have decreased expression in uveal melanoma 
tissues of patients who subsequently developed metastatic disease. 
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Figure 3.1 Representative 2D DIGE gel image of Cy2-labelled pool of protein 
lysates from primary uveal melanomas that were subsequently found to have 
metastasised (n=9) and the primary uveal melanomas that did not metastasise 
(n=16). Differentially expressed proteins that were successfully identified by 
LC/MS-MS are represented on the gel. Proteins are labelled numerically for clarity 
and are outlined in Table 3.2. 
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Figure 3.2 Two examples of differentially expressed protein spots as illustrated by 
Progenesis SameSpots software. Samples of non-metastasised specimens were 
compared to those which subsequently metastasised. (a) Spot number 6 was 
identified as F-actin capping protein subunit alpha-1 (CAPZA1), with an average 
ratio of 1.3 and p=0.028 between experimental groups. (b) Spot number 15 was 
found to be fatty acid-binding protein, heart type (FABP3), with an average ratio of 
2.2 and p=3.5x10
4
 between experimental groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
(b) 
Non-Metastasised Metastasised 
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3.4 Enrichment analysis within differentially expressed protein lists using 
DAVID 
In order to determine significant enrichment of biological processes, molecular 
functions, and cellular compartments involved within the differentially expressed 
protein lists, Database for Annotation, Visualization and Integrated Discovery 
(DAVID) and Gene Ontology (GO) analysis was used 
(http://david.abcc.ncifcrf.gov/). DAVID provides a comprehensive set of functional 
annotation tools in order to understand the biological meaning behind lists of 
differentially regulated proteins.  
Enrichment was considered to be significant when the Bonferroni p-value 
adjustment was ≤0.05. Differentially expressed proteins were divided into two 
groups; those which showed an increase in expression in subsequently metastasised 
primary uveal melanoma tumour tissue and those which showed a decrease in 
expression, and were analysed individually. 
This study identified the cytosol as being significantly involved in the list of 
upregulated features found in the metastasised tissue, as gene products of PARK7, 
TPI1, ENO1, FABP3, SELENBP1, and VIM were all found to be localised there 
(Table 3.3). In addition to this, intramolecular oxioreductase activity was identified 
as a molecular process involved in the overexpression of the following genes; TPI1, 
PDIA3, and ERP29 (Table 3.3).  
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Table 3.3 GO cellular compartment and molecular function enrichment for 
differentially expressed proteins which were upregulated in subsequently 
metastasised primary uveal melanoma tumour tissue (n=9). Enrichment was 
considered significant upon observation of a p-value ≤0.05 and a Bonferroni 
adjusted p-value ≤0.05. Count corresponds to the overlap between proteins on the 
list and a particular GO category. 
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3.5 Follow-Up of Selected 2-D DIGE Targets by Immunohistochemistry  
For follow-up of the 2D DIGE study, Dr. Annett Linge (a medical doctor with an 
interest in pathology in the lab) performed immunohistochemical analysis on eight 
non-metastasised uveal melanoma tissue specimens and eight uveal melanoma 
specimens of patients who did subsequently develop metastatic disease (see Table 
3.1 for clinical and histopathological features of the patients included in the study; 
note that two samples differ to the 2D DIGE study due to sample availability). Uveal 
melanoma tissue sections from the two patient groups were analysed for the 
expression of FABP3, TPI1, CAPZA1, PDIA3, SELENBP1 and PARK7. For semi-
quantitative immunohistochemical analysis, a combined score was obtained by 
multiplying the scores for the overall positivity and the intensity of stained tumour 
cells, giving a maximum score of 12.  
 
3.5.1 FABP3  
FABP3 showed positive cytoplasmic staining in fifteen of the sixteen of the uveal 
melanoma cases that were studied. Increased cytoplasmic positivity and 
membranous reactivity for FABP3 was observed in uveal melanomas that were 
found to have subsequently metastasised compared to those that did not (mean 
combined score, 8.5 versus 5) (Figure 3.3 (A)). 
 
3.5.2 TPI1  
TPI1 protein showed expression in the cytoplasm and the nucleus in the majority of 
the cases analysed (Figure 3.3 (B)). Increased positivity for TPI1 was observed in 
uveal melanomas that were found to have subsequently metastasised compared to 13 
those that did not (mean combined score, 8.75 versus 6.25). Two out of eight of the 
non-metastasised uveal melanomas were found to be completely negative for TPI1 
protein expression. 
 
3.5.3 CAPZA1  
CAPZA1 showed an overall reduced cytoplasmic expression pattern in the majority 
of the uveal melanoma tissues that were found to have subsequently metastasised 
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(mean combined score, 4) compared to those that did not (mean combined score, 10) 
(Figure 3.4 (A) and (B)). Parallel staining of sections for CAPZA1 and the 
histiocyte/monocyte/macrophage marker CD68 confirmed CAPZA1 positivity in 
both tumour cells and tumour-infiltrating macrophages, but not all of those 
macrophages stained positive for CAPZA1. 
 
3.5.4 PDIA3  
PDIA3 (Figure 3.5 (A)) showed decreased expression in uveal melanomas that were 
found to have subsequently metastasised compared to those that did not (mean 
combined score, 5.25 versus 7.5).  
 
3.5.5 SELENBP1   
SELENBP1 (Figure 3.5 (B)) showed only weak or no cytoplasmic expression in the 
majority of both non-metastasised and subsequently metastasised uveal melanoma 
groups (mean combined score, 2.875 versus 2.25). 
 
3.5.6 PARK7  
For PARK7 (Figure 3.5 (C)) positive, heterogeneous staining was observed in both 
non-metastasised and subsequently metastasised uveal melanoma groups (mean 
combined score, 5 versus 6.6).  
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Figure 3.3 Images representing immunohistochemical analysis of (a) FABP3 
(p=0.15) and (b) TPI1 (p=0.27) in primary uveal melanomas which subsequently 
metastasised (right, n=8) in comparison to those which did not (left, n=8). 
Magnification x400; scale bar = 100 μm. 
 
 
 
 
 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
(b) 
Non-Metastasised Metastasised 
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Figure 3.4 Images representing immunohistochemical analysis of (a) CAPZA1 
expression in primary uveal melanomas which remained as non-metastasised (n=8) 
and of (b) CAPZA1 expression in primary uveal melanomas which subsequently 
metastasised (n=8). Magnification x400; scale bar = 100 μm; p=0.08. 
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Figure 3.5 Representative images of the immunohistochemical analysis of (a) 
PDIA3 (p=0.20), (b) SELENBP1 (p=0.69) and (c) PARK7 (p=0.39) in non-
metastasised (n=8) primary uveal melanoma tumour tissue. Magnification x400; 
scale bar = 100 μm. 
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From the immunohistochemical analysis of CAPZA1, PDIA3, FABP3, TPI1, 
SELENBP1, and PARK7, it was decided to follow up FABP3, TPI1, and 
SELENBP1 with functional analysis (Section 3.7).  
 
From the 2-D DIGE study, TPI1 was found to be significantly upregulated in 
subsequently metastasised uveal melanoma tissue. The immunohistochemical 
staining for this protein also indicated a trend for upregulation in uveal melanomas 
which did metastasise. Both results illustrate that the potential biomarker may be 
involved in the development of the metastatic phenotype in uveal melanoma. TPI1 is 
a glycolytic enzyme which catalyses the conversion of dihydroxyacetone phosphate 
to glyceraldehyde 3-phosphate; a high rate of glycolysis is required to support 
tumour growth (Albery and Knowles 1976, Bui and Thompson 2006). TPI1 has also 
previously been shown to be expressed in uveal melanoma primary cell cultures 
(Pardo, Garcia et al. 2005).  
 
FABP3 was found to be upregulated by 2.2-fold in primary uveal melanoma tissue 
which metastasised. This result correlated with the outcome of the FABP3 
immunohistochemistry study. However, the function of FABP3 is poorly 
understood. It has been shown to exhibit inhibitory activity of mammary epithelial 
cell proliferation and reduce the tumorgenicity of breast cancer cells in nude mice 
(Yang, Spitzer et al. 1994). Positive correlations of FABP3 expression with tumour 
cell invasion, lymph node metastasis and poor patient survival have been identified 
in gastric carcinomas (Hashimoto, Kusakabe et al. 2004). 
 
SELENBP1 was found to be significantly upregulated in subsequently metastasised 
primary tumour tissue in comparison to non-metastasised tissue. However, the 
immunohistochemical analysis was non-conclusive due to the weak/absence of 
staining in both the metastasised and non-metastasised tumour tissue. SELENBP1 
has previously been suggested as a tumour suppressor as its expression is lost in 
several epithelial cancers (Scortegagna, Martin et al. 2009). Unlike PDIA3 and 
PARK7, SELENBP1 had not previously been associated with ocular cancer and 
hence, was novel in this regard (Pardo, Garcia et al. 2005, Bande, Santiago et al. 
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2012). Therefore, it was decided to follow up SELENBP1 with functional analysis 
(Section 3.7).  
 
3.6 Differential Protein Expression Analysis Between Non-Metastasised and 
Subsequently Metastasised Primary Tumour Tissue using Quantitative Label-
Free LC-MS Analysis  
Dr. Pathma Ramasamy (a medical doctor) and Mr. Michael Henry (a mass 
spectrometry specialist in the lab) carried out a quantitative LC-MS proteomic 
analysis of eight non-metastasised tumour tissues and eight which subsequently 
metastasised, 14 of which were also used in the 2-D DIGE study. The sample details 
are illustrated in Table 3.4.  
From this analysis, 50 proteins with a minimum of three matched peptides were 
identified as being differentially expressed between both sample sets (Table 3.4). Of 
these proteins, five had previously been identified in the 2-D DIGE study. Vimentin, 
alpha-enolase, TPI1, beta-hexosaminidase subunit alpha, and FABP3 were all found 
to be upregulated in primary uveal melanoma tissue which had metastasised, which 
correlated with the 2-D DIGE findings, see Table 3.2. In addition to this, heat shock 
protein beta-1 (HSP-27) was found at a lower abundance in the subsequently 
metastasised tissue in comparison to non-metastasised primary tissue. This result 
agrees with a study previously carried out by Jmor et al. which demonstrated that 
HSP-27 was expressed at a lower level in monosomy three tumours (which are 
typically associated with metastasis) than in disomy three tumours (often linked with 
a non-metastatic outcome) (Jmor, Kalirai et al. 2012). 
Of the proteins identified by quantitative label-free LC-MS, cytosolic non-specific 
dipeptidase (CNDP2), thioredoxin-dependent peroxide reductase (PRDX3), importin 
subunit beta-1 (KPNB1), and elongation factor 1-gamma (EEF1G) were selected for 
functional analysis. Dr. Ramasamy carried out the follow-up of other targets, using 
immunohistochemistry, for his M.D. thesis. 
The four selected proteins were chosen as, although some of these had previously 
been linked with other cancer studies, they had not been associated with uveal 
melanoma. In addition to this, they illustrated some of the lowest ANOVA scores of 
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the analysis, deeming them as a number of the most significant potential targets from 
the generated list (Table 3.5).  
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3.7 Functional Effects of siRNA-Mediated Downregulation of Targets of 
Interest in Uveal Melanoma Cell Lines 
RNA interference (RNAi) is a naturally-occurring mechanism which can exploited 
for knockdown studies when understanding the role of potential biomarkers. small 
interfering RNA (siRNA) are RNA duplexes which becomes separated in the 
cytoplasm of the cell, with the antisense strand bound to the RNA-induced silencing 
complex (RISC). This RNA-RISC complex then locates mRNA in the cytoplasm 
with homologous sequences and induces cleavage of the mRNA, thus preventing 
translation of the protein.  
siRNA transfected cells can be monitored for changes in tumorigenicity or 
metastatic potential following transfection, which can in turn highlight the role of 
the targets of interest.  
In order to determine the roles of the proteins of interest, siRNA were used to 
downregulate, or “knockdown”, their production. Subsequent functional analysis 
would then be carried out, using the transfected cells.  
TPI1, FABP3, and SELENBP1 were selected from the 2-D DIGE results (Table 
3.2), while CNDP2, PRDX3, EEF1G, and KPNB1 were selected from the 
quantitative label-free LC-MS results (Table 3.5).   
In order to determine if it was possible to downregulate the proteins of interest, the 
levels of each protein in 92.1 and MEL202 uveal melanoma cell lines was first 
determined. This was carried out using Western blotting with antibodies specific to 
each protein (Figure 3.6). From this, it was clear that all proteins, except CNDP2 
which was not noticeably produced (Figure 3.6 (d)), were expressed at sufficient 
levels in 92.1 and MEL202 cells. This resulted in CNDP2 being excluded from the 
analysis. 
siRNA specific to TPI1, FABP3, SELENBP1, PRDX3, EEF1G, and KPNB1 were 
selected for the transfection of 92.1 and MEL202 uveal melanoma cell lines. Two 
independent siRNA molecules were chosen for each target. In some cases, this 
required multiple siRNA to be tested prior to selecting the molecule which most 
efficiently downregulated expression. For example, of three siRNAs tested, siRNA 
#1 and #3 were selected for SELENBP1 knockdown studies. 
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For all proteins, except PRDX3, significant knockdown of each protein was 
achieved. The attempted optimisation of transfection conditions for PRDX3 was 
carried out in both cell lines. However, the transfection heavily impacted on the 
proliferation of MEL202 cells at an siRNA concentration of 20 nM, resulting in total 
cell death. At this concentration, knockdown of the protein did not occur (Figure 3.7 
(a)); hence the effect on proliferation observed was not as a result of PRDX3 
knockdown. In the 92.1 cell line the transfection did not successfully downregulate 
PRDX3 at siRNA concentrations of 20 nM, 40 nM or 60 nM. These concentrations 
were tested using 4.5 μL, 6.5 μL and 7.5 μL of transfection reagent (lipofectamine 
RNAiMax). The transfection was also tested using 80 nM of siRNA, which appeared 
to marginally reduce the levels of PRDX3 when 6.5 μL and 7.5 μL of lipofectamine 
were used (Figure 3.7 (b)). However, at high concentrations, siRNA can cause off-
target effects which can generate false results. A lower concentration of siRNA was 
used by pooling of two PRDX3 siRNA. This method was attempted at two 
concentrations; 20 nM and 40 nM, however, the extent of knockdown was not strong 
enough at either concentration (Figure 3.7 (c)). It was decided to exclude PRDX3 
from the functional analysis as a result. 
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Figure 3.7 The downregulation of PRDX3 in 92.1 and MEL202 cell lines was 
unsuccessful. (a) In the MEL202 cell line, the transfection of 20 nM PRDX3 siRNA 
appeared to severely impact proliferation. However, western blotting illustrated that 
the knockdown of the protein was unsuccessful at this level. This indicates that the 
observed cell death did not occur as a consequence of the transfection. (b) 
Knockdown did not occur in the 92.1 cell line at siRNA levels as high as 80 nM, 
using a range of transfection reagent volumes. (c) Combining two independent 
siRNA at concentration of 20 nM and 40 nM did not successfully result in the 
knockdown of PRDX3 in 92.1 cells either. Control refers to healthy, untreated cells. 
Lipo refers to healthy cells treated with lipofectamine only. Scrambled represents 
negative control cells which were transfected with a nonsense sequence of siRNA.  
 
(a) 
(b) 
(c) 
PRDX3 
 
 
 
α-Tubulin 
PRDX3 
 
α-Tubulin 
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3.7.1 TPI1 Downregulation in the 92.1 Uveal Melanoma Cell Line for the 
Determination of a Potential Role in Proliferation, Invasion and Migration 
To study the potential effect of TPI1 on the proliferation, invasion and motility of 
uveal melanoma cells, down-regulation experiments using siRNA molecules 
directed against the respective target gene were performed in the 92.1 primary uveal 
melanoma cell line. Two independent siRNA molecules were used to knockdown 
TPI1 and the subsequent reduction in protein levels was confirmed by Western blot 
analysis (Figure 3.8) 
 
3.7.1.1 Proliferation  
Proliferation assays were carried out following TPI1 siRNA transfection. No 
noteworthy effect on proliferation in 92.1 cells was observed when treated cells were 
compared with scrambled siRNA-treated cells (Figure 3.9 (A)). However, the 
downregulation of TPI1 notably decreased the rate of proliferation in the MEL202 
primary uveal melanoma cell line, with a significant effect observed in the replicate 
experiments (Figure 3.9 (B)). This could create complications by making it difficult 
to assess the impact of knockdown on properties such as invasion and migration. 
Hence, TPI1 knockdown studies were not carried out in this cell line. 
 
3.7.1.2 Invasion 
At 72 hours following siRNA transfection, invasion assays were carried out. The 
total number of 92.1 cells transfected with siRNA #2 invading through the 
membrane was significantly decreased while a strong effect on invasion was also 
observed for siRNA #1 transfected cells (Figure 3.10 (A)).  
 
3.7.1.3 Migration 
At 72 hours following siRNA transfection, migration assays were carried out. The 
reduction of TPI1 levels led to a significant decrease in the motility of 92.1 cells 
(Figure 3.10 (B)).  
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These results indicate that TPI1 is required for both invasion and migration in 92.1 
cells, and hence, may contribute to the metastatic process of uveal melanoma.  
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Figure 3.8 Western blot analysis showing the reduction of TPI1 following siRNA 
knockdown. Control cells (untreated), transfection reagent-treated cells (Lipo), 
scrambled siRNA treated cells, siRNA #1 and siRNA #2 specific for TPI1-treated 
cells were lysed 72 hours after transfection and subjected to Western blot analysis. 
GAPDH served as an internal loading control. 
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Figure 3.9 Proliferation assay results for (A) 92.1 and (B) MEL202 cells treated 
with siRNA specific for TPI1. When 92.1 siRNA transfected cells were compared to 
the scrambled siRNA (negative control), there was no effect on proliferation for 
either siRNA #1 (p=0.59) or siRNA #2 (p=0.71). However, the knockdown of TPI1 
in MEL202 cells strongly affects proliferation in both siRNA #1 (p=0.13) and 
siRNA #2 (p=0.38) when compared to the negative control (scrambled). The 
combined result and statistics of three independent experiments is shown. All p-
values were determined by comparing each siRNA to the scrambled control. n=3. 
 
B 
A 
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Figure 3.10 siRNA knockdown of TPI1 decreases invasion and motility. (a) 
Invasion assay of 92.1 cells following siRNA transfection. The total number of 92.1 
cells invading through membranes after siRNA transfection is shown. siRNA #1 
p=0.08; siRNA #2 p=0.03. (b) Motility assay of 92.1 cells following siRNA 
transfection. The total number of 92.1 cells migrating through uncoated membrane 
after siRNA transfection is shown. siRNA #1 p=0.008; siRNA #2 p=0.007. The 
combined result and statistics of two independent experiments is shown. *p<0.05, 
**p<0.01 when compared with scrambled siRNA-treated controls. n=2. 
A 
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3.7.2 FABP3 Downregulation in the 92.1 Uveal Melanoma Cell Line for the 
Determination of a Potential Role in Proliferation, Invasion and Migration 
To study the potential effect of FABP3 on the proliferation, invasion and migration 
of uveal melanoma cells, down-regulation experiments using siRNA molecules 
directed against FABP3 were performed in the 92.1 primary uveal melanoma cell 
line. Two independent siRNA molecules were used to knockdown TPI1 and the 
subsequent reduction in protein levels was confirmed by Western blot analysis 
(Figure 3.11). 
 
3.7.2.1 Proliferation  
Proliferation assays were carried out following siRNA transfection; no effect on the 
proliferation of 92.1 cells was observed when treated cells were compared with 
scrambled siRNA-treated cells (Figure 3.12 (A)). However, the downregulation of 
FABP3 notably decreased the rate of proliferation in the MEL202 primary uveal 
melanoma cell line, with a significant effect observed in the individual replicate 
experiments (Figure 3.12 (B)). This could create complications by making it difficult 
to assess the impact of knockdown on properties such as invasion and migration. 
Hence, knockdown studies of FABP3 were not carried out in this cell line. 
 
3.7.2.2 Invasion 
At 72 hours following siRNA transfection, invasion assays were carried out. The 
total number of 92.1 cells invading through the membrane was significantly 
decreased following transfection (Figure 3.13 (A)). This indicates that FABP3 may 
be required for invasion.  
 
3.7.2.3 Migration  
At 72 hours following siRNA transfection, migration assays were carried out. The 
knockdown of FABP3 led to a significant decrease in motility of 92.1 cells (Figure 
3.13 (B)).  
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These results indicate that FABP3 may be required for both invasion and migration 
in 92.1 cells, and hence, may contribute to the metastatic process of uveal 
melanoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
 
Figure 3.11 Western blot analysis showing the reduction of FABP3 following 
siRNA knockdown. Control cells (untreated), transfection reagent-treated cells 
(Lipo), scrambled siRNA treated cells, siRNA #1 and siRNA #2 specific for TPI1-
treated cells were lysed 72 hours after transfection and subjected to Western blot 
analysis. GAPDH served as an internal loading control. 
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Figure 3.12 Proliferation assay results for (A) 92.1 and (B) MEL202 cells treated 
with siRNA specific for FABP3. When 92.1 cells were compared to the scrambled 
siRNA (negative control), the effect of the transfection was minimal on 92.1 cells; 
siRNA #1 p=0.97 and siRNA #2 p=0.84. The knockdown of FABP3 in MEL202 
cells strongly affects proliferation in both siRNA #1 (p=0.13) and siRNA #2 
(p=0.38). The combined result and statistics of three independent experiments is 
shown. All p-values were determined by comparing each siRNA to the scrambled 
control. n=3. 
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Figure 3.13 siRNA knockdown of FABP3 decreases invasion and motility. (A) 
Invasion assay of 92.1 cells following siRNA transfection. The total number of 92.1 
cells invading through membranes of invasion chambers after siRNA transfection is 
shown. siRNA #1 p=0.04; siRNA #2 p=0.02. (B) Motility assay of 92.1 cells 
following siRNA transfection. The total number of 92.1 cells migrating through 
uncoated membrane after siRNA transfection is shown. siRNA #1 p=0.002; siRNA 
#2 p=0.04. The combined result and statistics of two independent experiments is 
shown. *p<0.05, **p<0.01 when compared with scrambled siRNA-treated controls. 
n=2. 
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3.7.3 SELENBP1 Downregulation in MEL202 and 92.1 Cell Lines for the 
Determination of a Potential Role in Proliferation, Invasion, Migration, and 
Oxidative Metabolism 
In order to determine the effect of downregulation of SELENBP1 on the invasion 
and migration properties of uveal melanoma cells, two siRNA molecules directed 
against respective target gene, siRNA #1 and #3, were transfected into the 92.1 and 
MEL202 primary uveal melanoma cell lines. The reduction in protein levels for both 
cell lines was confirmed by Western blot analysis (Figure 3.14 (A) and (B), i).  
 
3.7.3.1 Proliferation  
Proliferation assays were carried out following siRNA transfection which illustrated 
that there was no significant effect on proliferation in either 92.1 (Figure 3.15 (A)) 
or MEL202 (Figure 3.12 (B)) cells treated with SELENBP1 siRNA in comparison to 
scrambled siRNA treated cells Hence, it was decided to carry out the knockdown 
studies in both cell lines. 
 
3.7.3.2 Invasion  
Invasion assays were performed at 72 hours following the transfection of both cell 
lines. This illustrated that the total number of cells invading through the membrane 
was significantly decreased following transfection with siRNA molecules specific 
for SELENBP1 in the 92.1 cell line (Figure 3.13 (A), i). The same was observed in 
the MEL202 cell line for siRNA #1 but not for siRNA #3. 
 
3.7.3.3 Migration  
Migration assays were performed at 72 hours following the transfection for both cell 
lines. A significant reduction in the migration of 92.1 cells was observed following 
transfection with siRNA molecules specific for SELENBP1 (Figure 3.13 (A) and 
(B), ii). However, no significant effect on the migration of MEL202 cells was 
observed following transfection, although a clear trend in decreased cell number was 
observed. This may have been due to the nature of MEL202 cells as they aggregate 
quite easily, creating both dense and sparsely populated areas within the chamber, 
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hence producing a wide range of cell counts per experiment. This may have 
therefore affected the overall validity of the experiment. 
These results indicate that SELENBP may be required for both invasion and 
migration in 92.1 and MEL202 cells, and hence, may play a role the process of 
metastasis in uveal melanoma. 
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Figure 3.14 Western blot analysis showing the reduction of SELENBP following 
siRNA knockdown siRNA knockdown of SELENBP in (A) 92.1 and (B) MEL202 
uveal melanoma cell lines. Control cells (untreated), transfection reagent-treated 
cells (Lipo), scrambled siRNA treated cells, siRNA #1 and siRNA #3 specific for 
SELENBP treated cells were lysed 72 hours after transfection and subjected to 
Western blot analysis. GAPDH served as an internal loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
133 
 
 
 
 
Figure 3.15 Proliferation assay results for (a) 92.1 cells treated with SELENBP1 
siRNA #1 (p=0.68) and siRNA #3 (p=0.55), and (b) MEL202 cells treated with 
SELENBP1 siRNA #1 (p=0.36) and siRNA #3 (p=0.78). No impact on proliferation 
was noted following siRNA transfection in either the 92-1 or the MEL202 cell line. 
The combined results and statistics of three independent experiments is shown. All 
p-values were determined by comparing each siRNA to the scrambled control. n=3. 
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Figure 3.16 siRNA knockdown of SELENBP in the (A) 92.1 and (B) MEL202 
uveal melanoma cell line decreases invasion and motility. (i) Invasion assays 
following siRNA transfection. The total number of cells invading through 
membranes after siRNA transfection is displayed. 92.1 siRNA #1 p=0.02; siRNA #3 
p=0.03. MEL202 siRNA #1 p=0.02; siRNA #3 p=0.03. (ii) Motility assays 
following siRNA transfection. The total number of cells migrating through uncoated 
chambers after siRNA transfection is illustrated. 92.1 siRNA #1 p=0.004; siRNA #3 
p=0.01. MEL202 siRNA #1 p=0.3; siRNA #3 p=0.4.  The combined result and 
statistics of three independent experiments is shown. *p<0.05, **p<0.01 when 
compared with scrambled siRNA-treated controls. n=3. 
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3.7.3.4 Determination of the Effect of SELENBP1 Knockdown on 
Oxidative Metabolism in 92.1 Uveal Melanoma Cells 
Reactive oxygen species (ROS) play an essential role in oxidative metabolism.  
However when an over-abundance is produced, for example during cell stress such 
as inflammation, ROS can disrupt the cell through the peroxidation of lipids and 
destruction of structural proteins, enzymes and nucleic acids. Selenium is an 
essential trace element which is involved in the function of antioxidant enzymes and 
proteins that protect the cell against ROS. SELENBP1, a member of the 
selenoprotein family, is known to bind selenium covalently in order to mediate the 
intracellular transport of selenium (Zhou, Zhang et al. 2009, Zeng, Yi et al. 2013). 
Hence, it was decided to examine the ability of 92.1 cells transfected with 
SELENBP1 siRNA to deactivate ROS, relative to the negative control. 
2‟,7‟-dichlorofluorescein-diacetate (DCFH-DA) was used to quantify intracellular 
produced H2O2. DCFH-DA is first transported across the cell membrane where it is 
deacetylated, becoming trapped within the cell. Through the action of peroxide, it is 
then converted to 2‟,7‟-dichlorofluorescein (DCF), a highly fluorescent compound, 
which can be used for measuring the quantity of ROS present. The greater the 
fluorescence intensity measured, the higher the ROS activity present in the cells. 
Overall, no significant difference in ROS activity was observed (Figure 3.14). 
However, from the Figure 3.14, there appeared to be a mild increase in the activity 
of ROS in cells transfected with SELENBP1 siRNA in comparison to the 
lipofectamine-treated controls (Lipo) and negative controls (scrambled). This would 
suggest that without SELENBP1, selenium cannot sufficiently exert antioxidant 
effects, hence, the cell cannot control the quantity of ROS produced.  
The increase in SELENBP expression does not appear to correlate with the initial 
establishing of the malignancy, as a significant fold increase was observed in the 
subsequently metastasised primary uveal melanoma tumour tissue in comparison to 
the non-metastasised specimens. This increase in abundance may be due to the more 
aggressive nature of a tumour which has the potential to spread, in comparison to 
that which does not.  
136 
 
 
Figure 3.14 Reactive oxygen species (ROS) activity of SELENBP1 siRNA-
transfected 92.1 uveal melanoma cells. Analysis was carried out in lipofectamine-
treated cells (Lipo), negative controls (scrambled), and cell transfected with two 
independent siRNA molecules. The ability of SELENBP1 knockdown to increase 
ROS is shown through increasing fluorescence relative to the negative control. The 
combined result of three independent experiments is shown. siRNA #1 p=0.14,  
siRNA #3 p=0.29 when compared to scrambled controls. n=3. 
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3.7.4 KPNB1 Downregulation in MEL202 and 92.1 Cell Lines for the 
Determination of a Potential Role in Invasion and Migration 
92.1 and MEL202 uveal melanoma cells were transfected with two independent 
siRNA, siRNA #2 and #3, in order to determine the effect of downregulation of 
KPNB1 on the invasive and migratory properties of uveal melanoma cells. Using 
western blotting, the reduction in protein levels of KPNB1 in both cell lines was 
confirmed (Figure 3.15 (A) and (B)).  
 
3.7.4.1 Proliferation  
Proliferation assays illustrated that there was no significant effect on proliferation in 
either 92.1 or MEL202 cells treated with both KPNB1 siRNA in comparison to 
scrambled siRNA treated cells (Figure 3.16 (A) and (B)).  
 
3.7.4.2 Invasion 
Invasion assays were carried out at 72 hours following transfection. From this, it was 
found that the total number of cells invading through the membrane was 
significantly decreased following transfection, in 92.1 cells and in MEL202 cells 
treated with siRNA #2 (Figure 3.17 (A) and (B), i).  
 
3.7.4.3 Migration 
Migration assays were carried out at 72 hours following transfection. From this, it 
was found that there was a significant reduction in the number of 92.1 cells 
migrating across the membrane (Figure 3.17 (A), ii). No significant effect on the 
migration of MEL202 cells was observed following transfection, although a clear 
trend in decreased cell number was observed. This again may have been due to the 
nature of MEL202 cells, as outlined in section 3.7.3.3. 
These results indicate that KPNB1 may be required for both invasion and migration 
in 92.1 and MEL202 cells, and hence, may play a role the process of metastasis in 
uveal melanoma. 
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Figure 3.15 Western blot analysis showing the reduction of KPNB1 in (A) 92.1 and 
(B) MEL202 cell lines following siRNA knockdown. Control cells (untreated), 
transfection reagent-treated cells (Lipo), scrambled siRNA treated cells, siRNA #1 
and siRNA #3 specific for KPNB1 treated cells were lysed 72 hours after 
transfection and subjected to Western blot analysis. GAPDH served as an internal 
loading control.  
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Figure 3.16 Proliferation assay results for (a) 92.1 cells treated with KPNB1 siRNA 
#2 (p=0.59) and siRNA #3 (p=0.41), and (b) MEL202 cells treated with KPNB1 
siRNA #2 (p=0.25) and siRNA #3 (p=0.38). No effect on proliferation was noticed 
following siRNA transfection in both the 92-1 and MEL202 cell lines. The 
combined results and statistics of three independent experiments is shown. All p-
values were determined by comparing each siRNA to the scrambled control. n=3. 
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Figure 3.17 siRNA knockdown of KPNB1 in (A) 92.1 and (B) MEL202 cell lines 
decreases invasion and motility. (i). Invasion assays of 92.1 cells following siRNA 
transfection. The total number of 92.1 cells invading through membranes of invasion 
chambers after siRNA transfection is shown. 92.1 siRNA #2 p=0.04; siRNA #3 
p=0.02. MEL202 siRNA #2 p=0.04; siRNA #3 p=0.07.  (ii) Motility assays of 92.1 
cells following siRNA transfection. The total number of 92.1 cells migrating through 
uncoated membrane after siRNA transfection is shown. 92.1 siRNA #2 p=0.003; 
siRNA #3 p=0.002. MEL202 siRNA #2 p=0.32; siRNA #3 p=0.35.  The combined 
result and statistics of three independent experiments is shown. *p<0.05, **p<0.01 
when compared with scrambled siRNA-treated controls. n=3. 
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3.7.5 EEF1G Downregulation in MEL202 and 92.1 Cell Lines for the 
Determination of a Potential Role in Invasion and Migration 
Two independent siRNA, siRNA #2 and #4, were transfected into 92.1 and MEL202 
uveal melanoma cells in order to downregulate the production of EEF1G. The 
knockdown cells would then be used to determine the role of the protein in processes 
of invasion and migration. Western blotting illustrated a reduction in EEF1G levels 
for both cell lines, thus confirming the transfection (Figure 3.18 (A) and (B), i).  
 
3.7.5.1 Proliferation  
Proliferation assays illustrated that there was no effect on proliferation in 92.1 and 
MEL202 cells treated with EEF1G siRNA in comparison to the negative control 
(Figure 3.19 (A) and (B)).  
 
3.7.5.2 Invasion 
Invasion assays were carried out at 72 hours following the transfection of both cell 
lines. From this, it was found that the total number of cells invading through the 
membrane was significantly decreased for both cell lines, as a result of the 
transfection (Figure 3.20 (A) and (B), i).  
 
3.7.5.3 Migration  
Migration assays were carried out 72 hours following the transfection of both cell 
lines. A significant reduction in the number of 92.1 cells migrating across the 
membrane was observed (Figure 3.20 (A), ii). No significant effect on the migration 
of MEL202 cells was observed following transfection, although a clear reduction of 
cell number was observed. This again may have been due to the nature of MEL202 
cells, as outlined in section 3.7.3.3. 
These results indicate that EEF1G may be required for invasion and migration in 
92.1 and MEL202 cells, and hence, may play a role in metastatic uveal melanoma. 
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Figure 3.18 Western blot analysis showing the reduction of EEF1G following 
siRNA knockdown. Control cells (untreated), transfection reagent-treated cells 
(Lipo), scrambled siRNA treated cells, siRNA #2 and siRNA #4 specific for EEF1G 
treated cells were lysed 72 hours after transfection and subjected to Western blot 
analysis. GAPDH served as an internal loading control. 
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Figure 3.17 Proliferation assay results for (A) 92.1 cells treated with EEF1G siRNA 
#2 (p=0.53) and siRNA #4 (p=0.77), and (B) MEL202 cells treated with EEF1G 
siRNA #4 (p=0.54) and siRNA #4 (p=0.82). No effect on proliferation was noticed 
following transfection in either cell line. The combined results and statistics of three 
independent experiments is shown. All p-values were determined by comparing each 
siRNA to the scrambled control. n=3. 
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Figure 3.18 siRNA knockdown of EEF1G decreases invasion and motility in (A) 
92.1 and (B) MEL202 cell lines. (i). Invasion assays of 92.1 cells following siRNA 
transfection. The total number of 92.1 cells invading through invasion chamber 
membranes after siRNA transfection is shown. 92.1 siRNA #2 p=0.02; siRNA #4 
p=0.02. MEL202 siRNA #2 p=0.07; siRNA #4 p=0.03. (ii) Motility assays of 92.1 
cells following siRNA transfection. The total number of 92.1 cells migrating through 
uncoated membrane after siRNA transfection is shown. 92.1 siRNA #2 p=0.001; 
siRNA #4 p=0.004. MEL202 siRNA #2 p=0.3; siRNA #4 p=0.4. The combined 
results of three independent experiments is shown. *p<0.05, **p<0.01 when 
compared with scrambled siRNA-treated controls. n=3. 
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3.7.6 Gelatin Zymography Analysis of Cells treated with SELENBP1, KPNB1 
and EEF1G siRNA   
Zymography can be used to detect and characterise proteases, such as matrix 
metalloproteases (MMPs), using either casein or gelatin as a substrate, depending on 
the species of enzyme to be detected. Initially, the proteins are separated under non-
reducing and denaturing, i.e. inactivating, conditions. The zymography gel consists 
of polyacrylamide which is co-polymerised with a substrate. Following 
electrophoresis, the gel is placed in a solution of Triton X-100 which renatures and 
reactivates the enzymes, allowing them to digest the substrate. Coomassie Blue is 
then used to stain the background of undegraded substrate, with MMPs remaining 
unstained and appearing as clear bands (Snoek-van Beurden and Von den Hoff 
2005).  
As SELENBP1, EEF1G, and KPNB1 were all found to play a role in invasion, it 
was hypothesised that MMP-9 and MMP-2 may be involved in this process. MMPs 
have long been associated with tumour progression and the invasion process, and are 
often upregulated in tumours and tumour cell lines. In particular, MMP-2 and MMP-
9 are often connected with melanoma disease progression (Coussens, Fingleton et al. 
2002, Schnaeker, Ossig et al. 2004, Nikkola, Vihinen et al. 2005). MMP-2 and -9 
have also previously been implicated in uveal melanoma metastasis (Lai, Conway et 
al. 2008, Jannie, Stipp et al. 2012). 
The 92.1 and MEL202 uveal melanoma cell lines were both transfected with siRNA 
specific to SELENBP1, KPNB1, and EEF1G. The knockdown cells were then 
grown for 24 hours before being incubated with serum-free media for a further 48 
hours. The media from the cells was then collected, and concentrated prior to 
zymography. In parallel, conditioned media was collected from large flasks of 
healthy cells. This analysis indicated that MMP-2 and MMP-9 were unaffected 
following transfection of either cell line with any of the siRNA (Figure 3.19). This 
would suggest that neither MMP-2 nor MMP-9 play a role in the invasion pathways 
affected by the knockdown of any of the three proteins. 
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Figure 3.19 Gelatin zymograms illustrating the effect of siRNA-mediated 
knockdown of SELENBP, EEF1G and KPNB1 on MMP-9 and MMP-2 activity. In 
both the (a) 92.1 and (b) MEL202 uveal melanoma cell lines, no effect on the 
abundance of either MMP-2 or -9 was observed following the downregulation of 
SELENBP1, EEF1G, or KPNB1. (c) When the expression of MMP-2 and MMP-9 
was examined in healthy 92.1 and MEL202 cells, MMP-9 was found to be expressed 
in both cell lines while MMP-2 was only identified in MEL202 cells. n=2. 
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3.7.7 Analysis of Early, Late, and Total Apoptosis in SELENBP1, EEF1G, and 
KPNB1 92.1 Knockdowns 
Apoptosis is defined as programmed cell death and is essential for tissue 
homeostasis. Its inhibition is often required for tumorigenesis; for example, the bcl-2 
gene encodes a cell death inhibitory protein which aids the development of cancer 
and can prevent apoptosis following treatment with an array of toxins or drugs. A 
high rate of apoptosis may also be observed in various cancers, which can often 
explain why a tumour, such as a basal cell carcinoma, is slow growing. Both pro- 
and anti-apoptotic features have been described in uveal melanoma. Tumour 
necrosis factor-related apoptosis inducing ligand (TRAIL) has been identified as a 
pro-apoptotic feature while Bcl-2 gene proteins have been shown to inhibit apoptosis 
in uveal melanoma (Wang, Boonman et al. 2003, Ren, Mayhew et al. 2004, Gill and 
Char 2012). 
In order to determine the potential roles of SELENBP1, EEF1G, and KPNB1 in the 
apoptotic pathways of uveal melanoma, 92.1 cells were transfected with siRNA 
specific to each protein and stained with fluorescent markers of apoptosis, followed 
by measurement of fluorescence using flow cytometry (Figure 3.20).  
Apoptosis was examined by labelling the cells with 7-aminactinomycin D (7-AAD) 
and Phycoerythrin (PE) annexin-V, and measuring the level of fluorescence with 
flow cytometry. Loss of plasma membrane integrity is one of the earliest features of 
apoptosis. This involves the translocation of phosphatidylserine (PS) from the inner 
to the outer leaflet of the membrane. Thus annexin V, which may be conjugated to a 
fluorochrome such as PE, can bind to the exposed PS and hence, can measure 
apoptosis at an early stage. PE annexin V is often used in conjunction with a vital 
dye such as 7-AAD; a fluorescent compound which specifically binds to GC regions 
of the DNA, to allowing for the identification of early apoptotic cells (e.g. 7-AAD 
negative, PE annexin V positive). Viable cells with intact membranes exclude 7-
AAD, while the membranes of dead and damaged cells are permeable to 7-AAD 
(Zembruski, Stache et al. 2012).  
No statistically significant results were generated from the analysis of early, 
apoptosis, late apoptosis/death, or total apoptosis across all knockdowns when 
compared to the negative control (Figure 3.21). This would suggest that none of the 
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three proteins of interest appear to play a role in apoptosis. Individual graphs for 
early apoptosis, late apoptosis/death, and total apoptosis are illustrated in Figures 
3.22, 3.23, and 3.24, respectively. 
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Figure 3.20 Dot plots illustrating the overall trend of healthy cells, and early, and 
late/death stage apoptosis across all knockdowns with two independent siRNA. No 
significant differences in the number of apoptosing cells were observed for either of 
the two independent siRNA used to downregulate the production of each of the three 
SELENBP 
EEF1G 
KPNB1 
Scrambled 
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proteins, when compared to the scrambled (negative) control.  One representative 
result of three independent experiments is shown. n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
151 
 
 
Figure 3.21 Bar charts illustrating the overall trend of early, late/death, and total 
apoptosis across all knockdowns. No statistically significant differences in the 
number of cells undergoing apoptosis were observed for either of the two 
independent siRNA used to downregulate the production of each of the three 
proteins, in comparison to the scrambled (negative) control.  The results shown 
represent the average of three independent experiments. n=3. 
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Figure 3.22 Bar chart and box and whisker plot of early apoptosis across all three 
downregulated proteins of interest, with two independent siRNA each, in 92.1 cells. 
In comparison to the scrambled (negative) control, no statistically significant change 
in apoptosis was observed for both siRNA against any of the three proteins. There 
appeared to be a trend of decreased early apoptosis in EEF1G and KPNB1 
transfected cells, however, this was not deemed as significant. n=3. 
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Figure 3.23 Bar chart and box and whisker plot of late apoptosis/deaths across all 
three downregulated proteins of interest, with two independent siRNA each, in 92.1 
cells. In comparison to the scrambled (negative) control, no significant trend in 
apoptosis was observed for both siRNA against any of the three proteins. n=3. 
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Figure 3.24 Bar chart and box and whisker plot of total apoptosis across all three 
downregulated proteins of interest, with two independent siRNA each, in 92.1 cells. 
In comparison to the scrambled (negative) control, no significant trend in apoptosis 
was observed for both siRNA knockdowns against any of the three proteins. n=3. 
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CHAPTER FOUR 
Vitreous Fluid Sample Optimisation 
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4.1  Background 
Vitreous humour is a gel-like substance contained in the posterior chamber of the 
eye. As it is often in close proximity to sites of trauma within the eye, it may be a 
valuable specimen for clinical proteomic analyses.  
The fluid may be collected during surgery such as enucleation, hence it can be 
collected from uveal melanoma patients. However, a minimal number of proteomic 
studies, which are outlined in chapter one, have been carried out to date in uveal 
melanoma vitreous specimens. In addition to this, it can be a variable and sometimes 
difficult specimen to work with, often only providing information on highly 
abundant proteins (Shitama, Hayashi et al. 2008). Little information was available 
on the best methods for pre-processing and proteomic analysis of vitreous fluid, as 
most methods appeared to generate the same data.  
In this regard, it was decided that prior to examining the vitreous fluid, methods of 
sample pre-treatment and analysis would first have to be devised. A summary of all 
tested pre-treatment and analytical methods used in the work presented is shown at 
the end of this chapter (Figure 4.21). Following this it would be possible to perform 
a proteomic analysis of the vitreous extracted from uveal melanoma patients, with 
the intention of identifying potential biomarkers which may correlate with a poor 
outcome in uveal melanoma, thus improving our understanding of the metastatic 
disease and identifying potential therapeutic targets. 
 
4.2 1-D Gel Analysis of Vitreous Fluid  
21 vitreous fluid samples were acquired from the Royal Victoria Eye and Ear 
Hospital, Dublin. Initially, protein assays were performed in order to quantify the 
protein levels across all of the six control (collected from patients with macular hole 
degeneration) and 13 disease samples. The protein concentrations varied 
significantly between the samples with values ranging from 0.27 mg/mL to 34 
mg/mL.  
In order to get an overall view of the general content of the proteome, two control 
samples, which had been extracted from macular hole degeneration patients, were 
selected for preliminary analysis by separation on a 1-D gel (Figure 4.1). Following 
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staining, it was clear that there were significant levels of high abundant proteins 
present in the vitreous fluid which had smeared across other regions. This would 
create difficulties in identifying less abundant proteins as, once digested, high 
abundance proteins can produce elevated quantities of tryptic peptides thus creating 
proteolytic background and a bias for the identification of such proteins. Hence, a 
limited dynamic range is available which can only be improved through extra 
chromatographic fractionation (Fonslow, Stein et al. 2013).  
Despite this, eight regions were excised from the gel and digested using trypsin to 
generate peptides which were subsequently identified by LC-MS/MS. The table of 
identifications generated, Table 4.1, illustrates that many of proteins found in the 
samples were highly abundant and commonly found in clinical specimens such as 
serum or plasma. As the vitreous fluid proteome is only beginning to be mapped in 
its entirety, proteins which are known to be of high or medium abundance in the 
plasma proteome were used as a measure of potentially high or medium abundance 
proteins in the vitreous. In this way it would be possible to examine how well a pre-
treatment method worked. For each qualitative table of this chapter, proteins of high 
or medium abundance are noted. Serum albumin, transferrin, fibrinogen, alpha-2-
macroglobulin, alpha-1-antitrypsin, complement C3, haptoglobin, IgM, IgA, IgG, 
IgD and their components were all denoted as highly abundant, as 90% of plasma is 
known to be composed of these proteins. Apolipoprotein A1, apolipoprotein A2, 
apolipoprotein B, acid-1-glycoprotein, ceruloplasmin, complement C4, complement 
C1q, prealbumin, and plasminogen, which make up a further 9% of the plasma 
proteome, were all denoted as being of medium abundance. Only the remaining 1% 
of the plasma proteome is composed of low abundance proteins which may consist 
of more potential targets of interest (Anderson and Anderson 2002). It is important 
to note that although the levels of high abundant proteins were depleted initially, any 
patterns of differential regulation seen with such proteins later on were not ruled out. 
Table 4.1 indicated that vitreous fluid would have to be pre-processed by removing 
the majority of the high and medium abundant proteins present. This would allow 
for the identification of any low abundant proteins which may be masked by more 
highly abundant proteins. 
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Figure 4.1 1-D separation of control vitreous fluid samples (n=2) was used in order 
to examine the vitreous fluid proteome.  Proteins were separated through a 10% Bis-
Tris gel and stained with Coomassie Brilliant Blue. The regions of interest, indicated 
by an arrow and a corresponding letter, were then excised and the in-gel digestion of 
proteins to peptides was carried out using trypsin. The samples were analysed in the 
following order to ensure a minimum carry-over of high abundance proteins; F, H, 
G, E, D, B, A, C. 
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Table 4.1 Combined protein identifications of control #1 and control #2 from the 
regions of interest indicated in Figure 4.1. Abundance refers to the quantity of each 
protein typically found in clinical specimens, such as plasma. Many of the proteins 
identified were of high or medium abundance (Anderson and Anderson 2002).  
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As the gel contained a large band which smeared across the gel in the 60-70 kDa 
region, it was expected that the protein was serum albumin. This band covered the 
majority of the middle section of the gel and so it contaminated other protein bands. 
Hence, the vitreous was treated with a multiple affinity removal immunodepletion 
column which removes 14 of the most abundant proteins found in clinical samples; 
serum albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha2-
macroglobulin, alpha1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein 
AII, complement C3 and transthyretin.  
A western blot was used to compare the immunodepleted sample to the crude 
sample (Figure 4.2 (a)). This confirmed the high levels of serum albumin in the 
crude sample as it was smeared throughout the blot. However, this also illustrated 
that although the majority of the protein had been removed by immunodepletion, 
some still remained.  
It was decided to immunodeplete the same sample twice and to compare it to the 
crude sample. This resulted in no detectable serum albumin being identified in the 
treated sample, while the crude samples remained the same as before (Figure 4.2 
(b)). 
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Figure 4.2 Western blot illustrating the effect of immunodepletion on the serum 
albumin concentration in a control vitreous sample. (a) Following one 
immunodepletion, the quantity of serum albumin in the vitreous was significantly 
decreased; however, a second immunodepletion would be required to appropriately 
deplete the level of serum albumin present. (b) Following a second 
immunodepletion, the concentration of serum albumin was sufficiently reduced. 
 
 
 
 
 
(a) 
(b) 
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The twice-immunodepleted sample was then separated on a 1-D gel which provided 
a clearer, more balanced view of the proteome with greater number of protein bands 
being clearly visible (Figure 4.3).  
Again, regions of the gel were excised, enzymatically digested and identified by MS. 
The identifications consisted of a higher number of less abundant and potentially 
more interesting proteins, while high abundant proteins, such as serum albumin, 
were less prominent in the list (Table 4.2).  
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Figure 4.3 1-D gel of twice-immunodepleted vitreous fluid. Various regions of the 
gel, which are indicated in red, were excised and any proteins present were in-gel 
digested using trypsin and analysed using mass spectrometry in order to identify 
them. It was hoped that low abundant proteins would be more easily detected 
following the removal of highly abundant proteins such as serum albumin. 
 
 
 
 
 
 
 
MW 
Marker 
Vitreous 
Fluid 
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Table 4.2 Proteins identified from the outlined regions of the gel illustrated in figure 
4.3. A significant decrease in the presence of high abundance proteins was observed 
as well as the identification of a greater number of less common molecules. Proteins 
which are unique to this list in comparison to Table 4.1 are written in red.  
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4.3 2-D Proteomic Analysis of Vitreous Fluid 
As the twice-immunodepleted vitreous humour appeared to generate the most 
promising proteomic profile, this sample preparation method was used prior to 2-D 
DIGE gel analysis. This would allow for the comparison of uveal melanoma vitreous 
fluid and control vitreous fluid for the identification of differentially expressed 
proteins. 
Separation in the second dimension creates better resolution of the proteome in 
comparison to a one dimensional separation, which may improve the view of both 
high and low abundance proteins. A sample which was doubly immunodepleted was 
compared to its crude counterpart, following 2D separation, in order to test this. The 
2-D gels were stained using a colloidal silver stain.  
As expected, the high abundance proteins present in the crude sample created a 
smear across the upper section of the gel, with few well resolved spots visible 
(Figure 4.4 (a)). In contrast, the immunodepleted gel illustrated clear protein spots 
with very little background (Figure 4.4 (b)).  
A selection of corresponding spots, Figure 4.4 (b), was extracted from an 
immunodepleted control gel and an immunodepleted uveal melanoma gel for 
enzymatic digestion and identification of proteins by LC-MS/MS. This produced 
two purely qualitative lists of proteins. Proteins which were found only in the control 
vitreous specimen are shown in Table 4.3 while those which were only identified in 
the uveal melanoma sample are listed in Table 4.4. Although this was not a 
statistically relevant quantitative comparison between both conditions, it represents a 
number of proteins which are specific to each sample set and hence, potential 
biomarkers. It was found that many of the proteins detected in the immunodepleted 
disease vitreous sample were classed as highly abundant. 
 
 
166 
 
 
Figure 4.4 Separation of immunodepleted and non-immunodepleted proteins in two 
dimensions based on pI and size. (a) The non-immunodepleted gel showed areas of 
high streaking and poor spot resolution (b) The immunodepleted gel was much 
better resolved with clear spots and little streaking. The region which contained most 
of the high abundance proteins in the upper region of the gel was also much clearer 
following immunodepletion. Spots outlined in red were selected for digestion and 
subsequent identification by LC-MS/MS. 
3                                                  pI                                               11 
MW 
3                                                  pI                                               11 
MW 
(a) 
(b) 
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Table 4.3 Proteins identified in control vitreous fluid which were not found in the 
uveal melanoma sample. This illustrates the effectiveness of immunodepletion as a 
vitreous fluid pre-treatment technique for identifying less abundant proteins. 
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Table 4.4 Proteins identified by mass spectrometry methods which were found 
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exclusively in uveal melanoma vitreous fluid in comparison to the control ocular 
fluid. Many of these proteins were highly abundant, despite immunodepletion. 
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4.4 2-D DIGE Analysis of Uveal Melanoma vs. Control Vitreous Fluid 
It was intended to utilise immunodepletion as a vitreous humour pre-treatment prior 
to 2-D DIGE analysis. Immunodepletion significantly depletes the quantity of 
protein in the ocular fluid because for the most part it is composed of high 
abundance proteins. This results in a more dilute sample. In addition to this, a very 
low volume of vitreous fluid is generally available for analysis. As the protein 
concentration of many of the vitreous fluid samples acquired was quite low and little 
sample was available, immunodepletion was not possible for the entire control and 
uveal melanoma sample sets.  
Due to the above issues, 2-D DIGE was carried out using 25 μg of crude uveal 
melanoma and control vitreous fluids. The 2-D DIGE method is outlined in more 
detail in section 3.3.  
The images generated from the 2-D DIGE analysis (Figure 4.5) illustrated that high 
abundance proteins which would have been removed by immunodepletion had 
streaked across the gel. The protein spots of the gels were also poorly resolved; 
hence, the Progenesis software could not identify protein spot differences between 
the gels of the two sample sets.  
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(a) 
 
(b) 
 
Figure 4.5 2-D DIGE images of 25 μg of non-immunodepleted vitreous fluid 
protein. As the concentration of protein and sample volume was too low in some of 
the vitreous fluid samples available, it was not possible to use immunodepletion as a 
pre-treatment. Streaking and poor protein spot resolution is evident in both images. 
(a) uveal melanoma vitreous fluid (b) vitreous fluid of a macular hole degeneration 
patient (control). 
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4.5 Quantitative Label-Free LC-MS Analysis of Control and Uveal 
Melanoma Vitreous Fluid 
Quantitative label-free proteomics involves the digestion of a fixed quantity of 
protein and the subsequent analysis of 1 μg of the sample by reverse-phase LC-
MS/MS. Acquired total ion chromatograms (TIC) are statistically analysed using 
Progenesis LC-MS software to generate quantitative information on differential 
protein expression patterns between the control and disease vitreous fluid. 
Progenesis LC-MS aligns all of the total ion chromatograms (TIC) generated by 
selecting a reference TIC to which all other runs are compared, thus correcting any 
minor drifts in retention times. MS/MS spectra are then exported to a protein 
identification programme.  
It was planned that label-free proteomics would be used to analyse the crude 
vitreous fluid of uveal melanoma patients in comparison to untreated controls for the 
detection of differentially expressed proteins. However when the samples were 
examined using the technique, it was found that the control and the melanoma 
groups were too different to compare (Figure 4.6). The controls showed similarities 
in their peak profiles and contained a wide variety of features. However, the disease 
samples generated very poor total ion chromatograms; the peaks were poor and were 
totally dissimilar to the control samples with virtually no common peaks detected 
between the sample sets.  This suggests that there were few detectable proteins 
which were mutual to both groups and hence no patterns of differential protein 
expression could be found. 
The lack of identified proteins in the uveal melanoma vitreous fluid may have been 
due to the high abundant proteins present; i.e. when the samples were all initially 
normalised to 10 μg of protein, this could have mainly consisted of background high 
abundance proteins in the disease sample set. This confirmed that a pre-processing 
method for the vitreous would be necessary prior to analysis.  
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4.6 ProteoMiner Pre-Treatment of Vitreous Fluid 
ProteoMiner is a bead-based technology used for the compression of the dynamic 
range of proteins present in complex biological samples through the equalisation of 
all protein abundances. This provides a representative view of the original proteome 
while enhancing the presence of proteins which may have been undetected 
otherwise. The technique is explained further in section 5.2. 
A ProteoMiner kit (Bio-Rad) was used in order to normalise the abundance of 
proteins within each vitreous sample, for both sample sets. It was hoped that this 
would enhance the concentration of the low abundance proteins which could 
potentially be of interest. However, the method requires a minimum protein 
concentration and sample volume higher than available in many of the vitreous 
samples available. Hence the analysis could not be performed as recommended by 
the manufacturer. 
Instead, an appropriate volume of beads was removed from each unit which ensured 
that the quantity of remaining beads was sufficient for a lower sample concentration 
and volume. One control and one uveal melanoma vitreous fluid sample was treated 
using the modified units and the resulting elution from each was separated via 1-D 
electrophoresis, along with the untreated samples (Figure 4.7). The resulting gel was 
stained with colloidal silver. A depletion of background proteins is visible between 
the crude and the treated sample, although an unknown interference diminished the 
resolution of the gels.  Each lane was cut into sections and digested using trypsin. 
Through LC-MS, the proteins present in each sample were identified (Table 4.5).   
This analysis showed that ten previously unseen proteins were identified in the 
disease vitreous fluid as a result of the ProteoMiner treatment. However, only 49 
identifications were found in the ProteoMiner-treated uveal melanoma specimen in 
comparison to 57 in its crude counterpart. In the control fluid, 36 proteins were 
identified in the raw sample while only ten were identified in the ProteoMiner-
treated sample. This indicates that the modified technique was unsatisfactory and 
another method should be utilised. 
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Crude Proteominer Crude Proteominer 
1266/96 1880/09 
Crude   ProteoMiner         Crude    ProteoMiner 
Crude Pr teominer Crude Proteominer 
1266/96 1880/09 
                
 
Figure 4.7 15 μg of ProteoMiner-treated and crude vitreous fluid from a control and 
a uveal melanoma sample was separated by 1-D electrophoresis and stained with a 
silver nitrate stain. Although an unknown contaminant interfered with the resolution 
of the gel, it is clear that some of the high abundance proteins, including serum 
albumin, were depleted from the samples. The gel lanes were excised and digested 
with trypsin prior to mass spectrometry analysis for the identification of the proteins 
present. 
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4.7 Profiling of Vitreous Fluid using SELDI-TOF 
SELDI-TOF is a variation of MALDI, where an analyte is bound to a surface 
through a specific, modified target. A number of affinity technologies can be used 
for this purpose, including cation exchange (CM10) and immobilised metal affinity 
chromatography (IMAC). The method is further explained in section 6.1. 
In this case, copper-activated IMAC chips were used to bind uveal melanoma 
vitreous fluid, cutaneous melanoma serum and conditioned media collected from 
cutaneous melanoma cell lines and to compare the protein profiles from each.  
In each sample set, an unknown 8.9 kDa potential marker was identified in the 
disease sample or the media conditioned by a cancer cell line. This work is outlined 
in more detail in Chapter 6. However, the peak of interest was identified in both 
crude and immunodepleted uveal melanoma vitreous fluid and remained absent from 
the control specimen (Figure 4.8). As SELDI cannot identify the protein peaks 
which it detects, it was necessary to devise a method in order to isolate and identify 
this protein.  
180 
 
 
Figure 4.8 SELDI analysis of both crude and immunodepleted vitreous fluid 
illustrated an 8.9 kDa peptide or protein, as indicated by a red arrow, which 
consistently appeared in the uveal melanoma specimens but was absent from the 
control samples. This potential marker also repeatedly appeared in SELDI spectra of 
advanced cutaneous melanoma sera but remained absent from the corresponding 
control samples. 
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A copper-activated IMAC resin contained in spin columns was employed for 
binding proteins of interest. In this way the resin would mimic the original 
technology used for SELDI analysis and should bind the protein of interest. This 
would allow for the elution and possible identification of the protein.  
One control and one uveal melanoma vitreous fluid sample were incubated with the 
copper-activated resin for sample binding. An ascending gradient of the following 
imidazole concentrations; 25 mM, 50 mM, 100 mM, 200 mM, and 500 mM, was 
then applied to the column and subsequent elution fractions were collected. The 
fractions were separated in the first dimension using a 4-20% low molecular weight 
gel and stained with a colloidal silver stain (Figure 4.9). The lower portion of each 
lane, beneath the red line in Figure 4.9, was excised and in-gel digested with trypsin 
for the generation of peptides which were then analysed by LC-MS/MS, with the 
aim of identifying the 8.9 kDa protein of interest. 
The qualitative results of this analysis illustrated that although the technique failed to 
identify an 8.9 kDa potential biomarker in the vitreous humour, it succeeded in 
identifying a host of proteins which were not found in the previous attempts to 
analyse the ocular fluid proteome. Included in these identifications was a family of 
proteins known as crystallins which are associated with the structure of the eye and 
associated ocular diseases. Although some of the proteins identified in the low 
molecular weight region of the gel were shown to have high molecular weights, they 
may be cleavage products of the larger molecule and hence could migrate to the 
region in question.  
Although this gel-based method does not illustrate significant expression differences 
between both experimental conditions, the identifications shown in Table 4.6 
illustrated substantial differences in peptide numbers between the control and the 
disease sample.  
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                           (a) 
 
 
 
 
 
 
                           
                         (b) 
 
 
 
 
 
 
Figure 4.9 1-D gels illustrating protein fractions which were collected from a 
column containing IMAC resin by applying increasing concentrations of imidazole; 
25 mM, 50 mM, 100 mM, 200 mM and 500 mM. The fractions were separated on a 
low molecular weight gel in the first dimension and stained with a colloidal silver 
stain. The region below the red line containing proteins weighing 30 kDa or less was 
then excised from both the disease (a) and control (b) gels. Each fraction in the low 
molecular weight region of both gels was digested into peptides and analysed by 
mass spectrometry. FT = flowthrough, i.e. unbound proteins. 
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4.8 Qualititative Analysis of Vitreous Fluid Fractionated from IMAC Resin 
The flowthrough, 20 mM fraction, 50 mM fraction and the raw starting material of 
one uveal melanoma vitreous fluid sample were separated by 1-D electrophoresis in 
order to visually represent how well the technique worked (Figure 4.10). This gel 
illustrates the elevated levels of high abundance proteins, such as serum albumin, 
which dominate the starting material and flowthrough lanes to the point where they 
were found to leach into the gel. Although such proteins were still visible in the 20 
mM and 50 mM fractions, they were severely depleted.  
It was also noticeable that the presence of less abundant proteins had been enriched 
by the technique and in some cases bands were visible in the imidazole fractions 
which were previously undetectable.  
The fractions and starting material which correspond to the gel were qualitatively 
analysed by LC-MS/MS (Table 4.7). Overall, 27, 46, 58, and 59 proteins were 
identified in the starting material, the flowthrough, the 20 mM fraction, and the 50 
mM fraction, respectively.  
Of the flowthrough identifications, seven proteins were not found in either the 20 
mM or the 50 mM fraction. 25 and 29 proteins were found to be unique to the 20 
mM and 50 mM elutions, respectively, when compared to the flowthrough protein 
list.  
Of the starting material identifications, four were found to be unique as they were 
not identified in any of the other fractions. When compared to the starting material 
list, 31, 39, and 40 proteins were found to be enriched in the flowthrough, 20 mM 
and 50 mM fractions, respectively, following IMAC fractionation.  
A number of crystallins were only detected in the 20 mM and 50 mM fractions and 
not in the flowthrough or starting material. As crystallins are known to bind IMAC, 
this would suggest that the fractionation worked. 
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Figure 4.10 Uveal melanoma vitreous fluid fractionated from copper-activated 
IMAC resin. Although the starting material (SM) contained highly abundant proteins 
which dominated the lane, the IMAC fractionation method improved the resolution 
of less prominent bands while reducing the intensity of the more abundant proteins 
present. SM - Starting Material; FT - Flowthrough; 20 mM – 20 mM imidazole 
elution fraction; 50 mM - 50mM imidazole elution fraction 
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4.9 Quantitative LC-MS Analysis of Differentially Regulated, IMAC-Bound 
Vitreous Fluid Proteins 
In order to examine the efficiency of the IMAC-based fractionation technique with a 
larger sample set, 13 uveal melanoma vitreous humour specimens were selected for 
IMAC purification (Table 4.8). This would determine the reproducibility of the 
technique as a fractionation method and as an enhancer of the low abundance protein 
population. Six of the samples were collected from patients with monosomy of 
chromosome three; an indicator of poor prognosis in uveal melanoma, while the 
other seven were disomy of chromosome three. . It was postulated that proteins 
would be differentially expressed between specimens collected from patients with 
monosomy three (associated with poor prognosis) and disomy three (good 
prognosis) and that this analysis would highlight any potential differential protein 
expression patterns. 
Each specimen was bound to copper-activated IMAC resin as before and eluted in 
20 mM, 50 mM, 100 mM, 300 mM and 500 mM fractions. The unbound fraction 
was also collected. All samples were then quantified, however of the fractions, only 
enough protein to proceed with the analysis was present in the 20 mM and the 50 
mM elutions. The flowthrough and two fractions were in-solution digested with both 
lys-C and trypsin to produce peptides of which 1 μg was analysed by LC-MS/MS 
over the course of a one hour gradient. Technical replicates were performed for each 
sample. The resulting information was analysed with Progenesis LC-MS software. 
Identifications with ANOVA scores of <0.05 for peptides and proteins were 
accepted. Protein principal component analyses (PCA), which represents protein 
abundance variation between features, are shown for the flowthrough, 20 mM, and 
50 mM fractions in Figure 4.11. This illustrated good separation of protein 
abundances between the monosomy three and disomy three sample sets for each of 
the three fractions. 
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Table 4.8 Patient details for 13 vitreous humour specimens selected for IMAC 
fractionation. Seven disomy of chromosome three samples were compared with six 
monosomy of chromosome three specimens. All fluids were taken from patients 
with uveal melanoma.  
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Figure 4.11 Principal component analysis (PCA) for proteins in the flowthrough, 20 
mM and 50 mM fractions. Feature abundance levels across runs are plotted to 
determine the abundance variation between samples. This is useful in identifying run 
outliers. Each blue point corresponds to a monosomy of chromosome three sample 
(n=6) while each pink point corresponds to a disomy of chromosome three sample 
(n=7). 
 
 
 
20 mM Fraction 
50 mM Fraction 
Flowthrough Fraction 
Monosomy 3 
Monosomy 3 
Monosomy 3 
Disomy 3 
Disomy 3 
Disomy 3 
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Eight proteins were found to be differentially expressed between monosomy three 
and disomy three specimens in the flowthrough (Table 4.9). One such identification, 
Ig heavy chain V-I region V35 (Figure 4.11), had not previously been reported in the 
literature as being expressed in the vitreous.  
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Figure 4.11 Normalised abundance profile for Ig heavy chain V-I region V35 in the 
flowthrough fraction of IMAC fractionated vitreous fluid. An 11.28 max fold 
increase was observed in the monosomy three vitreous specimens (n=6, analysed in 
duplicate) in comparison to those which were disomy three (n=7, analysed in 
duplicate), p=0.04 between experimental groups. Each spot in the profile 
corresponds to Ig heavy chain V-I region V35 abundance per sample.  
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37 proteins were detected as potential targets of interest in the 20 mM fraction, 
including ocular-related proteins such as retinol-binding protein 3 and alpha 
crystallin B chain (Table 4.10).  
Retinol-binding protein 3 was identified as being upregulated in monosomy of 
chromosome three specimens in both the flow through and the 20 mM fraction 
(Figure 4.12). As it functions as a transporter of retinoids between the 
photoreceptors and the retinal pigment epithelium, it is necessary for normal rod and 
cone cell function (den Hollander, McGee et al. 2009).  
Meckelin, which mediates primary ciliary function, was identified as being 
decreased in the monosomy three sample set by 2.03-fold, as illustrated in Figure 
4.13 (Dawe, Smith et al. 2007).  Meckelin, Ig heavy chain V-III region GAL, and Ig 
kappa chain V-I region Roy, all of which were found to be differentially regulated 
between the disomy of chromosome three and monosomy of chromosome three 
sample sets, were not previously identified in vitreous humour, according to the 
literature, including a recent study carried out by Aretz et al. Using different protein 
pre-fractionation strategies, such as liquid phase isoelectric focusing, 1-D gel 
electrophoresis and a combination of both, followed by UPLC-MS/MS analysis of 
generated peptides, Aretz et al. identified 1111 unique proteins from three separate 
vitreous specimens (Aretz, Krohne et al. 2013). This is the most comprehensive 
qualitative study of a control vitreous fluid proteome carried out to date. As some of 
the proteins identified in this study were not found by Aretz et al., this may suggest 
that these proteins may be differentially regulated exclusively in uveal melanoma, 
and may be novel in terms of vitreous fluid proteomics. 
Other proteins which were found to be differentially expressed in this study have 
previously been identified in the vitreous, including pigment epithelium-derived 
factor (PEDF). PEDF was found to be decreased in the monosomy three sample set 
by 1.44-fold (Figure 4.14). This secreted protein has been long associated with anti-
angiogenic and anti-tumorigenic properties as well as being essential for the health 
and survival of the retina (Subramanian, Locatelli-Hoops et al. 2013).  
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Figure 4.12 Retinol-binding protein 3 was identified as being upregulated by 2.82-
fold in the monosomy three specimens of the 20 mM fraction (p=0.03 between 
experimental groups). However, two technical replicates from one of the samples 
(circled) appear to have biased the observed fold change. Despite this, the result was 
still considered significant across all samples (a) Normalised abundance view of 
retinol-binding protein 3 expression in disomy three (n=7, analysed in duplicate) and 
monosomy three (n=6, analysed in duplicate) vitreous samples. Each point 
corresponds to a sample and illustrates the quantity of the protein of interest per 
specimen. (b) Normalised abundance of identified retinol-binding protein 3 peptides 
per sample. Each line represents a peptide while each point indicates the abundance 
of the peptide per sample.  
 
 
 
 
 
(a) 
(b) 
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Figure 4.13 Meckelin was identified as being downregulated by 2.03-fold in the 
monosomy three specimens (n=6, analysed in duplicate) of the 20 mM fraction in 
comparison to that of the disomy three (n=7, analysed in duplicate), p=9.59x10
-3
 
between sample sets. Only one peptide was matched to this sample which indicates 
that meckelin may be a weak candidate. (a) Normalised abundance view of meckelin 
expression in disomy three and monosomy three vitreous samples. Each point on the 
figure corresponds to a sample and indicates the quantity of the protein of interest 
per specimen. (b) Normalised abundance of identified meckelin peptides per sample. 
The line represents a peptide while each point indicates the abundance of peptide per 
sample.  
 
 
 
 
 
 
(a) 
(b) 
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Figure 4.14 Pigment epithelium-derived factor (PEDF) was identified as being 
downregulated by 1.44-fold in the monosomy three specimens (n=6, analysed in 
duplicate) of the 20 mM fraction in comparison to the disomy three samples (n=7, 
analysed in duplicate), p=0.04 between sample sets. Only one peptide was matched 
to this sample which indicates that PEDF may be a weak candidate. (a) Normalised 
abundance view of PEDF expression in disomy three and monosomy three vitreous 
samples. Each point on the figure corresponds to a sample and indicates the quantity 
of the protein of interest per specimen. (b) Normalised abundance of identified 
PEDF peptides per sample. The line represents a peptide while each point indicates 
the abundance of peptide per sample.  
 
 
 
 
 
(a) 
(b) 
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For the 50 mM fraction, 17 proteins were found to be differentially expressed 
between both groups (Table 4.11).  
Retbindin, a secreted protein, was identified in the 50 mM fraction as showing an 
decreased abundance in the monosomy of chromosome three sample set (Figure 
4.15). This is a relatively novel, secreted protein which is thought to function in 
flavonoid or carotenoid binding (Wistow, Bernstein et al. 2002). Again, retbindin 
was not previously identified in vitreous fluid by Aretz et al. or in the literature.  
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Figure 4.15 Retbindin was identified as being upregulated by a maximum fold value 
of 9.74 in monosomy three specimens (n=6, with two of the samples analysed in 
duplicate) in comparison to disomy three specimens (n=7, with six of the samples 
analysed in duplicate), in the 50 mM fraction, p=1.62x10
-4
 between sample sets. (a) 
Normalised abundance view of retbindin expression in disomy three and monosomy 
three vitreous samples. Each point on the figure corresponds to a sample and 
indicates the quantity of the protein of interest per specimen. (b) Normalised 
abundance of identified retbindin peptides per sample. The lines represent peptides 
while each point indicates the abundance of peptide per sample. 
  
 
 
 
 
(a) 
(b) 
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For the flowthrough, the 20 mM, and the 50 mM fractions, the TIC profiles were 
similar between the samples in each group with good alignments of features between 
samples. This would indicate that the method was reproducible between fractions 
and hence, successful.  
 
4.10 Enrichment Analysis Within Differentially Expressed Protein Lists Using 
DAVID  
In order to determine significant enrichment of biological processes, molecular 
functions, and cellular compartments involved within the differentially expressed 
protein lists, DAVID and (GO analysis was used. Enrichment was considered to be 
significant when the Bonferroni p-value adjustment was ≤0.05. The differentially 
regulated protein lists for the flowthrough, 20 mM and 50 mM fractions were 
merged, and proteins either up or downregulated in monosomy three specimens were 
analysed as two separate lists. 
For the list of proteins which were downregulated in monosomy of chromosome 
three specimens, many of the identifications related to biological processes such as 
response to trauma, e.g. inflammatory response, regulation of blood coagulation 
(Table 4.12). This may be due to the breakdown of the blood-retinal barrier which 
can occur during uveal melanoma. Cellular compartments which were related to the 
downregulation of proteins in the monosomy of chromosome three sample set were 
associated with extracellular regions and lipoprotein complexes (Table 4.13). The 
molecular processes identified by the analysis involved enzyme inhibiting and 
cholesterol-binding activities (Table 4.14). Overall, DAVID found that the collective 
decrease in expression of five the proteins identified; kininogen-1, plasma protease 
C1 inhibitor, antithrombin-III, complement factor B and coagulation factor XII, 
would impact on B cell receptor signalling pathway in the complement and 
coagulation cascade (Figure 4.16). 
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Table 4.12 GO biological process enrichment for differentially expressed proteins 
which were downregulated in monosomy of chromosome three vitreous fluid. 
Enrichment was considered significant upon observation of a p-value ≤0.05 and a 
Bonferroni adjusted p-value ≤0.05. Count corresponds to the overlap between 
proteins on the list and a particular GO category. 
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Table 4.13 GO cellular compartment enrichment for differentially expressed 
proteins which were downregulated in monosomy of chromosome three vitreous 
fluid. Enrichment was considered significant upon observation of a p-value ≤0.05 
and a Bonferroni adjusted p-value ≤0.05. Count corresponds to the overlap between 
proteins on the list and a particular GO category. 
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Table 4.14 GO molecular function enrichment for differentially expressed proteins 
which were downregulated in monosomy of chromosome three vitreous fluid. 
Enrichment was considered significant upon observation of a p-value ≤0.05 and a 
Bonferroni adjusted p-value ≤0.05. Count corresponds to the overlap between 
proteins on the list and a particular GO category. 
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Figure 4.16 DAVID analysis of proteins which were downregulated in monosomy 
of chromosome three uveal melanoma vitreous fluid specimens found that five 
identifications; kininogen-1, plasma protease C1 inhibitor, antithrombin-III, 
complement factor B and coagulation factor XII, were involved in complement and 
coagulation cascades. The genes which are involved are highlighted in yellow. This 
illustrated that the downregulation of these proteins would ultimately affect B cell 
receptor signalling. 
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Proteins which were upregulated in monosomy of chromosome three ocular fluid 
were shown to relate to extracellular compartments (Table 4.15). No statistically 
significant biological or molecular processes were identified for the protein list. Two 
genes which express proteins from the list; fibrinogen alpha chain and complement 
C3, were found to play a role in the complement and coagulation cascades (Figure 
4.17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
210 
 
Table 4.15 GO cellular compartment enrichment for differentially expressed 
proteins which were upregulated in monosomy of chromosome three vitreous fluid. 
Enrichment was considered significant upon observation of a p-value ≤0.05 and a 
Bonferroni adjusted p-value ≤0.05. Count corresponds to the overlap between 
proteins on the list and a particular GO category. 
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Figure 4.17 DAVID analysis of proteins which were upregulated in monosomy of 
chromosome three uveal melanoma vitreous fluid specimens found that two 
identifications; fibrinogen alpha chain and complement C3, were involved in 
complement and coagulation cascades.  
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4.11 Analysis of Vitreous Fluid by Luminex Multiplex Assay 
The Luminex bioassay system uses xMAP technology which creates a multiplex 
approach to bioassaying. Through the combination of advanced fluidics, optics, and 
digital signal processing with a microsphere technology, it is possible to analyse up 
to 500 analytes per well. The microspheres used are tiny colour-coded polystyrene 
beads dyed with distinct proportions of red and near-infrared fluorophores. Each 
bead set can be coated with a reagent specific to a particular bioassay, allowing the 
capture and detection of specific analytes from a sample. Within the Luminex 
system, a light source excites the internal dyes which identify each microsphere 
particle and any reporter dye captured during the assay. Up to one hundred different 
detection reactions can be carried out simultaneously on the various bead 
populations in very small volumes. 
Results acquired from multiplex analysis can be further examined using MedCalc, a 
statistical software programme designed for biomedical science. This illustrates the 
sensitivity and specificity of a potential marker through ROC curve analysis. 
A Luminex 12-plex cytokine/chemokine assay was chosen for the analysis of 
vitreous humour from both uveal melanoma and control patients. The assay 
quantified the levels of FGF2, IFNɣ, TNFα, TGFα, MIP1α, IL-10, IL-15, IL-1α, IL-
2, IL-6, IL-8, and IP10 in eight uveal melanoma and six control vitreous samples. 
Within the disease sample set were seven patients who developed metastases and 
one who did not. The six control vitreous were obtained from macular hole 
degeneration patients. All samples used in the analysis are outlined in Table 4.16. 
This identified three potential chemokines of interest; basic fibroblast growth factor 
(FGF2), macrophage inhibitory protein 1 alpha (MIP1α) and interferon gamma 
(IFNɣ).  
In some cases t-test results were poor and ROC test results appeared implausibly 
high, which may have been due to the small sample set used and to variances 
between samples.  
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Table 4.16 Clinical data for control (from macular hole degeneration patients) and 
uveal melanoma vitreous fluid samples used in the Luminex 12-plex 
cytokine/chemokine assay.  
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4.11.1 FGF2 
As illustrated in Figure 4.18 (a), FGF2 was not shown to be significantly 
differentially expressed between the control and the uveal melanoma sample groups, 
although a trend appeared to indicate a higher abundance of the protein in the 
disease vitreous.  
The result was followed up using MedCalc (Figure 4.18 (b)) which presented a 
specificity of 100% and a sensitivity of 75%. This would indicate that FGF2 may be 
of interest as a potential biomarker; however analysis with a larger sample set would 
first be required.  
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(a) 
 
 
(b) 
 
 
 
 
 
Figure 4.18 Basic fibroblast growth factor (FGF2) was identified in vitreous fluid 
by a Luminex multiplex bioassay. (a) No statistically significant difference in 
expression of FGF2 was seen between the control (n=6) and uveal melanoma 
vitreous samples (n=7). (b) ROC curve analysis indicated the strength of FGF2 as a 
potentially specific marker. p-value=0.09, area under the ROC curve (AUC)=0.823. 
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4.11.2 MIP-1α 
A significant increase in MIP-1α expression was seen in the vitreous of uveal 
melanoma patients when compared to the controls, with an ANOVA score of <0.01 
(Figure 4.19 (a)).  
ROC curve analysis confirmed this finding with high sensitivity and specificity 
values generated for the comparison of control and uveal melanoma vitreous. 
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(a) 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
Figure 4.19 (a) Macrophage Inflammatory Protein 1 Alpha (MIP-1α) was found at 
statistically significantly higher levels in uveal melanoma vitreous (n=7) when 
compared to control vitreous (n=6) by Luminex multiplex assay. (b) Using ROC 
curve analysis, MIP-1α was found to be a potential biomarker. p-value=6.01x10-3, 
area under the ROC curve=0.958. ** p <0.01 
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4.11.3 IFNɣ 
IFNɣ was found to be more abundant in uveal melanoma vitreous in comparison to 
the control vitreous. This was found to be a statistically significant increase in 
expression, with an ANOVA score of <0.01 (Figure 4.20 (a)).  
ROC curve analysis correlated with this finding, illustrating both 100% sensitivity 
and 100% specificity (Figure 4.20 (b)).  
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(a) 
 
(b) 
 
 
 
 
 
Figure 4.20 (a) Interferon Gamma (IFNɣ) was found to be significantly 
overexpressed in the uveal melanoma vitreous (n=7) in comparison to the control 
(n=6). (b) ROC curve analysis illustrated high sensitivity and specificity. p-
value=3.87x10
-3
, area under the ROC curve (AUC)=1.0. ** p <0.01 
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Figure 4.21 Summary table illustrating all methods which were tested in the pre-
treatment and analysis of vitreous fluid. 
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CHAPTER FIVE 
Proteomic Analysis of Cutaneous Melanoma Disease Progression 
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5.1 Background 
In order to fully comprehend the nature of disease and its progression, a better 
understanding at the proteomic level is often necessary. It was hypothesised that 
protein expression differences would be present throughout the process of melanoma 
disease progression. Such protein differences may in turn lead to the discovery of 
biomarkers which can then be used in diagnostic tests or as therapeutic targets. It 
was decided to undertake a complete analysis of the cutaneous melanoma proteome 
by comparing fractionated advanced cutaneous melanoma serum to fractionated 
control serum (collected from potentially diabetic patients) using quantitative label-
free LC-MS proteomics. Quantitative LC-MS is a highly sensitive, reproducible and 
accurate method of determining differential protein expression patterns between 
disease and test groups. Any differentially regulated proteins identified would then 
be followed up in benign and early stage melanoma serum, as well as in uveal 
melanoma serum.  
It was intended that this approach could improve our understanding of the cutaneous 
melanoma proteome throughout disease progression and to investigate possible 
correlations between both uveal and cutaneous melanomas. It could also identify 
potential biomarkers for metastatic uveal melanoma, in comparison to non-
metastatic uveal melanoma.  
 
5.2 Quantitative Label-Free LC-MS Analysis of ProteoMiner Fractionated 
Serum 
ProteoMiner is a bead-based technology used for the compression of the dynamic 
range of proteins present in complex biological samples. Through the use of a large, 
bead-based library of combinatorial peptide ligands, ProteoMiner attempts to 
equalise levels of all proteins throughout the sample. This provides a representative 
view of the original proteome while enhancing the presence of proteins which may 
have been undetected otherwise. 
A group of eight control sera versus eight stage IV cutaneous melanoma sera were 
chosen for the experiment (Table 5.1). The control and disease samples were all 
matched by sex.  
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A ProteoMiner sequential elution kit was used to treat all of the above samples. This 
kit combines ProteoMiner bead technology with multiple elution reagents of various 
chemical properties, as outlined in section 2.17.1, hence providing a protein 
fractionation based on the characteristics of the individual molecules. This gave four 
elution fractions per sample, thus resulting in a good overview of the proteome.  
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Table 5.1 Details of eight advanced cutaneous melanoma sera vs. eight control sera 
treated using a ProteoMiner Sequential Elution method and subsequently analysed 
by quantitative label-free LC-MS proteomics for the discovery of differentially 
expressed proteins between both conditions. 
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5.3 1-D Analysis of ProteoMiner-Fractionated Serum Samples 
All elution fractions were treated with a 2-D clean up kit which involves selective 
precipitation in order to remove ionic contaminants, that can interfere with 
downstream analysis, from protein samples. In addition to this, it enables 
concentration of proteins allowing for higher sample load. The elution fractions were 
then quantified and an equal concentration of protein from each sample of four 
elution fractions was separated on a 1-D gel. The gels were subsequently stained 
with Coomassie Brilliant Blue Colloidal stain in order to give a visual representation 
of each elution (Figure 5.1). From this, it was clear that elution fractions three and 
four were very similar in their protein profiles.                         
Following the visual comparison of all 4 elution fraction 1-D profiles, each lane was 
excised from gels (a) and (d) shown in Figure 5.1 and in-gel digested using trypsin. 
LC-MS analysis provided a list of identifications for each elution; 128, 143, 126 and 
135 proteins were identified for fractions one, two, three and four, respectively, of 
the melanoma sera and 138, 127, 113 and 125 were identified in the corresponding 
fractions of the control sera, respectively.  
It was clear, however, that the proteins discovered in elution fraction three were less 
exclusive and, for the most part, were easily detected in fractions one, two and four. 
Following a comparison of the melanoma serum identifications acquired, only two 
proteins were found to be unique to fraction three when compared to fractions one, 
two and four (Appendix A). Similarly, for the control serum results, only three 
identifications were noted as exclusive to elution fraction three (Appendix A). 
Hence, it was decided to exclude fraction three from quantitative label-free LC-MS 
analysis. 
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5.4 Quantitative Label-Free Proteomics Analysis of Fractionated Cutaneous 
Melanoma Serum 
Elution fractions one, two and four of all eight control and eight melanoma sera 
were processed using C18 reverse-phase resin in order to remove interfering 
contaminants which could cause a strong signal suppression. C18 technology should 
reduce these effects, thus improving signal-to-noise ratios and sequence coverage.  
Each fraction was analysed by reverse-phase LC-MS/MS and the acquired data were 
statistically analysed using Progenesis LC-MS software to generate quantitative 
information on differential protein expression patterns between cutaneous melanoma 
and control sera. MS/MS spectra with ANOVA values of ≤0.1, and with charge 
states from +1 to +3 were exported to MASCOT, and subsequent identifications 
were selected based on a protein ANOVA score of ≤0.05 between experimental 
groups. From this it was found that 29, 39, and 54 proteins in fractions one, two and 
four, respectively, were differentially regulated between the control and advanced 
melanoma groups. Protein identifications for each fraction are outlined in Tables 5.3, 
5.4 and 5.5.  
However, the protein list generated for elution fraction four illustrated a pattern of 
downregulation in the cutaneous melanoma proteome in comparison to the control 
proteome for all but three proteins. This pattern of differential regulation seemed 
unlikely as some of the proteins identified in elution four showed an opposite trend 
of expression in comparison to previous elution fractions. For example, Vitamin D-
binding protein was upregulated in the cutaneous melanoma proteome by 2.08- and 
2.44-fold in elution fractions one and two, respectively, although in elution fraction 
four it was identified at a level of 2.51-fold higher in the control proteome in 
comparison to that of the melanoma samples. This unusual trend may have been due 
to the fourth elution reagent simply stripping all remaining proteins from the 
ProteoMiner column as it is a stringent organic buffer. It was decided that this may 
provide a disproportionate view of the proteome and could skew the overall results; 
hence, elution fraction four was excluded from the analysis. 
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5.5 Analysis of Differential Regulation of Proteins in Recombined Fractions 
One and Two 
Initially, 16 biological samples were fractionated in order to increase protein 
coverage and to have the best overall view of the proteome. However, in order to 
investigate how the proteins behave across the whole experiment, fractions of the 
same sample may be recombined. Progenesis LC-MS software normalises between 
elution fractions of the same sample and combines protein measurements to provide 
statistical analyses of the experiment as a whole.   
Elution fractions one and two of the same sample were recombined and analysed 
together to identify differential regulation patterns between eight control sera and 
eight advanced cutaneous melanoma sera. This resulted in the identification of 57 
differentially expressed proteins, of which nine proteins were found in both elution 
fractions one and two (Table 5.6).  
 
5.6 Comparison of 1-D and Quantitative Label-Free LC-MS Protein Profiles 
for the Selection of Targets for Validation 
The qualitative protein profiles were generated from digesting each band of the gels 
shown in Figure 5.1 (a) and (d) with trypsin and analysing the peptides over the 
course of an hour gradient.  
Shown in Table 5.7 are qualitative statistically identified proteins which were found 
in both control samples, DS 118 and DS 114, and both disease samples, 036 and 
017. Each identification shown in Table 5.7 was found only in one group, i.e. control 
or disease. The full list of identifications for elution one and two of 017, 036, 
DS114, and DS118 can be found in Appendix B. 
The proteins listed in Table 5.7 were then compared with the label-free protein list 
created from recombined fractions one and two (Table 5.6). From this, 10 potential 
targets of interest were identified (Table 5.8).  
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5.7 Selection of Potential Targets for Further Validation 
Following the fractionation and subsequent analysis of the differential regulation 
data acquired, it was decided to follow-up some of the notable targets using ELISA, 
as this is the method of clinical biomarker detection primarily used in hospitals.  
From the quantitative LC-MS label-free analysis combining elution fractions one 
and two, azurocidin and lactotransferrin (Table 5.6) were selected for follow-up 
analysis as was serotransferrin, which was identified in both the quantitative label-
free LC-MS data and the qualitative 1-D data (Table 5.8). As mentioned, all three 
targets were found to be upregulated in the advanced cutaneous melanoma serum in 
comparison to the control during the Progenesis analysis. Plasma serine protease 
inhibitor (Table 5.4) was also chosen as it was found to be significantly under-
expressed in the disease sera in comparison to the controls. Analysis of all proteins 
of interest demonstrated p-values of <0.05 as well as strong Mascot scores and good 
peptide overlap between samples. 
In addition to the above, three targets were chosen from a microarray study carried 
out by Dr. Paul Dowling and Dr. Steven Madden using Gene Expression Omnibus 
(GEO). Beta-secretase 2 (BACE-2), Matrix metalloprotease (MMP-1), and Tissue 
inhibitor of metalloproteinase 1 (TIMP-1) were identified by the analysis of two 
publically available array data sets for control tissue, and primary and metastasised 
cutaneous melanoma tumour tissue (Riker, Enkemann et al. 2008, Raskin, Fullen et 
al. 2013). All three proteins were significantly upregulated in the metastasised and 
primary tissues in comparison to the control. This data is shown in Table 5.9. 
In addition to using benign, early-stage and advanced-stage cutaneous melanoma 
serum for the analysis of the seven proteins of interest, serum collected from uveal 
melanoma patients was also included to examine the expression patterns of the 
proteins of interest between patients with monosomy of chromosome three, which is 
a known chromosomal aberration correlated with a poor prognosis, and those 
patients with no evidence of monosomy three, i.e. disomy three.  By including serum 
of ocular melanoma patients, this would also allow for the direct comparison of 
specific protein expression between uveal and cutaneous melanomas. An overview 
of the samples used in the ELISA validation of the seven targets is shown in Table 
5.10. Cutaneous melanoma sera were collected and clinically characterised by Dr. 
Benvon Moran of St. James‟s Hospital.  
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Table 5.10 Control, cutaneous melanoma and uveal melanoma sera were all used in 
the further analysis, by ELISA, of the seven proteins of interest; azurocidin, 
lactotransferrin, serotransferrin, MMP-1, TIMP-1 and BACE-2. A more 
comprehensive list of samples used is shown in Appendix C.                                      
* The early stage consisted of the following sub-stages; twelve stage I and two stage 
II.                                                                                                                                         
# 
The advanced stage group consisted of the following sub-stages; four stage III and 
eight stage IV.  
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5.8 ELISA Analysis of Potential Biomarkers of Interest 
ELISA results are presented in both bar chart and box-and-whisker formats. In 
addition to the standard bar graphs, box-and-whisker plots were included as they 
show a more accurate distribution of results. From the box-and-whisker plots the 
minimum, maximum, and median can be determined as well as the 25
th
 and 75
th
 
percentile, giving a more accurate representation of where the overall results lie. 
Comparisons between experimental groups with T-test ≤0.05 are marked by a single 
asterisk (*) and ≤0.01 are marked by two asterisks (**). 
 
5.8.1 Lactotransferrin 
Lactotransferrin, a major iron-binding and multifunctional protein, was found to be 
4.17-fold upregulated in advanced-stage cutaneous melanoma serum, see Figure 5.2 
(a). As illustrated by Figure 5.2 (b), lactotransferrin was identified in both elution 
fractions one and two in the quantitative LC-MS analysis and showed high 
reproducibility between samples containing the same eight peptides against 
lactotransferrin.  
According to the ELISA data acquired (Figure 5.3) lactotransferrin was significantly 
less abundant in benign or early-stage cutaneous melanoma serum when compared 
to control serum. There was no significant difference between the levels in control 
and advance-stage cutaneous melanoma serum, however an increase in 
lactotransferrin was observed in advanced-stage samples when compared to those 
which were benign.  
The uveal melanoma sample set, which contained both monosomy of chromosome 
three sera and disomy of chromosome three sera, showed a significantly decreased 
level of lactotransferrin when compared with that of the control sample set, as 
illustrated in Figure 5.3. When the uveal melanoma serum specimens which were 
positive for monosomy of chromosome three were compared to those which did not 
have this anomaly, no significant difference was observed between the two (Figure 
5.4).  
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Figure 5.3 Lactotransferrin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13). t-test scores: control vs. benign cutaneous = 6.48x10
-5
; control 
vs. early cutaneous = 3.93x10
-4
; control vs. uveal = 3.46x10
-6
; benign cutaneous vs. 
advanced cutaneous = 1.78x10
-4
; * t-test score between experimental groups of 
≤0.05, ** t-test score between experimental groups of ≤0.01. 
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Figure 5.4 Lactotransferrin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6). t-test scores: control vs. no evidence of monosomy three = 
1.83x10
-2
; control vs. monosomy three = 5.53x10
-5
. * t-test score between 
experimental groups of ≤0.05, ** t-test score between experimental groups of ≤0.01. 
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5.8.2 Serotransferrin 
Serotransferrin was initially found to be over-expressed by 3.47-fold in advanced-
stage melanoma sera when compared to healthy sera using quantitative label-free 
proteomics analysis, Figure 5.5 (a). Three peptides with a p-value of ≤0.05 which 
matched the serotransferrin sequence were identified in elution fraction two only, as 
shown in Figure 5.5 (b). 
However, the ELISA results directly contradicted this quantitative LC-MS data with 
a statistically significant trend of decreased serotransferrin levels observed in either 
early or advanced-stage cutaneous disease when compared to the control serum 
(Figure 5.6). Overall, a trend of decreased serotransferrin abundance was observed 
across all melanoma samples; benign, early-stage, advanced-stage, in relation to 
control serum.  
A statistically significant decrease in serotransferrin abundance was observed in 
uveal melanoma serum when compared to control serum, (Figure 5.6), as is the case 
in monosomy three serum compared to control serum. No statistically significant 
difference in abundance was observed between monosomy three and disomy three 
uveal melanoma specimens, when they were compared with one another (Figure 
5.7).  
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Figure 5.6 Serotransferrin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13). t-test scores: control vs. early cutaneous = 6.48x10
-3
; control 
vs. advanced cutaneous = 4.16x10
-3
; control vs. uveal = 1.59x10
-2
 * t-test score 
between experimental groups of ≤0.05; ** t-test score between experimental groups 
of ≤0.01. 
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Figure 5.7 Serotransferrin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6). * t-test score between experimental groups of ≤0.05. 
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5.8.3 Azurocidin 
As illustrated in Figure 5.8 (a), azurocidin was over-expressed in late-stage 
cutaneous melanoma serum specimens according to quantitative label-free LC-MS 
analysis. One peptide for the protein was found in elution fraction one and in elution 
fraction two, over-expressed at a maximum observed fold change of 14.2, Figure 5.8 
(b).  
Although a slight increase in azurocidin abundance was observed in advanced 
cutaneous melanoma sera in comparison to healthy sera, no statistically significant 
relationship was identified.  
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Figure 5.9 Azurocidin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13). 
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Figure 5.10 Azurocidin ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6).  
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5.8.4 Plasma Serine Protease Inhibitor 
Figure 5.11 (a) illustrates the downregulation of plasma serine protease inhibitor in 
advanced sera in comparison to normal melanoma sera, as detected by quantitative 
label-free LC-MS analysis. As shown in Figure 5.11 (b), three peptides were 
detected in elution fraction two, where an average fold change of 2.6 was observed.  
In contrast to the above results, a significant increase in the expression of plasma 
serine protease inhibitor in early stage cutaneous melanoma serum in comparison to 
that of either control or benign melanoma serum was noted (Figure 5.12). No 
significant or clear abundance difference of the protein was observed when control 
and advanced cutaneous melanoma serum were compared. Hence, the results of the 
ELISA do not validate those of the quantitative label-free LC-MS experiment.  
There was a statistically significant increase in the level of plasma serine protease 
inhibitor in uveal melanoma serum when compared to that of healthy patients 
(Figure 5.12). This increase in abundance was observed equally in both patients with 
monosomy of chromosome three and those with disomy of chromosome three, in 
relation to the level of plasma serine protease inhibitor produced in control serum, as 
shown in Figure 5.13.  
 
253 
 
 
 
 
F
ig
u
re
 5
.1
1
 Q
u
an
ti
ta
ti
v
e 
la
b
el
-f
re
e 
L
C
-M
S
 d
at
a 
fo
r 
p
la
sm
a 
se
ri
n
e 
p
ro
te
as
e 
in
h
ib
it
o
r.
 O
v
er
al
l,
 p
la
sm
a 
se
ri
n
e 
p
ro
te
as
e 
in
h
ib
it
o
r 
w
as
 i
d
en
ti
fi
ed
 i
n
 t
h
e 
re
co
m
b
in
ed
 e
lu
ti
o
n
 f
ra
ct
io
n
 a
n
al
y
si
s 
as
 b
ei
n
g
 u
n
d
er
ex
p
re
ss
ed
 i
n
 a
d
v
an
ce
d
 c
u
ta
n
eo
u
s 
m
el
an
o
m
a 
se
ru
m
 (
n
=
8
) 
as
 i
t 
w
as
 f
o
u
n
d
 t
o
 b
e
 e
le
v
at
ed
 i
n
 
co
n
tr
o
l 
se
ru
m
 
(n
=
8
) 
b
y
 
2
.4
-f
o
ld
, 
p
-v
al
u
e=
5
.1
1
x
1
0
-3
. 
(a
) 
S
ta
n
d
ar
d
 
ex
p
re
ss
io
n
 
in
d
iv
id
u
al
 
p
ro
te
in
 
p
ro
fi
le
 
fo
r 
al
l 
1
6
 
sa
m
p
le
s 
(b
) 
T
h
e 
p
ep
ti
d
e 
m
ea
su
re
m
en
t 
v
ie
w
 w
it
h
 a
n
 a
cc
o
m
p
an
y
in
g
 t
ab
le
 i
ll
u
st
ra
te
s 
u
n
iq
u
e 
p
ep
ti
d
es
 f
o
r 
p
la
sm
a 
se
ri
n
e 
p
ro
te
as
e 
in
h
ib
it
o
r 
in
 e
ac
h
 s
am
p
le
. 
 
(a
) 
(b
) 
254 
 
 
 
Figure 5.12 Plasma serine protease inhibitor ELISA data represented by both bar 
chart and Box and Whisker Plot. Serum samples from a variety of melanoma 
conditions were used; benign cutaneous melanoma (n=18), early-stage cutaneous 
disease (n=14), advanced-stage cutaneous disease (n=12), and uveal melanoma 
(n=13), as well as control serum (n=13). t-test scores: control vs. early cutaneous = 
1.55x10
-3
; control vs. uveal = 6.32x10
-4
; benign vs. early cutaneous = 1.56x10
-3
. ** 
t-test score between experimental groups of ≤0.01 
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Figure 5.13 Plasma serine protease inhibitor ELISA data represented by both bar 
chart and Box and Whisker Plot. Serum samples from two uveal melanoma 
conditions were used; monosomy of chromosome three (n=7) and no evidence of 
monosomy of chromosome three (n=6). t-test scores: control vs. no evidence of 
monosomy three = 1.79x10
-3
; control vs. monosomy three = 0.037. * t-test score 
between experimental groups of ≤0.05. ** t-test score between experimental groups 
of ≤0.01 
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5.8.5 BACE-2 
As illustrated in Figure 5.14, BACE-2 was shown to be elevated in both early and 
late stage cutaneous melanoma in comparison to serum of patients with benign 
disease. In addition to this, BACE-2 was also shown to be highly abundant in late-
stage disease when compared to healthy sera. 
No statistically significant difference in BACE-2 production was observed between 
the uveal melanoma serum group and the control sera, see Figure 5.14; neither was 
any difference noted between patients with or without monosomy of chromosome 
three (Figure 5.15). 
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Figure 5.14 BACE-2 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13). t-test scores: benign cutaneous vs. early cutaneous = 1.52x10
-
2
; benign cutaneous vs. advanced cutaneous = 2.78x10
-2
. * t-test score between 
experimental groups of ≤0.05.  
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Figure 5.15 BACE-2 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6).  
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5.8.6 TIMP-1 
As shown in Figure 5.16, no significant difference in the abundance of TIMP-1 was 
observed between control or benign disease serum and early or late stage disease. In 
addition to this, no differential production of the protein was noted when serum of 
uveal melanoma patients was compared to healthy serum (Figure 5.16). When the 
uveal melanoma samples were divided into those with either monosomy of 
chromosome three or disomy of chromosome three and compared, no differential 
abundance of TIMP-1 was detected (Figure 5.17). 
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Figure 5.16 TIMP-1 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13).  
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Figure 5.17 TIMP-1 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6). 
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5.8.7 MMP-1 
As shown in Figure 5.18, a statistically significant decrease in the level of MMP-1 
was observed in the sera of advanced cutaneous melanoma patients, when compared 
to control specimens. This result directly contradicts the findings of the microarray 
study. 
Uveal melanoma serum was not found to contain significantly less MMP-1 than that 
of healthy serum (Figure 5.18), in addition to this there was no significant difference 
in its abundance between uveal melanoma serum of patients with either monosomy 
of chromosome three or disomy of chromosome three (Figure 5.19). 
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Figure 5.18 MMP-1 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=18), early-stage cutaneous disease (n=14), 
advanced-stage cutaneous disease (n=12), and uveal melanoma (n=13), as well as 
control serum (n=13). t-test score: control vs. advanced cutaneous melanoma serum 
= 0.044. * t-test score between experimental groups of ≤0.05. 
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Figure 5.19 MMP-1 ELISA data represented by both bar chart and Box and 
Whisker Plot. Serum samples from two uveal melanoma conditions were used; 
monosomy of chromosome three (n=7) and no evidence of monosomy of 
chromosome three (n=6). 
 
 
 
 
 
265 
 
 
 
CHAPTER SIX 
Discovery of an 8.9 kDa Species by SELDI-ToF MS as a Potential 
Marker for Disease Progression in Melanoma 
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6.1 Background 
SELDI-TOF is used in biomarker discovery as it quickly and effectively analyses 
protein mixtures, such as urine, serum, and tissue lysates, in order to illustrate 
proteomic differences; such as those between control and disease specimens. 
Previously, Dr. Priyanka Maurya had used SELDI-TOF MS for the discovery of a 
7.6 kDa protein in the conditioned media of a paclitaxel-resistant superinvasive 
melanoma cell line variant (MDA-MB-435S-F/Taxol10p4pSI) (Dr. Pryanka 
Maurya, Ph.D. Thesis, 2009). MALDI-TOF/TOF MS subsequently identified the 
protein as a fragment of bovine transferrin (Dowling, Maurya et al. 2007). Following 
the profiling of conditioned media collected from a range of melanocytes and 
melanoma cell lines, it was discovered that the 7.6 kDa fragment was solely 
expressed in melanoma cell lines. In addition to this, a number of other proteins 
which were only identified in the melanoma cell lines were discovered, including an 
8.5 kDa ubiquitin-like marker, where they were found to be highly upregulated in 
comparison to normal melanocytes (Dr. Pryanka Maurya, Ph.D. Thesis, 2009).  
It was hypothesised that specific protein expression differences between a variety of 
sample sets could be highlighted using the SELDI TOF method. The aim of the 
study described here was to analyse the expression of the markers of interest in 
melanoma serum. Vitreous fluid collected from uveal melanoma patients would also 
be analysed in order to determine the presence of biomarkers of interest. 
 
6.2 SELDI-TOF MS Analysis  
SELDI-TOF MS is MALDI-based method which uses a target modified, e.g. nickel-
activated IMAC, to achieve biochemical affinity with the analyte in order to bind a 
specific subset of proteins. The sample is mixed with a matrix which co-crystallises 
with the analyte on a chip surface. A laser then strikes the mixture, causing 
ionisation of any bound proteins present. TOF is used to measure the m/z of each 
molecule which generates a spectrum where each peak corresponds to a protein.  
However, the technique does not provide any protein identifications, only the m/z 
ratio and the intensity of the peak. In order to identify the peaks, spin columns 
containing a resin which can mimic the SELDI surface can be employed.  
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6.3 Determination of the 7.6 kDa and 8.5 kDa Markers in Conditioned Media 
Cell lines secrete and shed proteins into the surrounding media. This media, without 
serum which can mask the secreted or shed proteins, is known as conditioned media.  
Serum-free RPMI-1640 media was conditioned by SK-MEL-5 cutaneous melanoma 
cells for 72 hours and the resulting media was analysed by SELDI-TOF using 
copper-activated IMAC as the target, which identified peaks corresponding to both 
the 7.6 kDa and 8.5 kDa markers (Figure 6.1 (a)). The conditioned media was also 
diluted in serum-free media at concentrations of 1:2, 1:10, 1:20 and 1:50 which 
illustrated that 1:10 and 1:20 were the most dilute levels at which the 7.6 kDa and 
8.5 kDa markers could be observed, respectively (Figure 6.1 (b), (c) and (d)).  
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Figure 6.1 Both targets of interest, the 7.6 kDa fragment and 8.5 kDa ubiquitin-like 
marker, as outlined in red, were found in (a) neat conditioned media of SK-MEL-5 
cutaneous melanoma cells, and at dilutions of (b) 1:2 and (c) 1:10 in serum-free 
media. (d) The 8.5 kDa marker was also found at a dilution of 1:20. One 
representative result of three is shown. 
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6.4 Detection of 7.6 kDa and 8.5 kDa Potential Markers in Serum-Diluted 
Conditioned Media 
In order to identify whether or not the markers of interest could be identified in a 
clinical sample, the SK-MEL-5 conditioned media was diluted in colorectal cancer 
serum and then analysed by SELDI using copper-activated IMAC 30 chips. This 
would prevent wasting valuable clinical specimens.  
The serum did not contain either biomarker. The markers were not clearly detectable 
at the 1:5 or the 1:10 dilution (Figure 6.2 (b) and (c)). This may have been due to the 
fact that the protein-rich serum easily masked the biomarkers in the resulting spectra 
and so it was difficult to identify the lowest level at which they were still detectable. 
However an unknown 8.9 kDa protein, or protein cleavage product, was found in all 
dilutions as well as in the neat conditioned media (Figure 6.2).  
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              (A)          
 
                            
(B) 
 
 
(C)  
 
Figure 6.2 SELDI-ToF spectra of (a) undiluted conditioned media, and (b) 1:5 and 
(c) 1:10 dilutions of SK-MEL-5 conditioned media in serum. The 7.6 kDa transferrin 
fragment and the 8.5 kDa fragment were potentially found in (b) and (c), albeit at 
minute levels. In all cases an 8.9 kDa protein, or protein cleavage product, was 
found. One representative result of three is shown in both cases.  
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6.5 Detection of an Approximate 8925 m/z Species in Cutaneous Melanoma 
Serum 
Immunodepleted stage IV melanoma sera were examined using SELDI-ToF MS and 
were compared to immunodepleted control sera (collected from potentially diabetic 
patients).  
The initial biomarkers of interest; a 7.6 kDa transferrin fragment and an 8.5 kDa 
ubiquitin-like marker, were not found. Despite this, an unknown 8.9 kDa protein was 
discovered which occurred in 10 of 12 disease samples, for at least one out of three 
replicates each (Figure 6.3).  
The 8.9 kDa protein was identified in three of 12 controls. When further examined, 
it was found that the levels of the marker were low in the controls in comparison to 
the levels in the samples (Figure 6.3).  
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Figure 6.3 SELDI spectra illustrating a protein, or cleavage product of a protein, 
with an approximate m/z value of 8925, circled in red which was identified in 
immunodepleted advanced-stage cutaneous melanoma serum (n=12) in comparison 
to healthy immunodepleted serum controls (n=12). The potential marker was found 
to occur in each disease sample at least once out of the three times the experiment 
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was performed. The 8.9 kDa protein was identified in 10 of 12 samples examined 
and at low levels in only three of 12 controls. One representative result is shown in 
each case.  
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6.6 Detection of an Approximate 8925 m/z Species in the Vitreous Fluid of a 
Patient with Metastatic Uveal Melanoma  
SELDI analysis was also performed on one metastatic uveal melanoma ocular fluid 
sample in order to determine whether or not the 7.6 kDa and 8.5 kDa markers of 
interest found in the cutaneous melanoma conditioned media, were also present in 
the vitreous fluid of uveal melanoma and hence, act as potential biomarkers for the 
disease.  
The 7.6 kDa transferrin fragment appeared to be present in both crude and 
immunodepleted samples. It was more abundant in the crude specimen than the 
immunodepleted fluid where it was detected at near-baseline levels. The 8.5 kDa 
ubiquitin-like protein was clearly detectable in the immunodepleted specimen, with 
only a small peak identified in one crude vitreous specimen (Figure 6.4).  
The 8.9 kDa unknown peak of interest was clearly visible in both crude and 
immunodepleted samples (Figure 6.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
277 
 
 
Figure 6.4 SELDI spectra illustrating the presence of an 8.9 kDa species in the 
vitreous fluid of a uveal melanoma patient (n=1) which was not identified in a 
corresponding vitreous fluid control (n=1). Red arrows indicate the 8.9 kDa peak of 
interest while the 7.6 kDa and 8.5 kDa peaks are indicated by a red circle. 
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6.7 Attempted Purification of the 8.9 kDa Protein Using IMAC Resin 
Copper-activated IMAC SELDI chips were used in the discovery of the 8.9 kDa 
peak of interest. As SELDI cannot be used for the identification of proteins, it was 
decided to use copper-activated IMAC resin to isolate the subset of proteins which 
have an affinity for copper. This would allow for the separation of the protein of 
interest and subsequent attempts to identify it.  
IMAC spin columns contain an uncharged resin which is based on the same 
principle of affinity chromatography as the IMAC SELDI chips. The resin must be 
activated and charged with a metal ion such as cobalt or nickel, to which proteins 
with an affinity for these ions bind, often through a histidine residue or a 
phosphorylation site.  In order to elute bound proteins from the column, a pH change 
or a competitive molecule, such as imidazole, may be employed. In this case, a 
gradient of increasing imidazole concentration was used. Imidazole would compete 
with histidine residues of the protein for binding sites on the resin, therefore as the 
concentration of imidazole increased; more bound protein would be eluted from the 
column.  
Cutaneous melanoma serum samples 4, 5, and 6 shown in Figure 6.3, which 
contained a high level of the 8.9 m/z potential marker according to their 
corresponding SELDI spectrum, were selected for IMAC purification and a gradient 
of 10 mM to 500 mM imidazole was used to elute bound proteins. Normal phase 
(NP20) SELDI chips, which bind all protein, were used to validate the IMAC resin 
technique and visualise the protein profile presence of the collected fractions. It was 
hoped that this would pin-point the concentration of imidazole that most 
successfully eluted the 8.9 kDa m/z species. However this analysis yielded no peaks 
whatsoever.  
The elution fractions were assayed for protein content, which indicated that no 
protein was present in the fractions. The fractions were also separated on a 4-20% 
gradient gel, which should resolve low molecular weight proteins such as the 8.9 
kDa target, and stained with a colloidal silver protein stain. This visualised an 
apparent array of bands in each lane. One band, circled in red, appeared to be located 
at the approximate molecular weight of 8.9 kDa (Figure 6.5). However, following 
the in-gel digestion of any proteins in that region and subsequent analysis by LC-
279 
 
MS/MS, very poor results and few protein identifications were yielded from the 
analysis.  
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Figure 6.5 Silver-stained gel illustrating advanced-stage cutaneous melanoma serum 
which was eluted from a copper-activated IMAC spin column using an imidazole 
gradient. Collected fractions were then separated on a 4-20% Tris-Glycine gel which 
was subsequently silver stained. The potential band of interest is circled in red. (a) 
Immunodepleted melanoma serum, (b) 10 mM imidazole fraction, (c) 200 mM 
imidazole fraction; (d) 500 mM imidazole fraction. 
 
 
 
 
 
 
 
 
 
 
(a) (d) (b) (c) 
281 
 
It was hypothesised that staining the gel with colloidal silver may have caused this 
as it is known to affect the identification of proteins in mass spectrometry, despite 
using a mass spectrometry-compatible protocol. Hence, the experiment was repeated 
using a reverse, zinc-based stain which stains the non-proteinaceous regions of the 
gel, thus leaving any protein bands clear. In this way the stain does not bind to the 
regions of interest and may improve the number of identifications acquired. This did 
not seem to improve the quality of identifications acquired which confirmed that the 
mass spectrometry-compatible silver staining method was not responsible for the 
poor list of identifications. 
LTQ mass spectrometry was used for the identification of proteins in the above 
analysis. However, Orbitrap-based mass spectrometry has a higher mass accuracy. It 
was decided to repeat the experiment using the more accurate, Orbitrap-based 
method of analysis. Additional reduction and alkylation steps were also included in 
the new method.  
The binding of protein to and subsequent imidazole-based elution from copper-
activated IMAC resin was repeated. The following samples which had previously 
confirmed the presence or absence of the 8.9 m/z species were chosen for the 
experiment; cutaneous melanoma serum, control serum, control vitreous fluid, uveal 
melanoma vitreous fluid, and media conditioned by SK-MEL-5 cutaneous 
melanoma cell lines. Imidazole concentrations of 25 mM, 50 mM, 100 mM, 200 
mM, and 500 mM were used to fractionate protein from the resin. Collected 
fractions were separated in the first dimension on a 4-20% gel and silver stained 
(Figure 6.6). Regions below the red line in Figure 6.6, i.e. the low molecular region 
of the gel, were excised into bands and in-gel digested with trypsin to generate 
peptides which were separated over the course of an hour gradient and analysed 
using an Orbitrap mass spectrometer. The results of the qualitative analysis are 
shown in Table 6.1. Identifications generated from a single peptide were accepted 
due to the low molecular weight of the protein or cleavage product of interest. As the 
low molecular weight region of the gel was excised, many of the proteins identified 
were larger than expected. This suggested that the protein in question may be a 
cleavage product of a larger molecule.   
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In addition to separating the fractions by 1-D electrophoresis, an in-solution digest 
was also carried out on the elution fractions. However, the results from this mainly 
consisted of high abundance proteins and did not overlap with those acquired in 
Table 6.1. 
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Figure 6.6 Silver-stained 4-20% 1-D gel of (a) melanoma serum, (b) control serum, 
(c) uveal melanoma vitreous, (d) control vitreous, and (e) SK-MEL-5 conditioned 
media which were eluted from IMAC spin columns using an imidazole gradient. The 
low molecular weight region of the gel, the region below the red line, was cut and 
each lane was sliced and in-gel digested.  
(a) (b) 
(c) (d) 
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In order to determine an effective method of isolating the 8.9 m/z species, 3-20 kDa 
cut-off spin devices were used for concentrating the low molecular weight portion of 
SK-MEL-5 conditioned media of cutaneous melanoma cells following IMAC resin 
binding and imidazole elution.  
The proteins bound to the column were eluted in one fraction (500 mM imidazole) 
and either run on a 1-D gel and silver stained or acetone precipitated and in-solution 
digested. This, however, did not produce any proteins which overlapped with Table 
6.1. The experiment may have been compromised as the high imidazole 
concentration may have damaged the columns.  
 
6.8 MALDI-TOF Analysis of Proteins Eluted Directly from IMAC Chips 
As SELDI is a form of matrix-enhanced laser desorption ionisation (MALDI), 
MALDI was used in an attempt to detect the 8.9 kDa protein of interest in a peak 
profile and subsequently fragment it into peptides whose sequence may be 
determined, thus identifying the protein. 
It was decided to attempt to remove the protein of interest directly from the SELDI 
chip from which it was known to bind as this may have concentrated the marker 
more successfully than the resin. The control and disease sera used in the analysis 
were also immunodepleted in order to reduce any high abundance proteins present. 
This would minimise the effect of large peaks diminishing the significance of 
smaller ones.  
Cutaneous melanoma and healthy sera were incubated on copper-activated SELDI 
chips, as before, and one fraction of 500 mM imidazole was used to elute all bound 
proteins from the surface. The fractions were co-crystallised with a sinapinic acid 
(SPA) matrix and analysed by MALDI. However, too much interference was present 
thus masking any peaks. This was due to the low protein concentration and high 
imidazole levels present in the samples. Hence, it was necessary to increase the 
concentration of protein being loaded onto the SELDI chip while keeping the 
quantity of imidazole used to a minimum. 
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The experiment was repeated using 10 mM, 50 mM and 100 mM imidazole 
concentrations to sequentially elute bound melanoma and control proteins from 
copper-activated IMAC SELDI chips (Figure 6.7).  
An internal calibrant was used for the accurate determination of size and as an 
indicator of abundance (Figure 6.8). When the samples were mixed with this internal 
calibrant, peaks were still visible which would suggest that a notable level of protein 
was detectable in all samples (Figure 6.9). Despite this, a species in the region of an 
m/z 8925 was not identified.  
Using colorectal serum, the MALDI technique was optimised. The most effective 
matrix was selected; SPA was found to ionise more efficiently than α-Cyano-4-
hydroxycinnamic acid (CHCA), and the most effective method of mixing matrix and 
sample for best co-crystallisation was also chosen. The chosen method involved 
layering the sample between matrix. This optimisation also allowed for a high 
volume of test serum to be used each time, thus avoiding wasting valuable 
melanoma serum. However, it was found that although a reasonably clear spectrum 
of protein could be generated (Figure 6.10), successful fragmentation of proteins to 
peptides was not achieved.  
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Figure 6.8 MALDI-TOF spectra of a set of internal calibrants used for 
determination of protein mass and as an indicator of abundance. The following 
proteins circled in red were included due to their low molecular weights; insulin 
(5734 m/z), thioredoxin (11674 m/z), apomyoglobin (16952 m/z).  
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6.9 Quantitative Analysis of Proteins Eluted Directly From IMAC Chips 
As the IMAC analysis which originally identified the 8.9 kDa protein of interest was 
carried out using SELDI chips, it was decided to repeat this procedure by binding 
and subsequently eluting proteins from the chip. Quantitative LC-MS would then be 
used for the identification of differentially expressed proteins between control and 
disease sera which would hopefully identify potential 8.9 kDa candidates. 
Two cutaneous melanoma sera and two control sera were incubated on copper-
activated IMAC chips. Any bound proteins were subsequently eluted from the chips 
using 250 mM imidazole. The fractions were then in-solution digested with trypsin 
and Lys-C to generate peptides which were analysed by quantitative label-free LC-
MS/MS.  
Apolipoprotein AII was identified as being significantly upregulated in the 
cutaneous melanoma serum samples in comparison to the controls by 2.46-fold 
(Figure 6.11). Although the protein is known to have a molecular weight of 17.38 
kDa, it has been reported in the literature as having numerous isoforms, one of 
which occurs at 8.9 kDa and has been identified by SELDI-TOF at approximately 
8.9 km/z (Malik, Ward et al. 2005). This suggested that apolipoprotein AII may have 
been the 8.9 kDa marker of interest which had previously been observed in the 
SELDI data.  
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This result was further examined using ELISA and western blotting. The ELISA 
results are shown in Figure 6.12; however, this did not demonstrate an increase in 
apolipoprotein AII abundance in advanced cutaneous melanoma serum in 
comparison to the control serum. In addition to this, benign and early stage sera from 
cutaneous melanoma patients were included which did not illustrate significant 
differential expression of the protein when compared to the control experimental 
group. Also, no significant differences in abundance of apolipoprotein AII were 
noted between control serum and serum of uveal melanoma patients.  
A western blot of control and advanced cutaneous melanoma serum was also carried 
out; however, this was unsuccessful in producing information on the abundance of 
apolipoprotein AII. This may have been due to the difficult nature of carrying out 
western blots using serum. 
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Figure 6.12 Apolipoprotein AII ELISA represented by both bar chart and Box and 
Whisker Plot. Serum samples from a variety of melanoma conditions were used; 
benign cutaneous melanoma (n=14), early-stage cutaneous melanoma disease 
(n=11), advanced-stage cutaneous disease (n=11), and uveal melanoma (n=11), as 
well as control serum (n=15). No significant difference in expression of 
apolipoprotein AII was observed between the control and the experimental groups. 
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It was decided to repeat the quantitative LC-MS experiment using IMAC resin 
contained in spin columns to fractionate a larger sample set.  
One fraction of 250 mM imidazole was used to elute bound proteins and 
subsequently digest them using Lys-C and trypsin. Generated peptides were 
separated over the course of a three-hour gradient. The resulting data was analysed 
with Progenesis LC-MS to check for the presence and expression of apolipoprotein 
AII in a larger pool of samples.  
Although apolipoprotein AII was identified in the analysis, it was found to be 
overexpressed in the control specimens in comparison to the disease sera (Table 
6.2). This directly contradicts the previous result and dismisses the possibility of 
apolipoprotein AII as the identity of 8.9 kDa SELDI peak. 
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Down in Cutaneous Melanoma Up in Cutaneous  
Melanoma 
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This analysis provided a list of 34 statistically significant proteins which were found 
to be differentially expressed between control and cutaneous melanoma serum 
samples. Of these, 16 proteins were found to be upregulated in the disease sample 
set while 18 showed a decreased abundance compared to controls. The 
chromatography of the samples was clear, with good overlap of total ion 
chromatograms (TIC) between samples. Protein principal component analysis (PCA) 
is shown in Figure 6.13. This illustrated good separation of protein abundances 
between the control and disease sample sets.  
Many of the proteins which were differentially expressed demonstrate potential as 
possible serum biomarkers for advanced cutaneous melanoma. For example, alpha 1 
antichymotrypsin was found to upregulated in cutaneous melanoma serum by 2.55-
fold (Figure 6.14). This has previously been associated with poor prognosis in 
malignant melanoma as well as in other cancers, such as prostate cancer, where it is 
complexed to prostate-specific antigen (PSA) (Martinez, Espana et al. 2002, Wang, 
Jiang et al. 2010). Immune- and inflammation-related proteins such as neutrophil 
defensin-1, scavenger receptor cysteine-rich type 1 protein M130 and complement 
component C9 (Figure 6.15) were also found to be significantly upregulated in 
cutaneous melanoma serum.  
A summary of all of the methods used in the attempted identification of the 8.9 kDa 
protein of interest are outlined in Figure 6.16. 
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Figure 6.13 Principal component analysis (PCA), generated by Progenesis LCMS, 
illustrating the separation of protein abundances between the control (n=13) and 
advanced cutaneous melanoma (n=13) sample sets. 
 
 
 
 
 
 
 
 
 
 
 
Cutaneous Melanoma Control 
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Figure 6.14 Alpha 1 antichymotrypsin was found to upregulated in cutaneous 
melanoma serum (n=13) in comparison to control serum (n=13) by 2.55-fold, p-
value=8.69x10
-4
 (a) Normalised abundance view of alpha 1 antichymotrypsin 
expression in melanoma serum. Each point corresponds to a sample and illustrates 
the quantity of the protein of interest per specimen. (b) Normalised abundance of 
two identified alpha 1 antichymotrypsin peptides identified. Each line represents a 
peptide while each point indicates the abundance of the peptide per sample.  
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Figure 6.15 (a) Neutrophil defensin-1 (p-value=2.45x10
-4
), (b) scavenger receptor 
cysteine-rich type 1 protein M130 (p-value=1.95x10
-3
), and (c) complement 
component C9 (p-value=2.17x10
-3
) were all found to be upregulated in cutaneous 
melanoma serum (n=13) in comparison to control serum (n=13) by maximum fold 
values of 11.7, 2.55, and 2.48, respectively. Each line represents a peptide while 
each point indicates the abundance of the peptide per sample.  
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6.10 Enrichment Analysis of Differentially Regulated Protein Lists Using 
DAVID 
It was decided to use DAVID to determine significant enrichment of biological 
processes, molecular functions, and cellular compartments associated with the list of 
proteins identified as being differentially expressed between the control and disease 
sample sets. Enrichment was considered to be significant when the Bonferroni p-
value adjustment was ≤0.05. Lists of proteins upregulated in either the control or the 
melanoma specimens were analysed individually.  
For the list of proteins which were downregulated in the cutaneous melanoma 
sample set in comparison to the control, the identifications related to extracellular 
regions of the cell (Table 6.3 (a)), with molecular functions based on the inhibition 
of enzymatic activity (Table 6.3 (b)).  
Of the list of proteins upregulated in cutaneous melanoma specimens, enriched 
biological processes involved a response to trauma, such as inflammation and blood 
coagulation (Table 6.4 (a)). This may be due to the advanced stage of the tumour 
where it induces damage as a result of its aggressive, invasive behaviour. Cellular 
compartments associated with the protein list were all extracellular (Table 6.4 (b)). 
Molecular functions which were enriched primarily involved anti-enzyme activities. 
This inhibition may be an anti-tumour response as the inhibition of endopeptidases 
has been associated with suppressed growth of tumour cells (Suzuki, Sakaguchi et 
al. 2013). In addition to the above, it was found that the complement pathway was 
affected in by the upregulation of multiple proteins in the disease proteome; 
complement C1r subcomponent, complement component 9, fibrinogen gamma 
chain, von Willebrand factor, and alpha-1-antitrypsin (Figure 6.17).  
The 16 proteins upregulated in the disease samples may now be followed up as 
potential identifications for the 8.9 kDa protein of interest as it is possible that it may 
be a fragment or an isoform of one of these 16. All 34 differentially expressed 
proteins can also be further examined as possible biomarkers for advanced 
cutaneous melanoma.  
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Table 6.3 GO cellular compartment (a) and molecular function enrichment (b) for 
differentially expressed proteins which were downregulated in the cutaneous 
melanoma sample set in comparison to the control. Enrichment was considered 
significant upon observation of a p-value ≤0.05 and a Bonferroni adjusted p-value 
≤0.05. Count corresponds to the overlap between proteins on the list and a particular 
GO category. 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Table 6.4 GO biological process (a), cellular compartment (b), and molecular 
function (c) enrichment for differentially expressed proteins which were upregulated 
in advanced cutaneous melanoma sera compared with control sera. Enrichment was 
considered significant upon observation of a p-value ≤0.05 and a Bonferroni 
adjusted p-value ≤0.05. Count corresponds to the overlap between proteins on the 
list and a particular GO category. 
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Figure 6.17 DAVID analysis of proteins which were upregulated in advanced 
cutaneous melanoma sera found that five identifications; complement C1r 
subcomponent, complement component 9, fibrinogen gamma chain, von Willebrand 
factor, and alpha-1-antitrypsin, were involved in complement and coagulation 
cascades. The genes which are involved are highlighted in yellow.  
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CHAPTER SEVEN 
Discussion 
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7.1 Introduction 
Although uveal melanoma is a rare malignancy of the uveal tract; the iris, the 
choroid, and the ciliary body, it is the most common intraocular malignancy in 
adults. The overall incidence of uveal melanoma is 5-7 cases per million per year 
with this number increasing to 20 per million per year after the age of 70. The 
majority of uveal melanomas develop in the choroid while the remainder (8%) arise 
in the iris and ciliary body. (Damato 2012, Ramasamy, Murphy et al. 2013).  
Substantial advances have been made in the diagnosis and local therapy of uveal 
melanoma over the past number of decades. The primary clinical diagnosis of uveal 
melanoma regularly initially involves reduced visual awareness, retinal detachment, 
and scotoma. Slit lamp biomicroscopy is also used to identify a tumour, while 
ultrasound investigation can be utilised to determine acoustic hollowness. With 
treatment, uveal melanoma has a five-year survival rate of 77-84%. Enucleation was 
the traditional method of treatment, however radioactive plaque brachytherapy, 
proton beam therapy, and local resection can also be used for the treatment of the 
primary tumour while maintaining the eyeball (Abildgaard and Vorum 2013).  
However, uveal remains classified as a high risk disease in the case of metastasis 
which occurs in up to 50% of patients. In the majority of cases, uveal melanoma 
spreads preferentially to the liver; a generally fatal metastasis within 15 months. 
Currently, metastasis is rarely detected at primary diagnosis, despite thorough 
investigations, and often develops in the subsequent months and years. Although the 
risk of metastasis may be predicted by chromosomal testing (monosomy of 
chromosome three and gain of chromosome eight are both indicative of poor 
prognosis), cell type (epithelioid tumours are more aggressive than those of spindle 
cell type), and molecular screening (BAP1 mutations occur late in the disease and 
signify a high likelihood of metastasis occurring) there is currently no effective 
treatment for metastatic uveal melanoma (Harbour 2012, Yonekawa and Kim 2012, 
Ramasamy, Murphy et al. 2013).  
Protein biomarkers indicative of prognosis could further our understanding of the 
biology of uveal melanoma, and could lead to the development of rational therapies 
which target differentially regulated proteins specific to the disease. Such 
biomarkers, together with complementary genetic information, may also potentially 
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aid in determining a prognosis in a clinical setting when monitoring patients who are 
at risk of metastasis.  
Cutaneous melanoma is a malignancy of skin melanocytes. Despite accounting for 
only 4% of all skin cancer cases, it is the form of skin cancer which has the highest 
death toll in the USA and Europe (Ugurel, Utikal et al. 2009). It is widely accepted 
that cutaneous melanoma risk is determined through genetic factors and exposure to 
sunlight; 80% of melanomas develop in areas which receive intermittent sun 
exposure or have a history of sunburn (Garbe and Leiter 2009).  
Primary cutaneous melanomas are characterised by horizontal growth within the 
epidermis only. When melanoma is detected and treated prior to the development of 
lymph node metastasis, the five-year survival rate is 99%. If the malignancy 
develops and becomes more aggressive, it can lead to rapid growth and invasion of 
the dermis. Later stages of the disease are associated with rapid invasion and 
metastasis of tissues other than the dermis; the five-year survival rate for distant 
stage melanoma patients is approximately 15% (Al-Ghoul, Bruck et al. 2008).  
Surgical removal of the tumour is the standard of care for primary cutaneous 
melanoma, often coupled with high-dose interferon therapy. Systemic metastatic 
melanoma was traditionally difficult to treat, with poor outcome, as therapies 
beyond surgery were very toxic. In addition to this, melanoma has been traditionally 
been recognised as difficult to treat, mainly due to the large number of patients who 
are resistance to immune therapy as well as chemotherapy (Mehnert and Kluger 
2012). New therapeutic strategies such as anti-PDI1 antibodies (such as 
ipilimumab), BRAF inhibitors (such as vemurafenib or dabrafenib), c-Kit inhibitors, 
and MEK inhibitors have illustrated significant anti-tumour effects, improving 
patient survival times and response rates.  
To date, few protein biomarkers have been identified as prognostic indicators of 
cutaneous melanoma and even less are used in the clinic as tools for diagnosis or 
prognosis. However, lactate dehydrogenase (LDH), melanoma inhibitory activity 
protein (MIA) and S-100 beta protein (S100B) are currently recognised as 
seriological markers for the disease.  
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Better prognostic and predictive markers in cutaneous melanoma are needed, but to 
date have been elusive. The experimental work detailed here was intended to further 
understand the cutaneous melanoma serum proteome over the course of disease 
progression. Therefore, this work could lead to the development of a prognostic test 
which could easily be used in a clinical setting and could also potentially lead to the 
discovery of a therapeutic target in cutaneous melanoma. 
Both cutaneous and uveal melanoma originate in melanocytes, albeit, their clinical 
behaviours and molecular mechanisms differ significantly. The differences between 
both melanomas are poorly understood, albeit, it was hoped that the proteomic 
analyses of the nature of melanoma as a disease would aid in understanding 
variations between both melanomas and further our understanding of metastasis. 
One aim of this thesis was to identify proteins which were differentially expressed 
between primary uveal melanoma tumour tissue which metastasised and that which 
did not. This work could improve our understanding of the biology of uveal 
melanoma tumours which subsequently metastasise through the identification of 
potential biomarkers. Such proteins could eventually be developed as targets for 
rationally designed therapies in the treatment of uveal melanoma, and could, along 
with genetic information, predict the outcome of the disease. It was also intended to 
study the vitreous fluid collected from uveal melanoma patients in order to identify 
unique proteins of interest for the same purposes. In the process of this, an ocular 
fluid sample preparation method could be developed. The study could also improve 
our overall understanding of the vitreous proteome. Finally, it was hoped to better 
understand the proteomic changes which occur throughout the course of cutaneous 
melanoma disease progression. It was anticipated that this may illustrate potential 
proteins biomarkers for disease progression in serum, a sample which is minimally 
invasive to collect and so, could easily be extracted for an assay in a clinical 
environment.  
Throughout this work, there were a number of shortcomings. For example, due to 
the rarity of uveal melanoma, few primary tumour tissue and vitreous specimens 
were available. Although cutaneous melanoma is not as rare, few samples were also 
available. Hence, this work was part of a discovery phase, pilot study. In addition to 
this, no metastasised uveal melanoma tumour tissue was available for analysis. 
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There were also a number of strengths of the studies carried out. The availability of 
rare clinical specimens with at least seven years of follow up was a clear advantage 
of this work. Also, the involvement of experienced pathologists was useful in 
determining clinical questions of interest. 
 
7.2 2-D DIGE and Quantitative Label-Free LC-MS Analysis of Uveal 
Melanoma Tumour Tissue 
Biological fluids are considered to be a good source of biomarkers as they are easily 
accessible and minimally invasive, are relatively cheap to obtain, and can be 
potentially used for the development of large-scale, prognostic/diagnostic tests 
(Good, Thongboonkerd et al. 2007).  
However, in order to detect tissue specific biomarkers, i.e. proteins directly 
produced by the tumour, in biological fluid, the target must first be secreted by the 
tissue. It must also be recognised as disease tissue-specific, which may be difficult 
as there are a variety of secreted proteins circulating at any one time (Shiwa, 
Nishimura et al. 2003).  
Hence, it may be more efficient to first identify a tumour-specific protein biomarker 
directly from the tissue and subsequently detect it in fluids such as serum.  
 
7.2.1 Identification of Differentially Expressed Proteins between Non-
Metastasised and Subsequently Metastasised Primary Tumour Tissue Using    
2-D DIGE  
It was decided to compare 16 non-metastasised uveal melanoma primary tumour 
tissues and nine primary tissues which subsequently metastasised in order to better 
our understanding of uveal melanoma metastasis through the identification of 
differentially expressed disease-specific biomarkers. In order to identify 
differentially regulated proteins, a 2-D DIGE analysis of primary uveal melanoma 
tumour tissue was carried out.  
From this analysis, 14 statistically significant differentially expressed proteins were 
identified, which agreed with the hypothesis that stated that patterns of differential 
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protein expression would be observed between both disease states. Protein 
disulphide-isomerase A3 precursor (PDIA3), selenium-binding protein 1 
(SELENBP1), alpha-enolase, F-actin capping protein subunit alpha-1 (CAPZA1), 
endoplasmic reticulum protein ERp29 precursor, triosephosphate isomerase (TPI1), 
protein DJ-1 (PARK7), and fatty acid-binding protein, heart-type (FABP3) were all 
found to be upregulated in subsequently metastasised primary tissue in comparison 
to non-metastasised tissue. Vimentin and beta-hexosaminidase subunit alpha were 
identified from the same protein spot which was identified as being more abundant 
in the metastatic proteome. Eukaryotic translation initiation factor 2 subunit 1, 
proteasome subunit alpha type 3, 40S ribosomal protein SA, tubulin beta chain and 
tubulin alpha-1B chain were shown to have decreased expression in uveal melanoma 
tissues of patients who subsequently developed metastatic disease.  
Of these proteins, four had previously been mentioned in the literature in relation to 
uveal melanoma at that time; vimentin, beta-hexosaminidase subunit alpha, alpha-
enolase, and 40S ribosomal protein SA.  
Alpha-enolase was previously identified as being downregulated in uveal melanoma 
cell lines derived from secondary tumours in comparison to a primary tumour cell 
line which was derived from the same patient (Zuidervaart, Hensbergen et al. 2006). 
Alpha enolase is a metalloenzyme which is required for catalysing the conversion of 
2-phospho-D-glycerate to phosphoenolpyruvate in glycolysis; a critical process in 
neoplastic cells (Capello, Ferri-Borgogno et al. 2011). Hence, it would be expected 
that an upregulation of glycolysis would be required for metastatic cells in 
comparison to the primary tumour cells they were derived from. Zuidervaart et al. 
explained that their observed result may be explained by the apparent higher growth 
rate of the primary tumour cell line in comparison to its metastatic counterpart. The 
result of our study is in agreement with previous tumour tissue studies which link an 
increase in alpha enolase production with metastasis through the Warburg effect; an 
increase in aerobic glycolysis (Altenberg and Greulich 2004, Yoshida, Okamoto et 
al. 2013). 
The expression of vimentin intermediate filaments acts a mesenchymal marker, and 
is typical of melanomas. Vimentin was identified by Hendrix et al. as contributing to 
the metastatic phenotype of uveal melanoma. They illustrated that uveal melanoma 
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cell lines which co-expressed keratin and vimentin intermediate filaments were six-
fold more invasive than those which expressed vimentin only and eight- to 13- fold 
more invasive than normal uveal melanocytes. These findings were confirmed with 
immunohistochemistry of tumour tissue specimens from which the uveal melanoma 
cell lines were derived (Hendrix, Seftor et al. 1998). Vimentin was also identified by 
Coupland et al. as being upregulated in uveal melanoma monosomy three tumour 
tissues in comparison to those which were disomy three (Coupland, Vorum et al. 
2010). In our study, vimentin was found to be upregulated in subsequently 
metastasised primary tissue in comparison to non-metastasised tumour specimens 
which corresponds with the above findings, thus linking vimentin expression to 
metastatic potential. 
Beta-hexosaminidase subunit beta is known to be required for cellular interaction 
with adhesion proteins, and hence play an important role in cellular motility. It was 
previously identified as being upregulated in uveal melanoma cell lines derived from 
secondary tumours in comparison to a primary tumour cell line which was derived 
from the same patient (Zuidervaart, Hensbergen et al. 2006). Although it was the 
alpha subunit which was discovered to be upregulated in the metastatic sample set in 
our study, beta-hexosaminidase subunit alpha has been linked with the development 
of metastases in cancers such as glioblastoma (He, Liu et al. 2011). This all concurs 
with our findings associating beta hexosamidase with metastasis.  
40S ribosomal protein SA functions as a laminin receptor; thus playing a role in cell 
adhesion, as well as being required for the full maturation of ribosomal subunits. As 
cancer cells can attach to laminin, this may aid the process of metastasis. Previously, 
gastric cancer cells were found to express 40S ribosomal protein SA on their surface 
which correlated with tumour aggressiveness (de Manzoni, Guglielmi et al. 1998). It 
has also been shown to be overexpressed in bile duct carcinoma, colorectal 
carcinoma, cervical cancer, and breast carcinoma (Kumazoe, Sugihara et al. 2013). 
The protein was identified as being associated with uveal melanoma primary cell 
cultures by Pardo et al (Pardo, Garcia et al. 2006). In our study, it was found to 
downregulated in metastatic specimens in comparison to the non-metastatic group 
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7.2.1.1 Immunohistochemical Validation of Six Proteins of Interest 
Identified by 2-D DIGE 
Following the identification of 16 differentially-regulated proteins between the 
metastasised and non-metastasised tissue sample sets, it was decided to follow up six 
proteins of interest by immunohistochemical staining of FFPE tissue; TPI1, FABP3, 
PDIA3, CAPZA1, PARK-7, and SELENBP1.  
For PDIA3, CAPZA1, and PARK-7, the trends in expression identified by the 2-D 
DIGE study were not observed in the immunohistochemical analysis. There are 
several possible reasons for this lack of correlation. Whole tumour homogenates 
were used for the 2-D DIGE study in order to study total than rather localised 
protein expression. Also, immunohistochemistry is examining formalin-fixed, 
paraffin-embedded tissue, whereas the proteins for 2-D DIGE were extracted from 
snap-frozen tissue, stored at -80 °C prior to use.  
In cases where the data from the two methods did not agree, it is not possible to 
determine, which result better reflects the protein expression in the tumour. 
However, the two very different approaches yielded concurrent results for FABP3 
and TPI1, which support the differential expression of both proteins. In the case of 
SELENBP, little or no staining was observed in either sample set; metastasised or 
non-metastasised.  
Protein disulfide isomerase (PDIA3) is a thiol oxidoreductase protein of the 
endoplasmic reticulum which is required for protein folding (Koivunen, Helaakoski 
et al. 1996, Garbi, Tanaka et al. 2006). In our study, it showed statistically 
significant differential expression in the 2-D DIGE study, with an abundance 
increase of 1.5-fold in the metastasised sample set in comparison to the non-
metastasised group.  PDIA3 has been known to play a role in oesophageal carcinoma 
(Qi, He et al. 2008). Its expression has been identified in the M14 melanoma cell 
line, and in other cancer cell lines, HeLa and Raji, where it was found to be bound to 
regulatory regions of the DNA, prompting the possibility of PDIA3 acting as a 
transcriptional regulator in non-endoplasmic reticulum regions (Aureli, Gaucci et al. 
2013). On this basis, it appeared to be a promising and novel potential target for 
uveal melanoma. Albeit, our immunohistochemistry results directly contradicted our 
2-D DIGE results, with a decreased expression observed in melanomas which 
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subsequently metastasised in comparison to those which did not, hence it was 
excluded from further analysis.  
F-actin capping protein subunit alpha-1 (CAPZA1) is a cytoskeletal protein. In our 
differential protein expression analysis, it was found to be upregulated by 1.3-fold in 
subsequently metastasised uveal tissue samples. Reports on CAPZA1 in cancer are 
rare; it has been reported to be increased ten-fold in HPV 18-positive oral squamous 
cell carcinoma patients in comparison to other HPV 18-positive cancers. CAPZA1 
was identified in the proteomic analysis of human gastric cancer clinical specimens, 
with its underexpression being associated with poor prognosis (Lee, Jeong et al. 
2013). It has also been identified to be differentially expressed in renal cell 
carcinoma compared to normal renal cells suggesting its possible involvement in 
tumorigenesis (Kellner, Lichtenfels et al. 2002). In the immunohistochemical 
analysis of uveal melanoma tumour tissue, CAPZA1 showed an overall reduced 
cytoplasmic expression pattern in the majority of primary specimens that were found 
to have metastasised compared to those that did not. Parallel staining of sections for 
CAPZA1 and the histiocyte/monocyte/macrophage marker CD68 confirmed 
CAPZA1 positivity in both tumour cells and tumour-infiltrating macrophages, but 
not all of those macrophages stained positive for CAPZA1. 
PARK-7, also known as DJ-1, is an oncogene which was originally cloned as a 
putative oncogene which could transform NIH-3T3 cells, with the cooperation of H-
ras. It has since been implicated in a number of processes, such as oxidative stress, 
and is thought to play a role in tumorigenesis; acting as a negative regulator of the 
tumour suppressor PTEN. Pardo et al. identified PARK-7 as being overexpressed in 
uveal melanoma cell lines in comparison to normal melanocytes. They also 
identified the protein as being secreted as it was detected in the serum of uveal 
melanoma patients. We identified PARK-7 as being upregulated in subsequently 
metastasised primary tumours by 1.2-fold in comparison to those which remained as 
non-metastasised. However, an upregulation of PARK7 during metastasis was not 
observed in the immunohistochemical analysis. 
SELENB1, TPI1, and FABP3 were selected for further analysis using in vitro 
functional studies. By using small interfering RNA (siRNA), the consequences of 
effectively knocking down or reducing expression of a protein of interest can be 
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examined in an assay of choice, hence illustrating the role of the aberrantly-
expressed protein. To understand the biology of a cancer, it is often necessary to 
study the deviant regulation of its cellular processes; this can be carried out using 
cell line models. Healthy cells, lipofectamine-treated cells, negative control cells, 
and cells transfected with two independent siRNA were included for each 
experiment, and the effects of the knockdown are measured by comparing the 
downregulated cells to the negative control. 
 
7.2.2 TPI1 
Triosephosphate isomerase (TPI1) was identified twice with an 1.6- and 1.7-fold 
upregulation in uveal melanoma samples of patients who subsequently developed 
metastatic disease, immunohistochemical analysis also showed a trend for 
upregulation of TPI1 in uveal melanomas which did metastasise. The double 
identification of TPI1 as an upregulated protein is very likely due its isoforms 
(Snapka, Sawyer et al. 1974, Kester and Gracy 1975).  
The glycolytic enzyme TPI1 catalyses the conversion of dihydroxyacetone 
phosphate to glyceraldehyde 3-phosphate (Albery and Knowles 1976), and a high 
rate of glycolysis is required to support tumour growth (Bui and Thompson 2006). 
TPI1 has previously been shown to be expressed in uveal melanoma primary cell 
cultures (Pardo, Garcia et al. 2005).  
As the 2-D DIGE and immunohistochemistry results both illustrated that TPI1 was 
upregulated in subsequently metastasised primary tumour tissue, our proteomics 
study provided evidence that TPI1 may have been involved in the development of 
the metastatic phenotype in uveal melanoma. Hence, it was decided to follow up 
TPI1 with functional analysis to further understand its role. 
Abnormal proliferation is required for tumorigenesis, as cancer involves the 
accumulation of clonal cells. The reduction in tumour cell number, or tumour 
burden, is often the goal of current cancer therapies. Hence, a better understanding 
of the key proteins behind abnormal cell proliferation in a cancer could aid the 
development of more effective targets for therapies (Andreeff 2000). Following the 
siRNA-mediated downregulation of TPI1 in the 92.1 uveal melanoma cell line, an 
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acid phosphatase assay was carried out which demonstrated that no extensive effect 
on proliferation was observed in vitro when the two independent siRNA 
transfections per target were compared against the negative control. However, when 
the MEL202 uveal melanoma cell line was transfected, a prominent significant 
decrease in proliferation was noted between the negative control and the transfected 
cells. The negative effect observed may have been due to the cell line rather than the 
knockdown of TPI1 as no comparable effect was seen in the 92.1 uveal melanoma 
cell line. Hence, any subsequent functional assays involving TPI1 were carried out 
only in the 92.1 cell line.  
Invasion and migration of cancer cells allow them to enter the blood or lymphatic 
system to grow at distant locations to the primary tumour in a process called 
metastasis. By 'knocking-down' expression, a role in migration and/or invasion of 
cancer cells can be elucidated. For the TPI1 siRNA-transfected 92.1 cells, a largely 
significant reduction of both invasion and migration was observed in vitro when 
compared with the negative control.  
As TPI1 was identified as being upregulated in subsequently metastasised uveal 
melanoma tumour tissue in comparison to that which did not metastasise, a result 
that was confirmed by immunohistochemistry, as well as apparently being involved 
in the invasiveness and motility of the uveal melanoma cells, it appears to be  
implicated in the aggressive nature of the metastasised disease. It may be possible to 
target TPI1 for the inhibition of glycolysis and inhibit the Warburg effect as a 
therapeutic strategy for uveal melanoma metastasis. The approach of using 
glycolytic inhibitors as anticancer drugs has been examined as a potential 
therapeutic strategy and has been experimentally applied to other cancers, such as 
colon cancer, leukaemia and lymphoma cell lines (Xu, Pelicano et al. 2005, 
Pelicano, Martin et al. 2006). 
 
7.2.3 FABP3 
2-D DIGE analysis revealed a 2.2-fold up-regulation of fatty acid-binding protein 
three (FABP3) in uveal melanomas which subsequently metastasised. This trend was 
confirmed by immunohistochemical studies.  
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FABP3 is a member of a multi-gene family including nine FABPs and the cellular 
retinoid binding proteins. Fatty acid-binding proteins show a broad tissue 
distribution, and tissues can contain more than one FABP (Storch and Corsico 2008, 
Storch and McDermott 2009). Though FABPs are known to be involved in 
intracellular transport of long-chain fatty acids, their in vivo functions are poorly 
understood (Ockner and Manning 1974). FABP3 was shown to inhibit cell 
proliferation in mammary epithelial cells and the ectopic expression of FABP3 in 
breast cancer cells led to reduced tumorigenicity in nude mice (Yang, Spitzer et al. 
1994). In contrast, positive correlations of FABP3 expression with tumour cell 
invasion, lymph node metastasis and poor patient survival have been found in gastric 
carcinomas (Hashimoto, Kusakabe et al. 2004).  
As the 2-D DIGE and immunohistochemistry results correlated with an upregulation 
of FABP3 in relation to metastasis, and the target appeared to be novel in uveal 
melanoma, FABP3 was chosen for follow-up functional studies in order to further 
understand its potential role in metastasis. 
Following the siRNA-mediated downregulation of FABP3 in the 92.1 uveal 
melanoma cell line, proliferation assays were carried out which demonstrated that no 
extensive effect was observed in vitro when the two independent siRNA 
transfections were compared against the negative control. However, when FABP3 
siRNA were used to transfect the MEL202 uveal melanoma cell line, a strongly 
significant decrease in proliferation was noted between the negative control and the 
transfected cells. The negative effect observed may, again, have been due to the 
MEL202 cells rather than the knockdown of FABP3 as no comparable effect was 
seen in the 92.1 uveal melanoma cell line. Hence, any subsequent functional assays 
involving FABP3 were carried out only in the 92.1 cell line.  
When the expression of FABP3 was reduced, a largely significant decrease in both 
invasion and migration was observed when compared to the negative control. This 
indicates that FABP3 appears to be involved in the processes of invasion and 
migration in uveal melanoma cells.  
Overall, it appears as though FABP3 may play a role in the spread of uveal 
melanoma as it was upregulated in subsequently metastasised tissue and its 
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downregulation affected invasion and migration in vitro, key processes in the 
aggressiveness of metastatic malignancies.  
 
7.2.4 SELENBP1 
Selenium-binding protein (SELENBP1), a member of the selenoprotein family, is 
known to bind selenium covalently in order to mediate the intracellular transport of 
selenium (Zhou, Zhang et al. 2009, Zeng, Yi et al. 2013).  
It has previously been suggested as a tumour suppressor as its expression is lost in 
several epithelial cancers (Scortegagna, Martin et al. 2009, Zeng, Yi et al. 2013). In 
addition to this, it has been identified as a potential marker for hepatocellular 
carcinoma by Di Statsio el al. They identified a decrease in SELENBP1 abundance 
in hepatocellular carcinoma liver tissue specimens. The gradual decrease in selenium 
levels correlated with an increased malignant grade, with the levels of selenium and 
of SELENBP1 directly correlating (M, Volpe et al. 2011).  
SELENBP1 had not previously been associated with ocular cancer and hence, was 
considered novel in this regard. In addition to this, SELENBP1 was not typically 
identified as being upregulated in cancer. Although the immunohistochemistry 
results did not correspond with the 2-D DIGE results, it was decided to further 
examine the role of SELENBP1 in uveal melanoma cell lines using functional 
analysis.  
After the downregulation of SELENBP1 in the 92.1 and MEL202 uveal melanoma 
cell lines, an acid phosphatase assay was carried out. This demonstrated that no 
extensive effect on proliferation was observed in vitro when the two independent 
siRNA transfections per target were compared against the negative control.  
Following the siRNA-mediated knockdown of SELENBP1, a significant reduction 
of both invasion and migration was observed, in compared to the negative control. 
This indicates that the protein appears to be involved in the invasiveness and 
motility of the 92.1 cell line, and possibly also in the MEL202 cell line. 
Specific invasion-related proteins, such as matrix metalloproteases (MMPs), may 
also be identified using zymography, an electrophoresis method by which proteases 
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present in a sample are detected through the digestion of a substrate-containing gel. 
92.1 and MEL202 uveal melanoma cell lines were transfected with siRNA specific 
to SELENBP1. Conditioned media was then collected from the cells as this 
contained the secreted MMPs. MMP-2 and -9 are typically implicated in melanoma 
disease progression and have been associated with uveal melanoma metastasis 
(Coussens, Fingleton et al. 2002, Lai, Conway et al. 2008). Hence, gelatin-based 
zymography was used as this is the substrate of choice for MMP-2 and -9. In spite of 
this, no difference was observed between the transfected cells and the negative 
controls, for either cell line. 
The inhibition of apoptosis is a key feature of many malignant cells as some 
oncogenic mutations allow for proliferating cancer cells to grow without hindrance 
by preventing apoptosis. Apoptosis is a tightly regulated mechanism which ensures 
homeostasis of all tissues and without it leading to tumour initiation, progression or 
metastasis. Also, mutations which suppress tumour development can affect 
treatment sensitivity, rendering it less effective (Andreeff 2000, Lowe and Lin 
2000). 7-AAV and PE-Annexin V were used to stain DNA and exposed 
phosphatidyserine, respectively. Fluorescence was subsequently measured using 
flow cytometry which quantified the degree of apoptosis. Apoptosis was measured 
in cells which were transfected with siRNA specific for SELENBP1; however, no 
significant effect on cell death was determined.  
Oxygen derived species are recognised as cytotoxic and have been implicated as 
carcinogens in the process of cancer. Such species may exert their effects through 
reactive oxygen species (ROS), which are generated during metabolism. Oxidative 
damage can occur in cellular DNA as a result, which can play a role in the 
development of various malignancies (Waris and Ahsan 2006). Selenium is an 
essential trace element which is involved in the function of antioxidant enzymes and 
proteins that protect the cell against ROS. SELENBP1 is known to bind selenium 
covalently in order to mediate the intracellular transport of selenium (Zhou, Zhang et 
al. 2009, Zeng, Yi et al. 2013). Hence, it was decided to downregulate SELENBP1 
production in order to determine its potential role in terms of protection from ROS. 
2‟,7‟-dichlorofluorescein-diacetate (DCFH-DA) was used to quantify intracellular 
produced H2O2; based on the activity of peroxide, DCFH-DA is converted to a 
fluorescent compound, 2‟,7‟-dichlorofluorescein (DCF), which indicates the quantity 
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of ROS present. Overall a visual trend of increased ROS activity was observed in the 
transfected cells when compared to their negative controls. However, this was not a 
statistically significant result. Although, the trend does illustrate what is expected, 
based on the literature. Zeng et al. demonstrated that the knockdown of SELENBP1 
induces human bronchial epithelial cell transformation and that it is an early event in 
in lung squamous cell cancer (Zeng, Yi et al. 2013). This indicates a potential 
increase in ROS activity as a result of the downregulation of SELENBP1 which may 
therefore play a role in protecting uveal melanoma cells from oxidative damage.  
Typically, SELENBP1 is reported as being downregulated in cancers such as in the 
case of colorectal cancer, ovarian cancer, lung cancer, and pleural mesothelioma 
(Pass, Liu et al. 2004, Huang, Park et al. 2006, Kim, Kang et al. 2006, Zeng, Yi et al. 
2013). Hence, its upregulation in uveal melanoma is potentially unique and may be a 
novel marker for metastasis as it was found to be significantly upregulated in 
subsequently metastasised primary tissue. It clearly plays a role in invasion and 
migration in vitro, but is not involved in proliferation and does not exert anti-
apoptotic effects. It is, however, possibly required for protection from oxidative 
damage. 
 
7.3 Identification of Differentially Expressed Proteins between Non-
Metastasised and Subsequently Metastasised Tissue Using Quantitative Label-
Free LC-MS  
2-D DIGE is a sensitive and high-throughput method for the identification of 
biomarkers from various sources. It is the most-widely used gel-based method for 
the detection of differentially regulated proteins. Mass spectrometry-based 
proteomic analysis has improved greatly since the last decade. The advent of label-
free quantitative LC-MS has allowed for the simultaneous and accurate 
identification of thousands of differentially regulated proteins, even from very 
minute quantities, thus potentially giving a more comprehensive view of the 
proteome in question. This advancement has helped enormously in the identification 
and delivery of candidate biomarkers for cancer diagnosis, prognosis and monitoring 
of treatment regimen (Paul, Kumar et al. 2013).  
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It was therefore decided to carry out a quantitative LC-MS proteomic analysis of 
eight non-metastasised tumour tissues and eight which subsequently metastasised. In 
total, 14 of these tissues had previously been used in the 2-D DIGE differential 
expression experiment.  
This approach also agreed with the hypothesis as 50 proteins with a minimum of 
three matched peptides were identified as being differentially expressed between 
both sample sets. Of these proteins, five were previously identified in the 2-D DIGE 
study. Vimentin, alpha-enolase, TPI1, beta-hexosaminidase subunit alpha, and 
FABP3 were all found to be upregulated in primary uveal melanoma tissue that had 
subsequently metastasised, which correlated with the 2-D DIGE findings.  
Heat shock protein beta-1 (HSP-27) was found at a lower level in primary tissue 
which subsequently metastasised in comparison to primary tissue which remained as 
non-metastasised. This result agrees with a study previously carried out by Coupland 
et al. which demonstrated that HSP-27 was expressed at a lower level in monosomy 
three tumour tissues than in disomy three tumour specimens. Monosomy three is 
indicative of poor prognosis while disomy three is often suggestive of a better 
outcome (Coupland, Vorum et al. 2010). This finding was subsequently followed-up 
by Jmor et al. who illustrated that in combination with basal tumour diameter, 
melanoma cytomorphology and mitotic rate, the level of HSP-27 enhanced the 
estimation of survival probability (Jmor, Kalirai et al. 2012). 
Vimentin, which was previously identified as being upregulated in the metastasised 
sample set in comparison to the non-metastasised group in the 2-D DIGE study, was 
again identified as being overexpressed in uveal melanoma monosomy three tumour 
tissues in comparison to those which were disomy three.  
Of the 50 proteins identified by label-free quantitative LC-MS, CNDP2, PRDX3, 
KPNB1, and EEF1G were selected for further studies through functional analysis. 
These were chosen as, although some of these had previously been linked with other 
cancer studies, they had not been associated with uveal melanoma. In addition to 
this, they illustrated some of the lowest ANOVA scores of the analysis, deeming 
them as a number of the most significant potential targets from the generated list. 
However, functional analysis could not be completed for two of these proteins; 
CNDP2 and PRDX3.  
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Cytosolic non-specific dipeptidase (CNDP2) is expressed in all human tissues. The 
loss of chromosome 18q, which encodes for the protein, results in carnosinemia, a 
rare autosomal recessive metabolic disorder. In addition to this, it may play a role 
tumour suppressor, as demonstrated in hepatocellular carcinoma cells (Zhang, Chan 
et al. 2006). Deletion of the CNDP2 gene has been identified in 27.2% cancer 
specimens from an aCGH study containing more than 3,000 cancer specimens, 
including many malignancies of the gastrointestinal tract (Lee, Giovannetti et al. 
2012). In our study, CNDP2 was found to be 1.75-fold more abundant in the non-
metastasised tissue in comparison to that which subsequently metastasised. This 
correlates with the above previous work which suggests that the downregulation of 
CNDP2 may be indicative of a poorer prognosis. However, as CNDP2 was not 
expressed in either of the chosen uveal melanoma cell lines; 92.1 and MEL202, it 
was excluded from the functional analysis.  
Peroxiredoxins are a family of peroxidases which catalyse the reduction of peroxides 
in the presence of thioredoxin (Wonsey, Zeller et al. 2002). They are present in all 
animals existing in multiple isoforms, with at least six isoforms in humans (Seo, 
Kang et al. 2000). They exhibit different expression patterns, with some providing 
defence against oxidative damage, and  participating in signalling by controlling 
H2O2 concentration, while others have been shown to play a role in apoptosis, and 
proliferation (Rhee, Kang et al. 2001, Wonsey, Zeller et al. 2002). Thioredoxin-
dependent peroxide reductase (PRDX3) has been found to be overexpressed in a 
number of endocrine tumours such as prostate cancer where it plays an essential role 
in regulating oxidation-induced apoptosis in anti-androgen resistant cells (Whitaker, 
Patel et al. 2013). The PRDX3 gene has also been identified as a target gene of the c-
Myc transcription factor. c-Myc functions to accelerate metabolic pathways such as 
glycolysis. As mitochondria are crucial for the execution of energy production and 
cell death, mitochondrial proteins such as PRDX3 may be involved in the regulation 
of proliferation and apoptosis. Hence, PRDX3, and other c-Myc target genes 
encoding mitochondrial proteins, could play an important role in tumorigenesis 
(Wonsey, Zeller et al. 2002). PRDX3 was found to be upregulated in subsequently 
metastasised tumour tissue by 1.58-fold when compared to the non-metastasised 
specimens. This correlates with the above previous work which suggests that the 
upregulation of PRDX3 may be indicative of a poorer prognosis. However, despite 
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many attempts, the optimisation of PRDX3 siRNA-mediated downregulation failed 
and hence, it was also excluded from the functional analysis. 
 
7.3.1 KPNB1 
Importin subunit beta-1 (KPNB1) is a major nuclear receptor protein which is 
required for the import of proteins, such as transcription factors, into the nuclear 
envelope and is plays a major role in maintaining normal cell homeostasis.  
In cancer cells, KPNB1 is often upregulated in order to maintain a high level of 
nuclear transport, thus it may be a potential biomarker (van der Watt, Stowell et al. 
2013). This pattern has been observed in cervical tumours, non-small cell lung 
cancer, and head and neck squamous cell carcinoma (van der Watt, Ngarande et al. 
2011, Martens-de Kemp, Nagel et al. 2013). 
KPNB1 was found to be upregulated by 1.47-fold in subsequently metastasised 
uveal melanoma tumour tissue in comparison to non-metastasised, which agrees 
with previous studies that may indicate a role of KPNB1 in tumour progression and 
ultimately metastasis. 
Following the siRNA-mediated downregulation of KPNB1 in the 92.1 and MEL202 
uveal melanoma cell lines, an acid phosphatase assay was carried out in vitro which 
demonstrated that no extensive effect on proliferation was observed for the two 
independent KPNB1 siRNA transfections in comparison to the negative control.  
A highly significant reduction of both invasion and migration was observed when 
the expression of KPNB1 was reduced, in comparison to the negative control, in 
92.1 cells. Hence, KPNB1 may play a role in the invasiveness and motility of uveal 
melanoma cells in vitro.  
92.1 and MEL202 uveal melanoma cell lines were transfected with siRNA specific 
to KPNB1. Conditioned media was then collected from the cells as this contained 
the secreted MMPs. However, using gelatin zymography, no difference in MMP 
expression was observed between the transfected cells and the negative controls, for 
either cell line. 
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Apoptosis was measured in cells which were transfected with siRNA specific for 
KPNB1; however, no significant effect on cell death was determined.  
KPNB1 appears to be necessary for the metastatic phenotype of uveal melanoma as 
it was found to be upregulated in subsequently metastasised tissue, and its 
downregulation decreases invasion and migration; however it does this 
independently of MMP-2 and -9. It also does not play anti-apoptotic role in uveal 
melanoma, which correlates with its lack of effect on proliferation. It is potentially a 
useful anticancer therapeutic target as it appears to be somewhat responsible for the 
increased rate of nuclear transport in cancer. However, the availability of drugs 
targeting such molecules is currently limited. One such drug which is available is 
Leptomycin, a small molecule inhibitor of CRM1, a major receptor for the export of 
nuclear proteins and a member of the karopherin family. Leptomycin has been 
shown to exhibit anticancer activity both in vivo and in vitro. Hence, it is very 
possible that KPNB1 may be affected in a similar manner, as it is also a member of 
the karyopherin family, and so, may be an effective target (Fornerod, Ohno et al. 
1997, van der Watt, Stowell et al. 2013) .  
 
7.3.2 EEF1G 
Elongation factor 1-gamma (EEF1G) is a GTP-binding protein involved in 
translation and protein biosynthesis by mediating the transport of aminoacyl-tRNA 
to 80S ribosome (Proud 1994, Negrutskii and El'skaya 1998).  
EEF1G has been associated with pancreatic cancer tumour tissues, where it was 
identified in seven out of nine specimens, relative to apparently normal adjacent 
tissue. It was also found to be overexpressed in 25 out of 29 colorectal carcinomas 
(Chi, Jones et al. 1992). The overexpression of EEF1G appears to be highly 
associated with cancers of the gastrointestinal tract and has also been identified in 
hepatic, ileocecel, duodenal, and colon carcinoma cell lines (Mimori, Mori et al. 
1995). It has also been associated with the co-upregulation of TNF receptor-
associated protein 1 (TRAP-1), a member of the heat shock protein (HSP) 90 protein 
family involved in protection from oxidative stress and apoptosis, in colon 
carcinoma cells (Matassa, Amoroso et al. 2013). 
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EEF1G was identified as being upregulated by 2.02-fold in uveal melanoma tumours 
which had subsequently produced metastases in comparison to non-metastasised 
tissues. It was chosen as it was potentially novel target for uveal melanoma as it 
appears to play a role in tumour progression.  
Following the siRNA-mediated downregulation of EEF1G in the 92.1 and MEL202 
uveal melanoma cell lines, a proliferation assay was carried out which demonstrated 
that the knock-down of the protein had no extensive effect on proliferation in vitro in 
either of the two independent KPNB1 siRNA transfections in comparison to the 
negative control.  
A highly significant reduction of both invasion and migration was observed when 
the expression of EEF1G was diminished, in comparison to the negative control, in 
92.1 cells. An effect was also observed in the MEL202 cell line. This indicates that 
EEF1G may play a role in the invasiveness and motility of the uveal melanoma cells 
in vitro.  
92.1 and MEL202 uveal melanoma cell lines were transfected with siRNA specific 
to EEF1G. Conditioned media was then collected from the cells as this contained the 
secreted MMPs. However, using gelatin zymography, no difference was observed 
between the EEF1G transfected cells and the negative controls, for either cell line. 
Apoptosis was measured in cells which were transfected with siRNA specific for 
EEF1G; however, no significant effect on cell death was determined. EEF1G 
appears to be necessary for the process of invasion and migration in uveal melanoma 
in vitro, albeit independently of MMP-2 and -9, and hence is required in metastasis. 
It does not play an anti-apoptotic role in uveal melanoma, which correlates with its 
lack of effect on proliferation.  
Previous studies have identified potent and selective inhibitors of other members of 
the elongation factor family, which could inhibit growth of the malignancy through 
downregulation of nutrient transporters and activation of autophagy. Arora et al. 
screened a series of imidazolium compounds for the inhibition of EEF2 (eukaryotic 
elongation factor 2) activity in several forms of malignancy. From this, they 
identified NH125 as a lead compound which decreased the viability of 10 cancer cell 
lines (Arora, Yang et al. 2003). Hait et al. described the combination of a growth 
327 
 
factor antagonist with an inhibitor of EEF-2 kinase in breast cancer in order to 
induce cell death (Hait, Wu et al. 2006). This illustrates the potential significance of 
EEF1G as a potential target for uveal melanoma treatment. 
 
7.4 Conclusion 
This proteomics study on primary uveal melanoma tissue samples led to the 
successful identification of proteins including FABP3, SELENBP1, EEF1G, 
KPNB1, and TPI1 that are possibly involved in the metastatic phenotype of uveal 
melanoma in vitro. These results correlated with the hypothesis that proteins are 
differentially expressed between disease states and that such proteins may be 
potential biomarkers. These proteins showed a strong differential expression and 
high statistical significance from either the 2-D DIGE or quantitative label-free LC-
MS analysis when compared to the non-metastasised group. Their siRNA-based 
knockdown significantly reduced invasion and migration of uveal melanoma cell 
lines, suggesting that they are functionally involved in the metastatic phenotype of 
uveal melanoma in vitro, and that they may be suitable candidates for targeted 
therapies in the treatment of aggressive uveal melanoma. This work has fulfilled the 
aim of identifying patterns of differential protein expression between subsequently 
metastasised and non-metastasised primary uveal melanoma tissue, which may 
further our understanding of the metastatic phenotype of uveal melanoma. 
 
7.5 Sample Preparation and Proteomic Analysis of Uveal Melanoma Vitreous 
Fluid 
The vitreous fluid is a hydrogel-like substance, located in the posterior segment of 
the eye. Physical and pathological conditions of nearby tissues, such as the retina, 
may be reflected in the vitreous humour (Angi, Kalirai et al. 2012).  
Proteomics of the vitreous fluid is a growing area as the specimen contains a variety 
of proteins. Soluble proteins are thought to filter from the plasma through 
fenestrated capillaries of the ciliary body stroma via the iris root. Proteins may also 
be secreted from posterior chamber tissues which may impact on the protein content 
of the fluid. Indeed, the vitreous should contain a complex mix of proteins as it 
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reacts to its environment when attempting to maintain homeostasis. In this regard, 
alterations in its proteome may be indicative of disease, or illustrate proteins which 
are actively involved in the pathogenic process (Chowdhury, Madden et al. 2010). 
Although we are still not close to fully understanding the biochemistry of the 
vitreous humour, a recent study was carried out which extensively detailed the entire 
vitreous proteome, listing a total of 1111 proteins (Aretz, Krohne et al. 2013). 
Therefore, progress is quickly being made in the field of vitreous fluid proteomics. 
In addition to this, a number of studies have been carried out which indicate its role 
in disease and in biomarker discovery, as well as in clinical diagnoses and 
prognoses. Autoimmune or autoinflammatory uveitis patients‟ vitreous has been 
used for the analysis of cytokine production. For example, an elevated level of TNF-
alpha has been identified in the vitreous of animal uveitis models (Damato, Angi et 
al. 2012). The specimen has also successfully been used in the differentiation of 
infectious, inflammatory, and malignant cases of uveitis (Lobo and Lightman 2003). 
A significant amount of research has been carried out in the vitreous of diabetic 
patients for the proteomic analysis of retinopathy. Fluid from patients undergoing 
vitreoretinal surgery is currently used to indirectly explore the synthesis of mediators 
of diabetic retinopathy produced by the retina as well as the infiltration of leukocytes 
(Yoshimura, Sonoda et al. 2009, Simo-Servat, Hernandez et al. 2012). A number of 
potential biomarkers have also been determined through this research. Orosomucoid 
was identified as being upregulated in the vitreous of proliferative vitreoretinopathy 
patients in comparison to that of proliferative diabetic retinopathy patients (Wu, 
Sauter et al. 2004). 
Due to the close proximity of the vitreous to many regions of the eye, high 
concentrations of proteins may be secreted into the fluid from various sites of 
disease, such as a tumour, thus illustrating pathophysiological events taking place. 
Hence, the vitreous humour qualifies as a suitable fluid for the clinical proteomic 
analysis of uveal melanoma, as it may contain significant numbers of secreted 
biomarkers.  
Little has been carried out in terms of uveal melanoma vitreous fluid proteomics. 
The majority of studies to date have consisted of multiplex bead arrays, such as 
those which are discussed in section 7.5.4.  
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Therefore, it was decided to examine the vitreous collected from uveal melanoma 
patients as it could be a specimen of interest in detecting potential prognostic 
markers.  
 
7.5.1 Vitreous Fluid Sample Preparation 
The analysis of vitreous fluid can be a challenging process due to the small sample 
volume and low protein concentration present. Improvements in mass spectrometry 
have improved the overall process with high sensitivity instruments now available 
which can provide both qualitative and quantitative information (Pollreisz, Funk et 
al. 2013). Despite this, the challenge still remains in efficiently mining the proteome 
to reach the concentration of low abundance proteins, which are often of most 
interest in terms of biomarker discovery. Hence it is necessary to fractionate the 
vitreous prior to experimentation in order to extract proteins of interest from the 
complex mixture (Angi, Kalirai et al. 2012). 
Following the separation of a control vitreous fluid sample, collected from a patient 
with macular hole degeneration, it was evident that the vitreous was rich in serum 
albumin and other proteins considered to be highly abundant such as; IgG, 
haptoglobin, complement C3. Following a double immunodepletion, the proteome 
appeared to be sufficiently “cleaned-up” as large regions of smeared protein were no 
longer present and less prominent bands were more visible. However, this impacted 
on the protein concentration, as high abundance proteins make up 80% of the 
vitreous fluid proteome. This resulted in insufficient quantities of protein being 
available for pre-fractionation methods, such as ProteoMiner treatment, and 
separation experiments, such as 2-D DIGE.  
A quantitative LC-MS label-free approach was adopted in order to identify potential 
differentially expressed proteins between the control and uveal melanoma sample 
sets. Highly sensitive mass spectrometry methods are capable of identifying 
quantitative differences between low abundance proteins, using the minimal quantity 
of sample to do so. Such approaches have been effectively used in the study of 
aqueous humour and tear fluid previously which would suggest that the same 
process could be successful in vitreous humour (de Souza, Godoy et al. 2006, 
Chowdhury, Madden et al. 2010). Nevertheless, the results of this analysis did not 
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produce differentially expressed proteins as spectra generated from the control group 
were entirely different to those from the disease group and could not be compared. 
This may have been as a result of the quantity of high abundance proteins which 
were present in uveal melanoma specimens in comparison to the controls. As all 
samples were normalised to 10 μg prior to analysis, the majority of this possibly 
consisted of a few abundant proteins in the uveal samples, hence creating an entirely 
different spectrum of peaks to the control sample set (which may have contained a 
variety of proteins).  
 
7.5.2 IMAC Fractionation of Uveal Melanoma Vitreous Fluid 
Little has been carried out in vitreous fluid using SELDI technology; hence, it was 
decided to compare a control and a uveal melanoma specimen as a pilot SELDI TOF 
MS study.  
This identified the presence of three protein peaks which were originally identified 
in cutaneous melanoma serum and the conditioned media of a cutaneous melanoma 
cell line. However, SELDI TOF MS does not provide identifications for peaks 
detected, only spectral profiles. As further explained in sections 7.7.3 and 7.7.4, it 
was decided to attempt to identify the protein peak at 8.9 kDa.  
Using an IMAC column, described in section 7.7.4.1, proteins with an affinity for 
copper were bound and subsequently eluted with an imidazole gradient from the 
resin in fractions. These elution fractions were separated in the first dimension using 
gel electrophoresis and stained. Following this, protein bands from the gel were 
digested and generated peptides were analysed using LC-MS/MS for their 
identification.  
This qualitative method succeeded in identifying a host of proteins which had not 
been found in our previous attempts to mine the uveal melanoma vitreous proteome. 
This fulfilled the aim of developing an effective method of vitreous fluid sample 
preparation. It was therefore decided to repeat the experiment and to analyse the 
imidazole fractions quantitatively. In this quantitative LC-MS analysis, six 
monosomy three uveal melanoma vitreous samples were compared to seven disomy 
three uveal melanoma vitreous specimens.  
331 
 
Previously, Coupland et al. had compared four primary uveal melanoma tumour 
tissue specimens from monosomy three patients to those of three disomy three 
patients, with the intention of identifying differentially regulated proteins between 
both groups. Monosomy three in uveal melanoma is regarded as an indicator of poor 
outcome; therefore, a biomarker providing prognostic relevance early on in the 
disease would be of great benefit. From this 2-D DIGE analysis, they discovered 
nine differentially expressed proteins, three of which were confirmed by western 
blotting; HSP-27, vimentin, pyruvate dehydrogenase beta. Immunohistochemistry 
further validated that low HSP-27 abundance correlated with monosomy three 
chromosomal status, and that HSP-27 appeared to be a promising prognostic marker 
(Coupland, Vorum et al. 2010).  
Therefore, other biomarkers indicating outcome in uveal melanoma could be 
detected in vitreous fluid by comparing monosomy three specimens to those of 
disomy three patients, as this has not been reported previously, using the IMAC 
quantitative method. It was hoped that this would improve our understanding of the 
metastatic disease, and potentially indicate any differentially regulated proteins 
which could act as therapeutic targets. 
 
7.5.3 Proteins of Interest Identified as a Result of IMAC Fractionation  
From the quantitative and qualitative analyses of the IMAC vitreous fluid samples a 
number of proteins of interest were discovered.  
From the 1-D gel-based qualitative study, a family of proteins known as crystallins 
were identified, which illustrated that the technique had uncovered a range of 
previously undiscovered proteins and hence, was a successful pre-treatment 
technique.  
From the quantitative LC-MS-based study, proteins such as retinol-binding protein 
three, meckelin, PEDF, retbindin, and alpha crystallin B were discovered to be 
differentially regulated between the monosomy three and disomy three sample sets. 
These may potentially be useful as novel prognostic markers, as some of these; 
retinol-binding protein 3, meckelin, and retbindin, have not previously been 
identified in relation to uveal melanoma. In addition to this, meckelin, and retbindin 
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have not been identified in the vitreous fluid. This work agreed with the hypothesis 
that proteins would be differentially expressed between monosomy 3 and disomy 3 
samples. It also satisfied the aim of identifying such proteins which could act as 
potential biomarkers or therapeutic targets. 
Enrichment analysis of the differentially expressed proteins identified in the 
qualitative study indicated that, overall, the complement and coagulation cascades 
would be upregulated as a result of the overexpression of proteins in the disomy 
three samples. This suggests that due to significant trauma caused by the 
malignancy, the immune system was triggered in an effort to regulate and repair the 
damage caused. This action may have activated an inflammatory response, as this 
response was detected following the enrichment of biological processes. This action 
could activate a cascade of cytokines in response which would potentially be 
detectable in vitreous fluid, and thus be identifiable using a Luminex multiplex 
method, such as that in section 7.5.4.  
 
7.5.3.1 Proteins of Interest Discovered in the Qualitative Analysis 
7.5.3.1.1 Crystallins  
Crystallins are water-soluble proteins of the lens which contribute to its transparency 
and refractive properties, with age-related post-translational modifications of the 
crystallins being associated with cataracts. These proteins were originally thought to 
merely be stable structural components, however, they have been shown to have 
further roles, such as molecular chaperones, and have been identified outside of the 
lens. Lens proteins are highly stable and do not age but do eventually undergo post-
translational modifications such as deamidation, and protein crosslinking, and can be 
oxidised by free radicals generated by UV light (Andley 2007).  
Beta-crystallin B1, beta-crystallin A4 and beta-crystallin A3, which were identified 
in our qualitative study, have been shown to be predominantly involved in cataract 
formation as they are both targets for crosslinking by tissue transglutaminasae (tTG). 
This crosslinking activity of tTG has also been implicated in many cell processes 
such as; motility, wound healing, extracellular matrix remodelling, differentiation, 
and apoptosis. Beta-crystallin B2, also discovered in the qualitative analysis, has 
been implicated as a potent glutamate substrate for tTG, but also as a target for 
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deamidation by tTG, which destabilises the protein. These processes of deamidation 
and crosslinking are thought to play a role, not only in cataractogenesis, but in aging 
and disintegration of the structural components of the eye (Andley 2007). Mutations 
of beta crystallin S have been associated with autosomal dominant congenital 
cataract formation (Sun, Ma et al. 2005).  
A mutation in gamma-crystallin D, P23T, is associated with a number of well-
known cataract phenotypes through the reduced solubility and subsequent 
condensation of the mutated protein without demonstrating any change in the protein 
structure (Pande, Annunziata et al. 2005). 
The alpha crystallins, chains A and B, were both discovered in uveal melanoma 
vitreous fluid following the qualitative analysis. Alpha-crystallin B is a small heat 
shock protein and has similar properties to those of a molecular chaperone. 
Increased levels of alpha-crystallin B have been associated with a variety of 
neurological diseases such as Alzheimer‟s disease, Parkinson‟s disease, and 
Creutzfeldt Jacob disease. However, it does not seem to be required for normal 
development of the refractive lens. Alpha-crystallin A has been shown to have a 
protective effect on other crystallins, and in particular gamma crystallin, however 
the mechanism by how this occurs is elusive (Horwitz 2003). Alpha-crystallin B 
appears to play an anti-tumorigenic role in nasopharyngeal carcinoma, as well as 
suppressing the progression of the cancer through its potent effect on invasion and 
adhesion (Huang, Cheng et al. 2012). The protein has also been linked with poor 
outcome and nodal status in a number of malignancies such as breast cancer, 
glioblastoma, renal cell carcinoma and head and neck squamous cell carcinoma 
(Aoyama, Steiger et al. 1993, Takashi, Katsuno et al. 1998, Moyano, Evans et al. 
2006, van de Schootbrugge, Bussink et al. 2013). 
Alpha-crystallin B has also been shown to be highly expressed in melanocytes and 
expressed at a lesser level in melanoma cells, where it is repressed as a result of 
upregulated BRAF-MEK signalling. It also contributes to the turnover of cyclin D1 
in both melanocytes and melanoma cells following DNA damage. Finally, although 
not discovered in this study, absent in melanoma 1 (AIM1) is an unusual member of 
the family of crystallins whose expression is known to suppress malignancy in 
melanoma (Aravind, Wistow et al. 2008). 
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As crystallins have been shown to bind to IMAC, this illustrates that the method was 
successful in binding proteins with an affinity for IMAC (Chiou, Huang et al. 2010, 
Huang, Wang et al. 2011).   
Due to using the IMAC fractionation method, it was possible to better observe the 
vitreous fluid proteome and to isolate a number of members of the crystallin family. 
These results may indicate the possible role of the crystallins in the vitreous fluid of 
uveal melanoma patients. In addition to this, this may improve our understanding of 
the vitreous fluid during malignancy of the uvea, and indeed, better our knowledge 
of the cancer itself. 
 
7.5.3.2 Differentially Regulated Proteins of Interest Discovered in the 
Quantitative Analysis 
Using quantitative LC-MS following IMAC fractionation, the protein content of 
monosomy of chromosome three and disomy of chromosome three uveal melanoma 
vitreous fluid sample sets were compared. This unearthed a total of 62 differentially 
expressed proteins which were identified from the flowthrough, 20 mM, and 50 mM 
fractions. From enrichment analysis of pathways involved, it was clear that the 
greatest effect was observed in downregulation of proteins in the monosomy 3 
specimens where complement and coagulation cascades were affected.    
A number of proteins which may be followed up are described in the following sub-
sections.  
 
7.5.3.2.1 Retinol-Binding Protein 3 
Retinol-binding protein 3 is a glycoprotein which functions as a transporter of 
retinoids between the photoreceptors and the retinal pigment epithelium, and is 
necessary for normal rod and cone cell function and development (Liou, Fei et al. 
1998, den Hollander, McGee et al. 2009). It has been associated with inducing 
uveoretinitis, and retinitis pigmentosa, a degenerative ocular disease (Eisenfeld, 
Bunt-Milam et al. 1987, Bianciotto, Shields et al. 2010). In addition to this, its 
expression has been linked with the development of retinoblastoma and pineocytoma 
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(Korf, Korf et al. 1992). However, it also may play a protective role as an anti-
oxidant (den Hollander, McGee et al. 2009). 
In our study, the protein was identified as being upregulated in monosomy of 
chromosome three specimens in both the flow through and the 20 mM fraction. This 
may indicate its role in tumour development and disease progression, as it was 
identified at a lower level in the disomy three sample set, which is less aggressive. It 
has previously been implicated in malignant cutaneous melanoma in a case where 
autoantibodies against the metastatic melanoma cross-reacted with retinol-binding 
protein three, i.e. a retinal autoantigen; this rare condition is referred to as 
melanoma-associated retinopathy (MAR). MAR is also known to occur in metastatic 
uveal melanoma, which raises the question if this would explain the observed 
increase in retinol-binding protein three expression in monosomy three samples, 
which are typically associated with metastasis, in comparison to the disomy three 
sample set (Bianciotto, Shields et al. 2010).  
However, it is also possible that retinol-binding protein three was upregulated in 
monosomy three vitreous samples as a result of extensive trauma to the eye due to 
the aggressive nature of the malignancy. An increase in the transport of retinoids to 
the retinal pigment epithelium for repair of the extensive damage caused by the 
tumour may have been necessary. 
Retinol-binding protein 3 has previously been discovered in the vitreous fluid 
(Aretz, Krohne et al. 2013), however, it has not yet been described in relation to 
uveal melanoma. Hence, it may a potential biomarker of interest for poor prognosis. 
 
7.5.3.2.2 Meckelin 
Meckelin is a transmembrane ciliary protein which mediates primary ciliary 
function. Little is known about the protein but it has been illustrated to be involved 
in intraflagellar transport and it appears to be critical for cilia function in organs such 
as the kidneys, liver, and retina (Tiwari, Hudson et al. 2013). Retinal rods and cones 
use cilia for the connection of the inner and outer segments of photoreceptors, and a 
disruption of this process may lead to retinal deterioration (Fliegauf, Benzing et al. 
2007). Mutations in the MKS3 gene, which encodes for meckelin, can result in eye 
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abnormalities, such as retinal degeneration (Dawe, Smith et al. 2007, Collin, Won et 
al. 2012).  
In our study, meckelin was identified as being decreased in the monosomy three 
sample set by 2.03-fold. The protein has not previously been identified in relation to 
the vitreous or uveal melanoma; hence, it may be an entirely novel protein in this 
regard.  Cellular component enrichment analysis illustrated that lipoprotein particles 
were involved in the proteins identified at a higher abundance in the disomy three 
specimens. This may implicate meckelin as it is a transmembrane protein which 
would therefore be embedded in the lipid bilayer.  
 
7.5.3.2.3 PEDF 
Pigment epithelium-derived factor (PEDF) has been long associated as being 
essential for the health and survival of the retina (Subramanian, Locatelli-Hoops et 
al. 2013). Its multiple functions include neurogenesis, neuroprotection, anti-
angiogenesis, and stem cell renewal, albeit, one of the more prominent features of 
the protein is its anti-cancer role. The protein appears to exhibit anti-angiogenic and 
antimetastatic activities, as well as inhibit tumour growth and prolong survival in 
animal models (Becerra and Notario 2013). PEDF-mediated antitumour activity is 
due to its action on the tumour microenvironment and on the tumour cells 
(Fernandez-Barral, Orgaz et al. 2012). A decrease in or loss of PEDF expression has 
been associated with an increased incidence of metastasis and with poor prognosis in 
cutaneous melanoma, prostate carcinoma, pancreatic carcinoma, neuroblastoma, and 
glioma (Yang and Grossniklaus 2010).  
PEDF was detected in the monosomy three sample set by a 1.44-fold lower 
abundance in comparison to the disomy three sample set, which correlates with 
previous findings of a lower expression of PEDF being associated with more 
aggressive phenotypes of malignancy.  
PEDF is highly expressed in melanocytes and less aggressive melanoma cells, but it 
is minimally expressed, if at all, in highly aggressive melanoma cells. It was first 
described as the most potent angiostatic factor of the eye, where it is produced by 
retinal pigment epithelial cells. PEDF elicits a highly potent inhibitory action on 
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melanoma cells, inducing apoptosis under stress conditions and annulling migration 
and invasion (Fernandez-Barral, Orgaz et al. 2012). The protein has been associated 
with uveal melanoma, where its overexpression has been shown to inhibit growth 
and hepatic micrometastasis in a mouse model. It has been previously been 
identified in the vitreous, however, it has not been identified in the uveal melanoma 
vitreous proteome (Aretz, Krohne et al. 2013).  
Therefore, our discovery of the differential expression of PEDF between monosomy 
three and disomy three vitreous fluid specimens may provide more information on 
the method of disease progression in uveal melanoma and may be a potential 
biomarker for prognosis. 
 
7.5.3.2.4 Retbindin 
Retbindin is a relatively novel, secreted protein which was originally identified in 
ocular tissue and is thought to be preferentially expressed in the retina. It is thought 
to function in flavonoid or carotenoid binding as it shares homology with riboflavin 
binding proteins (Wistow, Bernstein et al. 2002). Flavonoids have been shown in the 
past to inhibit multiple drug resistance efflux pump systems in mouse lymphoma and 
colon cancer cells (Gyemant, Tanaka et al. 2006). They have also illustrated anti-
angiogenesis, anti-metastasis, and pro-apoptosis effects on cancer cells. Li et al 
demonstrated the suppression of migration and invasion of breast cancer cell lines as 
a result of treatment with a flavonoid derivative (Li, Li et al. 2012). Carotenoids 
have also indicated anti-tumour effects (Tanaka, Shnimizu et al. 2012). 
The protein was identified in the 50 mM fraction as showing a decreased abundance 
in the monosomy of chromosome three sample set, in comparison to the disomy 
three sample set. Due to the potential carotenoid/flavonoid binding function of 
retbindin, an observed lower abundance in monosomy three vitreous samples in 
comparison to disomy three specimens would concur with previous anti-cancer 
findings associated with flavonoids and carotenoids. 
Retbindin was not previously identified in vitreous fluid nor does it appear to have 
been located in uveal melanoma or any other malignancy, which deems the protein 
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to potentially be entirely novel in cancer biomarker discovery. Hence it was decided 
that retbindin should be followed up in later studies. 
 
7.5.3.2.5 Alpha Crystallin B 
As illustrated above, a host of crystallins, including alpha crystallin B, were 
identified in the qualitative analysis of uveal melanoma vitreous fluid. Alpha 
crystallin B was also identified in the quantitative analysis as being highly 
upregulated in the monosomy three specimens.  
Alpha crystallin B functions as a stress-induced molecular chaperone which 
promotes cell survival. The ectopic expression of the protein may also protect an 
array of cell types against apoptotic signals including TNFα, and TRAIL, as well as 
conferring protection against oxidative stress. Previous studies have illustrated that 
by reducing the expression of the protein using RNA interference, cells may be 
sensitised to apoptosis, and by overexpressing it, the rates of invasion and migration 
are increased in vitro (Moyano, Evans et al. 2006). Alpha crystallin B has formerly 
been associated with poor outcome in a number of malignancies including; breast 
cancer, head and neck cancer, and laryngeal squamous cell carcinoma (Chin, Boyle 
et al. 2005, Moyano, Evans et al. 2006, Mao, Zhang et al. 2012) 
Zuidervaart et al. had previously discovered alpha-crystallin B as being 
overexpressed in two metastatic uveal melanoma cell lines, in comparison to the 
primary tumour from which they were derived (Zuidervaart, Hensbergen et al. 
2006). As it was overexpressed in the uveal melanoma vitreous fluid from patients 
with monosomy three and has been found to be upregulated in metastatic uveal 
melanoma cell lines, it appears that it may play a prognostic role. However, it has 
not yet been detected in uveal melanoma vitreous fluid and hence, may be a 
potential marker of interest which should be followed-up. 
 
7.5.4 Luminex Multiplex-Based Analysis of Control vs. Uveal Melanoma 
Vitreous Fluid 
Luminex xMAP technology is a highly sensitive bead-based array which allows for 
the multiplex analysis of proteins or nucleic acids. The microspheres have a capture 
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antibody covalently immobilized on a small surface area, thus requiring a low 
quantity of sample (Baker, Murphy et al. 2012).  
Vitreous fluid collected from uveal melanoma cases has been successfully studied 
using the Luminex system. Nagarkatti-Gude et al. studied the presence of 
inflammatory cytokines in uveal melanoma vitreous fluid in order to determine the 
relationship between the vitreal concentration of cytokines, and prognostic variables, 
such as tumour dimensions. Compared with control vitreous, a higher concentration 
of a variety of inflammatory mediators was identified in the disease fluid, which 
appeared to directly correlate with the size of the tumour and with the presence of 
immune cell infiltrate (Nagarkatti-Gude, Bronkhorst et al. 2012). Other such studies 
have also been carried out in vitreous in order to examine the link between 
inflammation and tumorigenesis in the uveal melanoma (Dunavoelgyi, Funk et al. 
2012). 
Prior to the publication of the above studies, it was decided to compare uveal 
melanoma vitreous samples, from both metastasised and non-metastasised cases, to 
control specimens using a Luminex 12-plex cytokine/chemokine assay as part of a 
pilot study. The assay quantified the levels of FGF2, IFNɣ, TNFα, TGFα, MIP1α, 
IL-10, IL-15, IL-1α, IL-2, IL-6, IL-8, and IP10. From this work, three cytokines of 
interest were identified; basic fibroblast growth factor (FGF2), macrophage 
inhibitory protein 1 alpha (MIP1α) and interferon gamma (IFNɣ). These were all 
validated for their sensitivity and specificity as potential biomarkers, however, a 
small sample set was used, and did not provide as comprehensive an analysis as 
other studies (Dunavoelgyi, Funk et al. 2012, Nagarkatti-Gude, Bronkhorst et al. 
2012). 
 
7.5.4.1 FGF2 
FGF2 is a member of fibroblast growth factor family which has more than 20 
structurally-related members. These proteins control a range of functions including; 
proliferation, motility, survival, and differentiation. FGF2 is known to play an 
important role in cancer development due to its role in angiogenesis (Polnaszek, 
Kwabi-Addo et al. 2003). 
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FGF2 has been described as being overexpressed in a variety of cancers including 
breast, prostate, melanoma, lung, and bladder (Polnaszek, Kwabi-Addo et al. 2003). 
In uveal melanoma, it was discovered that FGF2 is highly expressed in primary 
tumours. When the production of the protein was decreased in uveal melanoma cell 
lines, this severely impacted on cell proliferation and survival (Lefevre, Babchia et 
al. 2009). In addition to this, an FGF2-binding peptide has been shown to inhibit 
proliferation and angiogenesis in uveal melanoma (Yu, Gao et al. 2012). 
FGF2 was not shown to be significantly differentially expressed between the control 
and the uveal melanoma sample groups. The result was followed up using MedCalc 
which presented a specificity of 100% and a sensitivity of 75%.  
 
7.5.4.2 MIP1α 
MIP1α is a member of the C-C subfamily of chemokines which functions as an 
activator of monocytes and plays a role in host defence (Konishi, Okabe et al. 1996).  
It has previously been associated with lung cancer when it was found that lung 
cancer cells expressed MIP1α, suggesting that these cells can participate in 
inflammatory cell recruitment through the production of MIP1α (Konishi, Okabe et 
al. 1996). MIP1α overexpression has also been identified as being upregulated in 
breast cancer (Wolf, Clark-Lewis et al. 2003, Martinez-Outschoorn, Whitaker-
Menezes et al. 2011) 
MIP1α has previously been associated with uveal melanoma vitreous humour where 
it positively correlated with tumour prominence (Nagarkatti-Gude, Bronkhorst et al. 
2012). Our study agreed with this finding, illustrating a significant increase in MIP-
1α expression in the vitreous of uveal melanoma patients when compared to the 
controls, with an ANOVA score of <0.01. ROC curve analysis confirmed this 
finding with high sensitivity and specificity values.  
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7.5.4.3 IFNɣ 
IFNɣ is a cytokine known for protecting against malignancies as it inhibits 
proliferation, sensitises tumour cells to apoptosis, modulates cell differentiation and 
stimulates anti-tumour immune activity (Garcia-Tunon, Ricote et al. 2007, Wang, 
Xu et al. 2013).  
IFNɣ has been shown to inhibit the growth of multiple cell lines such as breast 
cancer cell lines and has been demonstrated to trigger the regression of skin 
metastases (Garcia-Tunon, Ricote et al. 2007). Reduced levels of IFNɣ in lung 
cancer have been associated with a shorter survival in lung cancer (Wang, Xu et al. 
2013). 
IFNɣ has previously identified in uveal melanoma vitreous humour where it directly 
correlated with tumour size (Nagarkatti-Gude, Bronkhorst et al. 2012). The same 
results were observed in our study where the cytokine was found to be significantly 
more abundant in uveal melanoma vitreous in comparison to the control vitreous. 
ROC curve analysis correlated with this finding, illustrating both 100% sensitivity 
and 100% specificity. This result differs to what is typically found in the literature, 
i.e. a decrease in IFNɣ as the disease progresses.  
 
7.5.5 Conclusion 
Although vitreous fluid is a reasonably difficult specimen to work with, the IMAC 
resin fractionation method appears to generate an interesting subset of proteins 
which may be analysed by gel-based qualitative methods or by LC-MS-based 
quantitative methods. The label-free quantitative analysis generated a total of 62 
differentially-expressed proteins, of which alpha crystallin B, retbindin, retinol-
binding protein three, and meckelin can now be followed up.  
The Luminex multiplex assay identified three cytokines of interest; FGF2, IFNɣ, and 
MIP1α. However, it should be noted that these results may be skewed by the small 
sample sizes used, and a larger study would have to be carried out to follow up these 
results. 
Overall, this work may further our understanding of the process of uveal melanoma 
metastasis which could lead to the development of potential therapeutic targets. 
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7.6 ProteoMiner Fractionation and Quantitative Label-Free LC-MS Analysis 
of Advanced Cutaneous Melanoma Serum 
As proteins are continuously varying in their expression, in accordance with the 
stage of disease or the treatment regimen, their levels can provide key information 
on a disease at the molecular level. Biomarkers may be secreted into the bloodstream 
either directly by the tumour, or indirectly through the destruction of cells. The 
blood is a potentially rich source of biomarkers, while being an easily accessible 
specimen. (Bougnoux and Solassol 2013).  
Many proteomic studies have been carried out where potential biomarkers have been 
detected in cutaneous melanoma serum specimens, across all stages. However, only 
LDH is used as a prognostic biomarker in stage IV melanoma, where the survival 
rate is less than 5%.  Hence, new methods for the detection of metastasis at an earlier 
stage are required (Bougnoux and Solassol 2013). 
The majority of cutaneous melanoma profiling experiments have been carried out 
using SELDI-TOF MS or MALDI-TOF MS, both of which have been effective 
methods. Caron et al. used SELDI-TOF MS as part of a serum proteome 
fingerprinting approach to determine if a protein profile could discriminate between 
healthy individuals and melanoma patients. From this, they identified a peak 
signature with 98.1% diagnostic accuracy (Caron, Mange et al. 2009). To compare 
the proteomic profile of serum from those with early stage melanoma to those who 
had relapsed, Wilson et al. used SELDI-TOF MS. This identified three peaks which 
appeared to correlate with recurrence following the curative resection of the primary 
melanoma tumour (Wilson, Tran et al. 2004). MALDI TOF was used in the 
discovery of serum amyloid A as a differentially regulated protein between early and 
advanced melanoma, and as a potential marker of prognosis (Findeisen, Zapatka et 
al. 2009). Newer methods are now coming on-stream, such as hydrogel core shell 
nanoparticles which are being used for the detection of biomarkers in clinical 
specimens. This method was used by Mian et al. to detect and compare biomarkers 
indicative of early or late stage melanoma in serum. This identified a pro-apoptotic 
protein named Bak the expression of which appeared to correlate with disease 
progression (Longo, Gambara et al. 2011). 
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It was decided to use LC-MS, a method which has not been widely used in 
cutaneous melanoma proteomics, to compare control serum and advanced cutaneous 
melanoma serum for the identification of potential biomarkers of interest. Any 
proteins identified would then be followed up over the course of disease progression; 
benign, early, and advanced stages. 
 
7.6.1 ProteoMiner Fractionation of Control and Advanced Cutaneous 
Melanoma Serum 
Although serum and plasma are highly interesting and potentially information-rich 
specimens in terms of novel biomarker analysis, 99% of the overall protein content 
is represented by a few high abundance proteins. Through signal suppression, these 
proteins can mask the presence of less abundant and potentially more interesting 
proteins during mass spectrometry analysis (Hartwig, Czibere et al. 2009).  
Therefore, it is often necessary to pre-treat serum prior to proteomic analysis. 
ProteoMiner is a method which enhances the sample proteome through equalisation, 
using a combinatorial library of hexapeptide ligands bound to beads. High 
abundance proteins will saturate their beads quickly, with any excess simply being 
washed away while lower abundance proteins will continue to bind to their 
appropriate ligands. The total quantity of bound proteins may then be eluted from 
the column. This results in a depletion of high abundance proteins, while 
concentrating those of lower abundance (Liang, Tan et al. 2012).  
Previous studies have been performed demonstrating the ability of ProteoMiner as a 
pre-fractionation technique for the analysis of low abundant proteins in the serum 
proteome. Hartwig at el. demonstrated the effectiveness of the ProteoMiner 
treatment of serum when combined with 2-D DIGE (Hartwig, Czibere et al. 2009). 
In addition to this, Frӧbel et al. illustrated a significant increase in the resolution of 
the serum proteome in SELDI-TOF MS profiling following ProteoMiner pre-
processing (Frobel, Hartwig et al. 2010). The quantitative LC-MS analysis of the 
cerebrospinal fluid proteome has been carried out utilising the ProteoMiner system 
as a pre-treatment method, resulting in the detection of over 1000 proteins from a 
pooled sample set (Mouton-Barbosa, Roux-Dalvai et al. 2010). The analysis of 
ProteoMiner-treated serum by quantitative LC-MS has not previously been carried 
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out according to the literature, however it was decided to utilise this method in order 
to detect differentially regulated proteins between control and advanced melanoma 
sera. 
Eight control and eight advanced melanoma disease sera were all treated with 
ProteoMiner in order to improve the likelihood of identifying novel proteins of 
interest. However, given that there are thousands of proteins present in serum, the 
fractionation of serum following pre-treatment can simplify the proteome for the 
most efficient identification of potential biomarkers. Therefore, a ProteoMiner 
sequential elution kit was used, which allows for bound proteins to be eluted in four 
separate fractions, with each containing proteins of different properties.  
 
7.6.2 Differential Expression Analysis of Control and Advanced Cutaneous 
Melanoma Serum Using LC-MS and Progenesis LC-MS 
The four fractions per sample were analysed using 1-D gel electrophoresis initially, 
in order to get a visual overview of how the fractionation worked. Following the in-
gel digestion of all protein bands in each lane and subsequent LC-MS/MS analysis, 
it was determined that elution fraction three did not produce as extensive a list of 
unique proteins in comparison to the other three fractions, for all samples. Hence, it 
was excluded from the analysis. 
Following quantitative label-free LC-MS analysis of fractions one, two, and four, a 
pattern of consistent protein upregulation in the control sample set was observed for 
fraction four. This appeared unlikely as some of the expression trends directly 
contradicted previously observed results from fractions one and two. It was possible 
that the fourth elution buffer was simply stripping any remaining proteins from the 
column. Therefore, fraction four was also excluded. 
29 and 39 differentially regulated proteins were identified in elution fraction one and 
two, respectively, for all samples. Following this, fractions one and two were 
recombined in order to identify the trends of protein expression across the whole 
experiment. This identified nine differentially regulated potential targets which were 
expressed in both fractions, of which two targets were selected for follow-up 
analysis; lactotransferrin and azurocidin. These were selected as both markers were 
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somewhat novel in terms of cutaneous melanoma. Lactotransferrin has previously 
been associated with anti-tumoural activity but has not been identified as a potential 
serum biomarker for cutaneous melanoma, despite being linked with choroidal 
melanoma, while azurocidin has not been associated with melanoma at all 
(Dikovskaya, Trunov et al. 2013). Identifications from the 1-D electrophoresis 
analysis were also taken into account, overlapping them with data acquired from the 
recombined analysis, thus identifying 10 mutual proteins, from which serotransferrin 
was chosen for further analysis. Although serotransferrin has previously been linked 
with melanoma, it has not been studied in relation to the progression of disease and 
so, it was decided to follow-up the protein in this regard (Richardson and Baker 
1990). Plasma serine protease inhibitor was also selected for follow-up validation as 
it was found to be significantly upregulated in disease sera in comparison to control 
sera. As it was not previously associated with cutaneous melanoma, it was decided 
to follow up plasma serine protease inhibitor also. 
Beta-secretase 2 (BACE-2), Matrix metalloprotease (MMP-1), and Tissue inhibitor 
of metalloproteinase 1 (TIMP-1) were previously identified by the analysis of two 
publically available array data sets for control tissue, and primary and metastasised 
cutaneous melanoma tumour tissue (Riker, Enkemann et al. 2008, Raskin, Fullen et 
al. 2013). All three were significantly upregulated in the metastasised and primary 
tissues in comparison to the control. BACE-2 had not previously been identified as a 
potential marker for cutaneous melanoma, and so, it was decided to further examine 
the protein. Both TIMP-1 and MMP-1 had, however, been identified in malignant 
melanoma as promoters of tumorigenicity, hence, it was decided to further examine 
their expression over the course of disease (Hoashi, Kadono et al. 2001, Iida and 
McCarthy 2007, Toricelli, Melo et al. 2013) 
All seven proteins; serotransferrin, lactotransferrin, azurocidin, plasma serine 
protease inhibitor, BACE-2, MMP-1, TIMP-1, were selected for further validation 
throughout the course of cutaneous melanoma disease progression.  
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7.6.3 Validation of Targets as Potential Biomarkers for Cutaneous Melanoma 
Disease Progression 
ELISA-based validation was selected for the follow-up of all seven proteins of 
interest. It was decided to examine the abundance of each across the course of 
disease, using serum which was collected from patients with benign, early stage, or 
advanced stage disease. In addition to this uveal melanoma serum collected from 
patients was also included. As chromosome status information was available, it was 
possible to examine the protein levels in both disomy of chromosome three and 
monosomy of chromosome three. Control sera were also included.  
 
7.6.3.1 Serotransferrin 
Serotransferrin is a glycopeptide which is produced by hepatocytes and is involved 
in cellular iron transport. It has been implicated in breast cancer where it was found 
to be upregulated in BRCA1 mutation carriers, a marker of poor prognosis 
(Custodio, Lopez-Farre et al. 2012). In a 2-D electrophoresis-based differential 
expression study, serotransferrin was identified as being overexpressed in 
endometrial adenocarcinoma (Byrjalsen, Mose Larsen et al. 1999). In addition to this 
serotransferrin has been linked with pancreatic carcinoma as it was found to be 
upregulated in serum in comparison serum collected from to other pancreatic disease 
patients, gastric carcinoma patients and healthy individuals (Sun, Zhu et al. 2007).  
Using quantitative label-free LC-MS analysis, serotransferrin was initially found to 
be over-expressed by 3.47-fold in advanced-stage melanoma sera when compared to 
control sera. Hence, this result agreed with studies which link an increase in 
serotransferrin levels and disease progression.  
However, the ELISA results directly contradicted this illustrating a significant 
decrease in serotransferrin levels in either early or advanced-stage cutaneous disease 
when compared to the control serum. A statistically significant decrease in 
serotransferrin levels was observed when uveal melanoma serum was compared with 
control serum. This was also the case when monosomy three uveal melanoma sera 
were compared with control sera. 
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7.6.3.2 Azurocidin 
Azurocidin is a mediator of inflammation and functions in host defence, and is a 
member of the serprocidin family of serine protease homologs (Brandt, Lundell et al. 
2011).  
It was previously considered to be inactive as a protease homologue, however, 
azurocidin was identified in the urine of multiple myeloma patients as specifically 
cleaving insulin-like growth factor-binding protein 1 (IGFBP-1) (Wang, Shafqat et 
al. 2006). Insulin-like growth factor (IGF-1) is known to foster cellular proliferation 
and inhibit apoptosis (Terry, Tworoger et al. 2009). IGF-1 and IGFBP-1 are both 
present in the circulation where they are acted upon by proteases, where IGF is 
cleaved and is available for biological actions (Khandwala, McCutcheon et al. 
2000). Azurocidin was found to cleave IGFBP-1, causing a lower affinity but a 
higher binding capacity for IGF-1, thus increasing rate of association and 
dissociation between the molecules. This in turn increased the turnover and IGF 
availability. It also induced a decreased inhibition of IGF-2-stimulated proliferation 
and glucose uptake (Wang, Shafqat et al. 2006).  
Azurocidin was over-expressed in late-stage cutaneous melanoma serum specimens 
by a maximum observed fold change of 14.2 according to quantitative label-free LC-
MS analysis. IGF-1 has also been shown to be a stimulator of cell growth in 
metastatic melanoma cell lines, therefore, it may be possible that an upregulation of 
azurocidin contributes to this phenotype (Khandwala, McCutcheon et al. 2000). 
Overall, there appeared to be a non-significant increase in azurocidin levels as the 
disease progressed from benign to late-stage. This may indicate that a larger sample 
set would provide a more comprehensive result. No difference in expression was 
noted between control sera and uveal melanoma sera.  
 
7.6.3.3 Lactotransferrin 
Lactotransferrin is a major iron-binding glycoprotein produced by mucosal epithelial 
cells. It is involved in a variety of activities such as iron homeostasis, and has 
bacteriostatic and immunomodulatory effects. In addition to this, it elicits anti-
tumour behaviour, mediated by mechanisms such anti-growth effects, immune 
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activation, and enhancement of apoptosis. Indeed, lactotransferrin has been shown 
on numerous occasions to protect against chemically-induced carcinogenesis in 
organs such as the liver, tongue, oesophagus, colon and bladder, and to reduce 
tumour growth and metastasis both in vitro and in vivo (Ward, Paz et al. 2005, 
Roseanu, Florian et al. 2010, Deng, Ye et al. 2013).  
Typically, lactotransferrin is reported to be downregulated in cancer as the loss of its 
protective effects increases the likelihood of tumorigenesis and subsequent disease 
progression (Shaheduzzaman, Vishwanath et al. 2007, Zhou, Zeng et al. 2008, Deng, 
Ye et al. 2013). However, the protein was found to be 4.17-fold upregulated in 
advanced-stage cutaneous melanoma serum, in both elution fractions one and two, 
according to the quantitative LC-MS analysis where it showed high reproducibility 
between samples.  
According to the ELISA data, lactotransferrin was significantly less abundant in 
benign or early-stage cutaneous melanoma serum when compared to control serum. 
There was no significant difference between the levels in control and advance-stage 
cutaneous melanoma serum, however an increase in lactotransferrin was observed in 
advanced-stage samples when compared to those which were benign. The uveal 
melanoma sample set, which contained both monosomy of chromosome 3 sera and 
disomy of chromosome 3 sera, showed a significantly decreased level of 
lactotransferrin when compared with that of the control sample set. When the uveal 
melanoma serum specimens which were positive for monosomy of chromosome 3 
were compared to those which did not have this anomaly, no significant difference 
was observed between the two. 
The downregulation of lactotransferrin in benign and early-stage melanoma may 
suggest that knock-down of the protein is required for establishing tumorigenesis. 
The decrease of lactotransferrin abundance in uveal melanoma serum agrees with 
this hypothesis.  
 
7.6.3.4 Plasma Serine Protease Inhibitor 
Plasma serine protease inhibitor regulates numerous serine proteases, such as 
thrombin and activated protein C, in the process of coagulation. It has been shown 
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inactivate cathepsin L, a lysosomal cysteine protease that has been implicated in the 
destruction of components of the extracellular matrix and can induce diseases such 
as cancer and atherosclerosis when upregulated. Plasma serine protease inhibitor has 
been illustrated as regulating breast tumour cell migration through the inhibition of 
cathepsin L (Fortenberry, Brandal et al. 2010). The protein has been shown to have 
the same role in renal cell carcinoma where it inhibits urinary plasminogen inhibitor 
(uPA), a protease which mediates metastasis and invasion (Wakita, Hayashi et al. 
2004). Other protein kinases have previously been associated with uveal melanoma, 
where they exerted anti-tumour behaviour (Wu, Li et al. 2012, Wu, Zhu et al. 2012) 
Plasma serine protease inhibitor was identified as being 2.6-fold downregulated in 
advanced cutaneous melanoma sera in comparison to control sera, as detected by 
quantitative label-free LC-MS analysis, which agrees with the previous findings 
from other groups. This may indicate that if the protein is downregulated, there is a 
higher possibility of tumorigenesis and metastasis. 
In contrast to the above results, a significant increase of plasma serine protease 
inhibitor abundance was observed in early stage cutaneous melanoma serum in 
comparison to that of either control or benign melanoma serum. No difference in 
protein levels was observed when control and advanced cutaneous melanoma serum 
were compared. Hence, the results of the ELISA do not validate those of the 
quantitative label-free LC-MS experiment.  
There was a statistically significant increase in the level of plasma serine protease 
inhibitor in uveal melanoma serum when compared to that of healthy patients. This 
increase in abundance was observed equally in both patients with monosomy of 
chromosome three and those with disomy of chromosome three, in relation to the 
level of plasma serine protease inhibitor produced in control serum. 
 
7.6.3.5 MMP-1 
Matrix metalloproteases (MMPs) are a family of zinc-dependent endopeptidases 
which hydrolyse extracellular matrix components. These enzymes are required for 
processes such as wound healing and angiogenesis. They have also been associated 
with cancer invasiveness and the development of metastases in numerous 
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malignancies such as colorectal cancer, breast cancer, and pancreatic cancer (Liu, 
Kato et al. 2012). MMP-1 has been suggested to play a role in malignant melanoma 
by enhancing processes of proliferation, invasion and anchorage-independent growth 
(Iida and McCarthy 2007).  
MMP-1 was shown to be significantly overexpressed in primary and metastasised 
tissue in comparison to control tissue according to the results of the microarray, 
which would correlate with studies observed in the literature.  
However, the ELISA illustrated a statistically significant decrease in the levels of 
MMP-1 in advanced cutaneous melanoma serum when compared with control 
serum. For the uveal melanoma serum, the ELISA did not indicate a pattern of 
differential expression of MMP-1 between healthy and uveal melanoma serum. 
 
7.6.3.6 TIMP-1 
Tissue inhibitor of metalloprotease-1 (TIMP-1) is an inhibitor of MMPs. Although it 
might therefore be assumed that the upregulation of TIMP-1 would hence inhibit 
tumour progression, this is not necessarily true. Several studies have shown that high 
levels of TIMP-1 are observed in the most aggressive tumours. This may be due to 
MMP-independent functions, such as inhibition of apoptosis through stimulation of 
the Akt pathway, that TIMP-1 possibly provides which may enhance the progression 
of cancer (Grunnet, Mau-Sorensen et al. 2013). TIMP-1 has been demonstrated as a 
potential prognostic and predictive factor in many cancers such as gastric cancer, 
breast cancer, and oesophageal cancer (Neri, Megha et al. 2012, Grunnet, Mau-
Sorensen et al. 2013, Kozlowski, Laudanski et al. 2013). Using cell culture-based 
studies, it has also been reported as being involved in stimulating the growth of both 
primary and metastatic melanoma cell lines (Hoashi, Kadono et al. 2001, Toricelli, 
Melo et al. 2013). 
A significant overexpression of TIMP-1 in primary and metastasised tissue in 
comparison to control tissue was observed in the microarray results. A higher fold 
change was noted when comparing the metastasised and control tissue than when 
comparing the primary and control tissue. This would agree with previous studies 
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which demonstrated that the level of TIMP-1 correlates with the degree of cancer 
aggressiveness. 
According to the ELISA results, no significant difference in the abundance of TIMP-
1 was observed between control or benign disease serum and early or late stage 
disease. In addition to this, no differential production of the protein was noted when 
serum of uveal melanoma patients was compared with healthy serum.  
 
7.6.3.7 BACE-2 
Beta secretase-2 (BACE-2) is a member of a family of membrane-bound aspartyl 
proteases (Fluhrer, Capell et al. 2002). Xin et al. previously associated BACE-2 with 
growth and metastasis in a highly tumorigenic and metastatic breast cancer cell line, 
MDA-MB-435, and correlated it with breast and colon tumour tissues, as well as 
liver metastases removed from the colon cancer patient (Xin, Stephans et al. 2000). 
However, the role of the protein appears to be linked to cell proliferation as it was 
discovered to be involved in controlling pancreatic beta-cell growth, and hence, it 
has been viewed as a potential target for diabetes (Southan 2013).  
BACE-2 was shown to be significantly upregulated in primary and metastasised 
cutaneous melanoma tissue in comparison to control tissue according to the results 
of the microarray.  
According to the ELISA results, the protein of interest was shown to be elevated in 
both early and late stage cutaneous melanoma in comparison to serum of patients 
with benign disease.  
No statistically significant difference in BACE-2 production was observed between 
the uveal melanoma serum group and the control sera; neither was any difference 
noted between patients with or without monosomy of chromosome three.  
 
This suggests that BACE-2 is potentially involved in cutaneous melanoma disease 
progression as it appears to be overexpressed in early and advanced disease sera 
when compared to controls. In addition to this, the protein was not significantly 
differentially expressed in the uveal melanoma sample set when compared to the 
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control which may indicate a disparity between the molecular mechanisms of uveal 
and cutaneous melanoma. 
 
7.6.4 Conclusion 
Overall, it was found that the ProteoMiner sequential elution technique was a less 
successful fractionation method than anticipated. For some of the identifications, 
there was an overlap between elution fractions which is not indicative of a good 
technique. 
This may be due to multiple binding mechanisms which a protein can have; some 
could strongly bind to a ligand, however, others could bind weakly, but multiple 
weak interactions create a somewhat stronger bond.  When bead-bound proteins are 
sequentially eluted using an increasing gradient of stringency, proteins may be found 
in more than one fraction. It is possible that this is as a result of both weak and 
strong binding interactions occurring between one protein type and multiple ligands 
on various beads (Boschetti and Righetti 2008).  
This may explain why inconsistencies were so often observed between the results of 
the quantitative LC-MS analysis and the results of the ELISA carried out. 
Considering this, it appears that the technology may not be entirely ready for the 
deconvolution of an entire proteome and may require further optimisation of affinity 
interactions.  
However, our method of ProteoMiner Sequential elution coupled with quantitative 
label-free LC-MS was effective as it illustrated differential protein expression 
patterns which agreed with previous findings in cutaneous melanoma proteomics 
studies in the literature. For example, a decrease in peroxiredoxin-2 has previously 
been associated with metastasis in cutaneous melanoma (Lee, Kang et al. 2013). Our 
study associated with this finding as we identified peroxiredoxin-2 to be expressed at 
a higher level in control sera in comparison to that of advanced cutaneous melanoma 
patients. We also identified insulin-like growth factor binding protein 3 (IGFBP-3) 
to be more abundant in control serum in comparison to that of advanced cutaneous 
melanoma patients. The reduction in IGFBP3 levels has been associated in with 
cutaneous melanoma progression, which matches our results (Panasiti, Naspi et al. 
2011). This work has fulfilled the aim of identifying differentially expressed proteins 
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between control and advanced stage cutaneous melanoma serum which were 
subsequently validated using ELISA. Although, the results did not agree with the 
hypothesis that protein expression changes would be observed across all stages of 
disease progression, as in some cases a significant difference was only seen between 
control or benign and advanced stage disease.  As stated above, this may have been 
affected by the disappointing and somewhat failed method of fractionation. 
Some of the targets followed-up in our analysis appear to be promising, such as 
BACE-2 and lactotransferrin, and may now be further examined as potential markers 
of melanoma disease progression in larger cohorts of patient samples. 
 
7.7 SELDI-TOF MS Analysis for the Identification of Potential Markers of 
Uveal and Cutaneous Melanoma  
SELDI-TOF can be useful for the discovery of biomarkers as it is high throughput 
and can demonstrate clear patterns of a proteome, hence illustrating variances 
between disease and control proteomes across large sample sets. The technique has 
previously been used for the identification of low molecular weight proteins, i.e. 
below 40 kDa, as potential biomarkers in clinical specimens (Srinivasan, Daniels et 
al. 2006). In other proteomic methods, such as 2-D DIGE, this can be difficult and 
many low molecular weight biomarkers could be missed. A variety of clinical 
specimens may be used and in the past, analysed body fluids have included; serum, 
plasma, amniotic fluid, urine, saliva, cerebrospinal liquid, bronchoalveolar wash out, 
tears, and nipple aspirate fluid. In addition to this, very little sample preparation, and 
low sample volumes are required (Liu 2011).  
Previously, Dr. Priyanka Maurya  used SELDI-TOF MS for the discovery of a 7.6 
kDa protein in the conditioned media of a paclitaxel-resistant superinvasive cell line 
variant (MDA-MB-435S-F/Taxol10p4pSI). This was subsequently identified as a 
fragment of bovine transferrin (Dowling, Maurya et al. 2007). Following the 
profiling of conditioned media collected from a range of melanocytes and melanoma 
cell lines, it was discovered that the 7.6 kDa fragment was solely expressed in 
melanoma cell lines. In addition to this, a number of other proteins which were only 
identified in the melanoma cell lines were discovered, including an 8.5 kDa 
ubiquitin-like marker (Dr. Pryanka Maurya, Ph.D. Thesis, 2009). 
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It was therefore decided to use IMAC SELDI-TOF MS to attempt to locate the 7.6 
kDa transferrin fragment and the 8.5 kDa ubiquitin-like marker in cutaneous 
melanoma serum and uveal melanoma vitreous fluid. This would indicate the 
possibility of either protein as a potential marker for melanoma. In addition to this, it 
was decided to profile the serum of advanced cutaneous melanoma patients in 
comparison to the serum of healthy individuals. A pilot IMAC SELDI-TOF MS 
analysis of vitreous fluid collected from uveal melanoma patients compared to a 
control vitreous specimen was also carried out.  
 
7.7.1 SELDI-TOF MS Analysis of Clinical Specimens for the Identification of 
Potential Biomarkers 
The main disadvantage of SELDI is that the identity of a peak of interest is not 
determined by the technique; it is only possible to acquire the m/z value, and the 
intensity of the peak. This creates challenges in discovering the identity of a 
potential biomarker, and hence, in developing commercial assays for use in a clinical 
environment.  
Despite this, SELDI-TOF MS has been used in a variety of clinical studies for the 
discovery of biomarkers which distinguish between test and control samples. For 
example, Li et al. utilised nickel-activated IMAC-based SELDI TOF MS technology 
for the discovery of three biomarkers in 169 sera specimens collected from breast 
cancer patients. These biomarkers were identified as spectrum peaks at 4.3, 8.1, and 
8.92 kDa, respectively. The combined analysis of the three proteins illustrated a 
sensitivity of 93% for  cancer patients and a specificity of 91% for  controls (Li, 
Zhang et al. 2002). Another study identified a number of potential markers, 
including PC1, PC2, and PC3, which distinguished between prostate cancer and 
benign prostate disease. They also found that the identified biomarkers illustrated a 
higher specificity than prostate-specific antigen (PSA) (Li, White et al. 2004).  
It should be noted that using a panel of biomarkers could greatly increase the 
specificity and sensitivity of cancer diagnosis. This is possible using SELDI 
technology as a panel of peaks may be detected at a time. This was previously 
carried out in hepatocellular carcinoma (HCC) serum samples, where an 11-protein 
signature was identified as being overexpressed (Zinkin, Grall et al. 2008). 
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7.7.2 SELDI-TOF MS Analysis of Cutaneous Melanoma Serum 
SELDI-TOF MS analyses of cutaneous melanoma specimens have been carried out, 
many with the intention of identifying prognostic outcomes. Mian et al. used serum 
samples collected from 101 early-stage patients which were compared to 104 
advanced melanoma sera for the profiling of cutaneous melanoma progression using 
SELDI technology. They identified signature proteomic profiles which were 
indicative for different stages of the disease (Mian, Ugurel et al. 2005). Another 
study used SELDI-TOF MS for the identification of melanoma-associated protein 
biomarkers of disease recurrence. Multiple protein peaks were identified in the 
region of 3.3-30 kDa which appeared to discriminate between those who developed 
recurrence in comparison to those who did not, with high sensitivity and specificity 
(Wilson, Tran et al. 2004).  
In our study, both the 7.6 kDa and the 8.5 kDa proteins of interest were identified as 
prominent peaks in the conditioned media collected from the SK-MEL5 cutaneous 
melanoma cell line, which is of low invasive potential. However, when examined for 
their presence in serum, they were not identified. This would suggest that both 
proteins are not secreted at a detectable level, or may not be expressed by the 
tumour, and that they may only be produced in melanoma cell lines. As the serum 
was immunodepleted, little to no interference from highly abundant proteins was 
present.  
Despite this, another protein, an unknown 8.9 kDa protein, was identified in the 
conditioned media of SK-MEL 5 cells, even when diluted to levels as low as 1:10. 
When 12 advanced cutaneous melanoma sera were examined, 10 samples were 
shown to express the protein of interest, where the potential marker was identified at 
least once in three replicates. It was also detected in three of 12 controls; however, it 
was present at a low level in these when compared to melanoma serum samples and 
hence was still deemed to be of interest.  
 
7.7.3 Pilot SELDI-TOF MS Analysis of Uveal Melanoma Vitreous Fluid 
Very little has been reported in the literature as regards the SELDI-TOF MS-based 
analysis of ocular fluids and nothing has been reported in relation to the vitreous 
humour of uveal melanoma patients. Using aqueous humour, Ayuso et al. 
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successfully identified transthyretin as a potential biomarker for juvenile idiopathic 
arthritis (JIA)-associated uveitis and silent chronic anterior uveitis (AU), 
inflammatory conditions of the eye (Kalinina Ayuso, de Boer et al. 2013). This 
illustrates the potential effectiveness of SELDI-TOF MS in determining potential 
biomarkers in samples which are of low volume or are of a precious nature.  
Hence, it was decided to examine vitreous fluid collected from metastatic uveal 
melanoma patients and control vitreous fluid collected from idopathic macular hole 
degeneration patients in order to determine the presence of differentially expressed 
proteins of interest.  
From this analysis, the 7.6 kDa transferrin fragment was identified in crude vitreous 
fluid. However, the 8.5 kDa ubiquitin-like marker was only found in the 
immunodepleted specimens. This suggests that the potential marker may be easily 
overshadowed by interference created by high abundance proteins. In the control 
specimen, this interference was very prominent and hence, no protein peaks were 
detected. This may have been caused as a result of the notable levels of high 
abundance proteins, such as serum albumin and immunoglobulin, present in the 
vitreous which account for over 80% of the whole vitreous fluid proteome (Angi, 
Kalirai et al. 2012). The 8.9 kDa unknown marker of interest was detected in both 
the crude and immunodepleted vitreous fluid at high levels.  
This suggested that the unknown 8.9 kDa peak could be of great interest as it was 
identified in SK-MEL 5 conditioned media, advanced cutaneous melanoma serum 
and metastatic uveal melanoma vitreous fluid, while being absent from either control 
group. It was therefore decided to attempt to isolate and identify the potential 
marker. 
 
7.7.4 Attempted Identification of the 8.9 kDa Protein of Interest 
As mentioned, the main disadvantage of SELDI-TOF MS is its lack of ability to 
identify the peaks generated. To overcome this problem, other groups had used spin 
columns containing a resin which mimicked the surface of the SELDI chip.  By 
allowing the protein to bind to the activated resin using the same chemistry as with a 
chip, the same protein species may be isolated. Proteins of interest can then be eluted 
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from the beads using either a competitor ligand, such as imidazole, reduction of the 
pH, or stripping of the immobilised metal.  
 
7.7.4.1 IMAC-Resin and Imidazole Elution 
Following the initial discovery of a peak of interest in rat plasma, Bouchal et al. 
successfully identified it as retinol-binding 4. As they used IMAC SELDI chips in 
the initial discovery of the peak, they used IMAC resin to subsequently mimic the 
chips conditions. Following this it was possible to elute the protein using imidazole, 
and separate the resulting fraction in the first dimension using an SDS gel. Resulting 
protein bands were stained and digested into peptides, prior to being identified by 
MALDI TOF (Bouchal, Jarkovsky et al. 2011).   
It was decided to follow this process using conditioned media, vitreous fluid (both 
control and uveal melanoma), and serum (both control and cutaneous melanoma). 
Each sample was eluted in fractions, separated in the first dimension and stained. 
However, the 8.9 kDa protein in question was not identified as no appropriate low 
molecular weight protein was found in each disease sample which was not present in 
the controls. It is possible, however, that the 8.9 kDa protein of interest was in fact a 
fragment of a larger protein. Some of the identifications from this analysis were 
clearly larger than the expected low molecular weight proteins which indicate that 
they may have been fragments of larger proteins. This may also have been true for 
the 8.9 kDa peak of interest. 
 
7.7.4.2 MALDI-TOF 
MALDI-TOF can also be used to generate a spectrum of proteins, but, it can also 
fragment specific peaks and analyse the resulting fragments in TOF/TOF mode in 
order to identify them (Cazares, Diaz et al. 2008). However, using MALDI-TOF to 
fragment the proteins present in each elution for the discovery of their 
identifications, was unsuccessful in this case. 
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7.7.4.3 On-Chip Elution 
It has previously been illustrated that it is possible to identify peaks of interest from 
a SELDI experiment using an on-chip elution method. Nilsen et al. tested this by 
binding and subsequently eluting four known proteins directly from a SELDI chip 
using a change in pH. Subsequently digested peptides were then analysed with LC-
MS/MS for the detection of bound proteins (Maeland Nilsen, Uleberg et al. 2011). 
It was decided to use an on-chip elution method, using imidazole, for the attempted 
identification of the 8.9 kDa potential marker. The peptides generated from this 
analysis were examined using quantitative label-free LC-MS. This identified one 
main protein of interest; apolipoprotein AII (ApoAII). This protein was found to be 
significantly upregulated in cutaneous melanoma sera in comparison to control sera. 
Although ApoAII is reported to have a molecular weight of 11.175 kDa, an 8.9 kDa 
isoform has been identified. Using LC-MS/MS and immunoassays, Malik et al. 
identified ApoAII as being upregulated in prostate cancer serum, a finding which 
correlated with immunohistochemistry results. They also found that the marker 
appeared to be more specific than PSA, as ApoAII was overexpressed in prostate 
disease when PSA was not (Malik, Ward et al. 2005).  
ApoAII has also been linked with pancreatic adenocarcinoma, where it was shown 
to be downregulated. However, its exact function in cancer is unclear. In healthy 
cells, it is required for the transport of lipids, hence, it may be that lipid metabolism 
is required for malignancies to thrive, such as prostate tumours, and apoAII is 
necessary for directing the lipid to the cancer. There is significant evidence that 
cancer cells can specifically alter different aspects of lipid metabolism which may 
have a knock-on effect on many cellular processes, including cell growth, 
proliferation, differentiation and motility (Xue, Scarlett et al. 2010, Santos and 
Schulze 2012). 
An ELISA was carried out which indicated that apoAII was not upregulated in 
advanced cutaneous melanoma sera in comparison to the control, and that it was 
unchanged across the clinical stages of the disease as well as in uveal melanoma 
serum. This may be due to the assay detecting other isoforms, as well as the 8.9 kDa 
potential marker, hence illustrating the abundance of all apoAII isoforms.  
359 
 
A quantitative label-free LC-MS experiment was repeated as before but with a larger 
cohort of samples. This also indicated that apoAII was not increased in the advanced 
disease sera. This, in combination with the ELISA results, would suggest that the 
apoAII isoform may not be the identity of the 8.9 kDa of interest.  
All of the above techniques have been shown to be successful in terms of identifying 
unknown SELDI peaks of interest, however they were not successful in this case, 
and thus, the identity of the 8.9 kDa potential biomarker remains elusive. 
However, the final differential expression analysis of the larger cohort of samples 
provided a list of 16 proteins which were upregulated in the disease sample set 
which can now be followed up. It is possible that the 8.9 kDa potential marker may 
be a fragment of one of these.  
 
7.7.5 34 Differentially Expressed Proteins were Identified Between Control and 
Advanced Cutaneous Melanoma Sera Using IMAC Purification  
From the quantitative label-free LC-MS analysis, 34 statistically significant proteins 
were found to be differentially regulated between advanced cutaneous melanoma 
and control sera. These proteins may include potential serum biomarkers for 
cutaneous melanoma and can now be followed up throughout the progression of 
melanoma, using serum collected from various stages of the disease. 
DAVID analysis indicated that, from the list of proteins upregulated in the cutaneous 
melanoma sample set, biological processes relating to inflammation and blood 
coagulation were involved which suggests that such events occurred in response to 
trauma. This could indicate the damage induced by the aggressive nature of the 
tumour. Molecular functions which were enriched primarily involved anti-enzyme 
activities. This inhibition may be an anti-tumour response as the inhibition of 
endopeptidases has been associated with suppressed growth of tumour cells (Suzuki, 
Sakaguchi et al. 2013). 
Many of the 34 proteins discovered have previously been reported in the literature in 
relation to cancer. For example, lumican, an anti-tumour proteoglycan, was found by 
Pietraszek et al. to be involved in the downregulation of melanoma growth and 
migration (Pietraszek, Brezillon et al. 2013). This result correlates with our study 
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where we identified it to be downregulated in cutaneous melanoma sera, in 
comparison to control sera. In addition to this, von Willebrand factor, which we 
identified as being differentially regulated between control and advanced melanoma 
sera, has been linked with melanoma-associated thrombin activity (Kerk, Strozyk et 
al. 2010). From our enrichment analysis, von Willebrand factor was also found to be 
associated with the upregulation of the complement pathway in advanced cutaneous 
melanoma. Insulin-like growth factor-binding protein 4 (IGFBP-4), which we 
identified as being upregulated in the advanced disease serum, has also been 
associated with the progression from primary to metastatic melanoma (Yu, Warycha 
et al. 2008). 
However, not all have been discussed in terms of melanoma. Below is a selection of 
some of the identified proteins which may be followed up in cutaneous melanoma 
serum as part of a future study.  
 
7.7.5.1 Alpha 1-Antitrypsin 
Alpha 1-antitrypsin is a circulating protease inhibitor which is known to perform an 
anti-apoptotic role (Topic, Ljujic et al. 2011). In addition to this, it has been shown 
to have anti-oxidant and anti-inflammatory activity (Jamnongkan, Techasen et al. 
2013).  
In our study, it was found to be upregulated in advanced cutaneous melanoma serum 
by 8.6-fold, in comparison to control serum. Using DAVID analysis, it was noted 
that anti-enzyme activities such as peptide inhibition, which alpha 1-antitrypsin was 
involved in, were recognised as statistically significant enriched molecular functions 
in the list of proteins upregulated in the melanoma group. In addition to this, its 
overexpression in the advanced disease was found to be associated with the 
upregulation of the complement pathway. 
Alpha 1-antitrypsin has previously been associated with colorectal cancer where it 
was found to be upregulated in the serum of cancer patients in comparison to 
controls. In addition to this, it was found to discriminate between early and advanced 
stages of disease. It has also been linked with gastric cancer where high levels of 
expression of alpha 1-antitrypsin were found to be produced in the gastric juice 
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(Bujanda, Sarasqueta et al. 2013). It has been associated with an array of other 
malignancies such as lung cancer, cholangiocarcinogenesis, and breast cancer 
(Topic, Ljujic et al. 2011, Lopez-Arias, Aguilar-Lemarroy et al. 2012, Jamnongkan, 
Techasen et al. 2013).  
However, alpha 1-antitrypsin has not previously been identified as a potential 
serological marker for cutaneous melanoma. Hence, it may of interest to follow its 
expression over the course of disease. 
 
7.7.5.2 Selenoprotein P 
Selenoprotein P is the main transporter of selenium as it can carry up to ten 
selenocysteine residues, the form of selenium which is incorporated into growing 
proteins. It has been shown to display anti-oxidant properties, protecting cells such 
as astrocytes, and endothelial cells from oxidative damage (Gonzalez-Moreno, 
Boque et al. 2011).  
In our study, selenoprotein P was found to be of lower abundance in disease serum 
in comparison to the control specimens by 2.09-fold, which may indicate that its 
downregulation is required for tumour progression. 
In the literature, selenoprotein has been associated with a number of malignancies 
including prostate cancer, lung cancer, and colon cancer, in all of which its 
expression was reduced (Gonzalez-Moreno, Boque et al. 2011).  
However, it is not well characterised in cutaneous melanoma and so, it may be an 
interesting protein to follow up. 
 
7.7.5.3 Alpha 1-Antichymotrypsin 
Alpha 1-antichymotrypsin is a serine protease inhibitor which was found to 
upregulated in our study in cutaneous melanoma sera by 2.55-fold. DAVID analysis 
indicated that anti-enzymatic molecular functions were found to be enriched in the 
disease sera, which alpha 1-antichymotrypsin was involved in.  
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This has previously been associated with poor prognosis in malignant melanoma as 
well as in other cancers, such as prostate cancer, where it is complexed to prostate-
specific antigen (PSA) (Martinez, Espana et al. 2002, Wang, Jiang et al. 2010). In 
addition this, it has been identified in pancreatic cancer as a possible biomarker for 
advanced stage pancreatic carcinoma (Roberts, Campa et al. 2012). It was also found 
to be upregulated in breast cancer and lung adenocarcinoma; in both cases it was 
thought to play a role in tumorigenesis (Higashiyama, Doi et al. 1995).  
As alpha 1-antichymotrypsin has not been linked with cutaneous melanoma serum 
previously, it may be an interesting protein to further examine. 
 
7.7.6 Conclusion 
SELDI-TOF MS is a suitable method for determining the individual protein profiles 
of sample sets, and for quickly discovering potential variances and potential peaks of 
interest between them in a high throughput fashion. However, as the identity of a 
protein may not be determined directly through SELDI-TOF MS, it can be 
problematic when subsequently identifying potential biomarkers.  
Using SELDI TOF MS, the 7.6 kDa transferrin fragment and 8.5 kDa ubiquitin-like 
marker have been identified in vitreous fluid, however, they were not detected in 
advanced cutaneous melanoma serum.  
Despite not identifying the 8.9 kDa protein/fragment of interest, a number of new 
potential candidates have been discovered. In addition to this, these proteins may 
also provide further information on the progression of cutaneous melanoma disease.  
Overall, this work fulfilled the aim of using SELDI TOF MS to compare the 
proteomic profiles of cutaneous melanoma serum, uveal melanoma vitreous fluid, 
and cutaneous melanoma conditioned media to relevant controls. It also agreed with 
the hypothesis described as this method highlighted the presence of a potential 
biomarker present in the disease samples and mostly absent from the control sample 
sets. 
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7.8 Comparing the Proteomic Basis of Uveal and Cutaneous Melanoma 
The work presented in this thesis illustrates patterns of differential protein 
expression between stages of disease progression in both uveal and cutaneous 
melanomas. Both melanomas are of a similar embryonic origin and, as described in 
section 1.5, some similarities do occur between the two diseases. However, the work 
illustrated here demonstrates that both melanomas are significantly different in terms 
of their mechanisms of disease progression.  
Although different specimens were examined in both studies; tissue and vitreous 
fluid in the uveal melanoma work and serum in the cutaneous melanoma work, no 
common proteins of interest were identified between the two studies. However, this 
may be due to the differing sample types used and/or the different experimental 
approaches used.  
Uveal melanoma serum was incorporated into the ELISA validation of cutaneous 
melanoma targets of interest, see section 5.8. This did not identify any patterns of 
expression which were mutually observed between both melanomas. Again, the lack 
of correlation observed may be due to the methods by which both melanomas 
disseminate; uveal melanoma spreads primarily through blood as the eye lacks any 
lymphatic drainage, while cutaneous melanoma may spread by either system.  
From this work, it can be said that both melanomas are entirely different on a 
proteomic level. However, the lack of correlation between both diseases may be 
enhanced by the difference in experimental design and the nature of the samples 
used in both studies.  
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CONCLUSIONS 
 
1. SELENBP1, FABP3, TPI1, EEF1G and KPNB1 all have potential as 
biomarkers for uveal melanoma metastasis in primary tumour tissue, however more 
follow-up work is now required.  
 All five proteins were identified as being upregulated in subsequently 
metastasised primary tumour tissue in comparison to that which did not 
metastasise.  
 Each protein was found to be involved in the processes of invasion 
(independent of MMP-2 and MMP-9) and migration in uveal melanoma cells.  
 SELENBP1 may also induce anti-oxidant effects in uveal melanoma cells.  
 However, none of the proteins were found to be implicated in either 
proliferation or apoptosis in uveal melanoma cell lines.  
 This work may have improved our understanding of uveal melanoma 
metastasis, identifying five proteins which may be indicative of poor outcome 
and may be developed as therapeutic targets in the treatment of metastatic 
uveal melanoma.  
 
2. Vitreous fluid is a complex sample in terms of its proteomic nature. 
 It requires significant pre-processing prior to experimental analysis in order to 
allow for the identification of a wide variety of both high and, in particular, 
low abundance proteins. For this purpose, a combination of IMAC 
chromatography and imidazole fractionation can be used for the successful 
identification of both low abundant proteins and specific protein subsets in 
vitreous fluid. 
 
3. Retbindin, retinol-binding protein 3, meckelin, alpha crystallin B, and PEDF 
were all found to be differentially regulated between the vitreous fluid of monosomy 
three uveal melanoma patients and that of disomy three uveal melanoma patients. Of 
these, retbindin, retinol-binding protein three, and meckelin have not previously 
been identified in uveal melanoma vitreous fluid. All five proteins may be suitable 
prognostic biomarkers for poor outcome in uveal melanoma, and may act as 
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therapeutic targets in the treatment of the disease, however, further studies are now 
required to test this. 
 
4. FGF2, MIP1α and IFNɣ may be useful as potential indicators of uveal 
melanoma in vitreous fluid, in comparison to control specimens and will now be 
followed up in a larger sample set.  
 
5. Serotransferrin, lactotransferrin, azurocidin, plasma serine protease inhibitor, 
MMP-1, TIMP-1 and BACE-2 may be potential biomarkers for cutaneous 
melanoma and will now be further examined in a larger study. 
 Using quantitative LC-MS, serotransferrin, lactotransferrin, and azurocidin 
were all identified as being upregulated in advanced cutaneous melanoma sera 
in comparison to control sera from healthy patients, while plasma serine 
protease inhibitor was found to be overexpressed in the control sample set. 
 MMP-1, TIMP-1, and BACE-2 mRNA levels were identified by Dr. Stephen 
Madden and Dr. Paul Dowling as being significantly upregulated in 
metastasised cutaneous melanoma tissue and primary melanoma tumour tissue 
in comparison to the healthy, control tissue. 
 Using ELISA, lactotransferrin was found to be significantly overexpressed in 
advanced cutaneous melanoma sera when compared to the benign disease 
sample set. 
 Using ELISA, BACE-2 was also identified as being significantly 
overexpressed in advanced cutaneous melanoma sera, when compared to 
either healthy, control or benign disease sera. 
 
6. SELDI-TOF is a suitable method for quickly and easily determining the individual 
protein profiles of sample sets, and for quickly discovering differentially expressed 
potential peaks of interest between them in a high throughput fashion; however, it 
may be difficult to subsequently determine the identity of these proteins. 
 A 7.6 kDa transferrin fragment and an 8.5 kDa ubiquitin-like marker were 
identified in uveal melanoma vitreous fluid and media conditioned by 
cutaneous melanoma cells, while being undetectable in control vitreous fluid 
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collected from a benign disease (macular hole degeneration). However, neither 
was detected in advanced cutaneous melanoma serum. 
 An unknown 8.9 kDa protein was discovered in uveal melanoma vitreous 
fluid, media conditioned by cutaneous melanoma cells, and in advanced 
cutaneous melanoma serum, while it was absent from control vitreous fluid, 
collected from a benign disease, and control serum.  
 Following an attempted IMAC purification and subsequent MALDI TOF or 
quantitative label-free LC-MS analysis of the fractions, the identification of 
the protein could not be determined. 
 Further evaluation discovered a number of proteins which were differentially 
expressed between control and advanced disease sera which may be 
candidates for the identity of the 8.9 kDa peak of interest. This protein list may 
also provide a number of potential biomarkers for advanced cutaneous 
melanoma. 
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FUTURE WORK 
 
1. Prior to further analysis, larger sample sets would be used in order to validate 
the results acquired from the work presented in this thesis. From these discovery 
phase data, power analysis would be used in order to calculate appropriate sample 
sizes.  
 
2. As CNDP2 was found to be downregulated in primary tumour tissue which 
subsequently metastasised in comparison to that which did not, the protein could be 
overexpressed in 92.1 and MEL202 uveal melanoma cells using a cDNA-based 
method.  
 CNDP2 may play a role as a tumour suppressor, as described in section 7.3, 
hence, it would be of interest to carry out invasion and migration assays with 
the transfected cells in order to determine the potential role of CNDP2 in uveal 
melanoma disease progression and the impact of its upregulation in the 
metastatic potential of the cells. 
 It would also be of relevance to examine the role of CNDP2 in proliferation, 
using the cDNA transfected uveal melanoma cells. 
 In addition to this, anoikis (anchorage-dependent cell death) and apoptosis 
(programmed cell death) assays could be performed for the analysis of the role 
of CNDP2 in cell death as part of uveal melanoma disease progression.  
 
3. It may be of interest to further examine the role of TPI1, FABP3, SELENBP1, 
KPNB1, and EEF1G in uveal melanoma disease progression. 
 A uveal melanoma cell line derived from a secondary tumour, such as 
OMM2.5, could be transfected with siRNA against the respective targets in 
order to decrease their expression. The transfected cells could then be assessed 
for changes in their proliferative, invasive and migratory potentials, as this 
would further indicate the role of the potential targets in metastasis.  
 In addition to this, anoikis assays may further determine a function of the five 
proteins in resistance to anchorage dependent cell death which is a commonly 
gained feature of cancer cells. 
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 Proteins of interest may assessed in cell culture as potential therapeutic targets 
through the application of targeted agents, such as glycolytic inhibitors and 
nuclear transport inhibitors in the case of TPI1, and KPNB1, respectively. The 
effects of these agents on cellular processes, such as proliferation, and their 
levels of toxicity may then be determined. 
 
4. For the vitreous fluid sample preparation, it may be interesting to use 
alternative methods of protein fractionation. 
 This may involve using another resin, such as cation exchange, as this may 
isolate another subtype of proteins. Hence, this may illustrate a new aspect of 
the uveal melanoma vitreous proteome and, using differential expression 
analysis between disease states, may allow for the identification of other 
proteins which are indicative of diagnosis or prognosis in uveal melanoma.  
 It may also be of interest to incorporate an immunodepletion step prior to 
IMAC-fractionation of the vitreous fluid. This would reduce the level of the 
most abundant proteins present in the vitreous, thus allowing for the most 
efficient mining of the low abundance proteome. 
 
5. Potential targets of interest identified as being differentially regulated 
throughout the progression of cutaneous melanoma, and between monosomy three 
and disomy three uveal melanoma vitreous fluids, could be further followed up. 
 Using ELISA validation, a larger cohort of samples could be used for the 
further validation of targets identified in the preliminary ELISA analysis, such 
as BACE-2 and lactotransferrin, as potential biomarkers of disease 
progression.  
 It may also be of interest to follow up panels of potential targets in larger 
sample sets using logistic regression and ROC curve analysis, as this may lead 
to the development of predictive models for various disease states, e.g. early 
stage cutaneous melanoma or monosomy three uveal melanoma, by providing 
stronger specificity and sensitivity values than the proteins on their own.  
 Cutaneous melanoma markers of interest could be examined in cutaneous 
melanoma cell lines, such as SK-MEL 5 and SK-MEL 28, to discover their 
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potential functional roles as secreted proteins. Using siRNA transfection, 
knockdown studies could be carried out in order to understand the potential 
roles of notable proteins, such as BACE-2 and lactotransferrin, in processes 
such as proliferation, invasion, and migration. 
 
6. The three targets identified in the preliminary Luminex multiplex assays; 
IFNɣ, MIP1α, and FGF2, could be validated in a larger sample set of vitreous fluid 
samples consisting of control, uveal melanoma monosomy three, and uveal 
melanoma disomy three specimens. This could indicate their potential roles in uveal 
melanoma metastasis, and as prognostic biomarkers for uveal melanoma. 
 
7. Proteins discovered as being differentially expressed between the control and 
advanced cutaneous melanoma serum samples could be followed up in relation to 
the elusive 8.9 kDa peak of interest. It is possible that the potential marker of interest 
is a fragment of one of these proteins. 
 Potential targets of interest which were identified in the quantitative LC-MS 
study as being differentially expressed between control and advanced 
cutaneous melanoma serum could also be followed up as potential biomarkers 
for advanced cutaneous melanoma. Using siRNA transfection and functional 
studies, such as invasion and migration assays, the roles of proteins such as 
alpha 1-antichymotrypsin and alpha 1-antitrypsin could be further examined in 
cutaneous melanoma and its progression. This could be carried out using both 
cell lines of high and low invasive potential, e.g. SK-MEL 5 and SK-MEL 28. 
 It may also be of interest to further examine the role of selenoprotein P in 
oxidative metabolism as it has previously been associated with anti-oxidant 
properties and was identified in my work as being less abundant in advanced 
cutaneous melanoma serum in comparison to control serum. This would 
require over-expression studies in cutaneous melanoma cell lines using cDNA 
specific to the target, and performing a ROS assay, for the analysis of its role 
as an anti-oxidant.  
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AppendixA
 
414 
 
 
Table 1 Fractionated cutaneous melanoma sera which were separated by 1-D electrophoresis were sliced up into thin gel sections and 
digested prior to analysis by LC-MS. The results of this qualitative analysis are shown in the table above. Identifications which were 
unique to an elution are written in red. 
415 
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Table 2. Fractionated control sera which were separated by 1-D electrophoresis were sliced up into thin gel sections and digested prior to 
analysis by LC-MS. The results of this qualitative analysis are shown in the table above. Identifications which were unique to an elution are 
written in red. 
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Appendix B 
 
Table 1. Complete list of qualitative identifications from elution one and two of 
cutaneous melanoma sample 017. 
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 Table 2. Complete list of qualitative identifications from elution one and two of 
cutaneous melanoma sample 036. 
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Table 3. Complete list of qualitative identifications from elution one and two of 
cutaneous melanoma sample DS114. 
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Table 4. Complete list of qualitative identifications from elution one and two of 
cutaneous melanoma sample DS118. 
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Appendix C 
Sample Type Sex Age Stage of Malignancy Identifier 
Control Serum M 30 - DS179 
Control Serum F 47 - DS27 
Control Serum F 55 - DS38 
Control Serum F 62 - DS43 
Control Serum F 47 - DS156 
Control Serum F 33 - DS22 
Control Serum M 37 - DS58 
Control Serum M 40 - DS46 
Control Serum F 52 - DS34 
Control Serum M 36 - DS57 
Control Serum M 32 - DS171 
Control Serum M 48 - DS56 
Control Serum F 54 - DS44 
Cutaneous Melanoma 
Serum 
F 32 Benign S1016505 
Cutaneous Melanoma 
Serum 
F 24 Benign S1027507 
Cutaneous Melanoma 
Serum 
F 52 Benign S1000545 
Cutaneous Melanoma 
Serum 
M 65 Benign S1045409 
Cutaneous Melanoma 
Serum 
F 39 Benign S1028513 
Cutaneous Melanoma 
Serum 
M 70 Benign S1012400 
Cutaneous Melanoma 
Serum 
F 39 Benign S1035502 
Cutaneous Melanoma 
Serum 
F 23 Benign S1046506 
Cutaneous Melanoma 
Serum 
M 42 Benign S1054471 
423 
 
Cutaneous Melanoma 
Serum 
F 30 Benign S1080541 
Cutaneous Melanoma 
Serum 
F 23 Benign S1065568 
Cutaneous Melanoma 
Serum 
M 27 Benign S1019429 
Cutaneous Melanoma 
Serum 
F 60 Benign S1021464 
Cutaneous Melanoma 
Serum 
F 44 Benign S1034536 
Cutaneous Melanoma 
Serum 
M 55 Benign S1017480 
Cutaneous Melanoma 
Serum 
F 47 Benign S1055557 
Cutaneous Melanoma 
Serum 
M 81 Benign S1008454 
Cutaneous Melanoma 
Serum 
F 19 Benign S1058570 
Cutaneous Melanoma 
Serum 
M 34 Stage IB S1096307 
Cutaneous Melanoma 
Serum 
F 50 Stage IA S1009509 
Cutaneous Melanoma 
Serum 
M 73 Stage IA S1089408 
Cutaneous Melanoma 
Serum 
M 72 Stage IA S1087466 
Cutaneous Melanoma 
Serum 
M 89 Stage IA S1059414 
Cutaneous Melanoma 
Serum 
F 44 Stage IA S1022577 
Cutaneous Melanoma 
Serum 
M 77  Stage IA S1093451 
Cutaneous Melanoma 
Serum 
M 52 Stage IA S1026478 
Cutaneous Melanoma 
Serum 
M 65 Stage IIB S1006438 
424 
 
Cutaneous Melanoma 
Serum 
M 44 Stage IB S1007447 
Cutaneous Melanoma 
Serum 
M 46 Stage IB S1037454 
Cutaneous Melanoma 
Serum 
M 39 Stage IB S1057451 
Cutaneous Melanoma 
Serum 
M 36 Stage IIA S1088486 
Cutaneous Melanoma 
Serum 
- 73 Stage IA S1062509 
Cutaneous Melanoma 
Serum 
F 28 Stage IV 023 
Cutaneous Melanoma 
Serum 
M 48 Stage IV BH-M-001 
Cutaneous Melanoma 
Serum 
M 45 Stage IV 019 
Cutaneous Melanoma 
Serum 
M 84 Stage III 034 
Cutaneous Melanoma 
Serum 
F 72 Stage IV 031 
Cutaneous Melanoma 
Serum 
F 73 Stage IV 017 
Cutaneous Melanoma 
Serum 
F 40 Stage III 039 
Cutaneous Melanoma 
Serum 
M 29 Stage III 029 
Cutaneous Melanoma 
Serum 
M 67 Stage IV 036 
Cutaneous Melanoma 
Serum 
M 36 Stage IV 010 
Cutaneous Melanoma 
Serum 
M 82 Stage IV 
SVUH-M-
006 
Cutaneous Melanoma 
Serum 
M 74 Stage III 014 
Uveal Melanoma 
Serum 
F 72 Monosomy 3 613325 
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Uveal Melanoma 
Serum 
M 53 
No evidence of 
Monosomy 3 
612963 
Uveal Melanoma 
Serum 
M 68 
No evidence of 
Monosomy 3 
614618 
Uveal Melanoma 
Serum 
M 54 
No evidence of 
Monosomy 3 
624972 
Uveal Melanoma 
Serum 
M 71 Monosomy 3 608420 
Uveal Melanoma 
Serum 
F 72 Monosomy 3 607486 
Uveal Melanoma 
Serum 
M 79 
No evidence of 
Monosomy 3 
606968 
Uveal Melanoma 
Serum 
M 80 
Monosomy 3 
Loss of Heterozygosity 3 
590077 
Uveal Melanoma 
Serum 
F 85 Monosomy 3 575817 
Uveal Melanoma 
Serum 
- - 
No evidence of 
Monosomy 3 
533028 
Uveal Melanoma 
Serum 
- - 
No evidence of 
Monosomy 3 
615989 
Uveal Melanoma 
Serum 
M 61 Monosomy 3 619357 
 
Table 1. Comprehensive list of samples used in ELISA analysis in Chapter Five. 
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Appendix D 
 
Presentations, Posters, and Publications Resulting From This Work: 
 
Presentations: 
 Proteomic Analysis of Both Uveal and Cutaneous Melanomas for the 
Identification of Novel Targets  
Irish Mass Spectrometry Society Annual General Meeting. May 2012 
 
 Functional Validation of Novel Targets in Uveal Melanoma  
Biotechnology in Action: Stem Cells & Tissue Engineering, Biopharmaceutical 
Production and Cancer Biomarkers. September 2012 
 
 Proteomic Analysis of Cutaneous Melanoma Metastasis using ProteoMiner 
Fractionation with Reverse Phase Chromatography and LC-MS/MS 
7
th
 Annual Conference on Analytical Sciences Ireland (CASi). July 2013 
 
Posters: 
 Triosephosphate Isomerase and Fatty Acid Binding Protein, Heart Type as  
Potential Protein Biomarkers of Metastatic Uveal Melanoma 
2
nd
 Annual Irish Melanoma Forum. November 2012 
 
Publications: 
 Differential expression of fourteen proteins between uveal melanoma from 
patients who subsequently developed distant metastases versus those who did not. 
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